{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "collapsed": true,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:21:55.846343100Z",
     "start_time": "2023-08-28T13:21:47.200164600Z"
    }
   },
   "outputs": [],
   "source": [
    "import glob\n",
    "import pandas as pd\n",
    "import json\n",
    "\n",
    "json_path = 'Notebooks/installations/Data/Results - Final Sprint Assignment/Drugs test conditions.json'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "outputs": [],
   "source": [
    "f = open(json_path)\n",
    "\n",
    "data = json.load(f)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:46:21.247369Z",
     "start_time": "2023-08-28T13:46:21.234407100Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "outputs": [],
   "source": [
    "drug_inter_manage = {}\n",
    "\n",
    "for elem in data.keys():\n",
    "    if data[elem] != 'Not available' and data[elem] != 'See individual agents':\n",
    "        try:\n",
    "            drug_inter_manage[elem] = {}\n",
    "            for test in data[elem].keys():\n",
    "                if data[elem][test].lower() == 'recommended' or 'recommended' in data[elem][test].lower():\n",
    "                    drug_inter_manage[elem][test] = (data[elem][test])\n",
    "\n",
    "            for test in drug_inter_manage[elem].keys():\n",
    "                del data[elem][test]\n",
    "        except:\n",
    "            a = 1\n",
    "    else:\n",
    "        drug_inter_manage[elem] = 'Not available'"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:46:22.835512800Z",
     "start_time": "2023-08-28T13:46:22.812531800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "outputs": [],
   "source": [
    "for drug in drug_inter_manage.keys():\n",
    "    if drug_inter_manage[drug] == {}:\n",
    "        drug_inter_manage[drug] = 'Not available'"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:46:58.349819200Z",
     "start_time": "2023-08-28T13:46:58.333864600Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "outputs": [
    {
     "data": {
      "text/plain": "{'5 + 2 (Cytarabine-Daunorubicin) (AML Induction)': 'Not available',\n '5 + 2 (Cytarabine-Daunorubicin) (AML Postremission)': 'Not available',\n '5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)': 'Not available',\n '5 + 2 (Cytarabine-Mitoxantrone) (AML Consolidation)': 'Not available',\n '5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) (AML Consolidation)': 'Not available',\n '7 + 3 (Cytarabine-Daunorubicin) (AML Induction)': 'Not available',\n '7 + 3 (Cytarabine-Idarubicin) (AML Induction)': 'Not available',\n '7 + 3 (Cytarabine-Mitoxantrone) (AML Induction)': 'Not available',\n '7 + 3 + 7 (Cytarabine-Daunorubicin-Etoposide) (AML Induction)': 'Not available',\n 'A-AVD (Hodgkin)': 'Not available',\n 'Abacavir and Lamivudine': 'Not available',\n 'Abacavir, Dolutegravir, and Lamivudine': 'Not available',\n 'Abacavir, Lamivudine, and Zidovudine': 'Not available',\n 'Abacavir': 'Not available',\n 'Abaloparatide': 'Not available',\n 'Abatacept': {'Glucose monitoring methods which utilize glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD)': 'recommended',\n  'Glucose oxidase': 'recommended',\n  'Glucose hexokinase': 'recommended'},\n 'Abciximab': 'Not available',\n 'Abemaciclib-Fulvestrant (Breast)': 'Not available',\n 'Abemaciclib': 'Not available',\n 'Abiraterone Acetate': 'Not available',\n 'Abiraterone-Methylprednisolone (Prostate)': 'Not available',\n 'Abiraterone-Prednisone (Prostate)': 'Not available',\n 'AbobotulinumtoxinA': 'Not available',\n 'Abrocitinib': 'Not available',\n 'ABV Hybrid (Hodgkin)': 'Not available',\n 'ABVD (Hodgkin)': 'Not available',\n 'ABVD Early Stage (Hodgkin)': 'Not available',\n 'AC (Breast)': 'Not available',\n 'AC (Dose-Dense) followed by Paclitaxel (Dose-Dense) (Breast)': 'Not available',\n 'AC (Dose-Dense) followed by Paclitaxel (Dose-Dense)-Trastuzumab (Breast)': 'Not available',\n 'AC (Dose-Dense) followed by Paclitaxel Weekly (Breast)': 'Not available',\n 'AC followed by Docetaxel Every 3 Weeks (Breast)': 'Not available',\n 'AC followed by Paclitaxel Weekly (Breast)': 'Not available',\n 'AC followed by Paclitaxel-Trastuzumab (Breast)': 'Not available',\n 'Acalabrutinib-Obinutuzumab (CLL)': 'Not available',\n 'Acalabrutinib': 'Not available',\n 'Acamprosate': 'Not available',\n 'Acarbose': 'Not available',\n 'Acebutolol': 'Not available',\n 'Acenocoumarol': 'Not available',\n 'Acetaminophen and Caffeine': 'Not available',\n 'Acetaminophen and Codeine': 'Not available',\n 'Acetaminophen and Diphenhydramine': 'Not available',\n 'Acetaminophen and Methocarbamol': 'Not available',\n 'Acetaminophen and Pamabrom': 'Not available',\n 'Acetaminophen and Phenylephrine': 'Not available',\n 'Acetaminophen and Phenyltoloxamine': 'Not available',\n 'Acetaminophen and Pseudoephedrine': 'Not available',\n 'Acetaminophen and Tramadol': 'Not available',\n 'Acetaminophen, Aspirin, and Caffeine': 'Not available',\n 'Acetaminophen, Caffeine, and Codeine': 'Not available',\n 'Acetaminophen, Caffeine, and Dihydrocodeine': 'Not available',\n 'Acetaminophen, Caffeine, and Pyrilamine': 'Not available',\n 'Acetaminophen, Codeine, and Doxylamine': 'Not available',\n 'Acetaminophen, Dextromethorphan, and Doxylamine': 'Not available',\n 'Acetaminophen, Dextromethorphan, and Phenylephrine': 'Not available',\n 'Acetaminophen, Diphenhydramine, and Phenylephrine': 'Not available',\n 'Acetaminophen, Guaifenesin, and Phenylephrine': 'Not available',\n 'Acetaminophen, Isometheptene, and Dichloralphenazone': 'Not available',\n 'Acetaminophen': 'Not available',\n 'AcetaZOLAMIDE': 'Not available',\n 'Acetic Acid (Otic)': 'Not available',\n 'Acetic Acid (refer to route-specific monograph)': 'Not available',\n 'Acetic Acid (Topical)': 'Not available',\n 'Acetic Acid and Hydrocortisone': 'Not available',\n 'Acetohydroxamic Acid': 'Not available',\n 'Acetone': 'Not available',\n 'Acetylcholine': 'Not available',\n 'Acetylcysteine': 'Not available',\n 'Acitretin': 'Not available',\n 'Aclidinium and Formoterol': 'Not available',\n 'Aclidinium': 'Not available',\n 'Acrivastine and Pseudoephedrine': 'Not available',\n 'Acyclovir (Ophthalmic)': 'Not available',\n 'Acyclovir (refer to route-specific monograph)': 'Not available',\n 'Acyclovir (Systemic)': 'Not available',\n 'Acyclovir (Topical)': 'Not available',\n 'Acyclovir and Hydrocortisone': 'Not available',\n 'AD (Soft Tissue Sarcoma)': 'Not available',\n 'Adagrasib': 'Not available',\n 'Adalimumab': 'Not available',\n 'Adapalene and Benzoyl Peroxide': 'Not available',\n 'Adapalene': 'Not available',\n 'Adefovir': 'Not available',\n 'Adenosine': 'Not available',\n 'Adenovirus (Types 4, 7) Vaccine': 'Not available',\n 'Ado-Trastuzumab Emtansine': 'Not available',\n 'Aducanumab': 'Not available',\n 'Afamelanotide': 'Not available',\n 'Afatinib': 'Not available',\n 'Aflibercept (Ophthalmic)': 'Not available',\n 'Aflibercept (refer to route-specific monograph)': 'Not available',\n 'Agalsidase Alfa': 'Not available',\n 'Agalsidase Beta': 'Not available',\n 'AIM (Soft Tissue Sarcoma)': 'Not available',\n 'Air Polymer-Type A': 'Not available',\n 'Albendazole': 'Not available',\n 'Albiglutide': 'Not available',\n 'Albumin': 'Not available',\n 'Albuterol and Budesonide': 'Not available',\n 'Albuterol': 'Not available',\n 'Alcaftadine': 'Not available',\n 'Alclometasone': 'Not available',\n 'Alcohol (Ethyl)': 'Not available',\n 'Alcohol (Isopropyl)': 'Not available',\n 'Aldesleukin': 'Not available',\n 'Alectinib': 'Not available',\n 'Alemtuzumab': 'Not available',\n 'Alendronate and Cholecalciferol': 'Not available',\n 'Alendronate': 'Not available',\n 'Alfacalcidol': 'Not available',\n 'ALfentanil': 'Not available',\n 'Alfuzosin': 'Not available',\n 'Alglucosidase Alfa': 'Not available',\n 'Alirocumab': 'Not available',\n 'Aliskiren and Hydrochlorothiazide': 'Not available',\n 'Aliskiren': 'Not available',\n 'Alitretinoin (refer to route-specific monograph)': 'Not available',\n 'Alitretinoin (Systemic)': 'Not available',\n 'Alitretinoin (Topical)': 'Not available',\n 'Allopurinol': 'Not available',\n 'Almotriptan': 'Not available',\n 'Alogliptin and Metformin': 'Not available',\n 'Alogliptin and Pioglitazone': 'Not available',\n 'Alogliptin': 'Not available',\n 'Alosetron': 'Not available',\n 'Alpelisib-Fulvestrant (Breast)': 'Not available',\n 'Alpelisib': 'Not available',\n 'Alpha-Galactosidase': 'Not available',\n 'Alpha1-Proteinase Inhibitor': 'Not available',\n 'ALPRAZolam': 'Not available',\n 'Alprostadil': 'Not available',\n 'Alteplase': 'Not available',\n 'Altretamine': 'Not available',\n 'Alum Irrigation': 'Not available',\n 'Aluminum Acetate': 'Not available',\n 'Aluminum Chloride Hexahydrate': 'Not available',\n 'Aluminum Chloride': 'Not available',\n 'Aluminum Hydroxide and Magnesium Carbonate': 'Not available',\n 'Aluminum Hydroxide and Magnesium Hydroxide': 'Not available',\n 'Aluminum Hydroxide and Magnesium Trisilicate': 'Not available',\n 'Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone': 'Not available',\n 'Aluminum Hydroxide': 'Not available',\n 'Alvimopan': 'Not available',\n 'Amantadine': 'Not available',\n 'Ambrisentan': 'Not available',\n 'Amcinonide': 'Not available',\n 'Amifampridine': 'Not available',\n 'Amifostine': 'Not available',\n 'Amikacin (refer to route-specific monograph)': 'Not available',\n 'Amikacin (Systemic)': 'Not available',\n 'Amikacin Liposome (Oral Inhalation)': 'Not available',\n 'Amiloride and Hydrochlorothiazide': 'Not available',\n 'AMILoride': 'Not available',\n 'Amino Acid Injection': 'Not available',\n 'Aminocaproic Acid': 'Not available',\n 'Aminolevulinic Acid (refer to route-specific monograph)': 'Not available',\n 'Aminolevulinic Acid (Systemic)': 'Not available',\n 'Aminolevulinic Acid (Topical)': 'Not available',\n 'Aminophylline': 'Not available',\n 'Aminosalicylic Acid': 'Not available',\n 'Amiodarone': 'Not available',\n 'Amisulpride (Injection)': 'Not available',\n 'Amitriptyline and Chlordiazepoxide': 'Not available',\n 'Amitriptyline and Perphenazine': 'Not available',\n 'Amitriptyline': 'Not available',\n 'Amivantamab': 'Not available',\n 'Amlodipine and Atorvastatin': 'Not available',\n 'Amlodipine and Benazepril': 'Not available',\n 'Amlodipine and Celecoxib': 'Not available',\n 'Amlodipine and Olmesartan': 'Not available',\n 'Amlodipine and Valsartan': 'Not available',\n 'Amlodipine, Valsartan, and Hydrochlorothiazide': 'Not available',\n 'AmLODIPine': 'Not available',\n 'Ammonia Spirit (Aromatic)': 'Not available',\n 'Amobarbital': 'Not available',\n 'Amorolfine [INT]': 'Not available',\n 'Amoxapine': 'Not available',\n 'Amoxicillin and Clavulanate': {'glucose tests based on enzymatic glucose oxidase reactions (eg, Clinistix)': 'recommended'},\n 'Amoxicillin': 'Not available',\n 'Amphetamine': 'Not available',\n 'Amphotericin B (Lipid Complex)': 'Not available',\n 'Amphotericin B (Liposomal)': 'Not available',\n 'Amphotericin B Deoxycholate': 'Not available',\n 'Ampicillin and Sulbactam': 'Not available',\n 'Ampicillin': 'Not available',\n 'Amsacrine': 'Not available',\n 'Amyl Nitrite': 'Not available',\n 'Anacaulase': 'Not available',\n 'Anagrelide': 'Not available',\n 'Anakinra': 'Not available',\n 'Anastrozole': 'Not available',\n 'Andexanet Alfa (Coagulation Factor Xa [Recombinant], Inactivated)': 'Not available',\n 'Angiotensin II': 'Not available',\n 'Anidulafungin': 'Not available',\n 'Anifrolumab': 'Not available',\n 'Ansuvimab': 'Not available',\n 'Anthralin': 'Not available',\n 'Anthrax Immune Globulin (Human)': 'Not available',\n 'Anthrax Vaccine Adsorbed': 'Not available',\n 'Anti-inhibitor Coagulant Complex (Human)': 'Not available',\n 'Anticoagulant Citrate Dextrose': 'Not available',\n 'Anticoagulant Sodium Citrate': 'Not available',\n 'Antihemophilic Factor (Human)': 'Not available',\n 'Antihemophilic Factor (Recombinant [Fc Fusion Protein])': 'Not available',\n 'Antihemophilic Factor (Recombinant [Fc-VWF-XTEN Fusion Protein])': 'Not available',\n 'Antihemophilic Factor (Recombinant [Pegylated])': 'Not available',\n 'Antihemophilic Factor (Recombinant [Porcine Sequence])': 'Not available',\n 'Antihemophilic Factor (Recombinant)': 'Not available',\n 'Antihemophilic Factorvon Willebrand Factor Complex (Human)': 'Not available',\n 'Antithrombin': 'Not available',\n 'Antithymocyte Globulin (Equine)': 'Not available',\n 'Antithymocyte Globulin (Rabbit)': 'Not available',\n 'Antivenin (Latrodectus mactans)': 'Not available',\n 'Antivenin (Micrurus fulvius)': 'Not available',\n 'Apalutamide': 'Not available',\n 'Apixaban': 'Not available',\n 'Apomorphine': 'Not available',\n 'Apraclonidine': 'Not available',\n 'Apremilast': 'Not available',\n 'Aprepitant': 'Not available',\n 'Arformoterol': 'Not available',\n 'Argatroban': 'Not available',\n 'Arginine': 'Not available',\n 'ARIPiprazole Lauroxil': 'Not available',\n 'ARIPiprazole': 'Not available',\n 'Armodafinil': 'Not available',\n 'Arsenic Trioxide': 'Not available',\n 'Artemether and Lumefantrine': 'Not available',\n 'Artesunate': 'Not available',\n 'Articaine and Epinephrine': 'Not available',\n 'Artichoke': 'Not available',\n 'Artificial Tears': 'Not available',\n 'Asciminib': 'Not available',\n 'Ascorbic Acid': 'Not available',\n 'Asenapine': 'Not available',\n 'Asfotase Alfa': 'Not available',\n 'Asparaginase (Erwinia [Recombinant])': 'Not available',\n 'Asparaginase (Erwinia)': 'Not available',\n 'Aspirin and Dipyridamole': 'Not available',\n 'Aspirin and Omeprazole': 'Not available',\n 'Aspirin, Citric Acid, and Sodium Bicarbonate': 'Not available',\n 'Aspirin': 'Not available',\n 'Atazanavir and Cobicistat': 'Not available',\n 'Atazanavir': 'Not available',\n 'Atenolol and Chlorthalidone': 'Not available',\n 'Atenolol': 'Not available',\n 'Atezolizumab-Bevacizumab (Hepatocellular)': 'Not available',\n 'Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Atezolizumab-Carboplatin-Etoposide (Small Cell Lung Cancer)': 'Not available',\n 'Atezolizumab-Carboplatin-Paclitaxel (Protein Bound) (NSCLC)': 'Not available',\n 'Atezolizumab-Cobimetinib-Vemurafenib (Melanoma)': 'Not available',\n 'Atezolizumab': 'Not available',\n 'Atogepant': 'Not available',\n 'Atoltivimab, Maftivimab, and Odesivimab': 'Not available',\n 'Atomoxetine': 'Not available',\n 'Atorvastatin': 'Not available',\n 'Atovaquone and Proguanil': 'Not available',\n 'Atovaquone': 'Not available',\n 'Atracurium': 'Not available',\n 'Atropine (Ophthalmic)': 'Not available',\n 'Atropine (refer to route-specific monograph)': 'Not available',\n 'Atropine (Systemic)': 'Not available',\n 'Atropine and Pralidoxime': 'Not available',\n 'Auranofin': 'Not available',\n 'Avacopan': 'Not available',\n 'Avalglucosidase Alfa': 'Not available',\n 'Avanafil': 'Not available',\n 'Avapritinib': 'Not available',\n 'Avatrombopag': 'Not available',\n 'Avelumab-Axitinib (RCC)': 'Not available',\n 'Avelumab': 'Not available',\n 'Avocado': 'Not available',\n 'Axicabtagene Ciloleucel': 'Not available',\n 'Axitinib': 'Not available',\n 'AzaCITIDine': 'Not available',\n 'AzaTHIOprine': 'Not available',\n 'Azelaic Acid': 'Not available',\n 'Azelastine (Nasal)': 'Not available',\n 'Azelastine (Ophthalmic)': 'Not available',\n 'Azelastine (refer to route-specific monograph)': 'Not available',\n 'Azelastine and Fluticasone': 'Not available',\n 'Azilsartan and Chlorthalidone': 'Not available',\n 'Azilsartan': 'Not available',\n 'Azithromycin (Ophthalmic)': 'Not available',\n 'Azithromycin (refer to route-specific monograph)': 'Not available',\n 'Azithromycin (Systemic)': 'Not available',\n 'Aztreonam (Oral Inhalation)': 'Not available',\n 'Aztreonam (refer to route-specific monograph)': 'Not available',\n 'Aztreonam (Systemic)': 'Not available',\n 'Bacitracin (Ophthalmic)': 'Not available',\n 'Bacitracin (refer to route-specific monograph)': 'Not available',\n 'Bacitracin (Systemic)': 'Not available',\n 'Bacitracin (Topical)': 'Not available',\n 'Bacitracin and Polymyxin B (Ophthalmic)': 'Not available',\n 'Bacitracin and Polymyxin B (refer to route-specific monograph)': 'Not available',\n 'Bacitracin and Polymyxin B (Topical)': 'Not available',\n 'Bacitracin, Neomycin, and Polymyxin B (Ophthalmic)': 'Not available',\n 'Bacitracin, Neomycin, and Polymyxin B (refer to route-specific monograph)': 'Not available',\n 'Bacitracin, Neomycin, and Polymyxin B (Topical)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Ophthalmic)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (refer to route-specific monograph)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Topical)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Pramoxine': 'Not available',\n 'Baclofen': 'Not available',\n 'Balanced Salt Solution': 'Not available',\n 'Baloxavir Marboxil': 'Not available',\n 'Balsalazide': 'Not available',\n 'Balsam Peru and Castor Oil': 'Not available',\n 'Bamlanivimab and Etesevimab': 'Not available',\n 'Bamlanivimab': 'Not available',\n 'Baricitinib': 'Not available',\n 'Barium': 'Not available',\n 'Basiliximab': 'Not available',\n 'BCG (Intravesical)': 'Not available',\n 'BCG (refer to route-specific monograph)': 'Not available',\n 'BCG Vaccine (Immunization)': 'Not available',\n 'BEACOPP Escalated (Hodgkin)': 'Not available',\n 'BEACOPP Escalated Plus Standard (Hodgkin)': 'Not available',\n 'BEACOPP Standard (Hodgkin)': 'Not available',\n 'BEACOPP-14 (Hodgkin)': 'Not available',\n 'Bebtelovimab': 'Not available',\n 'Becaplermin': 'Not available',\n 'Beclomethasone (Nasal)': 'Not available',\n 'Beclomethasone (Oral Inhalation)': 'Not available',\n 'Beclomethasone (refer to route-specific monograph)': 'Not available',\n 'Beclomethasone (Topical)': 'Not available',\n 'Bedaquiline': 'Not available',\n 'Belantamab Mafodotin': 'Not available',\n 'Belatacept': 'Not available',\n 'Belimumab': 'Not available',\n 'Belinostat': 'Not available',\n 'Belladonna and Opium': 'Not available',\n 'Belumosudil': 'Not available',\n 'Belzutifan': 'Not available',\n 'Bempedoic Acid and Ezetimibe': 'Not available',\n 'Bempedoic Acid': 'Not available',\n 'Benazepril and Hydrochlorothiazide': 'Not available',\n 'Benazepril': 'Not available',\n 'Bendamustine-Bortezomib-Rituximab (NHL-Follicular)': 'Not available',\n 'Bendamustine-Lenalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bendamustine-Obinutuzumab (NHL-Follicular)': 'Not available',\n 'Bendamustine-Rituximab (CLL)': 'Not available',\n 'Bendamustine-Rituximab (NHL-Follicular)': 'Not available',\n 'Bendamustine-Rituximab (NHL-Mantle Cell)': 'Not available',\n 'Bendamustine-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Bendamustine': 'Not available',\n 'Benralizumab': 'Not available',\n 'Benserazide and Levodopa': 'Not available',\n 'Bentoquatam': 'Not available',\n 'Benzalkonium Chloride and Benzocaine': 'Not available',\n 'Benzhydrocodone and Acetaminophen': 'Not available',\n 'Benznidazole': 'Not available',\n 'Benzocaine and Docusate': 'Not available',\n 'Benzocaine, Butamben, and Tetracaine': 'Not available',\n 'Benzocaine': 'Not available',\n 'Benzoin': 'Not available',\n 'Benzonatate': 'Not available',\n 'Benzoyl Peroxide and Hydrocortisone': 'Not available',\n 'Benzoyl Peroxide': 'Not available',\n 'Benzphetamine': 'Not available',\n 'Benztropine': 'Not available',\n 'Benzydamine': 'Not available',\n 'Benzyl Alcohol': 'Not available',\n 'Benzylpenicilloyl Polylysine': 'Not available',\n 'BEP (Ovarian)': 'Not available',\n 'BEP (Testicular)': 'Not available',\n 'Bepotastine': 'Not available',\n 'Beractant': 'Not available',\n 'Berotralstat': 'Not available',\n 'Besifloxacin': 'Not available',\n 'Beta-Carotene': 'Not available',\n 'Betahistine': 'Not available',\n 'Betaine': 'Not available',\n 'Betamethasone (refer to route-specific monograph)': 'Not available',\n 'Betamethasone (Systemic)': 'Not available',\n 'Betamethasone (Topical)': 'Not available',\n 'Betamethasone and Clotrimazole': 'Not available',\n 'Betamethasone and Gentamicin': 'Not available',\n 'Betamethasone and Salicylic Acid': 'Not available',\n 'Betaxolol (Ophthalmic)': 'Not available',\n 'Betaxolol (refer to route-specific monograph)': 'Not available',\n 'Betaxolol (Systemic)': 'Not available',\n 'Bethanechol': 'Not available',\n 'Betibeglogene Autotemcel': 'Not available',\n 'Bevacizumab + FOLFIRI (Colorectal)': 'Not available',\n 'Bevacizumab + XELOX (Colorectal)': 'Not available',\n 'Bevacizumab FOLFOX (Colorectal)': 'Not available',\n 'Bevacizumab-Carboplatin-Doxorubicin (Liposomal) (Ovarian)': 'Not available',\n 'Bevacizumab-Carboplatin-Gemcitabine (Ovarian)': 'Not available',\n 'Bevacizumab-Carboplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Bevacizumab-Carboplatin-Paclitaxel (Ovarian)': 'Not available',\n 'Bevacizumab-Carboplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Bevacizumab-Cisplatin-Paclitaxel (Cervical)': 'Not available',\n 'Bevacizumab-Cisplatin-Pemetrexed (Mesothelioma)': 'Not available',\n 'Bevacizumab-Cisplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Bevacizumab-Doxorubicin (Liposomal) (Ovarian)': 'Not available',\n 'Bevacizumab-Fluorouracil-Leucovorin (Colorectal)': 'Not available',\n 'Bevacizumab-Irinotecan (Glioblastoma)': 'Not available',\n 'Bevacizumab-Lomustine (Glioblastoma)': 'Not available',\n 'Bevacizumab-Lonsurf (Colorectal)': 'Not available',\n 'Bevacizumab-Paclitaxel (Breast)': 'Not available',\n 'Bevacizumab-Paclitaxel (Ovarian)': 'Not available',\n 'Bevacizumab-Paclitaxel-Topotecan (Cervical)': 'Not available',\n 'Bevacizumab-Topotecan Daily (Ovarian)': 'Not available',\n 'Bevacizumab-Topotecan Weekly (Ovarian)': 'Not available',\n 'Bevacizumab': 'Not available',\n 'Bexagliflozin': 'Not available',\n 'Bexarotene (refer to route-specific monograph)': 'Not available',\n 'Bexarotene (Systemic)': 'Not available',\n 'Bexarotene (Topical)': 'Not available',\n 'Bezafibrate': 'Not available',\n 'Bezlotoxumab': 'Not available',\n 'Bicalutamide': 'Not available',\n 'Bictegravir, Emtricitabine, and Tenofovir Alafenamide': 'Not available',\n 'Bilastine': 'Not available',\n 'Bimatoprost': 'Not available',\n 'Bimekizumab': 'Not available',\n 'Binimetinib': 'Not available',\n 'Biotin': 'Not available',\n 'Bisacodyl': 'Not available',\n 'Bismuth Subcitrate, Metronidazole, and Tetracycline': 'Not available',\n 'Bismuth Subgallate': 'Not available',\n 'Bismuth Subsalicylate': 'Not available',\n 'Bisoprolol and Hydrochlorothiazide': 'Not available',\n 'Bisoprolol': 'Not available',\n 'Bivalirudin': 'Not available',\n 'Bleomycin': 'Not available',\n 'Blinatumomab': 'Not available',\n 'Boric Acid (Vaginal)': 'Not available',\n 'Bortezomib-Dexamethasone (Amyloidosis)': 'Not available',\n 'Bortezomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bortezomib-Dexamethasone-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Bortezomib-Doxorubicin (Liposomal) (Multiple Myeloma)': 'Not available',\n 'Bortezomib-Doxorubicin-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bortezomib-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Bortezomib-Thalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bortezomib': 'Not available',\n 'Bosentan': 'Not available',\n 'Bosutinib': 'Not available',\n 'Botulism Antitoxin, Heptavalent': 'Not available',\n 'Botulism Immune Globulin (Intravenous-Human)': 'Not available',\n 'Bovine Lipid Extract Surfactant': 'Not available',\n 'Bremelanotide': 'Not available',\n 'Brentuximab Vedotin': 'Not available',\n 'Bretylium': 'Not available',\n 'Brexanolone': 'Not available',\n 'Brexpiprazole': 'Not available',\n 'Brexucabtagene Autoleucel': 'Not available',\n 'Brigatinib': 'Not available',\n 'Brilliant Blue G': 'Not available',\n 'Brimonidine (Ophthalmic)': 'Not available',\n 'Brimonidine (refer to route-specific monograph)': 'Not available',\n 'Brimonidine (Topical)': 'Not available',\n 'Brimonidine and Timolol': 'Not available',\n 'Brincidofovir': 'Not available',\n 'Brinzolamide and Brimonidine': 'Not available',\n 'Brinzolamide and Timolol': 'Not available',\n 'Brinzolamide': 'Not available',\n 'Brivaracetam': 'Not available',\n 'Brodalumab': 'Not available',\n 'Brolucizumab': 'Not available',\n 'Bromazepam': 'Not available',\n 'Bromfenac': 'Not available',\n 'Bromocriptine': 'Not available',\n 'Brompheniramine and Phenylephrine': 'Not available',\n 'Brompheniramine and Pseudoephedrine': 'Not available',\n 'Brompheniramine, Dextromethorphan, and Phenylephrine': 'Not available',\n 'Brompheniramine, Pseudoephedrine, and Dextromethorphan': 'Not available',\n 'Budesonide (Nasal)': 'Not available',\n 'Budesonide (Oral Inhalation)': 'Not available',\n 'Budesonide (refer to route-specific monograph)': 'Not available',\n 'Budesonide (Systemic)': 'Not available',\n 'Budesonide (Topical)': 'Not available',\n 'Budesonide and Formoterol': 'Not available',\n 'Budesonide, Glycopyrrolate, and Formoterol': 'Not available',\n 'Bumetanide': 'Not available',\n 'BUPivacaine (Liposomal)': 'Not available',\n 'Bupivacaine and Epinephrine': 'Not available',\n 'Bupivacaine and Meloxicam': 'Not available',\n 'BUPivacaine': 'Not available',\n 'Buprenorphine and Naloxone': 'Not available',\n 'Buprenorphine': 'Not available',\n 'BuPROPion': 'Not available',\n 'Burosumab': 'Not available',\n 'Buserelin': 'Not available',\n 'BusPIRone': 'Not available',\n 'Busulfan': 'Not available',\n 'Butabarbital': 'Not available',\n 'Butalbital and Acetaminophen': 'Not available',\n 'Butalbital, Acetaminophen, and Caffeine': 'Not available',\n 'Butalbital, Acetaminophen, Caffeine, and Codeine': 'Not available',\n 'Butalbital, Aspirin, and Caffeine': 'Not available',\n 'Butalbital, Aspirin, Caffeine, and Codeine': 'Not available',\n \"Butcher's Broom\": 'Not available',\n 'Butenafine': 'Not available',\n 'Butoconazole': 'Not available',\n 'Butorphanol': 'Not available',\n 'C-MOPPABV Hybrid (Hodgkin)': 'Not available',\n 'C1 Inhibitor (Human)': 'Not available',\n 'C1 Inhibitor (Recombinant)': 'Not available',\n 'Cabazitaxel-Prednisone (Prostate)': 'Not available',\n 'Cabazitaxel': 'Not available',\n 'Cabergoline': 'Not available',\n 'Cabotegravir and Rilpivirine': 'Not available',\n 'Cabotegravir': 'Not available',\n 'Cabozantinib-Nivolumab (RCC)': 'Not available',\n 'Cabozantinib': 'Not available',\n 'Caffeine': 'Not available',\n 'Calamine': 'Not available',\n 'Calaspargase Pegol': 'Not available',\n 'Calcifediol': 'Not available',\n 'Calcipotriene and Betamethasone': 'Not available',\n 'Calcipotriene': 'Not available',\n 'Calcitonin': 'Not available',\n 'Calcitriol (refer to route-specific monograph)': 'Not available',\n 'Calcitriol (Systemic)': 'Not available',\n 'Calcitriol (Topical)': 'Not available',\n 'Calcium Acetate': 'Not available',\n 'Calcium and Vitamin D': 'Not available',\n 'Calcium Carbonate and Magnesium Carbonate': 'Not available',\n 'Calcium Carbonate and Magnesium Hydroxide': 'Not available',\n 'Calcium Carbonate and Simethicone': 'Not available',\n 'Calcium Carbonate': 'Not available',\n 'Calcium Chloride': 'Not available',\n 'Calcium Citrate': 'Not available',\n 'Calcium Dobesilate and Lidocaine': 'Not available',\n 'Calcium Glubionate': 'Not available',\n 'Calcium Gluconate': 'Not available',\n 'Calcium Hydroxylapatite': 'Not available',\n 'Calcium Lactate': 'Not available',\n 'Calcium Polystyrene Sulfonate': 'Not available',\n 'Calfactant': 'Not available',\n 'CALGB 8811 Regimen (ALL)': 'Not available',\n 'CALGB 9111 Regimen (ALL)': 'Not available',\n 'Camphor and Menthol': 'Not available',\n 'Camphor and Phenol': 'Not available',\n 'Camphor': 'Not available',\n 'Canagliflozin and Metformin': 'Not available',\n 'Canagliflozin': 'Not available',\n 'Canakinumab': 'Not available',\n 'Candesartan and Hydrochlorothiazide': 'Not available',\n 'Candesartan': 'Not available',\n 'Candida albicans (Monilia)': 'Not available',\n 'Cangrelor': 'Not available',\n 'Cannabidiol': 'Not available',\n 'Cannabis': 'Not available',\n 'Cantharidin, Podophyllin Resin, and Salicylic Acid': 'Not available',\n 'Cantharidin': 'Not available',\n 'Capecitabine + Lapatinib (Breast)': 'Not available',\n 'Capecitabine-Docetaxel (Breast)': 'Not available',\n 'Capecitabine-Docetaxel (Gastric Cancer)': 'Not available',\n 'Capecitabine-Gemcitabine (Pancreatic)': 'Not available',\n 'Capecitabine-Ixabepilone (Breast)': 'Not available',\n 'Capecitabine-Oxaliplatin (Gastric)': 'Not available',\n 'Capecitabine-Oxaliplatin (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Capecitabine-Trastuzumab (Breast)': 'Not available',\n 'Capecitabine': 'Not available',\n 'Caplacizumab': 'Not available',\n 'Capmatinib': 'Not available',\n 'CAPOX (Biliary Cancer)': 'Not available',\n 'CAPOX (Pancreatic)': 'Not available',\n 'Capreomycin': 'Not available',\n 'Caprylidene': 'Not available',\n 'Capsaicin': 'Not available',\n 'Captopril and Hydrochlorothiazide': 'Not available',\n 'Captopril': 'Not available',\n 'Carbachol': 'Not available',\n 'CarBAMazepine': 'Not available',\n 'Carbamide Peroxide': 'Not available',\n 'Carbetocin': 'Not available',\n 'Carbidopa and Levodopa': 'Not available',\n 'Carbidopa': 'Not available',\n 'Carbinoxamine': 'Not available',\n 'Carbon 14 Urea': 'Not available',\n 'Carboplatin-Cetuximab (Head and Neck Cancer)': 'Not available',\n 'Carboplatin-Docetaxel (Ovarian)': 'Not available',\n 'Carboplatin-Docetaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Carboplatin-Docetaxel (Unknown Primary, Squamous Cell)': 'Not available',\n 'Carboplatin-Docetaxel-Trastuzumab (Breast)': 'Not available',\n 'Carboplatin-Doxorubicin (Liposomal) (Ovarian)': 'Not available',\n 'Carboplatin-Etoposide (Ovarian Germ Cell Tumor)': 'Not available',\n 'Carboplatin-Etoposide (Small Cell Lung Cancer)': 'Not available',\n 'Carboplatin-Etoposide-Paclitaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Carboplatin-Fluorouracil (Head and Neck)': 'Not available',\n 'Carboplatin-Gemcitabine (Bladder)': 'Not available',\n 'Carboplatin-Gemcitabine (NSCLC)': 'Not available',\n 'Carboplatin-Gemcitabine (Ovarian)': 'Not available',\n 'Carboplatin-Irinotecan (Small Cell Lung Cancer)': 'Not available',\n 'Carboplatin-Paclitaxel (Cervical Cancer)': 'Not available',\n 'Carboplatin-Paclitaxel (Endometrial)': 'Not available',\n 'Carboplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel (Ovarian)': 'Not available',\n 'Carboplatin-Paclitaxel (Protein Bound) (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel (Protein Bound)-Pembrolizumab (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel (ThymomaThymic)': 'Not available',\n 'Carboplatin-Paclitaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Carboplatin-Paclitaxel-Pembrolizumab (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel-Trastuzumab (Breast)': 'Not available',\n 'Carboplatin-Pemetrexed (Mesothelioma)': 'Not available',\n 'Carboplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Carboplatin-Pemetrexed-Pembrolizumab (NSCLC)': 'Not available',\n 'CARBOplatin': 'Not available',\n 'Carboprost Tromethamine': 'Not available',\n 'Carboxymethylcellulose': 'Not available',\n 'Cardioplegic Solution': 'Not available',\n 'Carfilzomib, Cyclophosphamide, Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Carfilzomib, Lenalidomide, Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Carfilzomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Carfilzomib-Dexamethasone-Daratumumab (Multiple Myeloma)': 'Not available',\n 'Carfilzomib': 'Not available',\n 'Carglumic Acid': 'Not available',\n 'Cariprazine': 'Not available',\n 'Carisoprodol and Aspirin': 'Not available',\n 'Carisoprodol, Aspirin, and Codeine': 'Not available',\n 'Carisoprodol': 'Not available',\n 'Carmustine': 'Not available',\n 'Carteolol (Ophthalmic)': 'Not available',\n 'Carvedilol': 'Not available',\n 'Casimersen': 'Not available',\n 'Casirivimab and Imdevimab': 'Not available',\n 'Caspofungin': 'Not available',\n 'Castor Oil': 'Not available',\n 'CAV (Small Cell Lung Cancer)': 'Not available',\n 'Cefaclor': 'Not available',\n 'Cefadroxil': 'Not available',\n 'CeFAZolin': 'Not available',\n 'Cefdinir': 'Not available',\n 'Cefepime': 'Not available',\n 'Cefiderocol': 'Not available',\n 'Cefixime': 'Not available',\n 'Cefotaxime': 'Not available',\n 'CefoTEtan': 'Not available',\n 'CefOXitin': 'Not available',\n 'Cefpodoxime': 'Not available',\n 'Cefprozil': 'Not available',\n 'Ceftaroline Fosamil': 'Not available',\n 'Ceftazidime and Avibactam': 'Not available',\n 'CefTAZidime': 'Not available',\n 'Ceftibuten': 'Not available',\n 'Ceftobiprole': 'Not available',\n 'Ceftolozane and Tazobactam': 'Not available',\n 'CefTRIAXone': 'Not available',\n 'Cefuroxime': {'Glucose oxidase or hexokinase-based methods': 'recommended'},\n 'Celecoxib and Tramadol': 'Not available',\n 'Celecoxib': 'Not available',\n 'Cellulose (Oxidized Regenerated)': 'Not available',\n 'Cellulose and Citric Acid': 'Not available',\n 'Cemiplimab': 'Not available',\n 'Cenegermin': 'Not available',\n 'Cenobamate': 'Not available',\n 'Centruroides Immune F(ab)2 (Equine)': 'Not available',\n 'Cephalexin': 'Not available',\n 'CEPP (NHL-DLBCL)': 'Not available',\n 'Ceritinib': 'Not available',\n 'Cerliponase Alfa': 'Not available',\n 'Certolizumab Pegol': 'Not available',\n 'Cetirizine (Ophthalmic)': 'Not available',\n 'Cetirizine (refer to route-specific monograph)': 'Not available',\n 'Cetirizine (Systemic)': 'Not available',\n 'Cetirizine and Pseudoephedrine': 'Not available',\n 'Cetrorelix': 'Not available',\n 'Cetuximab (Biweekly)-Irinotecan (Colorectal)': 'Not available',\n 'Cetuximab + FOLFIRI (Colorectal)': 'Not available',\n 'Cetuximab-Carboplatin-Fluorouracil (Head and Neck Cancer)': 'Not available',\n 'Cetuximab-Cisplatin-Fluorouracil (Head and Neck Cancer)': 'Not available',\n 'Cetuximab-Encorafenib (Colorectal)': 'Not available',\n 'Cetuximab-Irinotecan (Colorectal)': 'Not available',\n 'Cetuximab': 'Not available',\n 'Cetylpyridinium': 'Not available',\n 'Cevimeline': 'Not available',\n 'Charcoal, Activated': 'Not available',\n 'Chenodiol': 'Not available',\n 'Chlophedianol and Dexbrompheniramine': 'Not available',\n 'Chlophedianol, Dexbrompheniramine, and Pseudoephedrine': 'Not available',\n 'Chloral Hydrate': 'Not available',\n 'Chlorambucil-Obinutuzumab (CLL)': 'Not available',\n 'Chlorambucil-Ofatumumab (CLL)': 'Not available',\n 'Chlorambucil-Prednisone (CLL)': 'Not available',\n 'Chlorambucil': 'Not available',\n 'Chloramphenicol (Systemic)': 'Not available',\n 'ChlordiazePOXIDE': 'Not available',\n 'Chlorhexidine Gluconate (Oral)': 'Not available',\n 'Chlorhexidine Gluconate (refer to route-specific monograph)': 'Not available',\n 'Chlorhexidine Gluconate (Topical)': 'Not available',\n 'Chlorophyll': 'Not available',\n 'Chloroprocaine (Ophthalmic)': 'Not available',\n 'Chloroprocaine (refer to route-specific monograph)': 'Not available',\n 'Chloroprocaine (Systemic)': 'Not available',\n 'Chloroquine': 'Not available',\n 'Chlorothiazide': 'Not available',\n 'Chlorpheniramine and Acetaminophen': 'Not available',\n 'Chlorpheniramine and Phenylephrine': 'Not available',\n 'Chlorpheniramine and Pseudoephedrine': 'Not available',\n 'Chlorpheniramine, Phenylephrine, and Dextromethorphan': 'Not available',\n 'Chlorpheniramine, Pseudoephedrine, and Codeine': 'Not available',\n 'Chlorpheniramine': 'Not available',\n 'ChlorproMAZINE': 'Not available',\n 'Chlorthalidone': 'Not available',\n 'Chlorzoxazone': 'Not available',\n 'Cholecalciferol': 'Not available',\n 'Cholera Vaccine': 'Not available',\n 'Cholestyramine Resin': 'Not available',\n 'Cholic Acid': 'Not available',\n 'Choline C 11': 'Not available',\n 'Choline Magnesium Trisalicylate': 'Not available',\n 'CHOP (NHL-AIDS-Related)': 'Not available',\n 'Chorionic Gonadotropin (Human)': 'Not available',\n 'Chorionic Gonadotropin (Recombinant)': 'Not available',\n 'Chromic Chloride': 'Not available',\n 'Ciclesonide (Nasal)': 'Not available',\n 'Ciclesonide (Oral Inhalation)': 'Not available',\n 'Ciclesonide (refer to route-specific monograph)': 'Not available',\n 'Ciclopirox': 'Not available',\n 'Cidofovir': 'Not available',\n 'Cilazapril and Hydrochlorothiazide': 'Not available',\n 'Cilazapril': 'Not available',\n 'Cilostazol': 'Not available',\n 'Ciltacabtagene Autoleucel': 'Not available',\n 'Cimetidine': 'Not available',\n 'Cinacalcet': 'Not available',\n 'Ciprofloxacin (Ophthalmic)': 'Not available',\n 'Ciprofloxacin (Otic)': 'Not available',\n 'Ciprofloxacin (refer to route-specific monograph)': 'Not available',\n 'Ciprofloxacin (Systemic)': 'Not available',\n 'Ciprofloxacin and Dexamethasone': 'Not available',\n 'Ciprofloxacin and Fluocinolone': 'Not available',\n 'Ciprofloxacin and Hydrocortisone': 'Not available',\n 'Cisapride': 'Not available',\n 'Cisatracurium': 'Not available',\n 'Cisplatin-Capecitabine (Esophageal Cancer)': 'Not available',\n 'Cisplatin-Capecitabine (Gastric Cancer)': 'Not available',\n 'Cisplatin-Cetuximab (Head and Neck Cancer)': 'Not available',\n 'Cisplatin-Docetaxel (NSCLC)': 'Not available',\n 'Cisplatin-Docetaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Cisplatin-Docetaxel (Unknown Primary, Squamous Cell)': 'Not available',\n 'Cisplatin-Docetaxel-Fluorouracil (Unknown Primary, Squamous Cell)': 'Not available',\n 'Cisplatin-Docetaxel-Gemcitabine (Bladder)': 'Not available',\n 'Cisplatin-Doxorubicin (Endometrial)': 'Not available',\n 'Cisplatin-Doxorubicin-Paclitaxel (Endometrial)': 'Not available',\n 'Cisplatin-Etoposide (NSCLC)': 'Not available',\n 'Cisplatin-Etoposide (Small Cell Lung Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil (Bladder Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil (Esophageal Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil (Head and Neck Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil-Paclitaxel (Unknown Primary, Squamous Cell)': 'Not available',\n 'Cisplatin-Gemcitabine (Bladder)': 'Not available',\n 'Cisplatin-Gemcitabine (Cervical)': 'Not available',\n 'Cisplatin-Gemcitabine (Mesothelioma)': 'Not available',\n 'Cisplatin-Gemcitabine (NSCLC)': 'Not available',\n 'Cisplatin-Gemcitabine (Pancreatic)': 'Not available',\n 'Cisplatin-Gemcitabine (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Cisplatin-Gemcitabine-Necitumumab (NSCLC)': 'Not available',\n 'Cisplatin-Irinotecan (Gastric)': 'Not available',\n 'Cisplatin-Irinotecan (NSCLC)': 'Not available',\n 'Cisplatin-Irinotecan (Small Cell Lung Cancer)': 'Not available',\n 'Cisplatin-Paclitaxel (Cervical Cancer)': 'Not available',\n 'Cisplatin-Paclitaxel (Head and Neck Cancer)': 'Not available',\n 'Cisplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Cisplatin-Paclitaxel Intraperitoneal (Ovarian)': 'Not available',\n 'Cisplatin-Pemetrexed (Mesothelioma)': 'Not available',\n 'Cisplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Cisplatin-Pemetrexed-Pembrolizumab (NSCLC)': 'Not available',\n 'Cisplatin-Raltitrexed (Mesothelioma)': 'Not available',\n 'Cisplatin-Topotecan (Cervical Cancer)': 'Not available',\n 'Cisplatin-Vinblastine (NSCLC)': 'Not available',\n 'Cisplatin-Vinorelbine (Adjuvant NSCLC)': 'Not available',\n 'Cisplatin-Vinorelbine (Cervical Cancer)': 'Not available',\n 'Cisplatin-Vinorelbine (Metastatic NSCLC)': 'Not available',\n 'CISplatin': 'Not available',\n 'Citalopram': 'Not available',\n 'Citric Acid, Magnesium Carbonate, and Glucono-Delta-Lactone': 'Not available',\n 'Citric Acid, Sodium Citrate, and Potassium Citrate': 'Not available',\n 'Cladribine-Rituximab (NHL-Mantle Cell)': 'Not available',\n 'Cladribine-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Cladribine': 'Not available',\n 'CLAG (AML Induction)': 'Not available',\n 'CLAG-M (AML Induction)': 'Not available',\n 'Clarithromycin': 'Not available',\n 'Clascoterone': 'Not available',\n 'Clemastine': 'Not available',\n 'Clevidipine': 'Not available',\n 'Clidinium and Chlordiazepoxide': 'Not available',\n 'Clindamycin (refer to route-specific monograph)': 'Not available',\n 'Clindamycin (Systemic)': 'Not available',\n 'Clindamycin (Topical)': 'Not available',\n 'Clindamycin and Benzoyl Peroxide': 'Not available',\n 'Clindamycin and Tretinoin': 'Not available',\n 'Clioquinol and Flumethasone': 'Not available',\n 'Clioquinol and Hydrocortisone': 'Not available',\n 'CloBAZam': 'Not available',\n 'Clobetasol': 'Not available',\n 'Clobetasone': 'Not available',\n 'Clocortolone': 'Not available',\n 'Clodronate': 'Not available',\n 'Clofarabine-Cyclophosphamide-Etoposide (ALL)': 'Not available',\n 'Clofarabine-Cytarabine (AML)': 'Not available',\n 'Clofarabine': 'Not available',\n 'Clofazimine': 'Not available',\n 'Clofedanol': 'Not available',\n 'ClomiPHENE': 'Not available',\n 'ClomiPRAMINE': 'Not available',\n 'ClonazePAM': 'Not available',\n 'CloNIDine': 'Not available',\n 'Clopidogrel': 'Not available',\n 'Clorazepate': 'Not available',\n 'Clotrimazole (Oral)': 'Not available',\n 'Clotrimazole (refer to route-specific monograph)': 'Not available',\n 'Clotrimazole (Topical)': 'Not available',\n 'Cloxacillin': 'Not available',\n 'CloZAPine': 'Not available',\n 'CMF Oral (Breast)': 'Not available',\n 'CMV (Bladder)': 'Not available',\n 'Coal Tar and Salicylic Acid': 'Not available',\n 'Coal Tar': 'Not available',\n 'Cobicistat': 'Not available',\n 'Cobimetinib-Vemurafenib (Melanoma)': 'Not available',\n 'Cobimetinib': 'Not available',\n 'Cocaine (Topical)': 'Not available',\n 'Coccidioides immitis Skin Test': 'Not available',\n 'Codeine and Chlorpheniramine': 'Not available',\n 'Codeine, Phenylephrine, and Triprolidine': 'Not available',\n 'Codeine': 'Not available',\n 'CODOX-M (NHL-Burkitt)': 'Not available',\n 'CODOX-MIVAC (NHL-Burkitt)': 'Not available',\n 'Colchicine and Probenecid': 'Not available',\n 'Colchicine': 'Not available',\n 'Colesevelam': 'Not available',\n 'Colestipol': 'Not available',\n 'Colistimethate': 'Not available',\n 'Collagen (AbsorbableDental)': 'Not available',\n 'Collagen Hemostat': 'Not available',\n 'Collagenase (refer to route-specific monograph)': 'Not available',\n 'Collagenase (Systemic)': 'Not available',\n 'Collagenase (Topical)': 'Not available',\n 'Conivaptan': 'Not available',\n 'Continuous Renal Replacement Therapy Solutions': 'Not available',\n 'Copanlisib': 'Not available',\n 'Copper Cu 64 Dotatate': 'Not available',\n 'Copper IUD': 'Not available',\n 'Copper': 'Not available',\n 'Corticorelin': 'Not available',\n 'Corticotropin': 'Not available',\n 'Cortisone': 'Not available',\n 'Cosyntropin': 'Not available',\n 'COVID-19 Vaccine (Adenovirus Vector)': 'Not available',\n 'COVID-19 Vaccine (mRNA)': 'Not available',\n 'COVID-19 Vaccine (Subunit)': 'Not available',\n 'COVID-19 Vaccine (Virus-like Particles)': 'Not available',\n 'Crisaborole': 'Not available',\n 'Crizanlizumab': 'Not available',\n 'Crizotinib': 'Not available',\n 'Crofelemer': 'Not available',\n 'Cromolyn (Nasal)': 'Not available',\n 'Cromolyn (Ophthalmic)': 'Not available',\n 'Cromolyn (Oral Inhalation)': 'Not available',\n 'Cromolyn (refer to route-specific monograph)': 'Not available',\n 'Cromolyn (Systemic)': 'Not available',\n \"Crotalidae Immune F(ab')2 (Equine)\": 'Not available',\n 'Crotalidae Polyvalent Immune FAB (Ovine)': 'Not available',\n 'Crotamiton': 'Not available',\n 'Cyanocobalamin': 'Not available',\n 'Cyclobenzaprine': 'Not available',\n 'Cyclopentolate and Phenylephrine': 'Not available',\n 'Cyclopentolate': 'Not available',\n 'Cyclophosphamide-Bortezomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Cyclophosphamide-Epirubicin (Breast)': 'Not available',\n 'Cyclophosphamide-Topotecan (Ewing Sarcoma)': 'Not available',\n 'Cyclophosphamide-Topotecan (Rhabdomyosarcoma)': 'Not available',\n 'CycloPHOSphamide': 'Not available',\n 'CycloSERINE': 'Not available',\n 'CycloSPORINE (Ophthalmic)': 'Not available',\n 'CycloSPORINE (refer to route-specific monograph)': 'Not available',\n 'CycloSPORINE (Systemic)': 'Not available',\n 'Cyproheptadine': 'Not available',\n 'Cyproterone and Ethinyl Estradiol': 'Not available',\n 'Cyproterone': 'Not available',\n 'Cysteamine (Ophthalmic)': 'Not available',\n 'Cysteamine (refer to route-specific monograph)': 'Not available',\n 'Cysteamine (Systemic)': 'Not available',\n 'Cysteine': 'Not available',\n 'Cytarabine (Conventional)': 'Not available',\n 'Cytarabine (High Dose)-Daunorubicin (AML Induction)': 'Not available',\n 'Cytarabine (High Dose)-Daunorubicin-Etoposide (AML Induction)': 'Not available',\n 'Cytarabine (High-Dose Single-Agent AML Induction Regimen)': 'Not available',\n 'Cytarabine (Liposomal)': 'Not available',\n 'Cytarabine (Single-Agent AML Consolidation Regimen)': 'Not available',\n 'Cytarabine (SUBQ Single-Agent AML Induction Regimen)': 'Not available',\n 'Cytomegalovirus Immune Globulin (Intravenous-Human)': 'Not available',\n 'Dabigatran Etexilate': 'Not available',\n 'Dabrafenib-Trametinib (Melanoma)': 'Not available',\n 'Dabrafenib-Trametinib (NSCLC)': 'Not available',\n 'Dabrafenib': 'Not available',\n 'Dacarbazine': 'Not available',\n 'Daclatasvir': 'Not available',\n 'Dacomitinib': 'Not available',\n 'DACTINomycin': 'Not available',\n 'Dalbavancin': 'Not available',\n 'Dalfampridine': 'Not available',\n 'Dalteparin': 'Not available',\n 'Danaparoid': 'Not available',\n 'Danazol': 'Not available',\n 'Dantrolene': 'Not available',\n 'Dapagliflozin and Metformin': 'Not available',\n 'Dapagliflozin and Saxagliptin': 'Not available',\n 'Dapagliflozin': 'Not available',\n 'Daprodustat': 'Not available',\n 'Dapsone (refer to route-specific monograph)': 'Not available',\n 'Dapsone (Systemic)': 'Not available',\n 'Dapsone (Topical)': 'Not available',\n 'DAPTOmycin': 'Not available',\n 'Daratumumab and Hyaluronidase': 'Not available',\n 'Daratumumab-Bortezomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Bortezomib-Melphalan-Prednisone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Bortezomib-Thalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Lenalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Pomalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab': 'Not available',\n 'Darbepoetin Alfa': 'Not available',\n 'Daridorexant': 'Not available',\n 'Darifenacin': 'Not available',\n 'Darolutamide': 'Not available',\n 'Darunavir and Cobicistat': 'Not available',\n 'Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide': 'Not available',\n 'Darunavir': 'Not available',\n 'Dasatinib': 'Not available',\n 'Dasiglucagon': 'Not available',\n 'DAUNOrubicin (Conventional)': 'Not available',\n 'DAUNOrubicin (Liposomal)': 'Not available',\n 'Daunorubicin and Cytarabine (Liposomal)': 'Not available',\n 'DaxibotulinumtoxinA': 'Not available',\n 'Decitabine and Cedazuridine': 'Not available',\n 'Decitabine': 'Not available',\n 'Deferasirox': 'Not available',\n 'Deferiprone': 'Not available',\n 'Deferoxamine': 'Not available',\n 'Defibrotide': 'Not available',\n 'Deflazacort': 'Not available',\n 'Degarelix': 'Not available',\n 'Delafloxacin': 'Not available',\n 'Delavirdine': 'Not available',\n 'Demeclocycline': 'Not available',\n 'Dengue Tetravalent Vaccine (Live)': 'Not available',\n 'Denosumab': 'Not available',\n 'Deoxycholic Acid': 'Not available',\n 'Dequalinium': 'Not available',\n 'Desflurane': 'Not available',\n 'Desipramine': 'Not available',\n 'Desirudin': 'Not available',\n 'Desloratadine and Pseudoephedrine': 'Not available',\n 'Desloratadine': 'Not available',\n 'Desmopressin': 'Not available',\n 'Desonide': 'Not available',\n 'Desoximetasone': 'Not available',\n 'Desvenlafaxine': 'Not available',\n 'Deucravacitinib': 'Not available',\n 'Deutetrabenazine': 'Not available',\n 'DexAMETHasone (Ophthalmic)': 'Not available',\n 'DexAMETHasone (refer to route-specific monograph)': 'Not available',\n 'DexAMETHasone (Systemic)': 'Not available',\n 'Dexbrompheniramine and Phenylephrine': 'Not available',\n 'Dexchlorpheniramine and Pseudoephedrine': 'Not available',\n 'Dexchlorpheniramine, Dextromethorphan, and Phenylephrine': 'Not available',\n 'Dexchlorpheniramine': 'Not available',\n 'Dexlansoprazole': 'Not available',\n 'DexmedeTOMIDine': 'Not available',\n 'Dexmethylphenidate': 'Not available',\n 'Dexrazoxane': 'Not available',\n 'Dextran': 'Not available',\n 'Dextranomer and Hyaluronate Derivatives': 'Not available',\n 'Dextroamphetamine and Amphetamine': 'Not available',\n 'Dextroamphetamine': 'Not available',\n 'Dextromethorphan and Bupropion': 'Not available',\n 'Dextromethorphan and Chlorpheniramine': 'Not available',\n 'Dextromethorphan and Menthol': 'Not available',\n 'Dextromethorphan and Phenylephrine': 'Not available',\n 'Dextromethorphan and Pyrilamine': 'Not available',\n 'Dextromethorphan and Quinidine': 'Not available',\n 'Dextromethorphan': 'Not available',\n 'Dextrose 25% and Sodium Chloride 10%': 'Not available',\n \"Dextrose and Ringer's Injection (Lactated)\": 'Not available',\n 'Dextrose and Sodium Chloride': 'Not available',\n 'Dextrose': 'Not available',\n 'DHAP (Hodgkin)': 'Not available',\n 'DHAP (NHL-DLBCL)': 'Not available',\n 'Diamorphine': 'Not available',\n 'Diatrizoate Meglumine and Diatrizoate Sodium': 'Not available',\n 'Diatrizoate Meglumine': 'Not available',\n 'DiazePAM': 'Not available',\n 'Diazoxide': 'Not available',\n 'Dibekacin [INT]': 'Not available',\n 'Dibucaine': 'Not available',\n 'Dichlorphenamide': 'Not available',\n 'Diclofenac (Ophthalmic)': 'Not available',\n 'Diclofenac (refer to route-specific monograph)': 'Not available',\n 'Diclofenac (Systemic)': 'Not available',\n 'Diclofenac (Topical)': 'Not available',\n 'Diclofenac and Misoprostol': 'Not available',\n 'Dicloxacillin': 'Not available',\n 'Dicyclomine': 'Not available',\n ...}"
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drug_inter_manage"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:46:59.417203300Z",
     "start_time": "2023-08-28T13:46:59.376040Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "outputs": [
    {
     "data": {
      "text/plain": "{'5 + 2 (Cytarabine-Daunorubicin) (AML Induction)': 'Not available',\n '5 + 2 (Cytarabine-Daunorubicin) (AML Postremission)': 'Not available',\n '5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)': 'Not available',\n '5 + 2 (Cytarabine-Mitoxantrone) (AML Consolidation)': 'Not available',\n '5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) (AML Consolidation)': 'Not available',\n '7 + 3 (Cytarabine-Daunorubicin) (AML Induction)': 'Not available',\n '7 + 3 (Cytarabine-Idarubicin) (AML Induction)': 'Not available',\n '7 + 3 (Cytarabine-Mitoxantrone) (AML Induction)': 'Not available',\n '7 + 3 + 7 (Cytarabine-Daunorubicin-Etoposide) (AML Induction)': 'Not available',\n 'A-AVD (Hodgkin)': 'Not available',\n 'Abacavir and Lamivudine': 'Not available',\n 'Abacavir, Dolutegravir, and Lamivudine': 'Not available',\n 'Abacavir, Lamivudine, and Zidovudine': 'Not available',\n 'Abacavir': 'Not available',\n 'Abaloparatide': 'Not available',\n 'Abatacept': {'Dehydrogenase pyrroloquinolinequinone testing method': 'falsely elevated blood glucose levels',\n  'Glucose-dye-oxidoreductase testing method': 'falsely elevated blood glucose levels'},\n 'Abciximab': 'Not available',\n 'Abemaciclib-Fulvestrant (Breast)': 'Not available',\n 'Abemaciclib': 'Not available',\n 'Abiraterone Acetate': 'Not available',\n 'Abiraterone-Methylprednisolone (Prostate)': 'Not available',\n 'Abiraterone-Prednisone (Prostate)': 'Not available',\n 'AbobotulinumtoxinA': 'Not available',\n 'Abrocitinib': 'Not available',\n 'ABV Hybrid (Hodgkin)': 'Not available',\n 'ABVD (Hodgkin)': 'Not available',\n 'ABVD Early Stage (Hodgkin)': 'Not available',\n 'AC (Breast)': 'Not available',\n 'AC (Dose-Dense) followed by Paclitaxel (Dose-Dense) (Breast)': 'Not available',\n 'AC (Dose-Dense) followed by Paclitaxel (Dose-Dense)-Trastuzumab (Breast)': 'Not available',\n 'AC (Dose-Dense) followed by Paclitaxel Weekly (Breast)': 'Not available',\n 'AC followed by Docetaxel Every 3 Weeks (Breast)': 'Not available',\n 'AC followed by Paclitaxel Weekly (Breast)': 'Not available',\n 'AC followed by Paclitaxel-Trastuzumab (Breast)': 'Not available',\n 'Acalabrutinib-Obinutuzumab (CLL)': 'Not available',\n 'Acalabrutinib': 'Not available',\n 'Acamprosate': 'Not available',\n 'Acarbose': 'Not available',\n 'Acebutolol': {'Aldosterone / renin ratio (ARR)': 'false-positive'},\n 'Acenocoumarol': 'Not available',\n 'Acetaminophen and Caffeine': 'See individual agents',\n 'Acetaminophen and Codeine': 'See individual agents',\n 'Acetaminophen and Diphenhydramine': 'See individual agents',\n 'Acetaminophen and Methocarbamol': 'See individual agents',\n 'Acetaminophen and Pamabrom': 'See individual agents',\n 'Acetaminophen and Phenylephrine': 'See individual agents',\n 'Acetaminophen and Phenyltoloxamine': {'Urinary 5-hydroxyindoleacetic acid': 'false-positive'},\n 'Acetaminophen and Pseudoephedrine': 'See individual agents',\n 'Acetaminophen and Tramadol': 'See individual agents',\n 'Acetaminophen, Aspirin, and Caffeine': 'See individual agents',\n 'Acetaminophen, Caffeine, and Codeine': 'See individual agents',\n 'Acetaminophen, Caffeine, and Dihydrocodeine': 'See individual agents',\n 'Acetaminophen, Caffeine, and Pyrilamine': 'Not available',\n 'Acetaminophen, Codeine, and Doxylamine': 'See individual agents',\n 'Acetaminophen, Dextromethorphan, and Doxylamine': 'See individual agents',\n 'Acetaminophen, Dextromethorphan, and Phenylephrine': 'See individual agents',\n 'Acetaminophen, Diphenhydramine, and Phenylephrine': 'See individual agents',\n 'Acetaminophen, Guaifenesin, and Phenylephrine': 'Not available',\n 'Acetaminophen, Isometheptene, and Dichloralphenazone': {'urine glucose': 'false',\n  'urine catecholamine': 'false',\n  'urinary 5-hydroxyindoleacetic acid': 'false'},\n 'Acetaminophen': {'urinary 5-hydroxyindoleacetic acid': 'false-positive'},\n 'AcetaZOLAMIDE': {'urinary protein with Albustix': 'false-positive',\n  'urinary protein with Labstix': 'false-positive',\n  'urinary protein with Albutest': 'false-positive',\n  'urinary protein with Bumintest': 'false-positive',\n  'HPLC theophylline assay': 'interference',\n  'serum uric acid levels': 'interference',\n  'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Acetic Acid (Otic)': 'Not available',\n 'Acetic Acid (refer to route-specific monograph)': 'Not available',\n 'Acetic Acid (Topical)': 'Not available',\n 'Acetic Acid and Hydrocortisone': 'Not available',\n 'Acetohydroxamic Acid': 'Not available',\n 'Acetone': 'Not available',\n 'Acetylcholine': 'Not available',\n 'Acetylcysteine': 'Not available',\n 'Acitretin': 'Not available',\n 'Aclidinium and Formoterol': 'Not available',\n 'Aclidinium': 'Not available',\n 'Acrivastine and Pseudoephedrine': {'amphetamines': 'false-positive'},\n 'Acyclovir (Ophthalmic)': 'Not available',\n 'Acyclovir (refer to route-specific monograph)': 'Not available',\n 'Acyclovir (Systemic)': 'Not available',\n 'Acyclovir (Topical)': 'Not available',\n 'Acyclovir and Hydrocortisone': 'Not available',\n 'AD (Soft Tissue Sarcoma)': 'Not available',\n 'Adagrasib': 'Not available',\n 'Adalimumab': 'Not available',\n 'Adapalene and Benzoyl Peroxide': 'Not available',\n 'Adapalene': 'Not available',\n 'Adefovir': 'Not available',\n 'Adenosine': 'Not available',\n 'Adenovirus (Types 4, 7) Vaccine': 'Not available',\n 'Ado-Trastuzumab Emtansine': 'Not available',\n 'Aducanumab': 'Not available',\n 'Afamelanotide': 'Not available',\n 'Afatinib': 'Not available',\n 'Aflibercept (Ophthalmic)': 'Not available',\n 'Aflibercept (refer to route-specific monograph)': 'Not available',\n 'Agalsidase Alfa': 'Not available',\n 'Agalsidase Beta': 'Not available',\n 'AIM (Soft Tissue Sarcoma)': 'Not available',\n 'Air Polymer-Type A': 'Not available',\n 'Albendazole': 'Not available',\n 'Albiglutide': 'Not available',\n 'Albumin': 'Not available',\n 'Albuterol and Budesonide': {'Renin': 'increased in serum',\n  'Aldosterone': 'increased in serum'},\n 'Albuterol': {'Renin': 'increased in serum',\n  'Aldosterone': 'increased in serum'},\n 'Alcaftadine': 'Not available',\n 'Alclometasone': 'Not available',\n 'Alcohol (Ethyl)': 'Not available',\n 'Alcohol (Isopropyl)': 'Not available',\n 'Aldesleukin': 'Not available',\n 'Alectinib': 'Not available',\n 'Alemtuzumab': {'diagnostic serum tests that utilize antibodies': 'May interfere'},\n 'Alendronate and Cholecalciferol': {'bisphosphonates': 'May interfere',\n  'diagnostic imaging agents such as technetium-99m-diphosphonate in bone scans': 'May interfere'},\n 'Alendronate': {'bisphosphonates': 'May interfere',\n  'diagnostic imaging agents such as technetium-99m-diphosphonate in bone scans': 'May interfere'},\n 'Alfacalcidol': 'Not available',\n 'ALfentanil': 'Not available',\n 'Alfuzosin': 'Not available',\n 'Alglucosidase Alfa': 'Not available',\n 'Alirocumab': 'Not available',\n 'Aliskiren and Hydrochlorothiazide': 'See individual agents',\n 'Aliskiren': {'aldosterone/renin ratio (ARR)': 'false-positive or false-negative'},\n 'Alitretinoin (refer to route-specific monograph)': 'Not available',\n 'Alitretinoin (Systemic)': 'Not available',\n 'Alitretinoin (Topical)': 'Not available',\n 'Allopurinol': 'Not available',\n 'Almotriptan': 'Not available',\n 'Alogliptin and Metformin': 'Not available',\n 'Alogliptin and Pioglitazone': 'Not available',\n 'Alogliptin': 'Not available',\n 'Alosetron': 'Not available',\n 'Alpelisib-Fulvestrant (Breast)': 'Not available',\n 'Alpelisib': 'Not available',\n 'Alpha-Galactosidase': 'Not available',\n 'Alpha1-Proteinase Inhibitor': 'Not available',\n 'ALPRAZolam': 'Not available',\n 'Alprostadil': 'Not available',\n 'Alteplase': {'coagulation and fibrinolytic activity tests': 'altered results'},\n 'Altretamine': 'Not available',\n 'Alum Irrigation': 'Not available',\n 'Aluminum Acetate': 'Not available',\n 'Aluminum Chloride Hexahydrate': 'Not available',\n 'Aluminum Chloride': 'Not available',\n 'Aluminum Hydroxide and Magnesium Carbonate': 'Not available',\n 'Aluminum Hydroxide and Magnesium Hydroxide': 'Not available',\n 'Aluminum Hydroxide and Magnesium Trisilicate': 'Not available',\n 'Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone': 'Not available',\n 'Aluminum Hydroxide': 'Not available',\n 'Alvimopan': 'Not available',\n 'Amantadine': {'urine detection of amphetamines/methamphetamines': '(false-positive) interference'},\n 'Ambrisentan': 'Not available',\n 'Amcinonide': 'Not available',\n 'Amifampridine': 'Not available',\n 'Amifostine': 'Not available',\n 'Amikacin (refer to route-specific monograph)': 'Not available',\n 'Amikacin (Systemic)': {'Aminoglycoside serum concentration': 'potential underestimation caused by some penicillin derivatives accelerating aminoglycoside degradation in vitro'},\n 'Amikacin Liposome (Oral Inhalation)': 'Not available',\n 'Amiloride and Hydrochlorothiazide': {'Parathyroid function tests': 'Interference',\n  'Serum iodine (protein bound) test': 'Decreased without signs of thyroid disturbance'},\n 'AMILoride': {'Aldosterone/Renin Ratio (ARR)': 'False-negative'},\n 'Amino Acid Injection': 'Not available',\n 'Aminocaproic Acid': 'Not available',\n 'Aminolevulinic Acid (refer to route-specific monograph)': 'Not available',\n 'Aminolevulinic Acid (Systemic)': 'Not available',\n 'Aminolevulinic Acid (Topical)': 'Not available',\n 'Aminophylline': {'Plasma glucose': 'increased',\n  'Uric acid': 'increased',\n  'Free fatty acids': 'increased',\n  'Total cholesterol': 'increased',\n  'HDL': 'increased',\n  'HDL/LDL ratio': 'increased',\n  'Urinary free cortisol excretion': 'increased',\n  'Triiodothyronine': 'decreased'},\n 'Aminosalicylic Acid': 'Not available',\n 'Amiodarone': {'T4 levels': 'elevated',\n  'Thyroid stimulating hormone levels': 'high end of normal range',\n  'T3 levels': 'low end of normal range'},\n 'Amisulpride (Injection)': 'Not available',\n 'Amitriptyline and Chlordiazepoxide': 'Not available',\n 'Amitriptyline and Perphenazine': {'Pregnancy test': 'false-positive'},\n 'Amitriptyline': 'Not available',\n 'Amivantamab': 'Not available',\n 'Amlodipine and Atorvastatin': 'Not available',\n 'Amlodipine and Benazepril': 'See individual agents',\n 'Amlodipine and Celecoxib': 'See individual agents',\n 'Amlodipine and Olmesartan': 'Not available',\n 'Amlodipine and Valsartan': 'Not available',\n 'Amlodipine, Valsartan, and Hydrochlorothiazide': 'See individual agents',\n 'AmLODIPine': {'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Ammonia Spirit (Aromatic)': 'Not available',\n 'Amobarbital': 'Not available',\n 'Amorolfine [INT]': 'Not available',\n 'Amoxapine': 'Not available',\n 'Amoxicillin and Clavulanate': {\"glucose tests using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'interference',\n  'total conjugated estriol': 'transiently interfered',\n  'estriol-glucuronide': 'transiently interfered',\n  'conjugated estrone': 'transiently interfered',\n  'estradiol': 'transiently interfered'},\n 'Amoxicillin': {\"glucose tests (Benedict's solution, Clinitest, Fehling's Solution)\": 'interference',\n  'aminoglycoside serum concentration': 'underestimation'},\n 'Amphetamine': {'Plasma corticosteroid levels': 'elevated by amphetamines',\n  'Urinary steroid determinations': 'interference by amphetamines'},\n 'Amphotericin B (Lipid Complex)': 'Not available',\n 'Amphotericin B (Liposomal)': {'serum phosphate': 'falsely-elevated'},\n 'Amphotericin B Deoxycholate': 'Not available',\n 'Ampicillin and Sulbactam': {\"urinary glucose tests using cupric sulfate (Benedict's solution, Fehling’s solution, or Clinitest®)\": 'interference',\n  'aminoglycoside serum concentration': 'underestimation'},\n 'Ampicillin': {\"Urinary glucose tests using cupric sulfate (Benedict's solution, Clinitest)\": 'may interfere',\n  'Aminoglycoside serum concentration': 'potential underestimation'},\n 'Amsacrine': 'Not available',\n 'Amyl Nitrite': 'Not available',\n 'Anacaulase': 'Not available',\n 'Anagrelide': 'Not available',\n 'Anakinra': 'Not available',\n 'Anastrozole': 'Not available',\n 'Andexanet Alfa (Coagulation Factor Xa [Recombinant], Inactivated)': {'Anti-FXa activity assay': 'falsely elevated'},\n 'Angiotensin II': 'Not available',\n 'Anidulafungin': 'Not available',\n 'Anifrolumab': 'Not available',\n 'Ansuvimab': 'Not available',\n 'Anthralin': 'Not available',\n 'Anthrax Immune Globulin (Human)': {'Glucose monitoring devices and test strips utilizing the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase based methods': 'falsely elevated blood glucose levels',\n  'Urinalysis after anthrax immune globulin administration': 'transiently elevated glucose',\n  'Passively transferred antibodies': 'false-positive serologic testing results, false-positive direct and indirect Coombs’ test'},\n 'Anthrax Vaccine Adsorbed': 'Not available',\n 'Anti-inhibitor Coagulant Complex (Human)': {'blood group isohemagglutinins': 'may interfere with serological tests for red cell antibodies (eg, Coombs test)'},\n 'Anticoagulant Citrate Dextrose': 'Not available',\n 'Anticoagulant Sodium Citrate': 'Not available',\n 'Antihemophilic Factor (Human)': 'Not available',\n 'Antihemophilic Factor (Recombinant [Fc Fusion Protein])': 'Not available',\n 'Antihemophilic Factor (Recombinant [Fc-VWF-XTEN Fusion Protein])': 'Not available',\n 'Antihemophilic Factor (Recombinant [Pegylated])': 'Not available',\n 'Antihemophilic Factor (Recombinant [Porcine Sequence])': 'Not available',\n 'Antihemophilic Factor (Recombinant)': 'Not available',\n 'Antihemophilic Factorvon Willebrand Factor Complex (Human)': 'Not available',\n 'Antithrombin': 'Not available',\n 'Antithymocyte Globulin (Equine)': 'Not available',\n 'Antithymocyte Globulin (Rabbit)': {'rabbit antibody-based immunoassays': 'Potential interference',\n  'cross-match or panel-reactive antibody cytotoxicity assays': 'Potential interference',\n  'routine clinical laboratory tests which do not use immunoglobulins': 'Has not been shown to interfere'},\n 'Antivenin (Latrodectus mactans)': 'Not available',\n 'Antivenin (Micrurus fulvius)': 'Not available',\n 'Apalutamide': 'Not available',\n 'Apixaban': {'anti-Factor Xa assays': 'falsely elevated results and leading to inappropriate heparin dose reduction',\n  'aPTT': 'little or minor effect'},\n 'Apomorphine': 'Not available',\n 'Apraclonidine': 'Not available',\n 'Apremilast': 'Not available',\n 'Aprepitant': 'Not available',\n 'Arformoterol': 'Not available',\n 'Argatroban': {'PT/INR levels': 'elevated',\n  'chromogenic factor X assay': 'monitored',\n  'Factor Xa levels': '<45%'},\n 'Arginine': 'Not available',\n 'ARIPiprazole Lauroxil': 'Not available',\n 'ARIPiprazole': 'Not available',\n 'Armodafinil': 'Not available',\n 'Arsenic Trioxide': 'Not available',\n 'Artemether and Lumefantrine': 'Not available',\n 'Artesunate': 'Not available',\n 'Articaine and Epinephrine': 'Not available',\n 'Artichoke': 'Not available',\n 'Artificial Tears': 'Not available',\n 'Asciminib': 'Not available',\n 'Ascorbic Acid': {'stool occult blood': 'false-negative',\n  'glucose testing': 'falsely elevated',\n  'nitrite and bilirubin levels': 'interfered',\n  'leucocyte count': 'interfered'},\n 'Asenapine': 'Not available',\n 'Asfotase Alfa': {'ALP-conjugated test systems': 'interfered'},\n 'Asparaginase (Erwinia [Recombinant])': 'Not available',\n 'Asparaginase (Erwinia)': 'Not available',\n 'Aspirin and Dipyridamole': 'See individual agents',\n 'Aspirin and Omeprazole': 'Not available',\n 'Aspirin, Citric Acid, and Sodium Bicarbonate': 'Not available',\n 'Aspirin': {'Glucose oxidase urinary glucose tests (Clinistix)': 'False-negative',\n  'cupric sulfate method (Clinitest)': 'false-positives',\n  'Gerhardt test': 'interferes',\n  'VMA determination': 'interferes',\n  '5-HIAA': 'interferes',\n  'xylose tolerance test': 'interferes',\n  'T3': 'interferes',\n  'T4': 'interferes',\n  'aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Atazanavir and Cobicistat': 'See individual agents',\n 'Atazanavir': 'Not available',\n 'Atenolol and Chlorthalidone': 'Not available',\n 'Atenolol': {'glucose': 'Increased',\n  'HDL': 'decreased',\n  'aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Atezolizumab-Bevacizumab (Hepatocellular)': 'Not available',\n 'Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Atezolizumab-Carboplatin-Etoposide (Small Cell Lung Cancer)': 'Not available',\n 'Atezolizumab-Carboplatin-Paclitaxel (Protein Bound) (NSCLC)': 'Not available',\n 'Atezolizumab-Cobimetinib-Vemurafenib (Melanoma)': 'Not available',\n 'Atezolizumab': 'Not available',\n 'Atogepant': 'Not available',\n 'Atoltivimab, Maftivimab, and Odesivimab': 'Not available',\n 'Atomoxetine': 'Not available',\n 'Atorvastatin': 'Not available',\n 'Atovaquone and Proguanil': 'Not available',\n 'Atovaquone': 'Not available',\n 'Atracurium': 'Not available',\n 'Atropine (Ophthalmic)': 'Not available',\n 'Atropine (refer to route-specific monograph)': 'Not available',\n 'Atropine (Systemic)': 'Not available',\n 'Atropine and Pralidoxime': 'Not available',\n 'Auranofin': 'Not available',\n 'Avacopan': 'Not available',\n 'Avalglucosidase Alfa': 'Not available',\n 'Avanafil': 'Not available',\n 'Avapritinib': 'Not available',\n 'Avatrombopag': 'Not available',\n 'Avelumab-Axitinib (RCC)': 'Not available',\n 'Avelumab': 'Not available',\n 'Avocado': 'Not available',\n 'Axicabtagene Ciloleucel': 'Not available',\n 'Axitinib': 'Not available',\n 'AzaCITIDine': 'Not available',\n 'AzaTHIOprine': {'TPMT phenotyping': 'may not be accurate'},\n 'Azelaic Acid': 'Not available',\n 'Azelastine (Nasal)': 'Not available',\n 'Azelastine (Ophthalmic)': 'Not available',\n 'Azelastine (refer to route-specific monograph)': 'Not available',\n 'Azelastine and Fluticasone': 'Not available',\n 'Azilsartan and Chlorthalidone': 'Not available',\n 'Azilsartan': {'aldosterone/renin ratio (ARR)': 'May lead to false-negative'},\n 'Azithromycin (Ophthalmic)': 'Not available',\n 'Azithromycin (refer to route-specific monograph)': 'Not available',\n 'Azithromycin (Systemic)': 'Not available',\n 'Aztreonam (Oral Inhalation)': 'Not available',\n 'Aztreonam (refer to route-specific monograph)': 'Not available',\n 'Aztreonam (Systemic)': {\"urine glucose tests containing cupric sulfate (Benedict's solution, Clinitest)\": 'May interfere',\n  \"Coombs' test\": 'positive'},\n 'Bacitracin (Ophthalmic)': 'Not available',\n 'Bacitracin (refer to route-specific monograph)': 'Not available',\n 'Bacitracin (Systemic)': 'Not available',\n 'Bacitracin (Topical)': 'Not available',\n 'Bacitracin and Polymyxin B (Ophthalmic)': 'Not available',\n 'Bacitracin and Polymyxin B (refer to route-specific monograph)': 'Not available',\n 'Bacitracin and Polymyxin B (Topical)': 'Not available',\n 'Bacitracin, Neomycin, and Polymyxin B (Ophthalmic)': 'Not available',\n 'Bacitracin, Neomycin, and Polymyxin B (refer to route-specific monograph)': 'Not available',\n 'Bacitracin, Neomycin, and Polymyxin B (Topical)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Ophthalmic)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (refer to route-specific monograph)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Topical)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Pramoxine': 'Not available',\n 'Baclofen': 'Not available',\n 'Balanced Salt Solution': 'Not available',\n 'Baloxavir Marboxil': 'Not available',\n 'Balsalazide': {'Urinary normetanephrine levels': \"falsely elevated when measured by liquid chromatography with electrochemical detection because of similarity in chromatograms of normetanephrine and mesalamine's main metabolite\"},\n 'Balsam Peru and Castor Oil': 'Not available',\n 'Bamlanivimab and Etesevimab': 'Not available',\n 'Bamlanivimab': 'Not available',\n 'Baricitinib': 'Not available',\n 'Barium': 'Not available',\n 'Basiliximab': 'Not available',\n 'BCG (Intravesical)': {'tuberculin reactivity': 'positive'},\n 'BCG (refer to route-specific monograph)': 'Not available',\n 'BCG Vaccine (Immunization)': {'tuberculin skin test': 'positive/reactive',\n  'active tuberculosis': 'rule out',\n  'PPD reaction': '<5 mm induration',\n  'interferon-gamma release assay (IGRA)': 'acceptable'},\n 'BEACOPP Escalated (Hodgkin)': 'Not available',\n 'BEACOPP Escalated Plus Standard (Hodgkin)': 'Not available',\n 'BEACOPP Standard (Hodgkin)': 'Not available',\n 'BEACOPP-14 (Hodgkin)': 'Not available',\n 'Bebtelovimab': 'Not available',\n 'Becaplermin': 'Not available',\n 'Beclomethasone (Nasal)': 'Not available',\n 'Beclomethasone (Oral Inhalation)': 'Not available',\n 'Beclomethasone (refer to route-specific monograph)': 'Not available',\n 'Beclomethasone (Topical)': 'Not available',\n 'Bedaquiline': 'Not available',\n 'Belantamab Mafodotin': 'Not available',\n 'Belatacept': 'Not available',\n 'Belimumab': 'Not available',\n 'Belinostat': 'Not available',\n 'Belladonna and Opium': 'Not available',\n 'Belumosudil': 'Not available',\n 'Belzutifan': 'Not available',\n 'Bempedoic Acid and Ezetimibe': 'Not available',\n 'Bempedoic Acid': 'Not available',\n 'Benazepril and Hydrochlorothiazide': 'See individual agents',\n 'Benazepril': {'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Bendamustine-Bortezomib-Rituximab (NHL-Follicular)': 'Not available',\n 'Bendamustine-Lenalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bendamustine-Obinutuzumab (NHL-Follicular)': 'Not available',\n 'Bendamustine-Rituximab (CLL)': 'Not available',\n 'Bendamustine-Rituximab (NHL-Follicular)': 'Not available',\n 'Bendamustine-Rituximab (NHL-Mantle Cell)': 'Not available',\n 'Bendamustine-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Bendamustine': 'Not available',\n 'Benralizumab': 'Not available',\n 'Benserazide and Levodopa': {'Catecholamines testing': 'affected by Levodopa',\n  'Creatinine testing': 'affected by Levodopa',\n  'Uric acid testing': 'affected by Levodopa',\n  'Glucose testing': 'affected by Levodopa',\n  'Urine test for ketone bodies': 'false positive due to Levodopa'},\n 'Bentoquatam': 'Not available',\n 'Benzalkonium Chloride and Benzocaine': 'Not available',\n 'Benzhydrocodone and Acetaminophen': 'Not available',\n 'Benznidazole': 'Not available',\n 'Benzocaine and Docusate': 'Not available',\n 'Benzocaine, Butamben, and Tetracaine': 'Not available',\n 'Benzocaine': 'Not available',\n 'Benzoin': 'Not available',\n 'Benzonatate': 'Not available',\n 'Benzoyl Peroxide and Hydrocortisone': 'Not available',\n 'Benzoyl Peroxide': 'Not available',\n 'Benzphetamine': 'Not available',\n 'Benztropine': 'Not available',\n 'Benzydamine': 'Not available',\n 'Benzyl Alcohol': 'Not available',\n 'Benzylpenicilloyl Polylysine': 'Not available',\n 'BEP (Ovarian)': 'Not available',\n 'BEP (Testicular)': 'Not available',\n 'Bepotastine': 'Not available',\n 'Beractant': 'Not available',\n 'Berotralstat': 'Not available',\n 'Besifloxacin': 'Not available',\n 'Beta-Carotene': 'Not available',\n 'Betahistine': 'Not available',\n 'Betaine': 'Not available',\n 'Betamethasone (refer to route-specific monograph)': 'Not available',\n 'Betamethasone (Systemic)': {'skin test antigens': 'wheal and flare reactions suppressed'},\n 'Betamethasone (Topical)': {'wheal and flare reactions to skin test antigens': 'may suppress'},\n 'Betamethasone and Clotrimazole': 'See individual agents',\n 'Betamethasone and Gentamicin': 'Not available',\n 'Betamethasone and Salicylic Acid': 'Not available',\n 'Betaxolol (Ophthalmic)': 'Not available',\n 'Betaxolol (refer to route-specific monograph)': 'Not available',\n 'Betaxolol (Systemic)': {'Glaucoma screening tests': 'interference by oral betaxolol',\n  'Aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Bethanechol': 'Not available',\n 'Betibeglogene Autotemcel': {'polymerase chain reaction assays': 'positive for HIV due to integrated BB305 LVV proviral DNA, resulting in a false-positive test for HIV',\n  'PCR-based assay': 'should not be used for screening HIV infection'},\n 'Bevacizumab + FOLFIRI (Colorectal)': 'Not available',\n 'Bevacizumab + XELOX (Colorectal)': 'Not available',\n 'Bevacizumab FOLFOX (Colorectal)': 'Not available',\n 'Bevacizumab-Carboplatin-Doxorubicin (Liposomal) (Ovarian)': 'Not available',\n 'Bevacizumab-Carboplatin-Gemcitabine (Ovarian)': 'Not available',\n 'Bevacizumab-Carboplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Bevacizumab-Carboplatin-Paclitaxel (Ovarian)': 'Not available',\n 'Bevacizumab-Carboplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Bevacizumab-Cisplatin-Paclitaxel (Cervical)': 'Not available',\n 'Bevacizumab-Cisplatin-Pemetrexed (Mesothelioma)': 'Not available',\n 'Bevacizumab-Cisplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Bevacizumab-Doxorubicin (Liposomal) (Ovarian)': 'Not available',\n 'Bevacizumab-Fluorouracil-Leucovorin (Colorectal)': 'Not available',\n 'Bevacizumab-Irinotecan (Glioblastoma)': 'Not available',\n 'Bevacizumab-Lomustine (Glioblastoma)': 'Not available',\n 'Bevacizumab-Lonsurf (Colorectal)': 'Not available',\n 'Bevacizumab-Paclitaxel (Breast)': 'Not available',\n 'Bevacizumab-Paclitaxel (Ovarian)': 'Not available',\n 'Bevacizumab-Paclitaxel-Topotecan (Cervical)': 'Not available',\n 'Bevacizumab-Topotecan Daily (Ovarian)': 'Not available',\n 'Bevacizumab-Topotecan Weekly (Ovarian)': 'Not available',\n 'Bevacizumab': 'Not available',\n 'Bexagliflozin': 'Not available',\n 'Bexarotene (refer to route-specific monograph)': 'Not available',\n 'Bexarotene (Systemic)': {'CA125 assay': 'interference'},\n 'Bexarotene (Topical)': 'Not available',\n 'Bezafibrate': 'Not available',\n 'Bezlotoxumab': 'Not available',\n 'Bicalutamide': 'Not available',\n 'Bictegravir, Emtricitabine, and Tenofovir Alafenamide': 'Not available',\n 'Bilastine': 'Not available',\n 'Bimatoprost': 'Not available',\n 'Bimekizumab': 'Not available',\n 'Binimetinib': 'Not available',\n 'Biotin': {'troponin': 'false-negative',\n  'thyroid function tests': 'false-positive'},\n 'Bisacodyl': 'Not available',\n 'Bismuth Subcitrate, Metronidazole, and Tetracycline': 'See individual agents',\n 'Bismuth Subgallate': 'Not available',\n 'Bismuth Subsalicylate': 'Not available',\n 'Bisoprolol and Hydrochlorothiazide': 'See individual agents',\n 'Bisoprolol': {'aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Bivalirudin': {'PT/INR levels': 'elevated'},\n 'Bleomycin': 'Not available',\n 'Blinatumomab': 'Not available',\n 'Boric Acid (Vaginal)': 'Not available',\n 'Bortezomib-Dexamethasone (Amyloidosis)': 'Not available',\n 'Bortezomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bortezomib-Dexamethasone-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Bortezomib-Doxorubicin (Liposomal) (Multiple Myeloma)': 'Not available',\n 'Bortezomib-Doxorubicin-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bortezomib-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Bortezomib-Thalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bortezomib': 'Not available',\n 'Bosentan': 'Not available',\n 'Bosutinib': 'Not available',\n 'Botulism Antitoxin, Heptavalent': {'blood glucose': 'falsely elevated'},\n 'Botulism Immune Globulin (Intravenous-Human)': 'Not available',\n 'Bovine Lipid Extract Surfactant': 'Not available',\n 'Bremelanotide': 'Not available',\n 'Brentuximab Vedotin': 'Not available',\n 'Bretylium': 'Not available',\n 'Brexanolone': 'Not available',\n 'Brexpiprazole': 'Not available',\n 'Brexucabtagene Autoleucel': 'Not available',\n 'Brigatinib': 'Not available',\n 'Brilliant Blue G': 'Not available',\n 'Brimonidine (Ophthalmic)': 'Not available',\n 'Brimonidine (refer to route-specific monograph)': 'Not available',\n 'Brimonidine (Topical)': 'Not available',\n 'Brimonidine and Timolol': 'Not available',\n 'Brincidofovir': 'Not available',\n 'Brinzolamide and Brimonidine': 'Not available',\n 'Brinzolamide and Timolol': 'Not available',\n 'Brinzolamide': 'Not available',\n 'Brivaracetam': 'Not available',\n 'Brodalumab': 'Not available',\n 'Brolucizumab': 'Not available',\n 'Bromazepam': 'Not available',\n 'Bromfenac': 'Not available',\n 'Bromocriptine': 'Not available',\n 'Brompheniramine and Phenylephrine': 'See individual agents',\n 'Brompheniramine and Pseudoephedrine': 'See individual agents',\n 'Brompheniramine, Dextromethorphan, and Phenylephrine': 'Not available',\n 'Brompheniramine, Pseudoephedrine, and Dextromethorphan': 'See individual agents',\n 'Budesonide (Nasal)': 'Not available',\n 'Budesonide (Oral Inhalation)': 'Not available',\n 'Budesonide (refer to route-specific monograph)': 'Not available',\n 'Budesonide (Systemic)': 'Not available',\n 'Budesonide (Topical)': 'Not available',\n 'Budesonide and Formoterol': 'Not available',\n 'Budesonide, Glycopyrrolate, and Formoterol': 'Not available',\n 'Bumetanide': {'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'BUPivacaine (Liposomal)': 'Not available',\n 'Bupivacaine and Epinephrine': 'Not available',\n 'Bupivacaine and Meloxicam': 'Not available',\n 'BUPivacaine': 'Not available',\n 'Buprenorphine and Naloxone': 'Not available',\n 'Buprenorphine': 'Not available',\n 'BuPROPion': {'urine detection of amphetamine/methamphetamine': 'false-positive'},\n 'Burosumab': 'Not available',\n 'Buserelin': {'pituitary gonadotropic and gonadal function tests': 'interference during treatment, may last up to a few weeks after discontinuation'},\n 'BusPIRone': {'Urinary assay for metanephrine/catecholamine': 'false positive'},\n 'Busulfan': 'Not available',\n 'Butabarbital': 'Not available',\n 'Butalbital and Acetaminophen': {'Urinary 5-hydroxyindoleacetic acid': 'false positive'},\n 'Butalbital, Acetaminophen, and Caffeine': {'Urinary 5-hydroxyindoleacetic acid': 'false positive'},\n 'Butalbital, Acetaminophen, Caffeine, and Codeine': 'See individual agents',\n 'Butalbital, Aspirin, and Caffeine': 'Not available',\n 'Butalbital, Aspirin, Caffeine, and Codeine': 'See individual agents',\n \"Butcher's Broom\": 'Not available',\n 'Butenafine': 'Not available',\n 'Butoconazole': 'Not available',\n 'Butorphanol': 'Not available',\n 'C-MOPPABV Hybrid (Hodgkin)': 'Not available',\n 'C1 Inhibitor (Human)': 'Not available',\n 'C1 Inhibitor (Recombinant)': 'Not available',\n 'Cabazitaxel-Prednisone (Prostate)': 'Not available',\n 'Cabazitaxel': 'Not available',\n 'Cabergoline': 'Not available',\n 'Cabotegravir and Rilpivirine': 'Not available',\n 'Cabotegravir': 'Not available',\n 'Cabozantinib-Nivolumab (RCC)': 'Not available',\n 'Cabozantinib': 'Not available',\n 'Caffeine': 'Not available',\n 'Calamine': 'Not available',\n 'Calaspargase Pegol': 'Not available',\n 'Calcifediol': 'Not available',\n 'Calcipotriene and Betamethasone': 'See individual agents',\n 'Calcipotriene': 'Not available',\n 'Calcitonin': 'Not available',\n 'Calcitriol (refer to route-specific monograph)': 'Not available',\n 'Calcitriol (Systemic)': 'Not available',\n 'Calcitriol (Topical)': 'Not available',\n 'Calcium Acetate': 'Not available',\n 'Calcium and Vitamin D': 'Not available',\n 'Calcium Carbonate and Magnesium Carbonate': 'Not available',\n 'Calcium Carbonate and Magnesium Hydroxide': 'Not available',\n 'Calcium Carbonate and Simethicone': 'Not available',\n 'Calcium Carbonate': 'Not available',\n 'Calcium Chloride': 'Not available',\n 'Calcium Citrate': 'Not available',\n 'Calcium Dobesilate and Lidocaine': 'Not available',\n 'Calcium Glubionate': {'Magnesium': 'Decreased'},\n 'Calcium Gluconate': {'Serum magnesium concentration': 'falsely decreased',\n  'Urine magnesium concentration': 'falsely decreased'},\n 'Calcium Hydroxylapatite': {'CT scans': 'Visible calcium hydroxylapatite particles',\n  'Standard radiography': 'Possible visible calcium hydroxylapatite particles'},\n 'Calcium Lactate': 'Not available',\n 'Calcium Polystyrene Sulfonate': 'Not available',\n 'Calfactant': 'Not available',\n 'CALGB 8811 Regimen (ALL)': 'Not available',\n 'CALGB 9111 Regimen (ALL)': 'Not available',\n 'Camphor and Menthol': 'Not available',\n 'Camphor and Phenol': 'Not available',\n 'Camphor': 'Not available',\n 'Canagliflozin and Metformin': 'Not available',\n 'Canagliflozin': {'1,5-anhydroglucitol (1,5-AG) assay': 'interfered with by positive test for glucosuria',\n  'glycemic control monitoring': 'alternative methods should be used'},\n 'Canakinumab': 'Not available',\n 'Candesartan and Hydrochlorothiazide': 'See individual agents',\n 'Candesartan': {'aldosterone/renin ratio (ARR)': 'may be false-negative'},\n 'Candida albicans (Monilia)': 'Not available',\n 'Cangrelor': 'Not available',\n 'Cannabidiol': {'cannabis screening': 'may be false-positive'},\n 'Cannabis': {'drugs of abuse screening tests': 'include cannabinoids',\n  'medical use of cannabis': 'may result in a positive drug screen'},\n 'Cantharidin, Podophyllin Resin, and Salicylic Acid': 'Not available',\n 'Cantharidin': 'Not available',\n 'Capecitabine + Lapatinib (Breast)': 'Not available',\n 'Capecitabine-Docetaxel (Breast)': 'Not available',\n 'Capecitabine-Docetaxel (Gastric Cancer)': 'Not available',\n 'Capecitabine-Gemcitabine (Pancreatic)': 'Not available',\n 'Capecitabine-Ixabepilone (Breast)': 'Not available',\n 'Capecitabine-Oxaliplatin (Gastric)': 'Not available',\n 'Capecitabine-Oxaliplatin (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Capecitabine-Trastuzumab (Breast)': 'Not available',\n 'Capecitabine': 'Not available',\n 'Caplacizumab': 'Not available',\n 'Capmatinib': 'Not available',\n 'CAPOX (Biliary Cancer)': 'Not available',\n 'CAPOX (Pancreatic)': 'Not available',\n 'Capreomycin': 'Not available',\n 'Caprylidene': 'Not available',\n 'Capsaicin': 'Not available',\n 'Captopril and Hydrochlorothiazide': 'See individual agents',\n 'Captopril': {'Aldosterone/Renin Ratio Test': 'False Negative'},\n 'Carbachol': 'Not available',\n 'CarBAMazepine': {'Serum TCA Screen': 'False Positive',\n  'Pregnancy Test': 'Interference'},\n 'Carbamide Peroxide': 'Not available',\n 'Carbetocin': 'Not available',\n 'Carbidopa and Levodopa': {'Urinary glucose': 'false-positive',\n  'Glucosuria': 'false-negative',\n  'Urine ketones': 'false-positive',\n  'Pheochromocytoma diagnosis based on plasma and urine levels of catecholamines': 'false'},\n 'Carbidopa': {'Clinitest®': 'false-positive reaction for urinary glucose',\n  'Clinistix®': 'false-negative reaction',\n  'Acetest®': 'false-positive urine ketones',\n  'Ketostix®': 'false-positive urine ketones',\n  'Labstix®': 'false-positive urine ketones'},\n 'Carbinoxamine': 'Not available',\n 'Carbon 14 Urea': 'Not available',\n 'Carboplatin-Cetuximab (Head and Neck Cancer)': 'Not available',\n 'Carboplatin-Docetaxel (Ovarian)': 'Not available',\n 'Carboplatin-Docetaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Carboplatin-Docetaxel (Unknown Primary, Squamous Cell)': 'Not available',\n 'Carboplatin-Docetaxel-Trastuzumab (Breast)': 'Not available',\n 'Carboplatin-Doxorubicin (Liposomal) (Ovarian)': 'Not available',\n 'Carboplatin-Etoposide (Ovarian Germ Cell Tumor)': 'Not available',\n 'Carboplatin-Etoposide (Small Cell Lung Cancer)': 'Not available',\n 'Carboplatin-Etoposide-Paclitaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Carboplatin-Fluorouracil (Head and Neck)': 'Not available',\n 'Carboplatin-Gemcitabine (Bladder)': 'Not available',\n 'Carboplatin-Gemcitabine (NSCLC)': 'Not available',\n 'Carboplatin-Gemcitabine (Ovarian)': 'Not available',\n 'Carboplatin-Irinotecan (Small Cell Lung Cancer)': 'Not available',\n 'Carboplatin-Paclitaxel (Cervical Cancer)': 'Not available',\n 'Carboplatin-Paclitaxel (Endometrial)': 'Not available',\n 'Carboplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel (Ovarian)': 'Not available',\n 'Carboplatin-Paclitaxel (Protein Bound) (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel (Protein Bound)-Pembrolizumab (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel (ThymomaThymic)': 'Not available',\n 'Carboplatin-Paclitaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Carboplatin-Paclitaxel-Pembrolizumab (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel-Trastuzumab (Breast)': 'Not available',\n 'Carboplatin-Pemetrexed (Mesothelioma)': 'Not available',\n 'Carboplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Carboplatin-Pemetrexed-Pembrolizumab (NSCLC)': 'Not available',\n 'CARBOplatin': 'Not available',\n 'Carboprost Tromethamine': 'Not available',\n 'Carboxymethylcellulose': 'Not available',\n 'Cardioplegic Solution': 'Not available',\n 'Carfilzomib, Cyclophosphamide, Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Carfilzomib, Lenalidomide, Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Carfilzomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Carfilzomib-Dexamethasone-Daratumumab (Multiple Myeloma)': 'Not available',\n 'Carfilzomib': 'Not available',\n 'Carglumic Acid': 'Not available',\n 'Cariprazine': 'Not available',\n 'Carisoprodol and Aspirin': 'Not available',\n 'Carisoprodol, Aspirin, and Codeine': 'Not available',\n 'Carisoprodol': 'Not available',\n 'Carmustine': 'Not available',\n 'Carteolol (Ophthalmic)': 'Not available',\n 'Carvedilol': {'Aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Casimersen': {'pyrogallol red reagent': 'interfere with detection of urine protein (false positive)',\n  'laboratory test': 'use a laboratory test that does not contain pyrogallol red reagent',\n  'casimersen': 'use urine free of casimersen (eg, urine obtained prior to infusion or ≥48 hours after infusion)'},\n 'Casirivimab and Imdevimab': 'Not available',\n 'Caspofungin': 'Not available',\n 'Castor Oil': 'Not available',\n 'CAV (Small Cell Lung Cancer)': 'Not available',\n 'Cefaclor': {\"Direct Coombs' test\": 'Positive',\n  \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'False-positive'},\n 'Cefadroxil': {'Direct Coombs': 'Positive',\n  'Urinary Glucose': 'False-positive',\n  'Serum Creatinine': 'False-positive',\n  'Urine Creatinine': 'False-positive'},\n 'CeFAZolin': {\"Direct Coombs' Test\": 'positive',\n  \"Indirect Coombs' Test\": 'positive',\n  \"Urinary Glucose Test (based on Benedict's copper reduction reaction)\": 'false-positive',\n  'Serum or Urine Creatinine Test (with Jaffé reaction)': 'false-positive',\n  'Aminoglycoside Serum Concentration Test': 'may be underestimated'},\n 'Cefdinir': {'urinary ketones': 'false-positive',\n  'urine glucose': 'false-positive',\n  'direct Coombs’ test': 'positive'},\n 'Cefepime': {\"direct Coombs'\": 'positive',\n  'urinary glucose test': 'false-positive',\n  'serum or urine creatinine': 'false-positive',\n  'urinary proteins and steroids': 'false-positive'},\n 'Cefiderocol': {'Urine Protein': 'False-positive',\n  'Ketones': 'False-positive',\n  'Occult Blood': 'False-positive'},\n 'Cefixime': {\"direct Coombs'\": 'Positive',\n  \"urinary glucose test with cupric sulfate (Benedict's solution)\": 'False-positive',\n  'urinary glucose test with Clinitest®': 'False-positive',\n  \"urinary glucose test with Fehling's solution)\": 'False-positive',\n  'serum or urine creatinine with alkaline picrate-based Jaffé reaction': 'False-positive',\n  'urine ketones using tests with nitroprusside': 'False-positive'},\n 'Cefotaxime': {\"direct Coombs'\": 'Positive',\n  \"urinary glucose test with cupric sulfate (Benedict's solution)\": 'False-positive',\n  'urinary glucose test with Clinitest®': 'False-positive',\n  \"urinary glucose test with Fehling's solution)\": 'False-positive',\n  'serum or urine creatinine with Jaffé reaction': 'False-positive'},\n 'CefoTEtan': {\"Positive direct Coombs'\": 'positive',\n  \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'false-positive',\n  'serum or urine creatinine with Jaffé reaction': 'false-positive'},\n 'CefOXitin': {\"Positive direct Coombs'\": 'positive',\n  \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\": 'false-positive',\n  'serum or urine creatinine with Jaffé reaction': 'false-positive'},\n 'Cefpodoxime': {\"Positive direct Coombs'\": 'positive',\n  \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\": 'false-positive',\n  'serum or urine creatinine with Jaffé reaction': 'false-positive'},\n 'Cefprozil': {'Direct Coombs': 'positive',\n  \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'false positive',\n  'Enzyme-based tests for glycosuria (eg, Clinistix)': 'negative',\n  'Ferricyanide test for blood glucose': 'false negative'},\n 'Ceftaroline Fosamil': 'Not available',\n 'Ceftazidime and Avibactam': {'Ceftazidime': 'positive direct Coombs',\n  'Urinary glucose test with certain methods': 'false positive',\n  'Glucose tests based on enzymatic glucose oxidase reactions': 'true'},\n 'CefTAZidime': {\"Direct Coombs'\": 'positive',\n  \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\": 'false positive',\n  'Serum or urine creatinine with Jaffé reaction': 'false positive'},\n 'Ceftibuten': {\"Direct Coombs' test\": 'Positive',\n  'Urinary glucose test using cupric sulfate': 'False-positive',\n  'Serum or urine creatinine with Jaffé reaction': 'False-positive'},\n 'Ceftobiprole': {'Direct antiglobulin (Coombs) test': 'Positive',\n  'Urinary glucose test using cupric sulfate': 'False-positive',\n  'Serum or urine creatinine with Jaffé reaction assay': 'Falsely elevated'},\n 'Ceftolozane and Tazobactam': 'Not available',\n 'CefTRIAXone': {\"Direct Coombs' test\": 'Positive',\n  'Urinary glucose test using nonenzymatic methods': 'False-positive',\n  'Galactosemia tests': 'False-positive'},\n 'Cefuroxime': {\"Direct Coombs' test\": 'positive',\n  'Urinary glucose test using cupric sulfate': 'false-positive',\n  'Ferricyanide test': 'false-negative'},\n 'Celecoxib and Tramadol': 'Not available',\n 'Celecoxib': 'Not available',\n 'Cellulose (Oxidized Regenerated)': 'Not available',\n 'Cellulose and Citric Acid': 'Not available',\n 'Cemiplimab': 'Not available',\n 'Cenegermin': 'Not available',\n 'Cenobamate': 'Not available',\n 'Centruroides Immune F(ab)2 (Equine)': 'Not available',\n 'Cephalexin': {\"Direct Coombs' test\": 'positive',\n  'Urinary glucose test using cupric sulfate': 'false-positive',\n  'Serum or urine creatinine with Jaffé reaction': 'false-positive',\n  'Urinary proteins and steroids': 'false-positive'},\n 'CEPP (NHL-DLBCL)': 'Not available',\n 'Ceritinib': 'Not available',\n 'Cerliponase Alfa': 'Not available',\n 'Certolizumab Pegol': {'Latent tuberculosis tests': 'falsely negative',\n  'aPTT assays with PTT-Lupus Anticoagulant (LA) and Standard Target Activated Partial Thromboplastin time (STA-PTT) tests from Diagnostica Stago': 'falsely elevated',\n  'aPTT assays with HemosiL APTT-SP liquid and HemosiL lyophilized silica tests from Instrumentation Laboratories': 'falsely elevated'},\n 'Cetirizine (Ophthalmic)': 'Not available',\n 'Cetirizine (refer to route-specific monograph)': 'Not available',\n 'Cetirizine (Systemic)': {'serum TCA screen': 'false-positive',\n  'wheal and flare reactions to skin test antigens': 'suppressed'},\n 'Cetirizine and Pseudoephedrine': 'See individual agents',\n 'Cetrorelix': 'Not available',\n 'Cetuximab (Biweekly)-Irinotecan (Colorectal)': 'Not available',\n 'Cetuximab + FOLFIRI (Colorectal)': 'Not available',\n 'Cetuximab-Carboplatin-Fluorouracil (Head and Neck Cancer)': 'Not available',\n 'Cetuximab-Cisplatin-Fluorouracil (Head and Neck Cancer)': 'Not available',\n 'Cetuximab-Encorafenib (Colorectal)': 'Not available',\n 'Cetuximab-Irinotecan (Colorectal)': 'Not available',\n 'Cetuximab': 'Not available',\n 'Cetylpyridinium': 'Not available',\n 'Cevimeline': 'Not available',\n 'Charcoal, Activated': 'Not available',\n 'Chenodiol': 'Not available',\n 'Chlophedianol and Dexbrompheniramine': 'Not available',\n 'Chlophedianol, Dexbrompheniramine, and Pseudoephedrine': 'Not available',\n 'Chloral Hydrate': {'copper sulfate tests for glycosuria': 'interference',\n  'fluorometric urine catecholamine tests': 'interference',\n  'urinary 17-hydroxycorticosteroid tests': 'interference'},\n 'Chlorambucil-Obinutuzumab (CLL)': 'Not available',\n 'Chlorambucil-Ofatumumab (CLL)': 'Not available',\n 'Chlorambucil-Prednisone (CLL)': 'Not available',\n 'Chlorambucil': 'Not available',\n 'Chloramphenicol (Systemic)': 'Not available',\n 'ChlordiazePOXIDE': 'Not available',\n 'Chlorhexidine Gluconate (Oral)': 'Not available',\n 'Chlorhexidine Gluconate (refer to route-specific monograph)': 'Not available',\n 'Chlorhexidine Gluconate (Topical)': {'midstream urine collection': 'chlorhexidine disinfectant can cause false-positive urine protein (when using dipstick method based upon a pH indicator color change)'},\n 'Chlorophyll': 'Not available',\n 'Chloroprocaine (Ophthalmic)': 'Not available',\n 'Chloroprocaine (refer to route-specific monograph)': 'Not available',\n 'Chloroprocaine (Systemic)': 'Not available',\n 'Chloroquine': 'Not available',\n 'Chlorothiazide': {'parathyroid function': 'may interfere',\n  'aldosterone/renin ratio (ARR)': 'may lead to false-negative'},\n 'Chlorpheniramine and Acetaminophen': 'See individual agents',\n 'Chlorpheniramine and Phenylephrine': 'See individual agents',\n 'Chlorpheniramine and Pseudoephedrine': 'See individual agents',\n 'Chlorpheniramine, Phenylephrine, and Dextromethorphan': 'See individual agents',\n 'Chlorpheniramine, Pseudoephedrine, and Codeine': 'See individual agents',\n 'Chlorpheniramine': {'skin test antigens': 'may suppress wheal and flare reactions'},\n 'ChlorproMAZINE': {'phenylketonuria': 'false-positives',\n  'amylase': 'false-positives',\n  'uroporphyrins': 'false-positives',\n  'urobilinogen': 'false-positives',\n  'pregnancy test': 'may cause false-positive',\n  'amphetamine/methamphetamine and methadone test': 'may interfere with urine detection (false-positives)'},\n 'Chlorthalidone': {'serum protein bound iodine': 'decreased',\n  'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Chlorzoxazone': 'Not available',\n 'Cholecalciferol': 'Not available',\n 'Cholera Vaccine': 'Not available',\n 'Cholestyramine Resin': {'Prothrombin time': 'Increased'},\n 'Cholic Acid': 'Not available',\n 'Choline C 11': 'Not available',\n 'Choline Magnesium Trisalicylate': {'glucose oxidase urinary glucose tests': 'false-negative results',\n  'cupric sulfate method': 'false-positives',\n  'Gerhardt test (urinary ketone analysis)': 'interference',\n  'VMA determination': 'interference',\n  '5-HIAA': 'interference',\n  'xylose tolerance test': 'interference',\n  'T3': 'interference',\n  'T4': 'interference',\n  'PBI': 'increased'},\n 'CHOP (NHL-AIDS-Related)': 'Not available',\n 'Chorionic Gonadotropin (Human)': {'radioimmunoassay of gonadotropins': 'cross-reacts, especially LH'},\n 'Chorionic Gonadotropin (Recombinant)': {'pregnancy tests': 'interference with interpretation',\n  'radioimmunoassay of luteinizing hormone and other gonadotropins': 'cross-reactivity'},\n 'Chromic Chloride': 'Not available',\n 'Ciclesonide (Nasal)': 'Not available',\n 'Ciclesonide (Oral Inhalation)': 'Not available',\n 'Ciclesonide (refer to route-specific monograph)': 'Not available',\n 'Ciclopirox': 'Not available',\n 'Cidofovir': 'Not available',\n 'Cilazapril and Hydrochlorothiazide': 'See individual agents',\n 'Cilazapril': {'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Cilostazol': 'Not available',\n 'Ciltacabtagene Autoleucel': 'Not available',\n 'Cimetidine': 'Not available',\n 'Cinacalcet': 'Not available',\n 'Ciprofloxacin (Ophthalmic)': 'Not available',\n 'Ciprofloxacin (Otic)': 'Not available',\n 'Ciprofloxacin (refer to route-specific monograph)': 'Not available',\n 'Ciprofloxacin (Systemic)': {'Urine screening result for opioids using commercially-available immunoassay kits': 'false-positive',\n  'levofloxacin and ofloxacin': 'most consistent demonstration of producing false-positive result',\n  'other quinolones': 'shown cross-reactivity in certain assay kits'},\n 'Ciprofloxacin and Dexamethasone': 'Not available',\n 'Ciprofloxacin and Fluocinolone': 'Not available',\n 'Ciprofloxacin and Hydrocortisone': 'See individual agents',\n 'Cisapride': 'Not available',\n 'Cisatracurium': 'Not available',\n 'Cisplatin-Capecitabine (Esophageal Cancer)': 'Not available',\n 'Cisplatin-Capecitabine (Gastric Cancer)': 'Not available',\n 'Cisplatin-Cetuximab (Head and Neck Cancer)': 'Not available',\n 'Cisplatin-Docetaxel (NSCLC)': 'Not available',\n 'Cisplatin-Docetaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Cisplatin-Docetaxel (Unknown Primary, Squamous Cell)': 'Not available',\n 'Cisplatin-Docetaxel-Fluorouracil (Unknown Primary, Squamous Cell)': 'Not available',\n 'Cisplatin-Docetaxel-Gemcitabine (Bladder)': 'Not available',\n 'Cisplatin-Doxorubicin (Endometrial)': 'Not available',\n 'Cisplatin-Doxorubicin-Paclitaxel (Endometrial)': 'Not available',\n 'Cisplatin-Etoposide (NSCLC)': 'Not available',\n 'Cisplatin-Etoposide (Small Cell Lung Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil (Bladder Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil (Esophageal Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil (Head and Neck Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil-Paclitaxel (Unknown Primary, Squamous Cell)': 'Not available',\n 'Cisplatin-Gemcitabine (Bladder)': 'Not available',\n 'Cisplatin-Gemcitabine (Cervical)': 'Not available',\n 'Cisplatin-Gemcitabine (Mesothelioma)': 'Not available',\n 'Cisplatin-Gemcitabine (NSCLC)': 'Not available',\n 'Cisplatin-Gemcitabine (Pancreatic)': 'Not available',\n 'Cisplatin-Gemcitabine (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Cisplatin-Gemcitabine-Necitumumab (NSCLC)': 'Not available',\n 'Cisplatin-Irinotecan (Gastric)': 'Not available',\n 'Cisplatin-Irinotecan (NSCLC)': 'Not available',\n 'Cisplatin-Irinotecan (Small Cell Lung Cancer)': 'Not available',\n 'Cisplatin-Paclitaxel (Cervical Cancer)': 'Not available',\n 'Cisplatin-Paclitaxel (Head and Neck Cancer)': 'Not available',\n 'Cisplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Cisplatin-Paclitaxel Intraperitoneal (Ovarian)': 'Not available',\n 'Cisplatin-Pemetrexed (Mesothelioma)': 'Not available',\n 'Cisplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Cisplatin-Pemetrexed-Pembrolizumab (NSCLC)': 'Not available',\n 'Cisplatin-Raltitrexed (Mesothelioma)': 'Not available',\n 'Cisplatin-Topotecan (Cervical Cancer)': 'Not available',\n 'Cisplatin-Vinblastine (NSCLC)': 'Not available',\n 'Cisplatin-Vinorelbine (Adjuvant NSCLC)': 'Not available',\n 'Cisplatin-Vinorelbine (Cervical Cancer)': 'Not available',\n 'Cisplatin-Vinorelbine (Metastatic NSCLC)': 'Not available',\n 'CISplatin': 'Not available',\n 'Citalopram': 'Not available',\n 'Citric Acid, Magnesium Carbonate, and Glucono-Delta-Lactone': 'Not available',\n 'Citric Acid, Sodium Citrate, and Potassium Citrate': 'Not available',\n 'Cladribine-Rituximab (NHL-Mantle Cell)': 'Not available',\n 'Cladribine-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Cladribine': 'Not available',\n 'CLAG (AML Induction)': 'Not available',\n 'CLAG-M (AML Induction)': 'Not available',\n 'Clarithromycin': 'Not available',\n 'Clascoterone': 'Not available',\n 'Clemastine': 'Not available',\n 'Clevidipine': {'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Clidinium and Chlordiazepoxide': 'Not available',\n 'Clindamycin (refer to route-specific monograph)': 'Not available',\n 'Clindamycin (Systemic)': 'Not available',\n 'Clindamycin (Topical)': 'Not available',\n 'Clindamycin and Benzoyl Peroxide': 'Not available',\n 'Clindamycin and Tretinoin': 'Not available',\n 'Clioquinol and Flumethasone': {'Thyroid function tests': 'decreased 131I uptake',\n  'ferric chloride test for phenylketonuria': 'false-positive'},\n 'Clioquinol and Hydrocortisone': {'Thyroid function tests': '',\n  'ferric chloride test for phenylketonuria': 'false-positive'},\n 'CloBAZam': 'Not available',\n 'Clobetasol': 'Not available',\n 'Clobetasone': 'Not available',\n 'Clocortolone': 'Not available',\n 'Clodronate': {'technetium-99m-diphosphonate in bone scans': 'interference with diagnostic imaging agents',\n  'radiopharmaceutical bone imaging': 'no interference.'},\n 'Clofarabine-Cyclophosphamide-Etoposide (ALL)': 'Not available',\n 'Clofarabine-Cytarabine (AML)': 'Not available',\n 'Clofarabine': 'Not available',\n 'Clofazimine': 'Not available',\n 'Clofedanol': 'Not available',\n 'ClomiPHENE': 'Not available',\n 'ClomiPRAMINE': {'urine detection of methadone': 'interference (false-positive)'},\n 'ClonazePAM': 'Not available',\n 'CloNIDine': {\"Coombs' test\": 'positive',\n  'aldosterone/renin ratio': 'false-positive'},\n 'Clopidogrel': 'Not available',\n 'Clorazepate': {'hematocrit': 'decreased',\n  'liver function tests': 'abnormal',\n  'renal function tests': 'abnormal'},\n 'Clotrimazole (Oral)': 'Not available',\n 'Clotrimazole (refer to route-specific monograph)': 'Not available',\n 'Clotrimazole (Topical)': 'Not available',\n 'Cloxacillin': {'urinary glucose tests': 'interference',\n  'aminoglycosides': 'inactivated in vitro',\n  'urine proteins': 'false-positive',\n  'serum proteins': 'false-positive',\n  'uric acid': 'false-positive',\n  'urinary steroids': 'false-positive'},\n 'CloZAPine': 'Not available',\n 'CMF Oral (Breast)': 'Not available',\n 'CMV (Bladder)': 'Not available',\n 'Coal Tar and Salicylic Acid': 'Not available',\n 'Coal Tar': 'Not available',\n 'Cobicistat': {'serum creatinine': '>0.4 mg/dL'},\n 'Cobimetinib-Vemurafenib (Melanoma)': 'Not available',\n 'Cobimetinib': 'Not available',\n 'Cocaine (Topical)': 'Not available',\n 'Coccidioides immitis Skin Test': 'Not available',\n 'Codeine and Chlorpheniramine': 'See individual agents',\n 'Codeine, Phenylephrine, and Triprolidine': 'Not available',\n 'Codeine': {'levofloxacin': 'false-positive',\n  'ofloxacin': 'false-positive',\n  'other quinolones': 'cross-reactivity'},\n 'CODOX-M (NHL-Burkitt)': 'Not available',\n 'CODOX-MIVAC (NHL-Burkitt)': 'Not available',\n 'Colchicine and Probenecid': 'Not available',\n 'Colchicine': {'urine tests for erythrocytes': 'false-positive',\n  'urine tests for hemoglobin': 'false-positive'},\n 'Colesevelam': {'Prothrombin time': 'Increased'},\n 'Colestipol': 'Not available',\n 'Colistimethate': 'Not available',\n 'Collagen (AbsorbableDental)': 'Not available',\n 'Collagen Hemostat': 'Not available',\n 'Collagenase (refer to route-specific monograph)': 'Not available',\n 'Collagenase (Systemic)': 'Not available',\n 'Collagenase (Topical)': 'Not available',\n 'Conivaptan': 'Not available',\n 'Continuous Renal Replacement Therapy Solutions': 'Not available',\n 'Copanlisib': 'Not available',\n 'Copper Cu 64 Dotatate': 'Not available',\n 'Copper IUD': 'Not available',\n 'Copper': 'Not available',\n 'Corticorelin': 'Not available',\n 'Corticotropin': {'Skin test antigen wheal and flare reactions': 'May be suppressed'},\n 'Cortisone': {'Skin test antigen wheal and flare reactions': 'May be suppressed'},\n 'Cosyntropin': {'spironolactone': 'concurrent or recent use',\n  'hydrocortisone': 'concurrent or recent use',\n  'cortisone': 'concurrent or recent use',\n  'etomidate': 'concurrent or recent use',\n  'estrogens': 'concurrent or recent use'},\n 'COVID-19 Vaccine (Adenovirus Vector)': {'Rapid Plasma Reagin (RPR)': 'possible false-positive for ≥5 months after COVID-19 vaccination',\n  'SARS-CoV-2 viral testing (antigen or nucleic acid amplification tests)': 'not affected by COVID-19 vaccines',\n  'test that detects nucleocapsid protein antibody': 'used to assess for prior infection in COVID-19–vaccinated individuals',\n  'SARS-CoV-2 spike protein antibody test': 'may indicate either prior infection or vaccination'},\n 'COVID-19 Vaccine (mRNA)': {'Rapid Plasma Reagin (RPR)': 'possible false-positive results',\n  'Treponemal testing': 'does not appear to be affected',\n  'SARS-CoV-2 viral testing (antigen or nucleic acid amplification tests)': 'not affected by COVID-19 vaccine',\n  'nucleocapsid protein antibody test': 'used to assess prior infection in COVID-19 vaccinated individuals',\n  'SARS-CoV-2 spike protein antibody test': 'positive results may indicate either prior infection or vaccination'},\n 'COVID-19 Vaccine (Subunit)': 'Not available',\n 'COVID-19 Vaccine (Virus-like Particles)': 'Not available',\n 'Crisaborole': 'Not available',\n 'Crizanlizumab': {'Automated platelet counts': 'unevaluable or falsely decreased',\n  'Dehydrogenase pyrroloquinolinequinone or glucose-dye-oxidoreductase testing methods on the day of infusion': 'falsely elevated'},\n 'Crizotinib': 'Not available',\n 'Crofelemer': 'Not available',\n 'Cromolyn (Nasal)': 'Not available',\n 'Cromolyn (Ophthalmic)': 'Not available',\n 'Cromolyn (Oral Inhalation)': 'Not available',\n 'Cromolyn (refer to route-specific monograph)': 'Not available',\n 'Cromolyn (Systemic)': 'Not available',\n \"Crotalidae Immune F(ab')2 (Equine)\": 'Not available',\n 'Crotalidae Polyvalent Immune FAB (Ovine)': 'Not available',\n 'Crotamiton': 'Not available',\n 'Cyanocobalamin': {'Folic acid and vitamin B12 diagnostic blood assays': 'invalidated'},\n 'Cyclobenzaprine': {'Serum TCA screen': 'false-positive'},\n 'Cyclopentolate and Phenylephrine': 'Not available',\n 'Cyclopentolate': 'Not available',\n 'Cyclophosphamide-Bortezomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Cyclophosphamide-Epirubicin (Breast)': 'Not available',\n 'Cyclophosphamide-Topotecan (Ewing Sarcoma)': 'Not available',\n 'Cyclophosphamide-Topotecan (Rhabdomyosarcoma)': 'Not available',\n 'CycloPHOSphamide': 'Not available',\n 'CycloSERINE': 'Not available',\n 'CycloSPORINE (Ophthalmic)': 'Not available',\n 'CycloSPORINE (refer to route-specific monograph)': 'Not available',\n 'CycloSPORINE (Systemic)': {'Specific whole blood assay for cyclosporine': 'falsely elevated'},\n 'Cyproheptadine': {'Diagnostic antigen skin test results': 'suppressed',\n  'serum TCA screen': 'false positive'},\n 'Cyproterone and Ethinyl Estradiol': {'coagulation factors': 'altered',\n  'lipids': 'altered',\n  'glucose tolerance': 'altered',\n  'thyroxine-binding globulin': 'altered',\n  'sex hormone-binding globulin': 'altered',\n  'cortisol-binding globulin': 'altered'},\n 'Cyproterone': 'Not available',\n 'Cysteamine (Ophthalmic)': 'Not available',\n 'Cysteamine (refer to route-specific monograph)': 'Not available',\n 'Cysteamine (Systemic)': 'Not available',\n 'Cysteine': {'estimations of nitrogen containing substances': 'may interfere',\n  'venous blood for blood chemistries': 'do not withdraw through the peripheral infusion site'},\n 'Cytarabine (Conventional)': 'Not available',\n 'Cytarabine (High Dose)-Daunorubicin (AML Induction)': 'Not available',\n 'Cytarabine (High Dose)-Daunorubicin-Etoposide (AML Induction)': 'Not available',\n 'Cytarabine (High-Dose Single-Agent AML Induction Regimen)': 'Not available',\n 'Cytarabine (Liposomal)': 'Not available',\n 'Cytarabine (Single-Agent AML Consolidation Regimen)': 'Not available',\n 'Cytarabine (SUBQ Single-Agent AML Induction Regimen)': 'Not available',\n 'Cytomegalovirus Immune Globulin (Intravenous-Human)': 'Not available',\n 'Dabigatran Etexilate': 'Not available',\n 'Dabrafenib-Trametinib (Melanoma)': 'Not available',\n 'Dabrafenib-Trametinib (NSCLC)': 'Not available',\n 'Dabrafenib': 'Not available',\n 'Dacarbazine': 'Not available',\n 'Daclatasvir': 'Not available',\n 'Dacomitinib': 'Not available',\n 'DACTINomycin': 'Not available',\n 'Dalbavancin': 'Not available',\n 'Dalfampridine': 'Not available',\n 'Dalteparin': 'Not available',\n 'Danaparoid': {'PT/INR': 'not reliable within 5 hours following danaparoid administration'},\n 'Danazol': {'Estradiol (Kishino 2010)': '',\n  'testosterone': 'may interfere with laboratory tests',\n  'androstenedione': 'may interfere with laboratory tests',\n  'dehydroepiandrosterone': 'may interfere with laboratory tests'},\n 'Dantrolene': 'Not available',\n 'Dapagliflozin and Metformin': {'Glucosuria test': 'positive',\n  '1,5-anhydroglucitol (1,5-AG) assay': 'inaccurate'},\n 'Dapagliflozin and Saxagliptin': {'Glucosuria test': 'positive',\n  '1,5-anhydroglucitol (1,5-AG) assay': 'inaccurate'},\n 'Dapagliflozin': {'Glucosuria test': 'positive',\n  '1,5-anhydroglucitol (1,5-AG) assay': 'inaccurate'},\n 'Daprodustat': 'Not available',\n 'Dapsone (refer to route-specific monograph)': 'Not available',\n 'Dapsone (Systemic)': {'HbA1c': 'may artificially lower by reducing erythrocyte survival time through hemolysis'},\n 'Dapsone (Topical)': 'Not available',\n 'DAPTOmycin': {'PT/INR': 'elevated'},\n 'Daratumumab and Hyaluronidase': {'Indirect antiglobulin test (indirect Coombs test)': 'positive',\n  'Serum protein electrophoresis and immunofixation assays': 'interference'},\n 'Daratumumab-Bortezomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Bortezomib-Melphalan-Prednisone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Bortezomib-Thalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Lenalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Pomalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab': {'CD38 on RBCs compatibility testing': 'interfered with by daratumumab binding',\n  'antibody screening': 'interfered with by daratumumab binding',\n  'cross matching': 'interfered with by daratumumab binding',\n  'serum protein electrophoresis (SPE) assay': 'may have false positive results for patients with IgG kappa myeloma protein',\n  'immunofixation (IFE) assay': 'may have false positive results for patients with IgG kappa myeloma protein',\n  'daratumumab-specific IFE assay': 'used to distinguish daratumumab from any residual endogenous M protein in patients with persistent very good partial response'},\n 'Darbepoetin Alfa': {'HbA1c': 'may be artificially lowered by erythropoiesis-stimulating agents through increased circulation of immature erythrocytes with less exposure to glucose'},\n 'Daridorexant': 'Not available',\n 'Darifenacin': 'Not available',\n 'Darolutamide': 'Not available',\n 'Darunavir and Cobicistat': 'Not available',\n 'Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide': 'Not available',\n 'Darunavir': 'Not available',\n 'Dasatinib': 'Not available',\n 'Dasiglucagon': 'Not available',\n 'DAUNOrubicin (Conventional)': 'Not available',\n 'DAUNOrubicin (Liposomal)': 'Not available',\n 'Daunorubicin and Cytarabine (Liposomal)': 'Not available',\n 'DaxibotulinumtoxinA': 'Not available',\n 'Decitabine and Cedazuridine': 'Not available',\n 'Decitabine': 'Not available',\n 'Deferasirox': 'Not available',\n 'Deferiprone': 'Not available',\n 'Deferoxamine': {'TIBC': 'may be falsely elevated with high serum iron concentrations or deferoxamine therapy'},\n 'Defibrotide': 'Not available',\n 'Deflazacort': 'Not available',\n 'Degarelix': {'pituitary-gonadal function': 'suppressed',\n  'diagnostic tests of pituitary gonadotropic': 'affected',\n  'diagnostic tests of gonadal functions': 'affected'},\n 'Delafloxacin': 'Not available',\n 'Delavirdine': 'Not available',\n 'Demeclocycline': 'Not available',\n 'Dengue Tetravalent Vaccine (Live)': 'Not available',\n 'Denosumab': 'Not available',\n 'Deoxycholic Acid': 'Not available',\n 'Dequalinium': 'Not available',\n 'Desflurane': 'Not available',\n 'Desipramine': {'amphetamines/methamphetamines': 'false-positive'},\n 'Desirudin': 'Not available',\n 'Desloratadine and Pseudoephedrine': 'See individual agents',\n 'Desloratadine': {'wheal reactions to skin test antigens': 'suppressed',\n  'flare reactions to skin test antigens': 'suppressed'},\n 'Desmopressin': 'Not available',\n 'Desonide': 'Not available',\n 'Desoximetasone': 'Not available',\n 'Desvenlafaxine': {'Urine detection of phencyclidine and amphetamine': 'false-positive'},\n 'Deucravacitinib': 'Not available',\n 'Deutetrabenazine': 'Not available',\n 'DexAMETHasone (Ophthalmic)': 'Not available',\n 'DexAMETHasone (refer to route-specific monograph)': 'Not available',\n 'DexAMETHasone (Systemic)': {'Skin test antigens': 'suppressed wheal and flare reactions'},\n 'Dexbrompheniramine and Phenylephrine': 'Not available',\n 'Dexchlorpheniramine and Pseudoephedrine': 'Not available',\n 'Dexchlorpheniramine, Dextromethorphan, and Phenylephrine': 'Not available',\n 'Dexchlorpheniramine': 'Not available',\n 'Dexlansoprazole': {'Serum chromogranin A (CgA) levels': 'false-positive due to decreased gastric acidity and temporarily stopping dexlansoprazole'},\n 'DexmedeTOMIDine': 'Not available',\n 'Dexmethylphenidate': 'Not available',\n 'Dexrazoxane': 'Not available',\n 'Dextran': {'Serum glucose testing methods that use high concentrations of acid': 'Falsely elevated',\n  'Bilirubin assays that use alcohol': 'Interference',\n  'Total protein assays using biuret reagents': 'Interference',\n  'Dextran 70': 'Erythrocyte aggregation and interference with blood typing and cross matching of blood'},\n 'Dextranomer and Hyaluronate Derivatives': 'Not available',\n 'Dextroamphetamine and Amphetamine': {'Plasma corticosteroid levels': 'Significantly elevated',\n  'Urinary steroid testing': 'Interference'},\n 'Dextroamphetamine': {'Plasma corticosteroid levels': 'Elevated',\n  'Urinary steroid determinations': 'Interference'},\n 'Dextromethorphan and Bupropion': {'urine detection of amphetamine/methamphetamine': 'false-positive'},\n 'Dextromethorphan and Chlorpheniramine': 'See individual agents',\n 'Dextromethorphan and Menthol': 'Not available',\n 'Dextromethorphan and Phenylephrine': 'See individual agents',\n 'Dextromethorphan and Pyrilamine': {'phencyclidine': 'False-positive',\n  'opioids': 'False-positive',\n  'heroin': 'False-positive'},\n 'Dextromethorphan and Quinidine': 'See individual agents',\n 'Dextromethorphan': {'phencyclidine': 'False-positive',\n  'opioids': 'False-positive',\n  'heroin': 'False-positive'},\n 'Dextrose 25% and Sodium Chloride 10%': 'Not available',\n \"Dextrose and Ringer's Injection (Lactated)\": 'Not available',\n 'Dextrose and Sodium Chloride': 'Not available',\n 'Dextrose': 'Not available',\n 'DHAP (Hodgkin)': 'Not available',\n 'DHAP (NHL-DLBCL)': 'Not available',\n 'Diamorphine': 'Not available',\n 'Diatrizoate Meglumine and Diatrizoate Sodium': {'Protein bound iodine uptake studies': 'inaccurate for up to 1 year after enteral administration of iodinated contrast agents',\n  'Radioactive iodine update studies': 'inaccurate for up to 1 year after enteral administration of iodinated contrast agents',\n  'Trypsin values (determined spectrophotometrically)': 'false low due to oral contrast agents'},\n 'Diatrizoate Meglumine': {'Urine specimen assay': 'may be interfered with by contrast agent instillation into bladder'},\n 'DiazePAM': {'Urinary glucose determinations when using Clinistix® or Diastix®': 'false-negative'},\n 'Diazoxide': {'Serum renin concentrations': 'increased',\n  'IgG concentrations': 'increased',\n  'Serum cortisol concentrations': 'decreased',\n  'Insulin response to glucagon': 'false-negative'},\n 'Dibekacin [INT]': 'Not available',\n 'Dibucaine': 'Not available',\n 'Dichlorphenamide': 'Not available',\n 'Diclofenac (Ophthalmic)': 'Not available',\n 'Diclofenac (refer to route-specific monograph)': 'Not available',\n 'Diclofenac (Systemic)': {'aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Diclofenac (Topical)': 'Not available',\n 'Diclofenac and Misoprostol': 'Not available',\n 'Dicloxacillin': {'Urine proteins': 'false-positive',\n  'Serum proteins': 'false-positive',\n  'Uric acid': 'false-positive',\n  'Urinary steroids': 'false-positive',\n  'Urinary glucose tests using cupric sulfate': 'interference',\n  'Aminoglycosides': 'inactivated'},\n 'Dicyclomine': 'Not available',\n ...}"
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:47:00.091761200Z",
     "start_time": "2023-08-28T13:47:00.048876600Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Glucose monitoring methods which utilize glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD)': 'recommended', 'Glucose oxidase': 'recommended', 'Glucose hexokinase': 'recommended'}\n",
      "{'glucose tests based on enzymatic glucose oxidase reactions (eg, Clinistix)': 'recommended'}\n",
      "{'Glucose oxidase or hexokinase-based methods': 'recommended'}\n",
      "{'HIV infection using a PCR-based assay': 'not recommended'}\n",
      "{'serum creatinine': 'markedly false elevations when the Ektachem® analyzer is used. The Jaffé reaction is recommended for determining'}\n",
      "{'Cutaquig, Octagam 5%, and Octagam 10%': 'falsely elevated blood glucose levels when glucose dehydrogenase pyrroloquinolinequinone based methods are used; glucose specific method recommended'}\n",
      "{'Glucose-specific Test': 'recommended'}\n",
      "{'Confirmation of positive opioid screens by more specific methods': 'recommended'}\n",
      "{'bleeding time': 'recommended alternative coagulation test', 'factor Xa (chromogenic assay)': 'recommended alternative coagulation test', 'platelet aggregation study': 'recommended alternative coagulation test', 'thrombin time': 'recommended alternative coagulation test'}\n",
      "{'TSH levels': 'Not recommended after thyrotropin alfa use'}\n"
     ]
    }
   ],
   "source": [
    "for elem in drug_inter_manage.keys():\n",
    "    if drug_inter_manage[elem] != 'Not available':\n",
    "        print(drug_inter_manage[elem])"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:47:00.271282300Z",
     "start_time": "2023-08-28T13:47:00.246348100Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Dehydrogenase pyrroloquinolinequinone testing method': 'falsely elevated blood glucose levels', 'Glucose-dye-oxidoreductase testing method': 'falsely elevated blood glucose levels'}\n",
      "{'Aldosterone / renin ratio (ARR)': 'false-positive'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'Urinary 5-hydroxyindoleacetic acid': 'false-positive'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'urine glucose': 'false', 'urine catecholamine': 'false', 'urinary 5-hydroxyindoleacetic acid': 'false'}\n",
      "{'urinary 5-hydroxyindoleacetic acid': 'false-positive'}\n",
      "{'urinary protein with Albustix': 'false-positive', 'urinary protein with Labstix': 'false-positive', 'urinary protein with Albutest': 'false-positive', 'urinary protein with Bumintest': 'false-positive', 'HPLC theophylline assay': 'interference', 'serum uric acid levels': 'interference', 'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'amphetamines': 'false-positive'}\n",
      "{'Renin': 'increased in serum', 'Aldosterone': 'increased in serum'}\n",
      "{'Renin': 'increased in serum', 'Aldosterone': 'increased in serum'}\n",
      "{'diagnostic serum tests that utilize antibodies': 'May interfere'}\n",
      "{'bisphosphonates': 'May interfere', 'diagnostic imaging agents such as technetium-99m-diphosphonate in bone scans': 'May interfere'}\n",
      "{'bisphosphonates': 'May interfere', 'diagnostic imaging agents such as technetium-99m-diphosphonate in bone scans': 'May interfere'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive or false-negative'}\n",
      "{'coagulation and fibrinolytic activity tests': 'altered results'}\n",
      "{'urine detection of amphetamines/methamphetamines': '(false-positive) interference'}\n",
      "{'Aminoglycoside serum concentration': 'potential underestimation caused by some penicillin derivatives accelerating aminoglycoside degradation in vitro'}\n",
      "{'Parathyroid function tests': 'Interference', 'Serum iodine (protein bound) test': 'Decreased without signs of thyroid disturbance'}\n",
      "{'Aldosterone/Renin Ratio (ARR)': 'False-negative'}\n",
      "{'Plasma glucose': 'increased', 'Uric acid': 'increased', 'Free fatty acids': 'increased', 'Total cholesterol': 'increased', 'HDL': 'increased', 'HDL/LDL ratio': 'increased', 'Urinary free cortisol excretion': 'increased', 'Triiodothyronine': 'decreased'}\n",
      "{'T4 levels': 'elevated', 'Thyroid stimulating hormone levels': 'high end of normal range', 'T3 levels': 'low end of normal range'}\n",
      "{'Pregnancy test': 'false-positive'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{\"glucose tests using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'interference', 'total conjugated estriol': 'transiently interfered', 'estriol-glucuronide': 'transiently interfered', 'conjugated estrone': 'transiently interfered', 'estradiol': 'transiently interfered'}\n",
      "{\"glucose tests (Benedict's solution, Clinitest, Fehling's Solution)\": 'interference', 'aminoglycoside serum concentration': 'underestimation'}\n",
      "{'Plasma corticosteroid levels': 'elevated by amphetamines', 'Urinary steroid determinations': 'interference by amphetamines'}\n",
      "{'serum phosphate': 'falsely-elevated'}\n",
      "{\"urinary glucose tests using cupric sulfate (Benedict's solution, Fehling’s solution, or Clinitest®)\": 'interference', 'aminoglycoside serum concentration': 'underestimation'}\n",
      "{\"Urinary glucose tests using cupric sulfate (Benedict's solution, Clinitest)\": 'may interfere', 'Aminoglycoside serum concentration': 'potential underestimation'}\n",
      "{'Anti-FXa activity assay': 'falsely elevated'}\n",
      "{'Glucose monitoring devices and test strips utilizing the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase based methods': 'falsely elevated blood glucose levels', 'Urinalysis after anthrax immune globulin administration': 'transiently elevated glucose', 'Passively transferred antibodies': 'false-positive serologic testing results, false-positive direct and indirect Coombs’ test'}\n",
      "{'blood group isohemagglutinins': 'may interfere with serological tests for red cell antibodies (eg, Coombs test)'}\n",
      "{'rabbit antibody-based immunoassays': 'Potential interference', 'cross-match or panel-reactive antibody cytotoxicity assays': 'Potential interference', 'routine clinical laboratory tests which do not use immunoglobulins': 'Has not been shown to interfere'}\n",
      "{'anti-Factor Xa assays': 'falsely elevated results and leading to inappropriate heparin dose reduction', 'aPTT': 'little or minor effect'}\n",
      "{'PT/INR levels': 'elevated', 'chromogenic factor X assay': 'monitored', 'Factor Xa levels': '<45%'}\n",
      "{'stool occult blood': 'false-negative', 'glucose testing': 'falsely elevated', 'nitrite and bilirubin levels': 'interfered', 'leucocyte count': 'interfered'}\n",
      "{'ALP-conjugated test systems': 'interfered'}\n",
      "See individual agents\n",
      "{'Glucose oxidase urinary glucose tests (Clinistix)': 'False-negative', 'cupric sulfate method (Clinitest)': 'false-positives', 'Gerhardt test': 'interferes', 'VMA determination': 'interferes', '5-HIAA': 'interferes', 'xylose tolerance test': 'interferes', 'T3': 'interferes', 'T4': 'interferes', 'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "See individual agents\n",
      "{'glucose': 'Increased', 'HDL': 'decreased', 'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'TPMT phenotyping': 'may not be accurate'}\n",
      "{'aldosterone/renin ratio (ARR)': 'May lead to false-negative'}\n",
      "{\"urine glucose tests containing cupric sulfate (Benedict's solution, Clinitest)\": 'May interfere', \"Coombs' test\": 'positive'}\n",
      "{'Urinary normetanephrine levels': \"falsely elevated when measured by liquid chromatography with electrochemical detection because of similarity in chromatograms of normetanephrine and mesalamine's main metabolite\"}\n",
      "{'tuberculin reactivity': 'positive'}\n",
      "{'tuberculin skin test': 'positive/reactive', 'active tuberculosis': 'rule out', 'PPD reaction': '<5 mm induration', 'interferon-gamma release assay (IGRA)': 'acceptable'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'Catecholamines testing': 'affected by Levodopa', 'Creatinine testing': 'affected by Levodopa', 'Uric acid testing': 'affected by Levodopa', 'Glucose testing': 'affected by Levodopa', 'Urine test for ketone bodies': 'false positive due to Levodopa'}\n",
      "{'skin test antigens': 'wheal and flare reactions suppressed'}\n",
      "{'wheal and flare reactions to skin test antigens': 'may suppress'}\n",
      "See individual agents\n",
      "{'Glaucoma screening tests': 'interference by oral betaxolol', 'Aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'polymerase chain reaction assays': 'positive for HIV due to integrated BB305 LVV proviral DNA, resulting in a false-positive test for HIV', 'PCR-based assay': 'should not be used for screening HIV infection'}\n",
      "{'CA125 assay': 'interference'}\n",
      "{'troponin': 'false-negative', 'thyroid function tests': 'false-positive'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'PT/INR levels': 'elevated'}\n",
      "{'blood glucose': 'falsely elevated'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'urine detection of amphetamine/methamphetamine': 'false-positive'}\n",
      "{'pituitary gonadotropic and gonadal function tests': 'interference during treatment, may last up to a few weeks after discontinuation'}\n",
      "{'Urinary assay for metanephrine/catecholamine': 'false positive'}\n",
      "{'Urinary 5-hydroxyindoleacetic acid': 'false positive'}\n",
      "{'Urinary 5-hydroxyindoleacetic acid': 'false positive'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'Magnesium': 'Decreased'}\n",
      "{'Serum magnesium concentration': 'falsely decreased', 'Urine magnesium concentration': 'falsely decreased'}\n",
      "{'CT scans': 'Visible calcium hydroxylapatite particles', 'Standard radiography': 'Possible visible calcium hydroxylapatite particles'}\n",
      "{'1,5-anhydroglucitol (1,5-AG) assay': 'interfered with by positive test for glucosuria', 'glycemic control monitoring': 'alternative methods should be used'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'may be false-negative'}\n",
      "{'cannabis screening': 'may be false-positive'}\n",
      "{'drugs of abuse screening tests': 'include cannabinoids', 'medical use of cannabis': 'may result in a positive drug screen'}\n",
      "See individual agents\n",
      "{'Aldosterone/Renin Ratio Test': 'False Negative'}\n",
      "{'Serum TCA Screen': 'False Positive', 'Pregnancy Test': 'Interference'}\n",
      "{'Urinary glucose': 'false-positive', 'Glucosuria': 'false-negative', 'Urine ketones': 'false-positive', 'Pheochromocytoma diagnosis based on plasma and urine levels of catecholamines': 'false'}\n",
      "{'Clinitest®': 'false-positive reaction for urinary glucose', 'Clinistix®': 'false-negative reaction', 'Acetest®': 'false-positive urine ketones', 'Ketostix®': 'false-positive urine ketones', 'Labstix®': 'false-positive urine ketones'}\n",
      "{'Aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'pyrogallol red reagent': 'interfere with detection of urine protein (false positive)', 'laboratory test': 'use a laboratory test that does not contain pyrogallol red reagent', 'casimersen': 'use urine free of casimersen (eg, urine obtained prior to infusion or ≥48 hours after infusion)'}\n",
      "{\"Direct Coombs' test\": 'Positive', \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'False-positive'}\n",
      "{'Direct Coombs': 'Positive', 'Urinary Glucose': 'False-positive', 'Serum Creatinine': 'False-positive', 'Urine Creatinine': 'False-positive'}\n",
      "{\"Direct Coombs' Test\": 'positive', \"Indirect Coombs' Test\": 'positive', \"Urinary Glucose Test (based on Benedict's copper reduction reaction)\": 'false-positive', 'Serum or Urine Creatinine Test (with Jaffé reaction)': 'false-positive', 'Aminoglycoside Serum Concentration Test': 'may be underestimated'}\n",
      "{'urinary ketones': 'false-positive', 'urine glucose': 'false-positive', 'direct Coombs’ test': 'positive'}\n",
      "{\"direct Coombs'\": 'positive', 'urinary glucose test': 'false-positive', 'serum or urine creatinine': 'false-positive', 'urinary proteins and steroids': 'false-positive'}\n",
      "{'Urine Protein': 'False-positive', 'Ketones': 'False-positive', 'Occult Blood': 'False-positive'}\n",
      "{\"direct Coombs'\": 'Positive', \"urinary glucose test with cupric sulfate (Benedict's solution)\": 'False-positive', 'urinary glucose test with Clinitest®': 'False-positive', \"urinary glucose test with Fehling's solution)\": 'False-positive', 'serum or urine creatinine with alkaline picrate-based Jaffé reaction': 'False-positive', 'urine ketones using tests with nitroprusside': 'False-positive'}\n",
      "{\"direct Coombs'\": 'Positive', \"urinary glucose test with cupric sulfate (Benedict's solution)\": 'False-positive', 'urinary glucose test with Clinitest®': 'False-positive', \"urinary glucose test with Fehling's solution)\": 'False-positive', 'serum or urine creatinine with Jaffé reaction': 'False-positive'}\n",
      "{\"Positive direct Coombs'\": 'positive', \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'false-positive', 'serum or urine creatinine with Jaffé reaction': 'false-positive'}\n",
      "{\"Positive direct Coombs'\": 'positive', \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\": 'false-positive', 'serum or urine creatinine with Jaffé reaction': 'false-positive'}\n",
      "{\"Positive direct Coombs'\": 'positive', \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\": 'false-positive', 'serum or urine creatinine with Jaffé reaction': 'false-positive'}\n",
      "{'Direct Coombs': 'positive', \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'false positive', 'Enzyme-based tests for glycosuria (eg, Clinistix)': 'negative', 'Ferricyanide test for blood glucose': 'false negative'}\n",
      "{'Ceftazidime': 'positive direct Coombs', 'Urinary glucose test with certain methods': 'false positive', 'Glucose tests based on enzymatic glucose oxidase reactions': 'true'}\n",
      "{\"Direct Coombs'\": 'positive', \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\": 'false positive', 'Serum or urine creatinine with Jaffé reaction': 'false positive'}\n",
      "{\"Direct Coombs' test\": 'Positive', 'Urinary glucose test using cupric sulfate': 'False-positive', 'Serum or urine creatinine with Jaffé reaction': 'False-positive'}\n",
      "{'Direct antiglobulin (Coombs) test': 'Positive', 'Urinary glucose test using cupric sulfate': 'False-positive', 'Serum or urine creatinine with Jaffé reaction assay': 'Falsely elevated'}\n",
      "{\"Direct Coombs' test\": 'Positive', 'Urinary glucose test using nonenzymatic methods': 'False-positive', 'Galactosemia tests': 'False-positive'}\n",
      "{\"Direct Coombs' test\": 'positive', 'Urinary glucose test using cupric sulfate': 'false-positive', 'Ferricyanide test': 'false-negative'}\n",
      "{\"Direct Coombs' test\": 'positive', 'Urinary glucose test using cupric sulfate': 'false-positive', 'Serum or urine creatinine with Jaffé reaction': 'false-positive', 'Urinary proteins and steroids': 'false-positive'}\n",
      "{'Latent tuberculosis tests': 'falsely negative', 'aPTT assays with PTT-Lupus Anticoagulant (LA) and Standard Target Activated Partial Thromboplastin time (STA-PTT) tests from Diagnostica Stago': 'falsely elevated', 'aPTT assays with HemosiL APTT-SP liquid and HemosiL lyophilized silica tests from Instrumentation Laboratories': 'falsely elevated'}\n",
      "{'serum TCA screen': 'false-positive', 'wheal and flare reactions to skin test antigens': 'suppressed'}\n",
      "See individual agents\n",
      "{'copper sulfate tests for glycosuria': 'interference', 'fluorometric urine catecholamine tests': 'interference', 'urinary 17-hydroxycorticosteroid tests': 'interference'}\n",
      "{'midstream urine collection': 'chlorhexidine disinfectant can cause false-positive urine protein (when using dipstick method based upon a pH indicator color change)'}\n",
      "{'parathyroid function': 'may interfere', 'aldosterone/renin ratio (ARR)': 'may lead to false-negative'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'skin test antigens': 'may suppress wheal and flare reactions'}\n",
      "{'phenylketonuria': 'false-positives', 'amylase': 'false-positives', 'uroporphyrins': 'false-positives', 'urobilinogen': 'false-positives', 'pregnancy test': 'may cause false-positive', 'amphetamine/methamphetamine and methadone test': 'may interfere with urine detection (false-positives)'}\n",
      "{'serum protein bound iodine': 'decreased', 'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'Prothrombin time': 'Increased'}\n",
      "{'glucose oxidase urinary glucose tests': 'false-negative results', 'cupric sulfate method': 'false-positives', 'Gerhardt test (urinary ketone analysis)': 'interference', 'VMA determination': 'interference', '5-HIAA': 'interference', 'xylose tolerance test': 'interference', 'T3': 'interference', 'T4': 'interference', 'PBI': 'increased'}\n",
      "{'radioimmunoassay of gonadotropins': 'cross-reacts, especially LH'}\n",
      "{'pregnancy tests': 'interference with interpretation', 'radioimmunoassay of luteinizing hormone and other gonadotropins': 'cross-reactivity'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'Urine screening result for opioids using commercially-available immunoassay kits': 'false-positive', 'levofloxacin and ofloxacin': 'most consistent demonstration of producing false-positive result', 'other quinolones': 'shown cross-reactivity in certain assay kits'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'Thyroid function tests': 'decreased 131I uptake', 'ferric chloride test for phenylketonuria': 'false-positive'}\n",
      "{'Thyroid function tests': '', 'ferric chloride test for phenylketonuria': 'false-positive'}\n",
      "{'technetium-99m-diphosphonate in bone scans': 'interference with diagnostic imaging agents', 'radiopharmaceutical bone imaging': 'no interference.'}\n",
      "{'urine detection of methadone': 'interference (false-positive)'}\n",
      "{\"Coombs' test\": 'positive', 'aldosterone/renin ratio': 'false-positive'}\n",
      "{'hematocrit': 'decreased', 'liver function tests': 'abnormal', 'renal function tests': 'abnormal'}\n",
      "{'urinary glucose tests': 'interference', 'aminoglycosides': 'inactivated in vitro', 'urine proteins': 'false-positive', 'serum proteins': 'false-positive', 'uric acid': 'false-positive', 'urinary steroids': 'false-positive'}\n",
      "{'serum creatinine': '>0.4 mg/dL'}\n",
      "See individual agents\n",
      "{'levofloxacin': 'false-positive', 'ofloxacin': 'false-positive', 'other quinolones': 'cross-reactivity'}\n",
      "{'urine tests for erythrocytes': 'false-positive', 'urine tests for hemoglobin': 'false-positive'}\n",
      "{'Prothrombin time': 'Increased'}\n",
      "{'Skin test antigen wheal and flare reactions': 'May be suppressed'}\n",
      "{'Skin test antigen wheal and flare reactions': 'May be suppressed'}\n",
      "{'spironolactone': 'concurrent or recent use', 'hydrocortisone': 'concurrent or recent use', 'cortisone': 'concurrent or recent use', 'etomidate': 'concurrent or recent use', 'estrogens': 'concurrent or recent use'}\n",
      "{'Rapid Plasma Reagin (RPR)': 'possible false-positive for ≥5 months after COVID-19 vaccination', 'SARS-CoV-2 viral testing (antigen or nucleic acid amplification tests)': 'not affected by COVID-19 vaccines', 'test that detects nucleocapsid protein antibody': 'used to assess for prior infection in COVID-19–vaccinated individuals', 'SARS-CoV-2 spike protein antibody test': 'may indicate either prior infection or vaccination'}\n",
      "{'Rapid Plasma Reagin (RPR)': 'possible false-positive results', 'Treponemal testing': 'does not appear to be affected', 'SARS-CoV-2 viral testing (antigen or nucleic acid amplification tests)': 'not affected by COVID-19 vaccine', 'nucleocapsid protein antibody test': 'used to assess prior infection in COVID-19 vaccinated individuals', 'SARS-CoV-2 spike protein antibody test': 'positive results may indicate either prior infection or vaccination'}\n",
      "{'Automated platelet counts': 'unevaluable or falsely decreased', 'Dehydrogenase pyrroloquinolinequinone or glucose-dye-oxidoreductase testing methods on the day of infusion': 'falsely elevated'}\n",
      "{'Folic acid and vitamin B12 diagnostic blood assays': 'invalidated'}\n",
      "{'Serum TCA screen': 'false-positive'}\n",
      "{'Specific whole blood assay for cyclosporine': 'falsely elevated'}\n",
      "{'Diagnostic antigen skin test results': 'suppressed', 'serum TCA screen': 'false positive'}\n",
      "{'coagulation factors': 'altered', 'lipids': 'altered', 'glucose tolerance': 'altered', 'thyroxine-binding globulin': 'altered', 'sex hormone-binding globulin': 'altered', 'cortisol-binding globulin': 'altered'}\n",
      "{'estimations of nitrogen containing substances': 'may interfere', 'venous blood for blood chemistries': 'do not withdraw through the peripheral infusion site'}\n",
      "{'PT/INR': 'not reliable within 5 hours following danaparoid administration'}\n",
      "{'Estradiol (Kishino 2010)': '', 'testosterone': 'may interfere with laboratory tests', 'androstenedione': 'may interfere with laboratory tests', 'dehydroepiandrosterone': 'may interfere with laboratory tests'}\n",
      "{'Glucosuria test': 'positive', '1,5-anhydroglucitol (1,5-AG) assay': 'inaccurate'}\n",
      "{'Glucosuria test': 'positive', '1,5-anhydroglucitol (1,5-AG) assay': 'inaccurate'}\n",
      "{'Glucosuria test': 'positive', '1,5-anhydroglucitol (1,5-AG) assay': 'inaccurate'}\n",
      "{'HbA1c': 'may artificially lower by reducing erythrocyte survival time through hemolysis'}\n",
      "{'PT/INR': 'elevated'}\n",
      "{'Indirect antiglobulin test (indirect Coombs test)': 'positive', 'Serum protein electrophoresis and immunofixation assays': 'interference'}\n",
      "{'CD38 on RBCs compatibility testing': 'interfered with by daratumumab binding', 'antibody screening': 'interfered with by daratumumab binding', 'cross matching': 'interfered with by daratumumab binding', 'serum protein electrophoresis (SPE) assay': 'may have false positive results for patients with IgG kappa myeloma protein', 'immunofixation (IFE) assay': 'may have false positive results for patients with IgG kappa myeloma protein', 'daratumumab-specific IFE assay': 'used to distinguish daratumumab from any residual endogenous M protein in patients with persistent very good partial response'}\n",
      "{'HbA1c': 'may be artificially lowered by erythropoiesis-stimulating agents through increased circulation of immature erythrocytes with less exposure to glucose'}\n",
      "{'TIBC': 'may be falsely elevated with high serum iron concentrations or deferoxamine therapy'}\n",
      "{'pituitary-gonadal function': 'suppressed', 'diagnostic tests of pituitary gonadotropic': 'affected', 'diagnostic tests of gonadal functions': 'affected'}\n",
      "{'amphetamines/methamphetamines': 'false-positive'}\n",
      "See individual agents\n",
      "{'wheal reactions to skin test antigens': 'suppressed', 'flare reactions to skin test antigens': 'suppressed'}\n",
      "{'Urine detection of phencyclidine and amphetamine': 'false-positive'}\n",
      "{'Skin test antigens': 'suppressed wheal and flare reactions'}\n",
      "{'Serum chromogranin A (CgA) levels': 'false-positive due to decreased gastric acidity and temporarily stopping dexlansoprazole'}\n",
      "{'Serum glucose testing methods that use high concentrations of acid': 'Falsely elevated', 'Bilirubin assays that use alcohol': 'Interference', 'Total protein assays using biuret reagents': 'Interference', 'Dextran 70': 'Erythrocyte aggregation and interference with blood typing and cross matching of blood'}\n",
      "{'Plasma corticosteroid levels': 'Significantly elevated', 'Urinary steroid testing': 'Interference'}\n",
      "{'Plasma corticosteroid levels': 'Elevated', 'Urinary steroid determinations': 'Interference'}\n",
      "{'urine detection of amphetamine/methamphetamine': 'false-positive'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'phencyclidine': 'False-positive', 'opioids': 'False-positive', 'heroin': 'False-positive'}\n",
      "See individual agents\n",
      "{'phencyclidine': 'False-positive', 'opioids': 'False-positive', 'heroin': 'False-positive'}\n",
      "{'Protein bound iodine uptake studies': 'inaccurate for up to 1 year after enteral administration of iodinated contrast agents', 'Radioactive iodine update studies': 'inaccurate for up to 1 year after enteral administration of iodinated contrast agents', 'Trypsin values (determined spectrophotometrically)': 'false low due to oral contrast agents'}\n",
      "{'Urine specimen assay': 'may be interfered with by contrast agent instillation into bladder'}\n",
      "{'Urinary glucose determinations when using Clinistix® or Diastix®': 'false-negative'}\n",
      "{'Serum renin concentrations': 'increased', 'IgG concentrations': 'increased', 'Serum cortisol concentrations': 'decreased', 'Insulin response to glucagon': 'false-negative'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'Urine proteins': 'false-positive', 'Serum proteins': 'false-positive', 'Uric acid': 'false-positive', 'Urinary steroids': 'false-positive', 'Urinary glucose tests using cupric sulfate': 'interference', 'Aminoglycosides': 'inactivated'}\n",
      "{'Endocrine function tests': 'may interfere', 'Glucose tolerance test': 'may be affected', 'Serum folate test': 'may be affected', 'Lipoprotein level test': 'may be affected'}\n",
      "{'Serum salicylate test': 'falsely elevated', 'Aldosterone/Renin ratio (ARR)': 'false-positive'}\n",
      "{'Digitalis immunoassay test': 'may be interfered', 'Total serum digoxin concentration': 'clinically misleading'}\n",
      "{'digoxin radioimmunoassay': 'interference by Spironolactone'}\n",
      "{'Iodine I131 thyroidal uptake': 'decreased'}\n",
      "{'urine detection of methadone and phencyclidine': 'false-positives', 'serum TCA screen': 'false-positive', 'wheal and flare reactions to skin test antigens': 'suppressed'}\n",
      "{'skin test antigens': 'May suppress the wheal and flare reactions'}\n",
      "See individual agents\n",
      "{'urine antigen detection tests for H. influenzae': 'May interfere with interpretation, antigenuria may occur up to 2 weeks following immunization'}\n",
      "{'dipyridamole-thallium myocardial imaging': 'false-negative result'}\n",
      "{'tubular secretion of creatinine': 'May inhibit without affecting actual renal glomerular function'}\n",
      "{'Glucose oxidase tests': 'false-negative urine glucose', 'Fluorescence tests': 'false elevations of urinary catecholamines'}\n",
      "{'Urine drug screen': 'false positive for methadone, opiates, and PCP'}\n",
      "{'urine detection of methadone': 'may have false-positive results'}\n",
      "{'coagulation factors': 'changed results', 'lipids': 'changed results', 'glucose tolerance': 'changed results', 'thyroxine-binding globulin': 'changed results', 'sex hormone-binding globulin': 'changed results', 'cortisol-binding globulin': 'changed results'}\n",
      "{'metyrapone': 'reduced response'}\n",
      "{'coagulation factors': 'May be changed by contraceptive steroids', 'lipids': 'May be changed by contraceptive steroids', 'glucose tolerance': 'May be changed by contraceptive steroids', 'thyroxine-binding globulin': 'May be changed by contraceptive steroids', 'sex hormone-binding globulin': 'May be changed by contraceptive steroids', 'cortisol-binding globulin': 'May be changed by contraceptive steroids'}\n",
      "{'PSA levels': 'decrease', 'treated patients': None, 'therapy': '3 months', 'stabilize': None, 'new baseline': '~50% of pretreatment values', 'serial PSAs': 're-establish a new baseline after ≥3 months of use', 'isolated PSA value': 'double the PSA value for comparison'}\n",
      "{'PSA levels': 'decrease', 'therapy': '3 months', 'new baseline': '~50% of pretreatment values', 'serial PSAs': 're-establish new baseline after ≥3 months of use', 'isolated PSA value': 'double the PSA value for comparison'}\n",
      "Couldn't be interpreted\n",
      "{'Blood lead concentration test': 'falsely elevated'}\n",
      "{'Anti-factor Xa assay': 'falsely elevated', 'aPTT test': 'little or minor effect'}\n",
      "{'Screening assays for cannabinoids': 'false-positive', 'Confirmation test for cannabinoids': 'more specific'}\n",
      "{'Screening assays for cannabinoids': 'false-positive', 'Confirmation test for cannabinoids': 'more specific'}\n",
      "{'CEDIA DAU Multilevel THC assay': 'false-positive', 'Other assays for cannabinoids': 'no false-positives observed', 'Benzodiazepines tests': 'false-positive', 'Cause of benzodiazepines false-positive': '8-hydroxy-efavirenz major metabolite'}\n",
      "{'nuclear imaging': 'may show transient positive bone-imaging findings in response to growth factor therapy, interpret results accordingly'}\n",
      "{'coagulation factors': 'result', 'lipids': 'result', 'glucose tolerance': 'result', 'thyroxine-binding globulin': 'result', 'sex hormone-binding globulin': 'result', 'cortisol-binding globulin': 'result'}\n",
      "{'polymerase chain reaction (PCR) assays for HIV': 'positive', 'lentiviral vector proviral DNA': 'positive'}\n",
      "{'serum protein electrophoresis': 'may be affected by elotuzumab and show a small peak in the early gamma region when endogenous myeloma protein is IgA, IgM, IgD, or lambda light chain restricted', 'serum immunofixation assays': 'may be affected by elotuzumab and show a small peak in the early gamma region when endogenous myeloma protein is IgA, IgM, IgD, or lambda light chain restricted'}\n",
      "{'activated clotting time': 'affected', 'activated partial thromboplastin time': 'affected', 'one-stage factor VIII activity': 'affected'}\n",
      "{'glucosuria': 'positive', '1,5-anhydroglucitol assay': 'interference'}\n",
      "{'Glucosuria testing': 'positive', '1,5-AG assay': 'may be interfered', 'Glycemic control monitoring': 'use alternative methods'}\n",
      "See individual agents\n",
      "{'Aldosterone/renin ratio test': 'may be falsely negative'}\n",
      "{'Aldosterone/renin ratio test': 'may be falsely negative'}\n",
      "{'Assays involving prolonged incubation periods': 'falsely elevated free thyrotropin and free triiodothyronine levels'}\n",
      "{'Assays for digoxin levels': 'falsely-elevated or therapeutic digoxin levels for patients not taking digoxin'}\n",
      "{'Amphetamine EMIT assay': 'false-positive'}\n",
      "{'aldosterone/renin ratio': 'false negative'}\n",
      "{'HbA1c': 'artificially lower'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio': 'false-negative'}\n",
      "{'Glucosuria': 'positive test caused by Ertugliflozin', '1,5-anhydroglucitol': 'assay interference by Ertugliflozin'}\n",
      "{'Glucosuria testing': 'positive', '1,5-anhydroglucitol (1,5-AG) assay': 'interfered', 'Glycemic control monitoring': 'use alternative methods'}\n",
      "{'Glucosuria testing': 'positive', '1,5-anhydroglucitol (1,5-AG) assay': 'interfered', 'Glycemic control monitoring': 'use alternative methods'}\n",
      "{'fluorometric assay': 'false-positive urinary catecholamines', '17-hydroxycorticosteroids': 'false-positive', '17-ketosteroids': 'false-positive'}\n",
      "{'serum chromogranin A (CgA) levels': 'falsely elevated', 'neuroendocrine tumor': 'false-positive results'}\n",
      "{'laboratory tests': 'altered results', 'coagulation factors': 'altered results', 'lipids': 'altered results', 'glucose tolerance': 'altered results', 'thyroxine-binding globulin': 'altered results', 'sex hormone–binding globulin': 'altered results', 'cortisol-binding globulin': 'altered results', 'metyrapone test': 'reduced response'}\n",
      "{'Coagulation factors testing': 'altered results', 'Lipids testing': 'altered results', 'Glucose tolerance testing': 'altered results', 'Thyroxine-binding globulin testing': 'altered results', 'Sex hormone-binding globulin testing': 'altered results', 'Cortisol-binding globulin testing': 'altered results', 'Metyrapone test': 'reduced response'}\n",
      "{'Coagulation factors testing': 'changed results', 'Lipids testing': 'changed results', 'Glucose tolerance testing': 'changed results', 'Thyroxine-binding globulin testing': 'changed results', 'Sex hormone-binding globulin testing': 'changed results', 'Cortisol-binding globulin testing': 'changed results'}\n",
      "{'Coagulation factors testing': 'altered results', 'Lipids testing': 'altered results', 'Glucose tolerance testing': 'altered results', 'Thyroxine-binding globulin testing': 'altered results', 'Sex hormone–binding globulin testing': 'altered results', 'Cortisol-binding globulin testing': 'altered results'}\n",
      "{'Coagulation factors testing methods': 'altered results', 'Lipids testing methods': 'altered results', 'Glucose tolerance testing methods': 'altered results', 'Thyroxine-binding globulin testing methods': 'altered results', 'Sex hormone-binding globulin testing methods': 'altered results', 'Cortisol-binding globulin testing methods': 'altered results', 'Metyrapone test': 'reduced response'}\n",
      "{'Metyrapone test': 'reduced response'}\n",
      "{'Metyrapone test': 'reduced response'}\n",
      "{'coagulation factors': 'Altered results with use of estrogens and/or progestogens', 'lipids': 'Altered results with use of estrogens and/or progestogens', 'glucose tolerance': 'Altered results with use of estrogens and/or progestogens', 'thyroxine-binding globulin': 'Altered results with use of estrogens and/or progestogens', 'sex hormone-binding globulin': 'Altered results with use of estrogens and/or progestogens', 'cortisol-binding globulin': 'Altered results with use of estrogens and/or progestogens'}\n",
      "{'metyrapone test': 'reduced response'}\n",
      "{'metyrapone': 'reduced response'}\n",
      "{'coagulation factors': 'may show altered results due to the use of estrogens and/or progestins', 'lipids': 'may show altered results due to the use of estrogens and/or progestins', 'glucose tolerance': 'may show altered results due to the use of estrogens and/or progestins', 'thyroxine-binding globulin': 'may show altered results due to the use of estrogens and/or progestins', 'sex hormone-binding globulin': 'may show altered results due to the use of estrogens and/or progestins', 'cortisol-binding globulin': 'may show altered results due to the use of estrogens and/or progestins'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'Coagulation factors': 'changed results', 'Lipids': 'changed results', 'Glucose tolerance': 'changed results', 'Thyroxine-binding globulin': 'changed results', 'Sex hormone-binding globulin': 'changed results', 'Cortisol-binding globulin': 'changed results'}\n",
      "{'coagulation factors': 'changed results', 'lipids': 'changed results', 'glucose tolerance': 'changed results', 'thyroxine-binding globulin': 'changed results', 'sex hormone-binding globulin': 'changed results', 'cortisol-binding globulin': 'changed results'}\n",
      "{'coagulation factors': 'changed results', 'lipids': 'changed results', 'glucose tolerance': 'changed results', 'thyroxine-binding globulin': 'changed results', 'sex hormone–binding globulin': 'changed results', 'cortisol-binding globulin': 'changed results'}\n",
      "{'coagulation factors': 'alter results', 'lipids': 'alter results', 'glucose tolerance': 'alter results', 'thyroxine-binding globulin': 'alter results', 'sex hormone-binding globulin': 'alter results', 'cortisol-binding globulin': 'alter results'}\n",
      "Couldn't be interpreted\n",
      "{'coagulation factors': 'altered results', 'lipids': 'altered results', 'glucose tolerance': 'altered results', 'thyroxine-binding globulin': 'altered results', 'sex hormone-binding globulin': 'altered results', 'cortisol-binding globulin': 'altered results'}\n",
      "{'coagulation factors': 'altered results', 'lipids': 'altered results', 'glucose tolerance': 'altered results', 'thyroxine-binding globulin': 'altered results', 'sex hormone-binding globulin': 'altered results', 'cortisol-binding globulin': 'altered results'}\n",
      "{'coagulation factors': 'altered results', 'lipids': 'altered results', 'glucose tolerance': 'altered results', 'thyroxine-binding globulin': 'altered results', 'sex hormone-binding globulin': 'altered results', 'cortisol-binding globulin': 'altered results'}\n",
      "{'coagulation factors': 'changed due to use of estrogens and/or progestins', 'lipids': 'changed due to use of estrogens and/or progestins', 'glucose tolerance': 'changed due to use of estrogens and/or progestins', 'thyroxine-binding globulin': 'changed due to use of estrogens and/or progestins', 'sex hormone-binding globulin': 'changed due to use of estrogens and/or progestins', 'cortisol-binding globulin': 'changed due to use of estrogens and/or progestins'}\n",
      "{'technetium-99m-diphosphonate': 'interfered by bisphosphonates in bone scans'}\n",
      "Couldn't be interpreted\n",
      "{'urinary bilirubin': 'false-positive', 'ketone': 'false-positive', 'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'coagulation factors': 'altered', 'lipids': 'altered', 'glucose tolerance': 'altered', 'thyroxine-binding globulin': 'altered', 'sex hormone-binding globulin': 'altered', 'cortisol-binding globulin': 'altered'}\n",
      "{'aPTT-based one-stage clotting assay': 'positive', 'chromogenic substrate assay': 'negative'}\n",
      "{'serum and urine bilirubin assays': 'falsely elevated'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'Amerlex-M kit assay': 'interferes with values', 'total triiodothyronine': 'falsely elevated', 'free triiodothyronine': 'falsely elevated', 'aldosterone/renin ratio (ARR)': 'may lead to false-positive'}\n",
      "{'Serum iron levels': 'falsely elevated', 'transferrin bound iron levels': 'falsely elevated'}\n",
      "{'Serum iron levels': 'falsely elevated', 'transferrin bound iron levels': 'falsely elevated', 'Serum ferritin levels': 'falsely elevated'}\n",
      "{'guaiac test': 'false-positive'}\n",
      "{'guaiac test': 'false-positive'}\n",
      "{'MR imaging': 'interference; alterations may persist for ≤3 months following use, with peak alterations anticipated in the first 2 days following administration. T1- or proton density-weighted MR pulse sequences should be used to decrease effect on imaging if MR imaging is required within 3 months after administration. T2-weighted sequence MR imaging should not be used prior to 4 weeks following administration.', 'Serum iron': 'may be overestimated if level is drawn during the first 24 hours following administration (due to contribution of iron in ferumoxytol)', 'transferrin-bound iron': 'may be overestimated if level is drawn during the first 24 hours following administration (due to contribution of iron in ferumoxytol)'}\n",
      "See individual agents\n",
      "{'skin test antigens': 'negative'}\n",
      "Couldn't be interpreted\n",
      "{'Prostate specific antigen (PSA) levels': 'decrease'}\n",
      "{'PSA levels': 'decrease in treated patients', 'New baseline after 6 months of therapy': '~50% of pretreatment values', 'Re-establish a new baseline': 'after ≥6 months of use'}\n",
      "{'PSA levels': 'affect imaging performance of fluciclovine F18'}\n",
      "{}\n",
      "{'Nitrobluetetrazollum test for bacterial infection': 'false-negative results'}\n",
      "{'thyroxine-binding globulin': 'decreased levels', 'total T4 serum levels': 'decreased', 'resin uptake of T3 and T4': 'increased'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'Lactobacillus casei assay method': 'falsely low serum concentrations'}\n",
      "{'antifactor Xa activity of fondaparinux': 'not appropriate with international standards of heparin or LMWH as calibrators'}\n",
      "See individual agents\n",
      "{'Digi-Tab RIA kit for digoxin': 'false low serum digoxin levels', 'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'immunoanalytical techniques (eg, TDX, TDXFLX, Emit 2000) prior to complete conversion of fosphenytoin to phenytoin': 'falsely high plasma phenytoin concentrations due to cross-reactivity with fosphenytoin', 'dexamethasone or metyrapone tests': 'falsely low results', 'serum folate levels': 'potential decrease due to phenytoin'}\n",
      "{'estradiol immunoassay': 'falsely elevated estradiol levels due to interference with fulvestrant'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative results'}\n",
      "Couldn't be interpreted\n",
      "{'Ames N-Multistix SG® dipstick test': 'false positives'}\n",
      "{'Serum ferritin test': 'transient increase', 'Urine zinc test': 'transient increase (with renal disease)', 'Bilirubin test': 'transient increase (with hepatic metabolic disorders)'}\n",
      "{'colorimetric tests for serum calcium': 'apparent decrease'}\n",
      "{'serum iron': 'transient changes', 'copper': 'transient changes', 'zinc': 'transient changes', 'colorimetric tests for serum calcium': 'apparent decrease'}\n",
      "{'serum iron': 'falsely high or low values (if determined by complexometric methods)'}\n",
      "Couldn't be interpreted\n",
      "Couldn't be interpreted\n",
      "{'Methotrexate levels': 'the chromatographic method'}\n",
      "See individual agents\n",
      "{'Pituitary gonadotropic and gonadal function tests': 'interference during and for up to 12 weeks after discontinued'}\n",
      "{'Urinary VMA levels': 'false-positive (Rampini 1989)'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'5-HIAA and VMA': 'possible color interference, discontinue for 48 hours prior to test'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'urine antigen detection tests': 'may interfere', 'antigenuria': 'may occur up to 2 weeks following immunization'}\n",
      "{'Anti-factor Xa assay': 'falsely elevated results', 'aPTT': 'N/A', 'Free T4 assay': 'falsely elevated levels', 'Free T3 assay': 'falsely elevated levels', 'Thyroid stimulating hormone assay': 'not usually affected', 'Standard competitive free thyroid hormone assay': 'not usually affected'}\n",
      "{'HBsAg': 'transiently detected in blood samples within 28 days after receipt of hepatitis B vaccine'}\n",
      "{'Glucose monitoring': 'falsely elevated blood glucose levels', 'Serological testing': 'misleading positive test results', 'Coombs’ test': 'misleading positive test results'}\n",
      "{'hepatitis B surface antigen (HBsAg)': 'transiently detected in blood samples', 'serum HBsAg detection': 'may not have diagnostic value within 28 days after receipt of hepatitis B vaccine'}\n",
      "{'Hepatitis B surface antigen (HBsAg)': 'may not have diagnostic value within 28 days after receipt of hepatitis B vaccine'}\n",
      "{'Serum HBsAg detection': 'may not have diagnostic value within 28 days after receipt of hepatitis B vaccine'}\n",
      "{'Serum amylase levels': 'could interfere with the diagnosis of pancreatitis. Do not use serum amylase levels to assess or to evaluate for pancreatitis for 3 for 5 days after administration', 'Coagulation factors, plasma proteins, and /or hematocrit': 'may decrease due to dilutional effect of large hetastarch volumes'}\n",
      "{'diagnostic test of pituitary gonadotropic and gonadal functions': 'may be affected'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'parathyroid function tests': 'may interfere', 'serum iodine (protein bound)': 'may decrease without signs of thyroid disturbance', 'aldosterone/renin ratio (ARR)': 'may lead to false-negative'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'urine screening result for opioids': 'may produce false-positive'}\n",
      "{'Urine detection of phencyclidine': 'false-positives', 'Urine detection of cannabinoids': 'false-positives', 'Urine detection of barbiturates': 'false-positives'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'Urine screening result for opioids using commercially-available immunoassay kits': 'false-positive', 'Levofloxacin': 'cross-reactivity', 'Ofloxacin': 'cross-reactivity', 'Other quinolones': 'cross-reactivity'}\n",
      "{'Response to skin tests': 'decrease'}\n",
      "{'Urine screening test for opioids using immunoassay kits': 'false-positive', 'Dehydrogenase pyrroloquinolinequinone or glucose-dye-oxidoreductase testing methods on the day of infusion': 'falsely elevated'}\n",
      "{'Basophils': 'falsely elevated', 'Hemoglobin': 'falsely elevated', 'MCH': 'falsely elevated', 'MCHC': 'falsely elevated', 'Albumin': 'falsely elevated', 'Alkaline phosphatase': 'falsely elevated', 'Cholesterol': 'falsely elevated', 'Creatinine': 'falsely elevated', 'Glucose': 'falsely elevated', 'Total protein': 'falsely elevated', 'Triglycerides': 'falsely elevated', 'Bilirubin': 'falsely elevated', 'Urinalysis - Glucose': 'falsely elevated', 'Urinalysis - Protein': 'falsely elevated', 'Urinalysis - Erythrocytes': 'falsely elevated', 'Urinalysis - Leukocytes': 'falsely elevated', 'Urinalysis - Ketones': 'falsely elevated', 'Urinalysis - Bilirubin': 'falsely elevated', 'Urinalysis - Urobilinogen': 'falsely elevated', 'Urinalysis - Nitrite': 'falsely elevated', 'ALT': 'falsely decreased', 'Amylase': 'falsely decreased', 'AST': 'unpredictable', 'CK': 'unpredictable', 'CKMB': 'unpredictable', 'LDH': 'unpredictable', 'Phosphate': 'unpredictable', 'Uric acid': 'unpredictable', 'PT (quick or INR)': 'unpredictable', 'aPTT': 'unpredictable', 'Urine pH': 'unpredictable'}\n",
      "{'Coagulation factors': 'affected', 'Tests of hepatic function': 'affected', 'Tests of thyroid function': 'affected'}\n",
      "{'lactic acid': 'falsely elevated', 'urea': 'falsely elevated', 'uric acid': 'falsely elevated'}\n",
      "{'serum TCA screen': 'false-positive'}\n",
      "See individual agents\n",
      "{'technetium-99m-diphosphonate': 'interference'}\n",
      "{'Urinary 5-hydroxyindoleacetic acid testing': 'false-positive result', 'Phencyclidine detection in urine testing': 'false-positive result', 'Aldosterone/Renin ratio testing': 'false-positive result'}\n",
      "See individual agents\n",
      "{'Phencyclidine detection in urine testing': 'false-positive result', 'Aldosterone/Renin ratio testing': 'false-positive result'}\n",
      "{'Glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ), glucose-dye-oxidoreductase (GDO), or some glucose dehydrogenase flavin-adenine dinucleotide [GDH- FAD]-based methods testing': 'falsely elevated blood glucose levels', 'Enzymatic-based amylase assays testing': 'inaccurate serum amylase levels'}\n",
      "{'Urinary glucose determination using Clinitest®': 'interfered', \"Coombs' [direct]\": 'positive'}\n",
      "{'Coombs': 'positive'}\n",
      "{'Passively transferred antibodies': 'false-positive serologic testing results; false-positive direct and indirect Coombs test', 'beta-D-glucans': 'false positive readings in assays for diagnosis of fungal infection', 'GamaSTAN and GamaSTAN S/D [Canadian product]': 'Skin testing should not be performed because local chemical irritation can occur and be misinterpreted as a positive reaction'}\n",
      "{'parathyroid function tests': 'may interfere', 'serum iodine (protein bound)': 'may decrease without signs of thyroid disturbance', 'aldosterone/renin ratio (ARR)': 'may lead to false-negative'}\n",
      "{'PSA': 'falsely high values may result', 'Digoxin': 'falsely high values may result'}\n",
      "{'Radioactive iodine tests': 'Do not perform for at least 1 week following indocyanine green administration', 'Blood samples for analysis': 'Heparin solutions containing sodium bisulfate should not be used as an anticoagulant (reduces absorption peak)'}\n",
      "{'dexamethasone suppression test': 'false-negative', 'aldosterone/renin ratio': 'false-positive'}\n",
      "{'intranasal influenza virus vaccine': 'positive on rapid influenza diagnostic test for 7 days after administration'}\n",
      "{'thyroid function tests': 'altered with excessive absorption'}\n",
      "{'Thyroid function tests (protein bound and radioactive iodine uptake studies)': 'inaccurate for up to 16 days after administration', 'Multistix urine protein test': 'false positive', 'Urine specific gravity test': 'may be affected'}\n",
      "See individual agents\n",
      "{'Thyroid function tests': 'may interfere', 'Ferric chloride test for Phenylketonuria': 'false-positive'}\n",
      "{'Iodine-binding capacity test of thyroid tissue': 'may be reduced for up to 2 weeks following administration of contrast media', 'Diagnostic tests using iodine-containing isotopes': 'may be affected', 'Thyroid function tests independent of iodine estimation': 'not affected'}\n",
      "{'thyroid function tests': 'May interfere'}\n",
      "{'Iodine-binding capacity of thyroid tissue may be reduced for up to 2 weeks following administration of contrast media': 'may be affected', 'Thyroid function tests that are independent of iodine estimation for results are not affected (eg, T3 resin uptake, thyroxine assays)': 'not affected'}\n",
      "{'Thyroid function tests': 'not accurately assess function for at least 16 days following administration of iodinated contrast agents.', 'PTT': 'may be affected by Iopromide.', 'Calcium thromboplastin time': 'may be affected by Iopromide.', 'Thrombin activity': 'may be affected by Iopromide.', 'Factor XIIa': 'no effects have been demonstrated.'}\n",
      "{'Thyroid function tests': 'may be altered', 'Radioiodine uptake studies': 'may be affected', 'Diagnostic tests with iodinated contrast media': 'perform prior to'}\n",
      "{'athletic performance enhancement testing': 'may be interfered with the use of fenoterol.'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{' bony uptake': 'reduced', 'renal activity': 'marked', 'blood pooling': 'excess', 'soft tissue': ' accumulation'}\n",
      "{'Indirect antiglobulin test': 'false-positive test caused by Isatuximab binding to CD38 on RBCs', 'Antibody detection tests': 'false-positive tests caused by Isatuximab binding to CD38 on RBCs', 'Antibody identification panels': 'false-positive panels caused by Isatuximab binding to CD38 on RBCs', 'Antihuman globulin crossmatches': 'false-positive crossmatches caused by Isatuximab binding to CD38 on RBCs', 'Blood type and screening': 'required prior to first isatuximab infusion; interfered by isatuximab binding to CD38 on RBCs', 'Phenotyping': 'considered prior to initiating isatuximab treatment', 'Serum protein electrophoresis': 'accuracy interference by Isatuximab', 'Immunofixation tests': 'accuracy interference by Isatuximab'}\n",
      "{'Urinary glucose': 'false-positive with Clinitest®'}\n",
      "{'Peripheral oxygenation measurements': 'falsely low due to isosulfan blue interference (peak interference is 30 minutes after administration; minimal effect by ~4 hours postdose)', 'Methemoglobin levels via arterial blood gas analyzer': 'falsely elevated'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'urine detection of phencyclidine': 'false-positive'}\n",
      "{'albumin': 'interferes', 'bile salts': 'interferes', '17-ketosteroids': 'interferes', '17-hydroxycorticosteroids': 'interferes', 'proteinuria': 'no interference', 'aldosterone/renin ratio (ARR)': 'may lead to false-positive'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'urine catecholamines': 'false-positive', 'metanephrine': 'false-positive', 'normetanephrine': 'false-positive', 'vanillylmandelic acid (VMA)': 'false-positive', 'urine amphetamine': 'false-positive', 'aldosterone/renin ratio (ARR)': 'may lead to false-positive'}\n",
      "{'Rapid urine drug screens': 'may be interfered with', 'Phencyclidine test': 'may show false-positives'}\n",
      "{'activated partial thromboplastin time': 'increased'}\n",
      "See individual agents\n",
      "{'abdominal x-rays': 'radiopaque appearance'}\n",
      "See individual agents\n",
      "{'pituitary gonadotropic function tests': 'interferes', 'gonadal function tests': 'interferes'}\n",
      "{'aldosterone/renin ratio': 'false-negative'}\n",
      "{'Plasma levels of catecholamines': 'false positive', 'Urine levels of catecholamines': 'false positive'}\n",
      "{'Glucose-oxidase tests for glucosuria': 'false negative', 'Urine ketones': 'false positive', 'Plasma levels of catecholamines': 'false positive', 'Urine levels of catecholamines': 'false positive'}\n",
      "{'Urine screening result for opioids using commercially-available immunoassay kits': 'false positive'}\n",
      "{'urine screening result for opioids using commercially-available immunoassay kits': 'false-positive', 'levofloxacin': 'cross-reactivity', 'ofloxacin': 'cross-reactivity', 'other quinolones': 'cross-reactivity'}\n",
      "{'T4-binding globulin (TBG)': ''}\n",
      "See individual agents\n",
      "{'T4-binding globulin (TBG)': ''}\n",
      "{'Hemoglobin': 'interference due to elevated plasma lipids if blood sampled before lipids clear from bloodstream', 'Lactate dehydrogenase': 'interference due to elevated plasma lipids if blood sampled before lipids clear from bloodstream', 'Bilirubin': 'interference due to elevated plasma lipids if blood sampled before lipids clear from bloodstream', 'Oxygen saturation': 'interference due to elevated plasma lipids if blood sampled before lipids clear from bloodstream'}\n",
      "{'Hemoglobin': 'interference due to elevated plasma lipids if blood sampled before lipids clear from bloodstream', 'Lactate dehydrogenase': 'interference due to elevated plasma lipids if blood sampled before lipids clear from bloodstream', 'Bilirubin': 'interference due to elevated plasma lipids if blood sampled before lipids clear from bloodstream', 'Oxygen saturation': 'interference due to elevated plasma lipids if blood sampled before lipids clear from bloodstream'}\n",
      "{'Plasma corticosteroid levels': 'elevated due to amphetamines', 'Urinary steroid determinations': 'interference due to amphetamines'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "See individual agents\n",
      "{'skin test antigens': 'may suppress the wheal and flare reactions'}\n",
      "See individual agents\n",
      "{'Phenylketonuria test': 'false-positive', 'Amylase test': 'false-positive', 'Uroporphyrins test': 'false-positive', 'Urobilinogen test': 'false-positive'}\n",
      "{'magnesium': 'increased', 'protein': 'decreased', 'calcium': 'decreased', 'potassium': 'decreased'}\n",
      "{'magnesium': 'increased', 'protein': 'decreased', 'calcium (S)': 'decreased', 'potassium (S)': 'decreased'}\n",
      "{'blood ethylene glycol concentrations': 'false positive', 'inorganic phosphorus blood concentrations': 'false low'}\n",
      "{'Tuberculin skin test reactivity': 'temporarily suppressed'}\n",
      "{'Tuberculin skin test': 'may interfere with sensitivity'}\n",
      "{'Aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'coagulation factors': 'altered', 'lipids': 'altered', 'glucose tolerance': 'altered', 'sex hormone–binding globulin': 'altered'}\n",
      "{'urinary bilirubin': 'false-positive', 'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{\"Coombs' test [direct]\": 'False-positive'}\n",
      "{'Urine antigen tests for H. influenzae type b': 'May not be diagnostic within 1-2 weeks of vaccination'}\n",
      "{'Amylase (S)': 'Increased', 'Bromsulphalein retention test (BSP)': 'Increased', 'Creatine phosphokinase (CPK)': 'Increased'}\n",
      "{'TPMT testing': 'misinterpretation of actual TPMT activity due to recent transfusions; TPMT activity in blood may be influenced by concomitant drugs'}\n",
      "{\"Positive Coombs'\": 'positive result indicating the presence of antibodies on red blood cells'}\n",
      "{\"Positive Coombs' [direct]\": 'positive result indicating the presence of antibodies attached to red blood cells'}\n",
      "Couldn't be interpreted\n",
      "{'Urinary ketones': 'False-positive', 'CPK activity': 'Falsely low', 'Ascorbic acid': 'False-positive'}\n",
      "{\"Benedict's Test\": 'false-positive'}\n",
      "{'urine screening result for opioids': 'may produce false-positive', 'methadone screens': 'false-positive', 'diphenhydramine': 'reported', 'doxylamine': 'reported', 'clomipramine': 'reported', 'chlorpromazine': 'reported', 'thioridazine': 'reported', 'quetiapine': 'reported', 'verapamil': 'reported'}\n",
      "Couldn't be interpreted\n",
      "{'aldosterone/renin ratio': 'false-negative'}\n",
      "{'urinary catecholamines': 'increased', '17-hydroxycorticosteroid': 'increased', 'vanillylmandelic acid (VMA) levels': 'increased', 'urinary 5-hydroxyindoleacetic acid (5HIAA)': 'decreased', 'urine estriol levels': 'decreased'}\n",
      "{'screening tests for 5-HIAA': 'color interference', 'nitrosonaphthol reagent': 'color interference', 'screening tests for urinary VMA': 'color interference', 'Gitlow method': 'color interference'}\n",
      "{'pregnancy tests': 'false-positive or negative', 'Phenothiazines': 'cause'}\n",
      "{'Neutralizing antibody assay': 'Obtain serum samples at least a month after the last dose to prevent assay interference.', 'HbA1c': 'Erythropoiesis-stimulating agents may artificially lower HbA1c through increased circulation of immature erythrocytes in the peripheral blood stream that have less exposure to glucose'}\n",
      "See individual agents\n",
      "{'Urinary uric acid': 'Methyldopa interferes with the test (phosphotungstate method)', 'Serum creatinine': 'Methyldopa interferes with the test (alkaline picrate method)', 'AST': 'Methyldopa interferes with the test (colorimetric method)', 'Urinary catecholamines': 'Methyldopa causes falsely high levels', 'aldosterone/renin ratio': 'false-positive'}\n",
      "{'leucocyte esterase': 'may interfere with interpretation'}\n",
      "{'amphetamines/methamphetamines detection in urine': 'false-positive'}\n",
      "{'Skin test response': 'decreased'}\n",
      "{'Thyroxine-binding globulin levels': 'decreased', 'Total T4 serum levels': 'decreased', 'Resin uptake of T3 and T4': 'increased', 'Free thyroid hormone levels': 'not changed'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "See individual agents\n",
      "{'AST': 'May interfere', 'ALT': 'May interfere', 'triglycerides': 'May interfere', 'glucose': 'May interfere', 'LDH': 'May interfere'}\n",
      "{'AST': 'falsely negative or abnormally low', 'ALT': 'falsely negative or abnormally low', 'triglycerides': 'falsely negative or abnormally low', 'glucose': 'falsely negative or abnormally low', 'LDH': 'falsely negative or abnormally low'}\n",
      "{'cortisol measurement': 'Use liquid chromatography-tandem mass spectrometry assays for cortisol measurement in patients taking metyrapone'}\n",
      "{'urinary catecholamines': 'Increased'}\n",
      "{'Liver function test': 'Abnormal', 'ANA': 'Positive', 'Thrombocytopenia': ''}\n",
      "Couldn't be interpreted\n",
      "{'Fluorescence test for urinary catecholamines': 'False elevations'}\n",
      "{'Fluorescence test for urinary catecholamines': 'false elevations'}\n",
      "See individual agents\n",
      "{'BUN': 'increased', 'creatinine': 'increased', 'potassium': 'increased', \"Coombs' [direct]\": 'positive', 'cholesterol (S)': 'decreased', 'urine acetone determinations using sodium nitroprusside reagent': 'false-positive results', 'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'urine screening result for opioids using commercially-available immunoassay kits': 'false-positive', 'levofloxacin': 'causes false-positive', 'ofloxacin': 'causes false-positive', 'other quinolones': 'may show cross-reactivity'}\n",
      "See individual agents\n",
      "{'cellular CD22 detection': 'may be interfered with by Moxetumomab pasudotox', 'CD19+ B cells assay': 'may be used as a surrogate'}\n",
      "{'Urine screening test for opioids using commercially-available immunoassay kits': 'false-positive for some quinolones'}\n",
      "{'Aldosterone/Renin Ratio (ARR) test': 'false-positive'}\n",
      "{'Phentolamine test': 'false negative with bendroflumethiazide', 'Tyramine test': 'false negative with bendroflumethiazide', 'Phenolsulfonphthalein test': 'interference with bendroflumethiazide', 'Electrolyte levels (serum) test': 'diagnostic interference with bendroflumethiazide', 'Glucose (serum) test': 'diagnostic interference with bendroflumethiazide', 'Glucose (urine) test': 'diagnostic interference with bendroflumethiazide', 'PBI (serum) test': 'decreased levels without signs of thyroid disturbance with bendroflumethiazide'}\n",
      "{'aldosterone/renin ratio (ARR)': 'May lead to false-positive'}\n",
      "Couldn't be interpreted\n",
      "{\"Coombs' test (direct)\": 'positive', 'urinary proteins': 'false-positive', 'serum proteins': 'false-positive', 'aminoglycosides in vitro': 'inactivated'}\n",
      "{'opioids': 'May interfere'}\n",
      "{'opioid immunoassay methods': 'cross-reactivity'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'5-HIAA urinary assays': 'interference with Naproxen', 'Porter-Silber test': 'discontinued 72 hours before adrenal function testing due to an interaction with m-dinitrobenzene', 'aldosterone/renin ratio (ARR)': 'false-positive if Naproxen is used'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'plasma or urinary catecholamines': 'false elevations', 'urine glucose': \"false-positive (Benedict's reagent)\"}\n",
      "{'Plasma or urinary catecholamines': 'False elevations', 'Urine glucose': \"False-positive (Benedict's reagent)\"}\n",
      "{'aldosterone/renin ratio': 'false-negative', 'ARR': 'Funder 2016'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{\"Urine glucose (Benedict's method)\": 'False-positive', \"Urine glucose (Fehling's method)\": 'False-positive', 'Enzymatic tests': 'No false positives'}\n",
      "{'triglyceride assays dependent on glycerol oxidase': 'falsely elevated'}\n",
      "{'Multistix': 'False-positive for urobilinogen'}\n",
      "{'coagulation factors': 'may be changed', 'lipids': 'may be changed', 'glucose tolerance': 'may be changed', 'thyroxine-binding globulin': 'may be changed', 'sex hormone-binding globulin': 'may be changed', 'cortisol-binding globulin': 'may be changed', 'metyrapone test': 'reduced response'}\n",
      "{'CD20 assay for B-cell counts': 'interfered by ocrelizumab', 'CD19+ assay': 'to be used to measure B-cell counts'}\n",
      "{'urine screening': 'false-positive', 'immunoassay kits': 'commercially-available', 'quinolones': 'positive', 'levofloxacin': 'false-positive', 'ofloxacin': 'false-positive', 'cross-reactivity': 'certain assay kits', 'confirmation': 'positive opioid screens', 'specific methods': 'considered'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio': 'false-negative'}\n",
      "{'urinary normetanephrine levels': 'falsely elevated', 'liquid chromatography with electrochemical detection': 'May cause', \"mesalamine's main metabolite, N-acetylaminosalicylic acid\": 'similarity in the chromatograms'}\n",
      "{'serum chromogranin A (CgA) levels': 'falsely elevated'}\n",
      "{'serum chromogranin A (CgA) levels': 'falsely elevated'}\n",
      "{'serum chromogranin A (CgA) levels': 'falsely elevated'}\n",
      "{'aminotransferase [ALT/AST] (S)': 'Increased'}\n",
      "{'activated clotting time (ACT; ≤24 hours)': 'artificially prolongs coagulation tests', 'aPTT (≤120 hours)': 'artificially prolongs coagulation tests', 'prothrombin time (≤12 hours)': 'artificially prolongs coagulation tests', 'international normalized ratio (≤12 hours)': 'artificially prolongs coagulation tests', 'silica clot time (SCT; ≤18 hours)': 'artificially prolongs coagulation tests', \"dilute Russell's viper venom time (DRVVT; ≤72 hours)\": 'artificially prolongs coagulation tests', 'D-dimer (≤72 hours)': 'artificially prolongs coagulation tests', 'indirect antiglobulin tests': 'positive', 'direct antiglobulin tests': 'positive'}\n",
      "{\"urinary glucose tests using cupric sulfate (Benedict's solution, Clinitest®)\": 'may interfere', 'aminoglycosides in vitro': 'may inactivate', 'urinary proteins': 'false-positive', 'serum proteins': 'false-positive'}\n",
      "{'factors II': 'suppress', 'factor V': 'suppress', 'factor VII': 'suppress', 'factor X': 'suppress', 'PT': 'increase', 'thyroxine-binding globulin': 'decrease', 'radioactive iodine uptake': 'decrease'}\n",
      "{'urine immunoassay screening tests for benzodiazepines': 'False-positive', 'aldosterone/renin ratio (ARR)': 'may lead to false-positive'}\n",
      "{'Thyroid function tests': 'may depress serum T4 without affecting T3 levels or TSH'}\n",
      "{'skin test antigens': 'May suppress the wheal and flare reactions'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'urine screening result for opioids using commercially-available immunoassay kits': 'false-positive'}\n",
      "{'thyroxine-binding globulin, T4': 'decreased', 'resin uptake of T3 and T4': 'increased'}\n",
      "{'Urine screening result for opioids using commercially-available immunoassay kits': 'false-positive', 'Dehydrogenase pyrroloquinolinequinone or glucose-dye-oxidoreductase testing methods on the day of infusion': 'falsely elevated', 'Elevation in amylase': 'possible'}\n",
      "{'RSV diagnostic tests (antigen detection) and viral culture assays': 'false negatives', 'reverse-transcriptase-polymerase chain reaction-based assays': 'reliable'}\n",
      "{'Diagnostic imaging agents such as technetium-99m-diphosphonate in bone scans': 'interference'}\n",
      "{'Chromogranin A levels': 'increased'}\n",
      "{'Bilirubin': 'interference possible'}\n",
      "{'Serum creatinine': 'increased'}\n",
      "{'aPTT': 'interference from silica reagents; avoid use of silica reagents in coagulation panels'}\n",
      "{'Bone imaging studies': 'may be interfered; increased hematopoietic activity of bone marrow may appear as transient positive bone imaging changes'}\n",
      "{'Serum GH concentrations': 'may be interfered; commercially available GH assays may overestimate true GH levels'}\n",
      "{'Urinary glucose determination using Clinitest®': 'False-positive or negative', \"Coombs' [direct]\": 'positive', 'Urinary and/or serum proteins by certain test methods': 'false-positive'}\n",
      "{\"Urinary glucose tests using cupric sulfate (Benedict's solution, Clinitest®)\": 'May interfere', 'Aminoglycosides in vitro': 'May inactivate', \"Coombs' [direct]\": 'positive', 'Protein': 'Increased'}\n",
      "{\"Coombs' [direct]\": 'positive', 'Urinary and/or serum proteins': 'false-positive', 'Urinary glucose using Clinitest®': 'false-positive or negative'}\n",
      "{\"Coombs' [direct]\": 'Positive', 'Urinary and/or serum proteins': 'false-positive'}\n",
      "{'Urinary glucose determination using Clinitest®': 'False-positive or negative', \"Coombs' [direct]\": 'Positive', 'Urinary and/or serum proteins': 'false-positive'}\n",
      "{'Serum amylase levels': 'temporarily elevated'}\n",
      "{'theophylline levels': 'Concomitant administration increases'}\n",
      "{'pregnancy test': 'false-positive'}\n",
      "Couldn't be interpreted\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'glucose oxidase reagents': 'interference', 'urine ketone tests': 'interference'}\n",
      "{'urine detection of amphetamines/methamphetamines': 'false-positive'}\n",
      "{'immunoanalytical techniques (eg, TDX, TDXFLX, Emit 2000)': 'falsely high plasma phenytoin concentrations', 'serum concentrations of T4 and T3, and dexamethasone or metyrapone tests': 'falsely low results', 'thyroid-stimulating hormone (TSH)': 'increased serum levels'}\n",
      "{'aminotransferase [ALT/AST] (S)': 'increased', 'amylase (S)': 'increased'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{\"Coombs' test\": 'positive', 'urine glucose test using copper-reduction method (Clinitest)': 'false positive', 'Platelia Aspergillus enzyme immunoassay (EIA)': 'false positive'}\n",
      "{\"urinary glucose tests using cupric sulfate (Benedict's solution, Clinitest)\": 'interference/false-positive', \"Coombs' test [direct]\": 'positive', 'Platelia® Aspergillus EIA test (Bio-Rad Laboratories)': 'false positive', 'aminoglycoside serum concentration': 'potential underestimation'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false positive'}\n",
      "{'D-dimer': 'May elevate and complicate interpretation in patients being screened for venous thromboembolism (VTE); consider alternative tests to screen for VTE.'}\n",
      "{'tuberculin skin test sensitivity': 'temporarily suppressed'}\n",
      "{'β-human chorionic gonadotropin': 'positive'}\n",
      "{'ammonia': 'decreased'}\n",
      "{'thyroid function tests': 'altered due to iodide'}\n",
      "{'thyroid function tests': 'altered'}\n",
      "{'Urinary VMA': 'Increased 17%', 'Norepinephrine metabolite': 'Increased 42%', 'Pheochromocytoma screening': 'False positive'}\n",
      "{'Skin test responsiveness': 'May decrease'}\n",
      "{'Skin test responsiveness': 'Decreased'}\n",
      "{'Creatine phosphokinase levels': 'increased'}\n",
      "{'Glucosuria with Clinitest®': 'false-positive', 'Theophylline determination': 'falsely high', 'Renal excretion of phenolsulfonphthalein': 'inhibited', 'Renal excretion of 17-ketosteroids': 'inhibited', 'Renal excretion of bromsulfophthalein (BSP)': 'inhibited'}\n",
      "{'Fluorescence-based tests for procainamide/N-acetyl procainamide': 'may be affected'}\n",
      "{'phenylketonuria': 'false-positive', 'pregnancy': 'positive'}\n",
      "{'sulfobromophthalein retention': 'increased', 'hepatic function tests': 'abnormal', 'coagulation tests': 'elevated', 'prothrombin factors VII': 'elevated', 'prothrombin factors VIII': 'elevated', 'prothrombin factors IX': 'elevated', 'prothrombin factors X': 'elevated', 'metyrapone test': 'altered', 'pregnanediol determinations': 'altered', 'thyroid function': 'abnormal', 'PBI': 'elevated', 'butanol extractable protein bound iodine': 'elevated', 'T uptake values': 'decreased'}\n",
      "See individual agents\n",
      "See individual agents\n",
      "{'skin test antigens': 'suppress the wheal and flare reactions', 'pregnancy tests relying on immunological reactions between hCG and anti-hCG': 'false negative and positive reactions'}\n",
      "See individual agents\n",
      "{'Pregnancy tests (hCG-based)': 'false-negatives or false-positives', 'glucose tolerance tests': 'increased serum glucose', 'urine detection of amphetamine/methamphetamine': 'false-positives', 'intradermal allergen tests': 'may alter the flare response'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'aPTT': 'formulation contains heparin'}\n",
      "See individual agents\n",
      "{'Urine detection of amphetamine': 'false-positive'}\n",
      "{'Acetest® and Ketostix®': 'pinkish-brown color'}\n",
      "{'Urine detection of methadone': 'false-positives', 'Serum TCA screen': 'false-positive'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'urine detection of opioids': 'false-positive interference', \"Coombs' test\": 'positive', 'urinary steroids (when assayed by Zimmerman method) and catecholamines': 'false elevation', 'qualitative and quantitative urine dipstick protein assays': 'may interfere'}\n",
      "{'Chromogranin A': 'falsely elevated by PPIs causing false-positive results in the diagnosis of a neuroendocrine tumor', 'Secretin stimulation test': 'hyper-response in gastrin secretion in adults; falsely suggesting gastrinoma', 'Tetrahydrocannabinol urine screening tests': 'false-positive results reported'}\n",
      "{'Antiglobulin test': 'may interfere with serologic test for red cell antibodies'}\n",
      "See individual agents\n",
      "{'Direct Coombs test': 'positive', 'Urine acetone determinations using sodium nitroprusside reagent': 'false-positive results', 'Aldosterone/Renin ratio (ARR)': 'false-negative'}\n",
      "{'Urine protein test using Multistix': 'false-positive'}\n",
      "{'Uric acid testing': 'Samples must be analyzed within 4 hours of collection'}\n",
      "{'Coagulation factors testing': 'may be changed', 'Lipid testing': 'may be changed', 'Glucose tolerance testing': 'may be changed', 'Thyroxine-binding globulin testing': 'may be changed', 'Sex hormone–binding globulin testing': 'may be changed', 'Cortisol-binding globulin testing': 'may be changed'}\n",
      "{'Pituitary gonadotropic testing': 'may be affected during and after relugolix therapy', 'Gonadal function diagnostic testing': 'may be affected during and after relugolix therapy', 'Prostate specific antigen (PSA) testing': 'to monitor relugolix therapeutic efficacy', 'Serum testosterone testing': 'to be measured if PSA increases'}\n",
      "{'coagulation and fibrinolytic activity tests': 'Altered'}\n",
      "{'blood typing': 'affected', 'antibody screening test': 'affected', 'direct antiglobulin (Coombs’) test': 'affected', 'blood-typing result': 'false', 'blood glucose levels with dehydrogenase pyrroloquinolinequinone or glucose-dye-oxidoreductase testing methods': 'falsely elevated', 'Coombs’ tests': 'altered', 'antibodies to other Rh antigens (eg, anti-C antibodies)': 'detected'}\n",
      "{'urinalysis based on spectrometry': 'interfere', 'fluorometric determinations of catecholamines': 'false elevations', 'fluorometric determinations of urobilinogen': 'false elevations'}\n",
      "See individual agents\n",
      "{'Urine detection of opioids': 'false-positive', \"Coombs' reaction [direct]\": 'positive', 'Serum folate and B12': 'inhibited', 'LFTs': 'transiently increased', 'Biliary excretion of contrast media': 'decreased'}\n",
      "{'Standard microbiological assays for serum folate and vitamin B12': 'inhibited', 'Alternative assay methods': 'should be considered'}\n",
      "{'Technetium-99m-diphosphonate in bone scans': 'may be interfered with'}\n",
      "{'anti-factor Xa assay': 'falsely elevated results', 'aPTT': 'little or minor effect', 'HepTest': 'prolongation', 'Russell viper venom time': 'prolongation'}\n",
      "{'Tuberculin tests': 'Diminished diagnostic effect due to Rotavirus vaccine'}\n",
      "{'Plasma T4': 'False results due to test interactions with salicylic acid', 'Salicylic acid': 'Consider test interactions for accurate results'}\n",
      "{'Interferes with gastric secretion': 'Discontinue transdermal system ≥10 days prior to testing.'}\n",
      "{'coagulation factors': 'altered results', 'lipids': 'altered results', 'glucose tolerance': 'altered results', 'thyroxine-binding globulin': 'altered results', 'sex hormone–binding globulin': 'altered results', 'cortisol-binding globulin': 'altered results'}\n",
      "{'amphetamine/methamphetamine urine detection': 'false-positive'}\n",
      "{'urine detection of benzodiazepines': 'false-positive'}\n",
      "{'Propylene glycol': 'May affect the interpretation of laboratory tests.'}\n",
      "{'Rapid plasma reagin (RPR) test': 'Smallpox vaccine may induce false-positive RPR test for syphilis; confirm positive RPR test using a more specific test (eg, FTA assay).', 'Tuberculin skin (PPD) and blood tests': 'Smallpox vaccine may diminish the diagnostic utility of tuberculin skin (PPD) and blood tests; avoid skin test for ≥1 month after vaccine to prevent false-negative results.'}\n",
      "{'urinary metanephrine values': 'falsely increased', 'HPLC assay with solid phase extraction for determination of urinary catecholamines': 'not affected', 'aldosterone/renin ratio (ARR)': 'false positives'}\n",
      "{'radioimmunoassay for digoxin': 'interference', 'aldosterone/renin ratio (ARR)': 'false negatives'}\n",
      "{'ketones (U)': 'false positives using nitroprusside methods', 'serum CPK': 'falsely decreased', 'uric acid measurement': 'falsely decreased'}\n",
      "{'serum progesterone assay': 'interfere', 'sugammadex': 'interaction'}\n",
      "{'creatine': 'Increased', 'methotrexate': 'Increased'}\n",
      "{'urinary normetanephrine': 'false-positive'}\n",
      "{'aldosterone/renin ratio (ARR)': 'May lead to false-positive'}\n",
      "See individual agents\n",
      "{'T4': 'elevations (which may be explained by increases in thyroid-binding globulin)', 'vagina smear karyopyknotic index': 'variations', 'Pap smear estrogen effect': 'various degrees'}\n",
      "{'PT': 'artificially increased clotting times', 'INR': 'artificially increased clotting times', 'aPTT': 'artificially increased clotting times', 'ACT': 'artificially increased clotting times', 'Xa': 'artificially increased clotting times', 'urine protein': 'interference via qualitative dipstick and quantitative dye methods'}\n",
      "See individual agents\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'coagulation tests': 'altered results', 'fibrinolytic activity tests': 'altered results'}\n",
      "{'serum calcium': 'transiently increased'}\n",
      "{'thyroxine-binding globulin': 'May decrease', 'total T4': 'Decreased', 'resin uptake of T3 and T4': 'Increased', 'free thyroid hormone levels': 'Not changed'}\n",
      "See individual agents\n",
      "{'Serum amylase levels testing': 'temporarily elevated', 'Coagulation factors testing': 'decreased', 'Plasma proteins testing': 'decreased', 'Hematocrit testing': 'decreased'}\n",
      "{'Plasma glucose testing': 'increased', 'Uric acid testing': 'increased', 'Free fatty acids testing': 'increased', 'Total cholesterol testing': 'increased', 'HDL testing': 'increased', 'HDL/LDL ratio testing': 'increased', 'Urinary free cortisol excretion testing': 'increased', 'Triiodothyronine testing': 'decreased'}\n",
      "{'Uric acid using the phosphotungstate method': 'false-positive', \"Urobilinogen using the Ehrlich's reagent\": 'false-positive', 'Spectrophotometric determination of serum theophylline concentration': 'may interfere with large doses'}\n",
      "{'Detection of methadone in urine': 'false-positives', 'Detection of phencyclidine in urine': 'false-positives'}\n",
      "{'Pregnancy test': 'false-positive'}\n",
      "{'T4-binding globulin (TBG)': 'Factors that alter binding in serum (ATA/AACE [Garber 2012]):\\n\\nNote: T4 is ~99.97% protein bound. Factors that alter protein binding will affect serum total T4 levels; however, measurement of serum free T4 (the metabolically active moiety) has largely replaced serum total T4 for thyroid status assessment.\\n\\nConditions/states that increase TBG binding: Pregnancy, hepatitis, porphyria, neonatal state\\n\\nMedications that increase TBG binding: Estrogens, 5-fluorouracil, heroin, methadone, mitotane, perphenazine, selective estrogen receptor modulators (eg, tamoxifen, raloxifene)\\n\\nConditions/states that decrease TBG binding: Hepatic failure, nephrosis, severe illness\\n\\nMedications that decrease TBG binding: Androgens, anabolic steroids, glucocorticoids, L-asparaginase, nicotinic acid', 'Thyroxine (T4)': 'Serum binding inhibitors (ATA/AACE [Garber 2012]):\\n\\nMedications that inhibit T4 binding: Carbamazepine, furosemide, free fatty acids, heparin, NSAIDS (variable, transient), phenytoin, salicylates', 'Triiodothyronine (T3)': 'Serum binding inhibitors (ATA/AACE [Garber 2012]):\\n\\nMedications that inhibit T3 binding: Carbamazepine, furosemide, free fatty acids, heparin, NSAIDS (variable, transient), phenytoin, salicylates', 'Thyroid gland hormone': 'Interference with production and secretion (ATA/AACE [Garber 2012]):\\n\\nMedications affecting iodine uptake: Amiodarone, iodinated contrast agents, iodine, ethionamide\\n\\nMedications affecting hormone production: Amiodarone, ethionamide, iodinated contrast agents, iodine, sulfonylureas, sulfonamides, thionamides (carbimazole, methimazole, propylthiouracil)\\n\\nMedications affecting secretion: Amiodarone, iodinated contrast agents, iodine, lithium\\n\\nMedications inducing thyroiditis: Alemtuzumab, amiodarone, antiangiogenic agents (lenalidomide, thalidomide), denileukin diftitoxin, interferon alpha, interleukins, lithium, tyrosine kinase inhibitors (sunitinib, sorafenib)\\n\\nMedications potentially causing the development of Graves’: Alemtuzumab, interferon alpha, antiretroviral therapy\\n\\nMedications potentially ameliorating thyroiditis (if autoimmune) or Graves’: Glucocorticoids', 'Hypothalamic-pituitary axis and TSH': \"Interference with secretion (ATA/AACE [Garber 2012]):\\n\\nMedications decreasing TSH secretion: Bexarotene, dopamine, dopaminergic agonists (bromocriptine, cabergoline), glucocorticoids, interleukin-6, metformin, opiates, somatostatin analogues (octreotide, lanreotide), thyroid hormone analogues\\n\\nMedications increasing TSH secretion: Amphetamine, interleukin 2, metoclopramide, ritonavir, St John's wort Medications potentially causing hypophysitis: Ipilimumab\"}\n",
      "{'thyroglobulin assay': 'Confounded by thyroglobulin antibodies', 'thyroglobulin levels': 'Misinterpreted or difficult to interpret'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-positive'}\n",
      "{'Coagulation': 'altered', 'corticoid binding globulin': 'altered', 'glucose tolerance': 'altered', 'lipid': 'altered', 'sex hormone-binding globulin': 'altered', 'thyroid function': 'altered'}\n",
      "{'platelet activation functional assays': 'false-negative results'}\n",
      "{'aldosterone/renin ratio': 'false-positive'}\n",
      "{'AST': 'May interfere with testing', 'ALT': 'May interfere with testing', 'Triglycerides': 'May interfere with testing', 'Glucose': 'May interfere with testing', 'LDH': 'May interfere with testing'}\n",
      "{'HIV nucleic acid tests': 'false positive results'}\n",
      "{'penicillin derivatives': 'accelerate the degradation of aminoglycosides', 'aminoglycoside serum concentration': 'potential underestimation'}\n",
      "{'Protein': 'Increased', 'Bleeding time': 'Increased', 'Urine detection of cannabinoids': 'false-positive', 'Aldosterone/Renin Ratio (ARR)': 'false-positive'}\n",
      "{'Aldosterone/Renin Ratio (ARR)': 'false-negative'}\n",
      "{'Urine detection of phencyclidine': 'false-positive'}\n",
      "{'aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'Urine detection of amphetamine/methamphetamine': 'false-positive'}\n",
      "{'Fluorometric assay of quinidine': 'interferes', 'Aldosterone/renin ratio (ARR)': 'false-negative'}\n",
      "{'phenylketonuria': 'false-positive'}\n",
      "{'creatinine determination measured by the Jaffé alkaline picrate assay': 'falsely increase (~10%)', 'serum methotrexate when measured by methods that use a bacterial dihydrofolate reductase as the binding protein (eg, the competitive binding protein technique)': 'may interfere', 'RIA for methotrexate': 'does not interfere'}\n",
      "{'urine detection of amphetamine': 'Interferes (false-positive)', 'the wheal and flare reactions': 'May suppress (to skin test antigens)'}\n",
      "{'Pituitary-gonadal function': 'may be suppressed with chronic administration and for up to 8 weeks after triptorelin therapy has been discontinued'}\n",
      "{'False-positive reactions': 'may occur with BCG vaccination or previous mycobacteria (non-TB) infection (previous BCG vaccination is not a contraindication to testing; however, an interferon gamma release assay is preferred [CDC 2010])', 'False-negative reactions': 'may occur with any condition that impairs or attenuates cell-mediated immunity, including aging.'}\n",
      "{'CD20 assay': 'Interfered by Ublituximab', 'CD19+ assay': 'Measurement of B-cell counts'}\n",
      "{'Serologic testing': 'false-positive', 'Direct Coombs test': 'false-positive', 'Indirect Coombs test': 'false-positive'}\n",
      "{'Urine ketones test': 'false-positive', 'Thyroid function tests': 'altered'}\n",
      "See individual agents\n",
      "{'Aldosterone/renin ratio test (ARR)': 'false-negative'}\n",
      "{'immunity to VZV': 'false-positive', \"Coomb's test\": 'false-positive'}\n",
      "{'urine detection of phencyclidine': 'false-positive', 'urine detection of amphetamine': 'false-positive'}\n",
      "{'urine detection of methadone': 'false-positive'}\n",
      "{'AST and ALT activity in the plasma': 'undetectable', 'amino acids in the urine': 'false-positive'}\n",
      "{'urine protein': 'false positive'}\n",
      "{'urine glucose determinations': 'false negative', 'certain lab tests': 'incorrect test results'}\n",
      "{'Urine glucose determinations': 'false-negative due to Ascorbic acid in urine', 'Certain lab tests': 'incorrect test results due to interference from Biotin'}\n",
      "{'Urine glucose determinations': 'false-negative due to Ascorbic acid in urine', 'Certain lab tests': 'incorrect test results due to interference from Biotin'}\n",
      "{'Urine glucose determinations': 'false-negative due to Ascorbic acid in urine', 'Certain lab tests': 'incorrect test results due to interference from Biotin'}\n",
      "{'urine immunoassays for methadone': 'may cause false positive results'}\n",
      "{'HbA': 'measurement affected by Voxelotor', 'HbS': 'measurement affected by Voxelotor', 'HbF': 'measurement affected by Voxelotor'}\n",
      "{'Bone scans': 'interference with diagnostic imaging agents by Bisphosphonates', 'Technetium-99m-diphosphonate': 'interference with Bisphosphonates'}\n",
      "{'aminotransferase [ALT/AST]': 'increased', 'bilirubin (S)': 'increased', 'RAI uptake': 'decreased'}\n"
     ]
    }
   ],
   "source": [
    "for elem in data.keys():\n",
    "    if data[elem] != 'Not available':\n",
    "        print(data[elem])"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:47:11.967320800Z",
     "start_time": "2023-08-28T13:47:11.907724200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "outputs": [],
   "source": [
    "with open(\"Notebooks/installations/Data/Results - Final Sprint Assignment/drug-test-conditions.json\", \"w\") as outfile:\n",
    "    json.dump(data, outfile)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:51:04.829983800Z",
     "start_time": "2023-08-28T13:51:04.719279900Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "outputs": [],
   "source": [
    "with open(\"Notebooks/installations/Data/Results - Final Sprint Assignment/drug-test-management.json\", \"w\") as outfile:\n",
    "    json.dump(drug_inter_manage, outfile)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:51:19.459669600Z",
     "start_time": "2023-08-28T13:51:19.289609800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "\n",
    "excel_path = 'Notebooks/installations/Data/Results - Final Sprint Assignment/Extracted Drug Interaction.xlsx'\n",
    "df = pd.read_excel(excel_path)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:54:59.469722Z",
     "start_time": "2023-08-28T13:54:47.651813900Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "outputs": [
    {
     "data": {
      "text/plain": "       Generic Name       Generic interactive  \\\n0          Abacavir  Betibeglogene Autotemcel   \n1          Abacavir              Cabozantinib   \n2          Abacavir                Cladribine   \n3          Abacavir   Elivaldogene Autotemcel   \n4          Abacavir             Levomethadone   \n...             ...                       ...   \n126265          NaN                       NaN   \n126266          NaN                       NaN   \n126267          NaN                       NaN   \n126268          NaN                       NaN   \n126269          NaN                       NaN   \n\n                                              Interaction Risk  \\\n0       Antiretroviral Agents may diminish the therape...    X   \n1       MRP2 Inhibitors may increase the serum concent...    C   \n2       Agents that Undergo Intracellular Phosphorylat...    X   \n3       Antiretroviral Agents may diminish the therape...    X   \n4       May diminish the therapeutic effect of Abacavi...    C   \n...                                                   ...  ...   \n126265                                                NaN  NaN   \n126266                                                NaN  NaN   \n126267                                                NaN  NaN   \n126268                                                NaN  NaN   \n126269                                                NaN  NaN   \n\n                                                    Notes  \n0                                                          \n1                                                          \n2                                                          \n3                                                          \n4        Interacting drugs may not be individually lis...  \n...                                                   ...  \n126265                                                     \n126266                                                     \n126267                                                     \n126268                                                     \n126269                                                     \n\n[126270 rows x 5 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Generic interactive</th>\n      <th>Interaction</th>\n      <th>Risk</th>\n      <th>Notes</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Abacavir</td>\n      <td>Betibeglogene Autotemcel</td>\n      <td>Antiretroviral Agents may diminish the therape...</td>\n      <td>X</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Abacavir</td>\n      <td>Cabozantinib</td>\n      <td>MRP2 Inhibitors may increase the serum concent...</td>\n      <td>C</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Abacavir</td>\n      <td>Cladribine</td>\n      <td>Agents that Undergo Intracellular Phosphorylat...</td>\n      <td>X</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Abacavir</td>\n      <td>Elivaldogene Autotemcel</td>\n      <td>Antiretroviral Agents may diminish the therape...</td>\n      <td>X</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Abacavir</td>\n      <td>Levomethadone</td>\n      <td>May diminish the therapeutic effect of Abacavi...</td>\n      <td>C</td>\n      <td>Interacting drugs may not be individually lis...</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>126265</th>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>126266</th>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>126267</th>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>126268</th>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>126269</th>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>\n<p>126270 rows × 5 columns</p>\n</div>"
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T13:54:59.631024900Z",
     "start_time": "2023-08-28T13:54:59.471716200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "outputs": [
    {
     "data": {
      "text/plain": "          Generic Name       Generic interactive  \\\n0             Abacavir  Betibeglogene Autotemcel   \n1             Abacavir              Cabozantinib   \n2             Abacavir                Cladribine   \n3             Abacavir   Elivaldogene Autotemcel   \n4             Abacavir             Levomethadone   \n...                ...                       ...   \n123472  Zuclopenthixol               Revefenacin   \n123473  Zuclopenthixol                Topiramate   \n123474  Zuclopenthixol              Trimeprazine   \n123475             NaN                       NaN   \n123476             NaN                       NaN   \n\n                                              Interaction Risk  \\\n0       Antiretroviral Agents may diminish the therape...    X   \n1       MRP2 Inhibitors may increase the serum concent...    C   \n2       Agents that Undergo Intracellular Phosphorylat...    X   \n3       Antiretroviral Agents may diminish the therape...    X   \n4       May diminish the therapeutic effect of Abacavi...    C   \n...                                                   ...  ...   \n123472   Anticholinergic Agents may enhance the antich...    X   \n123473   Anticholinergic Agents may enhance the advers...    C   \n123474   May enhance the CNS depressant effect of CNS ...    C   \n123475                                                NaN  NaN   \n123476                                                NaN  NaN   \n\n                                                    Notes  \\\n0                                                           \n1                                                           \n2                                                           \n3                                                           \n4        Interacting drugs may not be individually lis...   \n...                                                   ...   \n123472                                                NaN   \n123473                                                NaN   \n123474                                                NaN   \n123475                                                NaN   \n123476                                                NaN   \n\n                                    Reference Interaction  \n0       Antiretroviral Agents may diminish the therape...  \n1       MRP2 Inhibitors may increase the serum concent...  \n2       Agents that Undergo Intracellular Phosphorylat...  \n3       Antiretroviral Agents may diminish the therape...  \n4       May diminish the therapeutic effect of Abacavi...  \n...                                                   ...  \n123472   Anticholinergic Agents may enhance the antich...  \n123473   Anticholinergic Agents may enhance the advers...  \n123474   May enhance the CNS depressant effect of CNS ...  \n123475                                                NaN  \n123476                                                NaN  \n\n[123477 rows x 6 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Generic interactive</th>\n      <th>Interaction</th>\n      <th>Risk</th>\n      <th>Notes</th>\n      <th>Reference Interaction</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Abacavir</td>\n      <td>Betibeglogene Autotemcel</td>\n      <td>Antiretroviral Agents may diminish the therape...</td>\n      <td>X</td>\n      <td></td>\n      <td>Antiretroviral Agents may diminish the therape...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Abacavir</td>\n      <td>Cabozantinib</td>\n      <td>MRP2 Inhibitors may increase the serum concent...</td>\n      <td>C</td>\n      <td></td>\n      <td>MRP2 Inhibitors may increase the serum concent...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Abacavir</td>\n      <td>Cladribine</td>\n      <td>Agents that Undergo Intracellular Phosphorylat...</td>\n      <td>X</td>\n      <td></td>\n      <td>Agents that Undergo Intracellular Phosphorylat...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Abacavir</td>\n      <td>Elivaldogene Autotemcel</td>\n      <td>Antiretroviral Agents may diminish the therape...</td>\n      <td>X</td>\n      <td></td>\n      <td>Antiretroviral Agents may diminish the therape...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Abacavir</td>\n      <td>Levomethadone</td>\n      <td>May diminish the therapeutic effect of Abacavi...</td>\n      <td>C</td>\n      <td>Interacting drugs may not be individually lis...</td>\n      <td>May diminish the therapeutic effect of Abacavi...</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>123472</th>\n      <td>Zuclopenthixol</td>\n      <td>Revefenacin</td>\n      <td>Anticholinergic Agents may enhance the antich...</td>\n      <td>X</td>\n      <td>NaN</td>\n      <td>Anticholinergic Agents may enhance the antich...</td>\n    </tr>\n    <tr>\n      <th>123473</th>\n      <td>Zuclopenthixol</td>\n      <td>Topiramate</td>\n      <td>Anticholinergic Agents may enhance the advers...</td>\n      <td>C</td>\n      <td>NaN</td>\n      <td>Anticholinergic Agents may enhance the advers...</td>\n    </tr>\n    <tr>\n      <th>123474</th>\n      <td>Zuclopenthixol</td>\n      <td>Trimeprazine</td>\n      <td>May enhance the CNS depressant effect of CNS ...</td>\n      <td>C</td>\n      <td>NaN</td>\n      <td>May enhance the CNS depressant effect of CNS ...</td>\n    </tr>\n    <tr>\n      <th>123475</th>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>123476</th>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>123477 rows × 6 columns</p>\n</div>"
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['Reference Interaction'] = df['Interaction']\n",
    "df = df.truncate(before=0, after=123476)\n",
    "df"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T14:07:33.429073900Z",
     "start_time": "2023-08-28T14:07:33.383188500Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "outputs": [],
   "source": [
    "interactions_new = []\n",
    "\n",
    "for i in range(len(df)):\n",
    "    inter = df.Interaction.iloc[i]\n",
    "    before_risk = str(inter).split('Risk ')[0]\n",
    "    interactions_new.append(before_risk)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T14:07:51.009907900Z",
     "start_time": "2023-08-28T14:07:49.485913900Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "outputs": [],
   "source": [
    "df['Interaction'] = interactions_new"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T14:07:53.241345900Z",
     "start_time": "2023-08-28T14:07:53.201453100Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "outputs": [
    {
     "data": {
      "text/plain": "          Generic Name       Generic interactive  \\\n0             Abacavir  Betibeglogene Autotemcel   \n1             Abacavir              Cabozantinib   \n2             Abacavir                Cladribine   \n3             Abacavir   Elivaldogene Autotemcel   \n4             Abacavir             Levomethadone   \n...                ...                       ...   \n123472  Zuclopenthixol               Revefenacin   \n123473  Zuclopenthixol                Topiramate   \n123474  Zuclopenthixol              Trimeprazine   \n123475             NaN                       NaN   \n123476             NaN                       NaN   \n\n                                              Interaction Risk  \\\n0       Antiretroviral Agents may diminish the therape...    X   \n1       MRP2 Inhibitors may increase the serum concent...    C   \n2       Agents that Undergo Intracellular Phosphorylat...    X   \n3       Antiretroviral Agents may diminish the therape...    X   \n4       May diminish the therapeutic effect of Abacavi...    C   \n...                                                   ...  ...   \n123472   Anticholinergic Agents may enhance the antich...    X   \n123473   Anticholinergic Agents may enhance the advers...    C   \n123474   May enhance the CNS depressant effect of CNS ...    C   \n123475                                                nan  NaN   \n123476                                                nan  NaN   \n\n                                                    Notes  \\\n0                                                           \n1                                                           \n2                                                           \n3                                                           \n4        Interacting drugs may not be individually lis...   \n...                                                   ...   \n123472                                                NaN   \n123473                                                NaN   \n123474                                                NaN   \n123475                                                NaN   \n123476                                                NaN   \n\n                                    Reference Interaction  \n0       Antiretroviral Agents may diminish the therape...  \n1       MRP2 Inhibitors may increase the serum concent...  \n2       Agents that Undergo Intracellular Phosphorylat...  \n3       Antiretroviral Agents may diminish the therape...  \n4       May diminish the therapeutic effect of Abacavi...  \n...                                                   ...  \n123472   Anticholinergic Agents may enhance the antich...  \n123473   Anticholinergic Agents may enhance the advers...  \n123474   May enhance the CNS depressant effect of CNS ...  \n123475                                                NaN  \n123476                                                NaN  \n\n[123477 rows x 6 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Generic interactive</th>\n      <th>Interaction</th>\n      <th>Risk</th>\n      <th>Notes</th>\n      <th>Reference Interaction</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Abacavir</td>\n      <td>Betibeglogene Autotemcel</td>\n      <td>Antiretroviral Agents may diminish the therape...</td>\n      <td>X</td>\n      <td></td>\n      <td>Antiretroviral Agents may diminish the therape...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Abacavir</td>\n      <td>Cabozantinib</td>\n      <td>MRP2 Inhibitors may increase the serum concent...</td>\n      <td>C</td>\n      <td></td>\n      <td>MRP2 Inhibitors may increase the serum concent...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Abacavir</td>\n      <td>Cladribine</td>\n      <td>Agents that Undergo Intracellular Phosphorylat...</td>\n      <td>X</td>\n      <td></td>\n      <td>Agents that Undergo Intracellular Phosphorylat...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Abacavir</td>\n      <td>Elivaldogene Autotemcel</td>\n      <td>Antiretroviral Agents may diminish the therape...</td>\n      <td>X</td>\n      <td></td>\n      <td>Antiretroviral Agents may diminish the therape...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Abacavir</td>\n      <td>Levomethadone</td>\n      <td>May diminish the therapeutic effect of Abacavi...</td>\n      <td>C</td>\n      <td>Interacting drugs may not be individually lis...</td>\n      <td>May diminish the therapeutic effect of Abacavi...</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>123472</th>\n      <td>Zuclopenthixol</td>\n      <td>Revefenacin</td>\n      <td>Anticholinergic Agents may enhance the antich...</td>\n      <td>X</td>\n      <td>NaN</td>\n      <td>Anticholinergic Agents may enhance the antich...</td>\n    </tr>\n    <tr>\n      <th>123473</th>\n      <td>Zuclopenthixol</td>\n      <td>Topiramate</td>\n      <td>Anticholinergic Agents may enhance the advers...</td>\n      <td>C</td>\n      <td>NaN</td>\n      <td>Anticholinergic Agents may enhance the advers...</td>\n    </tr>\n    <tr>\n      <th>123474</th>\n      <td>Zuclopenthixol</td>\n      <td>Trimeprazine</td>\n      <td>May enhance the CNS depressant effect of CNS ...</td>\n      <td>C</td>\n      <td>NaN</td>\n      <td>May enhance the CNS depressant effect of CNS ...</td>\n    </tr>\n    <tr>\n      <th>123475</th>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>nan</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>123476</th>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>nan</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>123477 rows × 6 columns</p>\n</div>"
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T14:07:54.466665400Z",
     "start_time": "2023-08-28T14:07:54.423285200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "outputs": [],
   "source": [
    "df.to_csv('Notebooks/installations/Data/Results - Final Sprint Assignment/ExtractedDrugInteraction.csv',index=False,encoding='utf-8-sig')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T14:09:13.201746800Z",
     "start_time": "2023-08-28T14:09:11.415493800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "123475\n"
     ]
    }
   ],
   "source": [
    "df = pd.read_excel('Notebooks/installations/Data/Results - Final Sprint Assignment/Drug Interactions.xlsx')\n",
    "print(len(df))"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T14:32:16.226531200Z",
     "start_time": "2023-08-28T14:32:08.387450100Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral).\n",
      "Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.\n",
      "May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).\n",
      "Opioid Agonists (metabolized by CYP3A4 and CYP2D6) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non- toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite. Management: Consider limiting acetaminophen use in combination with probenecid. Probenecid may reduce clearance of acetaminophen to one of its non-toxic metabolities, increasing the risk for acetaminophen toxicity, even a lower doses.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Serotonergic Opioids (High Risk) may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding.\n",
      " May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.\n",
      "May enhance the adverse/toxic effect of Acetaminophen. Specifically, the risk for high anion gap metabolic acidosis may be increased.\n",
      "Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.\n",
      "CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.\n",
      "QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Amiodarone. QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Amiodarone. Management: Consider alternatives to this combination. If combined, monitor for increased amiodarone toxicities, including QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib. QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Dasatinib. Management: Avoid this combination if possible. If combined, decrease dasatinib dose from 140 mg to 40 mg, 100 mg to 20 mg, or 70 mg to 20 mg. If taking 60 mg or 40 mg daily, stop dasatinib until the CYP3A4 inhibitor is discontinued. Monitor for prolonged QT interval\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of DroPERidol. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias (including TdP) with a continuous overnight ECG when fingolimod is combined with QT prolonging drugs. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Methadone. QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Methadone. Management: Consider alternatives to this combination. Methadone dose reductions may be necessary. With any concurrent use, monitor closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.\n",
      "Alcohol (Ethyl) may enhance the adverse/toxic effect of Didanosine. Specifically, the risk of pancreatitis may be increased.\n",
      "Alcohol (Ethyl) may enhance the adverse/toxic effect of Levomethadone. Specifically, the risk for sedation, respiratory depression, coma, and death may be increased.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.\n",
      "Alpelisib may decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).\n",
      "CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.\n",
      "May enhance the adverse/toxic effect of Thrombolytic Agents. Specifically, the risk of bleeding may be increased.\n",
      "Antacids may decrease the absorption of Atazanavir. Management: Administer antacids 1 to 2 hours before or 2 hours after atazanavir to minimize the risk of a clinically significant interaction.\n",
      "Antacids may decrease the serum concentration of Erlotinib. Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.\n",
      "Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. Specifically, the risk of metabolic alkalosis may be increased. Antacids may diminish the therapeutic effect of Sodium Polystyrene Sulfonate.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Tricyclic Antidepressants may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Hydroxide Polymaltose Complex. Specifically, the risk for angioedema or allergic reactions may be increased.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.\n",
      "May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).\n",
      "Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased.\n",
      "May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely.\n",
      "May enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine.\n",
      "Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.\n",
      "Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased.\n",
      "May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.\n",
      "May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk of neuroleptic malignant syndrome or increased QTc interval may be increased.\n",
      "QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Amiodarone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Escitalopram. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin.\n",
      "Aspirin may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Aspirin may increase the serum concentration of Edoxaban. Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.\n",
      "Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Specifically, the risk for Reye's syndrome may increase.\n",
      "Aspirin may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling states that low dose aspirin could be considered, but the use of antiplatelets are not recommended for stroke prevention in patients with atrial fibrillation.\n",
      "May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.\n",
      "Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.\n",
      "May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.\n",
      "Aspirin may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased.\n",
      "CYP3A4 Inhibitors (Strong) may increase the serum concentration of Delamanid. Management: Increase ECG monitoring frequency if delamanid is combined with strong CYP3A4 inhibitors due to the risk for QTc interval prolongation. Continue frequent ECG assessments throughout full delamanid treatment period.\n",
      "CYP3A4 Inhibitors (Strong) may increase the serum concentration of Midostaurin. Management: Seek alternatives to the concomitant use of midostaurin and strong CYP3A4 inhibitors if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions.\n",
      "May enhance the adverse/toxic effect of Thiazide and Thiazide-Like Diuretics. Specifically, the risk for intravascular volume depletion may be increased.\n",
      "May increase the serum concentration of Atorvastatin. Management: Avoid concomitant use of atorvastatin and telithromycin due to the risk of rhabdomyolysis. If a patient treated with atorvastatin requires telithromycin, discontinue atorvastatin for the duration of telithromycin therapy.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral).\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Probucol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Azithromycin (Systemic) may enhance the QTc-prolonging effect of RisperiDONE. Azithromycin (Systemic) may increase the serum concentration of RisperiDONE. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Hydrocortisone (Topical) may diminish the therapeutic effect of Calcipotriene. Management: Monitor for reduced calcipotriene efficacy if combined with hydrocortisone valerate. Consider separating the administration of these agents by 10 to 12 hours to minimize the risk of this potential interaction.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab. Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pacritinib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "Opioid Agonists may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.\n",
      "Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.\n",
      "May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments\n",
      "Corticosteroids (Systemic) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine- associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Yellow Fever Vaccine.\n",
      "Salicylic Acid may diminish the therapeutic effect of Calcipotriene. Management: Monitor for reduced calcipotriene efficacy if combined with salicylic acid. Consider separating the administration of these agents by 10 to 12 hours to minimize the risk of this potential interaction.\n",
      "May enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic). Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required. Adjustment of cyclosporine dose may be necessary.\n",
      "May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).\n",
      "May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate- release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.\n",
      "Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased.\n",
      "May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.\n",
      "May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti- inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.\n",
      "Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (Moderate Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral).\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased.\n",
      "Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Specifically, the risk for Reye's syndrome may increase.\n",
      " May enhance the adverse/toxic effect of Salicylates. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of salicylates and topical NSAIDs is not recommended. If salicylates and topical NSAIDs are coadministered, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities. \n",
      "May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.\n",
      "May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.\n",
      "Antacids may enhance the adverse/toxic effect of MiSOPROStol. More specifically, concomitant use with magnesium- containing antacids may increase the risk of diarrhea. Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).\n",
      "Antacids may decrease the serum concentration of Potassium Phosphate. Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.\n",
      "May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract).\n",
      "CarBAMazepine may enhance the adverse/toxic effect of LamoTRIgine. Specifically, the risk for hematologic toxicities may be increased. CarBAMazepine may enhance the arrhythmogenic effect of LamoTRIgine. CarBAMazepine may decrease the serum concentration of LamoTRIgine. Management: Consider the risk of serious arrhythmias or death versus benefit of this combination. For patients taking carbamazepine without valproate, lamotrigine dose adjustments are recommended for lamotrigine initiation. See full interact monograph for details.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.\n",
      "Aspirin may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased.\n",
      "Aspirin may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Aspirin may increase the serum concentration of Edoxaban. Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.\n",
      "May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.\n",
      "Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Specifically, the risk for Reye's syndrome may increase.\n",
      "Beta-Blockers may enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.\n",
      "Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.\n",
      "May enhance the CNS depressant effect of Serotonergic Opioids (High Risk). Serotonergic Non- Opioid CNS Depressants may enhance the serotonergic effect of Serotonergic Opioids (High Risk). This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and CNS depression.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products.\n",
      "May enhance the QTc-prolonging effect of Chloroquine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Dofetilide. Management: Although hydrochlorothiazide is specifically cited as a contraindication, the risk likely extends to all thiazide and thiazide-like diuretics and may be even greater with chlorthalidone or bendroflumethiazide. Consider alternatives when possible.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Amiodarone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QUEtiapine.\n",
      "Muscle Relaxants (Centrally Acting) may enhance the adverse/toxic effect of Botulinum Toxin- Containing Products. Specifically, the risk for increased muscle weakness may be enhanced.\n",
      "May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Live).\n",
      "Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins. Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Sacubitril. Specifically, the risk of angioedema may be increased with this combination.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Halofantrine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Antidepressants (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "Cladribine may enhance the adverse/toxic effect of Interferons (Beta). Specifically, the risk for lymphopenia may be increased.\n",
      "QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Propofol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.\n",
      "May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities.\n",
      "QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Clarithromycin. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "CloZAPine may enhance the anticholinergic effect of QuiNIDine. CloZAPine may enhance the QTc-prolonging effect of QuiNIDine.QuiNIDine may increase the serum concentration of CloZAPine. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Salicylic Acid may diminish the therapeutic effect of Calcipotriene. Management: Monitor for reduced calcipotriene efficacy if combined with salicylic acid. Consider separating the administration of these agents by 10 to 12 hours to minimize the risk of this potential interaction.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.\n",
      "May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "Probenecid may increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite. Management: Consider limiting acetaminophen use in combination with probenecid. Probenecid may reduce clearance of acetaminophen to one of its non-toxic metabolities, increasing the risk for acetaminophen toxicity, even a lower doses.\n",
      "Bile Acid Sequestrants may decrease the serum concentration of Pravastatin. Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products.\n",
      "May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.\n",
      "Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Selpercatinib. QT- prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Selpercatinib. Management: Avoid combination if possible. If use is necessary, reduce selpercatinib dose as follows: from 120mg twice/day to 80mg twice/day, or from 160mg twice/day to 120mg twice/day. Monitor QT interval more closely for QTc interval prolongation and arrhythmias.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "CycloPHOSphamide may enhance the adverse/toxic effect of Sargramostim. Specifically, the risk of pulmonary toxicity may be enhanced.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "Dabrafenib may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral).\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy).\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral).\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine.\n",
      "Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.\n",
      "Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline. Management: Limit duration of concurrent use of bedaquiline with strong CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued use outweighs the possible risks. Monitor for toxic effects of bedaquiline, including QTc interval prolongation.\n",
      "QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of PAZOPanib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products.\n",
      "Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine.\n",
      "Anthracyclines may enhance the adverse/toxic effect of Margetuximab. Specifically, the risk of cardiac dysfunction may be increased. Management: Avoid anthracycline-based therapy for up to 4 months after discontinuing margetuximab due to an increased risk of cardiac dysfunction. If anthracyclines must be used with margetuximab monitor cardiac function closely.\n",
      "Corticosteroids (Systemic) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine- associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Yellow Fever Vaccine.\n",
      "May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.\n",
      "May enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "May enhance the immunosuppressive effect of Denosumab. Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.\n",
      "QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.\n",
      "Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment. Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation. If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.\n",
      "Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "Corticosteroids (Systemic) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of BCG Products.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities.\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.\n",
      "Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.\n",
      "May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents.\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.\n",
      "May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.\n",
      "Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Specifically, the risk for Reye's syndrome may increase.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flupentixol.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Moxifloxacin (Systemic).\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Toremifene. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pimozide. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QUEtiapine.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Vemurafenib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "OCT2 Inhibitors may increase the serum concentration of Dalfampridine. Management: Consider alternatives to this combination. Carefully weigh the risk of seizures against the benefit of combining OCT2 inhibitors with dalfampridine.\n",
      "OCT2 Inhibitors may increase the serum concentration of Dalfampridine. Management: Consider alternatives to this combination. Carefully weigh the risk of seizures against the benefit of combining OCT2 inhibitors with dalfampridine.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Escitalopram may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities.\n",
      "May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.\n",
      "Anthracyclines may enhance the adverse/toxic effect of Margetuximab. Specifically, the risk of cardiac dysfunction may be increased. Management: Avoid anthracycline-based therapy for up to 4 months after discontinuing margetuximab due to an increased risk of cardiac dysfunction. If anthracyclines must be used with margetuximab monitor cardiac function closely.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "May enhance the QTc-prolonging effect of Dronedarone. Dronedarone may increase the serum concentration of Ivosidenib. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).\n",
      "QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Clarithromycin. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.\n",
      "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.\n",
      "Vaccines (Live) may enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).\n",
      "May enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin. Management: Avoid concomitant use of lefamulin with moderate CYP3A4 inducers unless the benefits outweigh the risks.\n",
      " May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "Dipeptidyl Peptidase-IV Inhibitors may enhance the adverse/toxic effect of Angiotensin- Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.\n",
      "May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      " May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.\n",
      "May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.\n",
      "Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.\n",
      "Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the adverse/toxic effect of MetFORMIN. Specifically, excessive alcohol ingestion (acute or chronic) may potentiate the risk of lactic acidosis.\n",
      "Dipeptidyl Peptidase-IV Inhibitors may enhance the adverse/toxic effect of Angiotensin- Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.\n",
      " QT-prolonging Antidepressants (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol. Haloperidol may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk. \n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk of hypovolemia, electrolyte disturbances, and prerenal azotemia may be increased.\n",
      "Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the adverse/toxic effect of Estrogen Derivatives (Contraceptive). Specifically, the risk of serious cardiovascular events (eg, stroke, venous thromboembolism, myocardial infarction) may be increased. Management: Avoid cigarette smoking in patients who use estrogen containing contraceptives whenever possible. If combined, monitor for signs and symptoms of serious cardiovascular events (eg, stroke, venous thromboembolism, myocardial infarction).\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "Antacids may decrease the serum concentration of Potassium Phosphate. Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.\n",
      "Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.\n",
      "CYP3A4 Inducers (Moderate) may decrease the serum concentration of Indinavir. Management: Consider avoiding the combination of indinavir and moderate CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure.\n",
      "May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).\n",
      "May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "Antacids may decrease the serum concentration of Elvitegravir. Management: Separate administration of aluminum and magnesium containing antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an interaction.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Chloroquine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of Fexinidazole. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may decrease serum concentrations of the active metabolite(s) of Fexinidazole. Management: Consider alternatives to this combination. If combined, monitor for QT interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QT prolongation may be at even higher risk. Also monitor for reduced fexinidazole efficacy.\n",
      "Fingolimod may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias (including TdP) with a continuous overnight ECG when fingolimod is combined with QT prolonging drugs. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Fingolimod may enhance the adverse/toxic effect of Zoster Vaccine (Live/Attenuated). The risk of herpes zoster infection may be increased. Fingolimod may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated). Management: Wait 1 month after zoster vaccine administration to initiate fingolimod therapy. Avoid the use of the zoster vaccine during fingolimod treatment, and for 2 months following treatment discontinuation.\n",
      "May enhance the QTc-prolonging effect of Flecainide. Amiodarone may increase the serum concentration of Flecainide. Management: Decrease flecainide dose by 50%. Monitor for QTc interval prolongation and ventricular arrhythmias, and consider monitoring for elevated flecainide concentrations. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Class IC Antiarrhythmics (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of other QT-prolonging Class IC Antiarrhythmics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the QTc-prolonging effect of other Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Ceritinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Ceritinib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QUEtiapine. QT- prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QUEtiapine. Management: Monitor for increased quetiapine toxicities including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.\n",
      "Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk of seizures may be increased.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine.\n",
      "Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Alteplase. Specifically, the risk for angioedema may be increased.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased.\n",
      "QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "May enhance the adverse/toxic effect of Gemcitabine. Specifically, the risk for thrombotic microangiopathy may be increased with this combination.\n",
      "Gemifloxacin may enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk).\n",
      "May enhance the QTc-prolonging effect of other QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).\n",
      "May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.\n",
      "May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.\n",
      "May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.\n",
      "Haloperidol may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding.\n",
      " May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Corticosteroids (Systemic) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "Aminoquinolines (Antimalarial) may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial.\n",
      "Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.\n",
      "May enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding.\n",
      "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased\n",
      "May enhance the adverse/toxic effect of Ibrutinib. Specifically, the risk for bleeding events may be increased.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.\n",
      "May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti- inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.\n",
      "Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.\n",
      "May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk for gastrointestinal toxicity is increased.\n",
      "May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non- toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite. Management: Consider limiting acetaminophen use in combination with probenecid. Probenecid may reduce clearance of acetaminophen to one of its non-toxic metabolities, increasing the risk for acetaminophen toxicity, even a lower doses.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.\n",
      "May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.\n",
      "May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flupentixol.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Nilotinib.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Anthracyclines may enhance the adverse/toxic effect of Margetuximab. Specifically, the risk of cardiac dysfunction may be increased. Management: Avoid anthracycline-based therapy for up to 4 months after discontinuing margetuximab due to an increased risk of cardiac dysfunction. If anthracyclines must be used with margetuximab monitor cardiac function closely.\n",
      "May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral).\n",
      "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.\n",
      "Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.\n",
      "Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Dofetilide. Management: Although hydrochlorothiazide is specifically cited as a contraindication, the risk likely extends to all thiazide and thiazide-like diuretics and may be even greater with chlorthalidone or bendroflumethiazide. Consider alternatives when possible.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding.\n",
      "May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti- inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.\n",
      "May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.\n",
      "QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Piperaquine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.\n",
      "Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination.\n",
      "Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination.\n",
      "Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination. Management: Consider using lower doses to minimize toxicity of this combination. Only coadminister aldesleukin and interferons (alfa) in patients in whom potential benefits outweigh the risk of severe toxicity. Monitor renal and cardiac function closely if combined.\n",
      "Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the CNS depressant effect of Methadone. Methadone may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, sedation, and respiratory depression. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-Prolonging Inhalational Anesthetics (Moderate Risk) may enhance the QTc- prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      " May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of CloZAPine. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias (including TdP) with a continuous overnight ECG when fingolimod is combined with QT prolonging drugs. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Levofloxacin-Containing Products (Systemic). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).\n",
      "May decrease the serum concentration of Ketoconazole (Systemic). Management: Avoid use of isoniazid from 2 weeks before and during treatment with ketoconazole when possible. If potential benefits outweigh the risks, monitor closely for reduced clinical response to ketoconazole and adjust the ketoconazole dose as needed.\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.\n",
      "CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.\n",
      "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased\n",
      "QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Doxepin-Containing Products. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of PAZOPanib.\n",
      "QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Kinase Inhibitors (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Allopurinol may enhance the adverse/toxic effect of Riluzole. Specifically, the risk of hepatotoxicity may be increased. Management: Consider alternatives to allopurinol in patients receiving treatment with riluzole due to the potential for additive hepatotoxicity.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.\n",
      "May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).\n",
      " May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).\n",
      "May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.\n",
      "May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased. MetFORMIN may increase the serum concentration of Topiramate. Topiramate may increase the serum concentration of MetFORMIN.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Clofazimine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased\n",
      "Lopinavir may increase the serum concentration of Atorvastatin. Management: Consider the risks and benefits of this combination. If coadministered, use the lowest dose of atorvastatin necessary and monitor patients for signs and symptoms of myopathy, especially at initiation of therapy and with any dose increase.\n",
      "May enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non- inhaled formulations of loxapine.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.\n",
      "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Antacids may decrease the serum concentration of Nilotinib. Management: Separate the administration of nilotinib and any antacid by at least 2 hours whenever possible in order to minimize the risk of a significant interaction.\n",
      "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.\n",
      "May enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased.\n",
      "May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti- inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.\n",
      "May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding.\n",
      "May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk for gastrointestinal toxicity is increased.\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.\n",
      "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities.\n",
      "CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased.\n",
      "Metaxalone may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Escitalopram. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Halofantrine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Nilotinib.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the CNS depressant effect of Methadone. Methadone may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, sedation, and respiratory depression. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Methadone may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      " Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, monoamine oxidase inhibitors may enhance dopamine blockade, possible increasing the risk for neuroleptic malignant syndrome. X: Avoid combination\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Methotrexate may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of Yellow Fever Vaccine.\n",
      "May enhance the adverse/toxic effect of Methotrimeprazine. Specifically, monoamine oxidase inhibitors may enhance dopamine blockade, possible increasing the risk for neuroleptic malignant syndrome. Methotrimeprazine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.\n",
      "May enhance the adverse/toxic effect of Thiazide and Thiazide-Like Diuretics. Specifically, the risk for intravascular volume depletion may be increased.\n",
      "May enhance the adverse/toxic effect of Thiazide and Thiazide-Like Diuretics. Specifically, the risk for intravascular volume depletion may be increased.\n",
      "Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.\n",
      "May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "CYP3A4 Inhibitors (Strong) may increase the serum concentration of Midostaurin. Management: Seek alternatives to the concomitant use of midostaurin and strong CYP3A4 inhibitors if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Mineral Oil may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, mineral oil may impair the absorption of fat-soluble vitamins. Management: Avoid concomitant oral administration of mineral oil and multivitamins when possible; consider separating the administration of these agents by several hours to minimize the risk of interaction.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin (Intravenous). Management: Avoid concomitant use of lefamulin (intravenous) with moderate CYP3A4 inducers unless the benefits outweigh the risks.\n",
      "Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Doxepin-Containing Products. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Haloperidol. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Vemurafenib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.\n",
      "May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.\n",
      "May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.\n",
      "May enhance the adverse/toxic effect of Opioid Antagonists. Specifically, the risk for opioid withdrawal may be increased.\n",
      "QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc- prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products.\n",
      "May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents.\n",
      "May enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "May enhance the adverse/toxic effect of Thiazide and Thiazide-Like Diuretics. Specifically, the risk for intravascular volume depletion may be increased.\n",
      "May enhance the adverse/toxic effect of Naloxegol. Specifically, the risk for gastrointestinal perforation may be increased.\n",
      "May enhance the adverse/toxic effect of BuPROPion. Specifically, the risk for seizures may be increased. BuPROPion may increase the serum concentration of Brexpiprazole. Management: Reduce brexpiprazole dose to 50% of usual dose with bupropion; reduce to 25% of usual if used with both bupropion and a strong or moderate CYP3A4 inhibitor. These recommendations do not apply if treating major depressive disorder. Monitor for seizures.\n",
      "May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). Management: Avoid concomitant use of fexinidazole and CYP2B6 substrates when possible. If combined, monitor for reduced efficacy of the CYP2B6 substrate.\n",
      "May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.\n",
      "Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.\n",
      "May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti- inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab. Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).\n",
      "May enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased.\n",
      "Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.\n",
      "May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral).\n",
      "OLANZapine may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of DroPERidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.\n",
      "Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Opioid Agonists (metabolized by CYP3A4 and CYP2D6) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Ondansetron may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.\n",
      "May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.\n",
      "Aspirin may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Aspirin may increase the serum concentration of Edoxaban. Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.\n",
      "Aspirin may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Ozanimod may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The risk of developing a clinical infection from the live vaccine may be increased. Ozanimod may diminish the therapeutic effect of Varicella Virus- Containing Vaccines.\n",
      "May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral).\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pilsicainide. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of QuiNINE. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "May enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract).\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract).\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the risk for serotonin syndrome or opioid toxicities (eg, respiratory depression, coma) may be increased. Management: Sufentanil should not be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for serotonin syndrome and/or excessive CNS depression.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.\n",
      "CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.\n",
      "Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased.\n",
      "Pioglitazone may enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs\n",
      "May increase the serum concentration of MetFORMIN. Management: Limit the metformin dose to a maximum of 1,700 mg per day when used together with ranolazine 1,000 mg twice daily. Monitor patients for metformin toxicities, including lactic acidosis and carefully weigh the risks and benefits of this combination.\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products.\n",
      "Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Antiplatelet Agents (P2Y12 Inhibitors) may increase the serum concentration of Dabigatran Etexilate.Specifically, clopidogrel may increase dabigatran serum concentrations. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flecainide. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Lofexidine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Probucol.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).\n",
      "May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk of neuroleptic malignant syndrome or increased QTc interval may be increased.\n",
      "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.\n",
      "May enhance the adverse/toxic effect of Promethazine. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "Propafenone may enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).\n",
      "Propofol may enhance the CNS depressant effect of FentaNYL. Management: Consider alternatives to this combination when possible. If the combination is used, monitor more closely for bradycardia, apnea, and excessive CNS depression. Propofol induction dose requirements may be reduced. Pediatric patients may be at greater risk.\n",
      "QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Midostaurin. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of Propofol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Toremifene. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).\n",
      "May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.\n",
      "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased\n",
      "May enhance the adverse/toxic effect of Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, and Protein S]. Specifically, the risk for thrombosis may be increased.\n",
      "Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased.\n",
      "QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Flupentixol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation, ventricular arrhythmias, including torsades de pointes, when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of QT- prolonging Antidepressants (Moderate Risk). QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of QT- prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.\n",
      " May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Hydroxide Polymaltose Complex. Specifically, the risk for angioedema or allergic reactions may be increased.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clarithromycin.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Chloroquine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions. Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the CNS depressant effect of RisperiDONE. QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.\n",
      "Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.\n",
      "Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased.\n",
      "May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Encorafenib. Management: Avoid use of encorafenib and moderate CYP3A4 inhibitors when possible. If combined, decrease encorafenib dose from 450 mg to 225 mg; 300 mg to 150 mg; and 225 mg or 150 mg to 75 mg. Monitor closely for QT interval prolongation.\n",
      "QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QUEtiapine. QT- prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QUEtiapine. Management: Monitor for increased quetiapine toxicities including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin. Management: Avoid concomitant use of lefamulin with strong CYP3A4 inducers unless the benefits outweigh the risks.\n",
      "May enhance the hepatotoxic effect of RifAMPin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection. Management: Rifampin-pyrazinamide is generally not preferred for the treatment of latent tuberculosis (TB) due to the risk of hepatotoxicity. However, it is an option for patients at high risk of developing active TB who are unlikely to complete preferred treatment.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products.\n",
      "May enhance the QTc-prolonging effect of RisperiDONE. Azithromycin (Systemic) may increase the serum concentration of RisperiDONE. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of OLANZapine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "RisperiDONE may enhance the QTc-prolonging effect of Vemurafenib. Vemurafenib may increase the serum concentration of RisperiDONE. Management: Monitor for increased risperidone toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Vaccines (Live) may enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).\n",
      "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased\n",
      "CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      " May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Sevoflurane. Specifically, the risk of hemodynamic instability may be increased.\n",
      " May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Encorafenib. Management: Avoid use of encorafenib and strong CYP3A4 inhibitors when possible. If combined, decrease encorafenib dose from 450 mg to 150 mg; or from 300 mg, 225 mg, or 150 mg to 75 mg. Monitor closely for QT interval prolongation.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Saquinavir may enhance the QTc-prolonging effect of Methadone. Saquinavir may decrease the serum concentration of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and opioid withdrawal symptoms. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of Saquinavir. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Ribociclib. Management: Avoid concomitant use of ribociclib and strong CYP3A4 inhibitors that prolong the QTc interval whenever possible. If combined, decrease the ribociclib dose to 400 mg daily. Monitor for ribociclib toxicities including QTc prolongation and arrhythmias.\n",
      "Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. Management: Avoid use of granulocyte colony-stimulating factors 24 hours before (14 days for pegfilgrastim) and 24 hours after the last dose of bleomycin.\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products.\n",
      "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of CloZAPine. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Gemifloxacin. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live).\n",
      "May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).\n",
      "Vaccines (Live) may enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).\n",
      "Antacids may decrease the absorption of Atazanavir. Management: Administer antacids 1 to 2 hours before or 2 hours after atazanavir to minimize the risk of a clinically significant interaction.\n",
      "Antacids may decrease the serum concentration of Nilotinib. Management: Separate the administration of nilotinib and any antacid by at least 2 hours whenever possible in order to minimize the risk of a significant interaction.\n",
      "Magnesium Sulfate may enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased.\n",
      "Sorbitol may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Domperidone.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Moxifloxacin (Systemic).\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QT- prolonging Strong CYP3A4 Inhibitors (Highest Risk). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination.\n",
      "Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased.\n",
      "Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Tamoxifen may enhance the adverse/toxic effect of Chloroquine. Specifically, concomitant use of tamoxifen and chloroquine may increase the risk of retinal toxicity.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "Telithromycin may increase the serum concentration of Atorvastatin. Management: Avoid concomitant use of atorvastatin and telithromycin due to the risk of rhabdomyolysis. If a patient treated with atorvastatin requires telithromycin, discontinue atorvastatin for the duration of telithromycin therapy.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "Thrombolytic Agents may enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.\n",
      "QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation, ventricular arrhythmias, including torsades de pointes, when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.\n",
      "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.\n",
      "May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.\n",
      "May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased.\n",
      "Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.\n",
      "May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.\n",
      "CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).\n",
      "QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).\n",
      "May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.\n",
      "May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk of hypovolemia, electrolyte disturbances, and prerenal azotemia may be increased.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.\n",
      "May enhance the serotonergic effect of Serotonergic Opioids (High Risk). This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes).\n",
      "May enhance the CNS depressant effect of Serotonergic Opioids (High Risk). Serotonergic Opioids (High Risk) may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and CNS depression.\n",
      "May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.\n",
      " Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, monoamine oxidase inhibitors may enhance dopamine blockade, possible increasing the risk for neuroleptic malignant syndrome. X: Avoid combination\n",
      "Monoamine Oxidase Inhibitors (Antidepressant) may enhance the adverse/toxic effect of TraMADol. Specifically, the risk for serotonin syndrome/serotonin toxicity and seizures may be increased..\n",
      "May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome.\n",
      "May enhance the adverse/toxic effect of Vaccines (Live). The risk for contracting an infection from the vaccine may be increased. Tildrakizumab may diminish the therapeutic effect of Vaccines (Live).\n",
      "Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral).\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the adverse/toxic effect of Valproate Products. Specifically, the risk of hepatotoxicity or hyperammonemia may be increased. Valproate Products may decrease the protein binding of Fosphenytoin-Phenytoin. This appears to lead to an initial increase in the percentage of unbound (free) phenytoin and to a decrease in total phenytoin concentrations. Whether concentrations of free phenytoin are increased is unclear. With long-term concurrent use, total phenytoin concentrations may increase. Fosphenytoin-Phenytoin may decrease the serum concentration of Valproate Products.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Gemifloxacin. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of OLANZapine. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Toremifene. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "May enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine- associated infection may be increased. Methotrexate may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk). QT-prolonging Class III Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Erythromycin (Systemic). Management: Avoid concomitant use of erythromycin and class III antiarrhythmic agents. Use of erythromycin with dronedarone is specifically contraindicated.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of SUNItinib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased.\n",
      "May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).\n",
      "Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Citalopram. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased.\n",
      "May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QUEtiapine. Management: Reduce the quetiapine dose to one-sixth of the regular dose when initiating these strong CYP3A4 inhibitors. In patients already receiving these strong CYP3A4 inhibitors, initiate quetiapine at the lowest dose and titrate cautiously as needed.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.\n",
      "Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.\n",
      "CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.\n",
      "May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.\n",
      "QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Delamanid. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias (including TdP) with a continuous overnight ECG when fingolimod is combined with QT prolonging drugs. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QT- prolonging Strong CYP3A4 Inhibitors (Highest Risk). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the QTc-prolonging effect of Ziprasidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.\n",
      "May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.\n",
      "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.\n"
     ]
    }
   ],
   "source": [
    "for i in range(1,len(df),17):\n",
    "    if 'risk' in df.Interaction.iloc[i].lower():\n",
    "        print(df.Interaction.iloc[i])"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T14:16:14.580785800Z",
     "start_time": "2023-08-28T14:16:14.475067900Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "outputs": [
    {
     "data": {
      "text/plain": "                                              Drug Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...   \n...                                                 ...   \n3152                                          Zopiclone   \n3153                    Zoster Vaccine (LiveAttenuated)   \n3154                       Zoster Vaccine (Recombinant)   \n3155                                        Zucapsaicin   \n3156                                     Zuclopenthixol   \n\n                                      Food Interactions  \\\n0                                                   NaN   \n1                                                   NaN   \n2                                                   NaN   \n3                                                   NaN   \n4                                                   NaN   \n...                                                 ...   \n3152  Effect/toxicity may be increased by grapefruit...   \n3153                                                NaN   \n3154                                                NaN   \n3155                                                NaN   \n3156                                                NaN   \n\n                           Food Management Interactions  \\\n0                                                   NaN   \n1                                                   NaN   \n2                                                   NaN   \n3                                                   NaN   \n4                                                   NaN   \n...                                                 ...   \n3152  Do not exceed 3.75 mg as starting dose; monito...   \n3153                                                NaN   \n3154                                                NaN   \n3155                                                NaN   \n3156                                                NaN   \n\n                                              Reference  \n0                                                   NaN  \n1                                                   NaN  \n2                                                   NaN  \n3                                                   NaN  \n4                                                   NaN  \n...                                                 ...  \n3152  Effect/toxicity may be increased by grapefruit...  \n3153                                                NaN  \n3154                                                NaN  \n3155                                                NaN  \n3156                                                NaN  \n\n[3157 rows x 4 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Drug Name</th>\n      <th>Food Interactions</th>\n      <th>Food Management Interactions</th>\n      <th>Reference</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3152</th>\n      <td>Zopiclone</td>\n      <td>Effect/toxicity may be increased by grapefruit...</td>\n      <td>Do not exceed 3.75 mg as starting dose; monito...</td>\n      <td>Effect/toxicity may be increased by grapefruit...</td>\n    </tr>\n    <tr>\n      <th>3153</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3154</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3155</th>\n      <td>Zucapsaicin</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3156</th>\n      <td>Zuclopenthixol</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>3157 rows × 4 columns</p>\n</div>"
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_excel('Notebooks/installations/Data/Results - Final Sprint Assignment/due 23-08-28/Drug-Food Interaction.xlsx')\n",
    "df"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T14:34:41.217323300Z",
     "start_time": "2023-08-28T14:34:41.014146200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "outputs": [],
   "source": [
    "food_ls = []\n",
    "for i in range(len(df)):\n",
    "    food = df['Food Interactions'].iloc[i]\n",
    "    try:\n",
    "        df['Food Interactions'].iloc[i] = food.split('Management: ')[0]\n",
    "    except:\n",
    "        food_ls.append(None)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T14:35:41.181923300Z",
     "start_time": "2023-08-28T14:35:41.034608400Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "outputs": [
    {
     "data": {
      "text/plain": "                                              Drug Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...   \n...                                                 ...   \n3152                                          Zopiclone   \n3153                    Zoster Vaccine (LiveAttenuated)   \n3154                       Zoster Vaccine (Recombinant)   \n3155                                        Zucapsaicin   \n3156                                     Zuclopenthixol   \n\n                                      Food Interactions  \\\n0                                                   NaN   \n1                                                   NaN   \n2                                                   NaN   \n3                                                   NaN   \n4                                                   NaN   \n...                                                 ...   \n3152  Effect/toxicity may be increased by grapefruit...   \n3153                                                NaN   \n3154                                                NaN   \n3155                                                NaN   \n3156                                                NaN   \n\n                           Food Management Interactions  \\\n0                                                   NaN   \n1                                                   NaN   \n2                                                   NaN   \n3                                                   NaN   \n4                                                   NaN   \n...                                                 ...   \n3152  Do not exceed 3.75 mg as starting dose; monito...   \n3153                                                NaN   \n3154                                                NaN   \n3155                                                NaN   \n3156                                                NaN   \n\n                                              Reference  \n0                                                   NaN  \n1                                                   NaN  \n2                                                   NaN  \n3                                                   NaN  \n4                                                   NaN  \n...                                                 ...  \n3152  Effect/toxicity may be increased by grapefruit...  \n3153                                                NaN  \n3154                                                NaN  \n3155                                                NaN  \n3156                                                NaN  \n\n[3157 rows x 4 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Drug Name</th>\n      <th>Food Interactions</th>\n      <th>Food Management Interactions</th>\n      <th>Reference</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3152</th>\n      <td>Zopiclone</td>\n      <td>Effect/toxicity may be increased by grapefruit...</td>\n      <td>Do not exceed 3.75 mg as starting dose; monito...</td>\n      <td>Effect/toxicity may be increased by grapefruit...</td>\n    </tr>\n    <tr>\n      <th>3153</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3154</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3155</th>\n      <td>Zucapsaicin</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3156</th>\n      <td>Zuclopenthixol</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>3157 rows × 4 columns</p>\n</div>"
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-28T14:35:48.820777600Z",
     "start_time": "2023-08-28T14:35:48.789326200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "outputs": [],
   "source": [
    "df.to_csv('Notebooks/installations/Data/Results - Final Sprint Assignment/Drug-Food Interaction.csv',index=False,encoding='utf-8-sig')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T08:01:58.045697Z",
     "start_time": "2023-08-29T08:01:58.014209600Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "outputs": [],
   "source": [
    "### Drug-Test Interactions\n",
    "import json\n",
    "\n",
    "path_json = 'Notebooks/installations/Data/Results - Final Sprint Assignment/drug-test-conditions.json'\n",
    "f = open(path_json)\n",
    "\n",
    "drug_test = json.load(f)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T09:15:46.721750900Z",
     "start_time": "2023-08-29T09:15:46.703800100Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "outputs": [
    {
     "data": {
      "text/plain": "{'5 + 2 (Cytarabine-Daunorubicin) (AML Induction)': 'Not available',\n '5 + 2 (Cytarabine-Daunorubicin) (AML Postremission)': 'Not available',\n '5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)': 'Not available',\n '5 + 2 (Cytarabine-Mitoxantrone) (AML Consolidation)': 'Not available',\n '5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) (AML Consolidation)': 'Not available',\n '7 + 3 (Cytarabine-Daunorubicin) (AML Induction)': 'Not available',\n '7 + 3 (Cytarabine-Idarubicin) (AML Induction)': 'Not available',\n '7 + 3 (Cytarabine-Mitoxantrone) (AML Induction)': 'Not available',\n '7 + 3 + 7 (Cytarabine-Daunorubicin-Etoposide) (AML Induction)': 'Not available',\n 'A-AVD (Hodgkin)': 'Not available',\n 'Abacavir and Lamivudine': 'Not available',\n 'Abacavir, Dolutegravir, and Lamivudine': 'Not available',\n 'Abacavir, Lamivudine, and Zidovudine': 'Not available',\n 'Abacavir': 'Not available',\n 'Abaloparatide': 'Not available',\n 'Abatacept': {'Dehydrogenase pyrroloquinolinequinone testing method': 'falsely elevated blood glucose levels',\n  'Glucose-dye-oxidoreductase testing method': 'falsely elevated blood glucose levels'},\n 'Abciximab': 'Not available',\n 'Abemaciclib-Fulvestrant (Breast)': 'Not available',\n 'Abemaciclib': 'Not available',\n 'Abiraterone Acetate': 'Not available',\n 'Abiraterone-Methylprednisolone (Prostate)': 'Not available',\n 'Abiraterone-Prednisone (Prostate)': 'Not available',\n 'AbobotulinumtoxinA': 'Not available',\n 'Abrocitinib': 'Not available',\n 'ABV Hybrid (Hodgkin)': 'Not available',\n 'ABVD (Hodgkin)': 'Not available',\n 'ABVD Early Stage (Hodgkin)': 'Not available',\n 'AC (Breast)': 'Not available',\n 'AC (Dose-Dense) followed by Paclitaxel (Dose-Dense) (Breast)': 'Not available',\n 'AC (Dose-Dense) followed by Paclitaxel (Dose-Dense)-Trastuzumab (Breast)': 'Not available',\n 'AC (Dose-Dense) followed by Paclitaxel Weekly (Breast)': 'Not available',\n 'AC followed by Docetaxel Every 3 Weeks (Breast)': 'Not available',\n 'AC followed by Paclitaxel Weekly (Breast)': 'Not available',\n 'AC followed by Paclitaxel-Trastuzumab (Breast)': 'Not available',\n 'Acalabrutinib-Obinutuzumab (CLL)': 'Not available',\n 'Acalabrutinib': 'Not available',\n 'Acamprosate': 'Not available',\n 'Acarbose': 'Not available',\n 'Acebutolol': {'Aldosterone / renin ratio (ARR)': 'false-positive'},\n 'Acenocoumarol': 'Not available',\n 'Acetaminophen and Caffeine': 'See individual agents',\n 'Acetaminophen and Codeine': 'See individual agents',\n 'Acetaminophen and Diphenhydramine': 'See individual agents',\n 'Acetaminophen and Methocarbamol': 'See individual agents',\n 'Acetaminophen and Pamabrom': 'See individual agents',\n 'Acetaminophen and Phenylephrine': 'See individual agents',\n 'Acetaminophen and Phenyltoloxamine': {'Urinary 5-hydroxyindoleacetic acid': 'false-positive'},\n 'Acetaminophen and Pseudoephedrine': 'See individual agents',\n 'Acetaminophen and Tramadol': 'See individual agents',\n 'Acetaminophen, Aspirin, and Caffeine': 'See individual agents',\n 'Acetaminophen, Caffeine, and Codeine': 'See individual agents',\n 'Acetaminophen, Caffeine, and Dihydrocodeine': 'See individual agents',\n 'Acetaminophen, Caffeine, and Pyrilamine': 'Not available',\n 'Acetaminophen, Codeine, and Doxylamine': 'See individual agents',\n 'Acetaminophen, Dextromethorphan, and Doxylamine': 'See individual agents',\n 'Acetaminophen, Dextromethorphan, and Phenylephrine': 'See individual agents',\n 'Acetaminophen, Diphenhydramine, and Phenylephrine': 'See individual agents',\n 'Acetaminophen, Guaifenesin, and Phenylephrine': 'Not available',\n 'Acetaminophen, Isometheptene, and Dichloralphenazone': {'urine glucose': 'false',\n  'urine catecholamine': 'false',\n  'urinary 5-hydroxyindoleacetic acid': 'false'},\n 'Acetaminophen': {'urinary 5-hydroxyindoleacetic acid': 'false-positive'},\n 'AcetaZOLAMIDE': {'urinary protein with Albustix': 'false-positive',\n  'urinary protein with Labstix': 'false-positive',\n  'urinary protein with Albutest': 'false-positive',\n  'urinary protein with Bumintest': 'false-positive',\n  'HPLC theophylline assay': 'interference',\n  'serum uric acid levels': 'interference',\n  'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Acetic Acid (Otic)': 'Not available',\n 'Acetic Acid (refer to route-specific monograph)': 'Not available',\n 'Acetic Acid (Topical)': 'Not available',\n 'Acetic Acid and Hydrocortisone': 'Not available',\n 'Acetohydroxamic Acid': 'Not available',\n 'Acetone': 'Not available',\n 'Acetylcholine': 'Not available',\n 'Acetylcysteine': 'Not available',\n 'Acitretin': 'Not available',\n 'Aclidinium and Formoterol': 'Not available',\n 'Aclidinium': 'Not available',\n 'Acrivastine and Pseudoephedrine': {'amphetamines': 'false-positive'},\n 'Acyclovir (Ophthalmic)': 'Not available',\n 'Acyclovir (refer to route-specific monograph)': 'Not available',\n 'Acyclovir (Systemic)': 'Not available',\n 'Acyclovir (Topical)': 'Not available',\n 'Acyclovir and Hydrocortisone': 'Not available',\n 'AD (Soft Tissue Sarcoma)': 'Not available',\n 'Adagrasib': 'Not available',\n 'Adalimumab': 'Not available',\n 'Adapalene and Benzoyl Peroxide': 'Not available',\n 'Adapalene': 'Not available',\n 'Adefovir': 'Not available',\n 'Adenosine': 'Not available',\n 'Adenovirus (Types 4, 7) Vaccine': 'Not available',\n 'Ado-Trastuzumab Emtansine': 'Not available',\n 'Aducanumab': 'Not available',\n 'Afamelanotide': 'Not available',\n 'Afatinib': 'Not available',\n 'Aflibercept (Ophthalmic)': 'Not available',\n 'Aflibercept (refer to route-specific monograph)': 'Not available',\n 'Agalsidase Alfa': 'Not available',\n 'Agalsidase Beta': 'Not available',\n 'AIM (Soft Tissue Sarcoma)': 'Not available',\n 'Air Polymer-Type A': 'Not available',\n 'Albendazole': 'Not available',\n 'Albiglutide': 'Not available',\n 'Albumin': 'Not available',\n 'Albuterol and Budesonide': {'Renin': 'increased in serum',\n  'Aldosterone': 'increased in serum'},\n 'Albuterol': {'Renin': 'increased in serum',\n  'Aldosterone': 'increased in serum'},\n 'Alcaftadine': 'Not available',\n 'Alclometasone': 'Not available',\n 'Alcohol (Ethyl)': 'Not available',\n 'Alcohol (Isopropyl)': 'Not available',\n 'Aldesleukin': 'Not available',\n 'Alectinib': 'Not available',\n 'Alemtuzumab': {'diagnostic serum tests that utilize antibodies': 'May interfere'},\n 'Alendronate and Cholecalciferol': {'bisphosphonates': 'May interfere',\n  'diagnostic imaging agents such as technetium-99m-diphosphonate in bone scans': 'May interfere'},\n 'Alendronate': {'bisphosphonates': 'May interfere',\n  'diagnostic imaging agents such as technetium-99m-diphosphonate in bone scans': 'May interfere'},\n 'Alfacalcidol': 'Not available',\n 'ALfentanil': 'Not available',\n 'Alfuzosin': 'Not available',\n 'Alglucosidase Alfa': 'Not available',\n 'Alirocumab': 'Not available',\n 'Aliskiren and Hydrochlorothiazide': 'See individual agents',\n 'Aliskiren': {'aldosterone/renin ratio (ARR)': 'false-positive or false-negative'},\n 'Alitretinoin (refer to route-specific monograph)': 'Not available',\n 'Alitretinoin (Systemic)': 'Not available',\n 'Alitretinoin (Topical)': 'Not available',\n 'Allopurinol': 'Not available',\n 'Almotriptan': 'Not available',\n 'Alogliptin and Metformin': 'Not available',\n 'Alogliptin and Pioglitazone': 'Not available',\n 'Alogliptin': 'Not available',\n 'Alosetron': 'Not available',\n 'Alpelisib-Fulvestrant (Breast)': 'Not available',\n 'Alpelisib': 'Not available',\n 'Alpha-Galactosidase': 'Not available',\n 'Alpha1-Proteinase Inhibitor': 'Not available',\n 'ALPRAZolam': 'Not available',\n 'Alprostadil': 'Not available',\n 'Alteplase': {'coagulation and fibrinolytic activity tests': 'altered results'},\n 'Altretamine': 'Not available',\n 'Alum Irrigation': 'Not available',\n 'Aluminum Acetate': 'Not available',\n 'Aluminum Chloride Hexahydrate': 'Not available',\n 'Aluminum Chloride': 'Not available',\n 'Aluminum Hydroxide and Magnesium Carbonate': 'Not available',\n 'Aluminum Hydroxide and Magnesium Hydroxide': 'Not available',\n 'Aluminum Hydroxide and Magnesium Trisilicate': 'Not available',\n 'Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone': 'Not available',\n 'Aluminum Hydroxide': 'Not available',\n 'Alvimopan': 'Not available',\n 'Amantadine': {'urine detection of amphetamines/methamphetamines': '(false-positive) interference'},\n 'Ambrisentan': 'Not available',\n 'Amcinonide': 'Not available',\n 'Amifampridine': 'Not available',\n 'Amifostine': 'Not available',\n 'Amikacin (refer to route-specific monograph)': 'Not available',\n 'Amikacin (Systemic)': {'Aminoglycoside serum concentration': 'potential underestimation caused by some penicillin derivatives accelerating aminoglycoside degradation in vitro'},\n 'Amikacin Liposome (Oral Inhalation)': 'Not available',\n 'Amiloride and Hydrochlorothiazide': {'Parathyroid function tests': 'Interference',\n  'Serum iodine (protein bound) test': 'Decreased without signs of thyroid disturbance'},\n 'AMILoride': {'Aldosterone/Renin Ratio (ARR)': 'False-negative'},\n 'Amino Acid Injection': 'Not available',\n 'Aminocaproic Acid': 'Not available',\n 'Aminolevulinic Acid (refer to route-specific monograph)': 'Not available',\n 'Aminolevulinic Acid (Systemic)': 'Not available',\n 'Aminolevulinic Acid (Topical)': 'Not available',\n 'Aminophylline': {'Plasma glucose': 'increased',\n  'Uric acid': 'increased',\n  'Free fatty acids': 'increased',\n  'Total cholesterol': 'increased',\n  'HDL': 'increased',\n  'HDL/LDL ratio': 'increased',\n  'Urinary free cortisol excretion': 'increased',\n  'Triiodothyronine': 'decreased'},\n 'Aminosalicylic Acid': 'Not available',\n 'Amiodarone': {'T4 levels': 'elevated',\n  'Thyroid stimulating hormone levels': 'high end of normal range',\n  'T3 levels': 'low end of normal range'},\n 'Amisulpride (Injection)': 'Not available',\n 'Amitriptyline and Chlordiazepoxide': 'Not available',\n 'Amitriptyline and Perphenazine': {'Pregnancy test': 'false-positive'},\n 'Amitriptyline': 'Not available',\n 'Amivantamab': 'Not available',\n 'Amlodipine and Atorvastatin': 'Not available',\n 'Amlodipine and Benazepril': 'See individual agents',\n 'Amlodipine and Celecoxib': 'See individual agents',\n 'Amlodipine and Olmesartan': 'Not available',\n 'Amlodipine and Valsartan': 'Not available',\n 'Amlodipine, Valsartan, and Hydrochlorothiazide': 'See individual agents',\n 'AmLODIPine': {'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Ammonia Spirit (Aromatic)': 'Not available',\n 'Amobarbital': 'Not available',\n 'Amorolfine [INT]': 'Not available',\n 'Amoxapine': 'Not available',\n 'Amoxicillin and Clavulanate': {\"glucose tests using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'interference',\n  'total conjugated estriol': 'transiently interfered',\n  'estriol-glucuronide': 'transiently interfered',\n  'conjugated estrone': 'transiently interfered',\n  'estradiol': 'transiently interfered'},\n 'Amoxicillin': {\"glucose tests (Benedict's solution, Clinitest, Fehling's Solution)\": 'interference',\n  'aminoglycoside serum concentration': 'underestimation'},\n 'Amphetamine': {'Plasma corticosteroid levels': 'elevated by amphetamines',\n  'Urinary steroid determinations': 'interference by amphetamines'},\n 'Amphotericin B (Lipid Complex)': 'Not available',\n 'Amphotericin B (Liposomal)': {'serum phosphate': 'falsely-elevated'},\n 'Amphotericin B Deoxycholate': 'Not available',\n 'Ampicillin and Sulbactam': {\"urinary glucose tests using cupric sulfate (Benedict's solution, Fehling’s solution, or Clinitest®)\": 'interference',\n  'aminoglycoside serum concentration': 'underestimation'},\n 'Ampicillin': {\"Urinary glucose tests using cupric sulfate (Benedict's solution, Clinitest)\": 'may interfere',\n  'Aminoglycoside serum concentration': 'potential underestimation'},\n 'Amsacrine': 'Not available',\n 'Amyl Nitrite': 'Not available',\n 'Anacaulase': 'Not available',\n 'Anagrelide': 'Not available',\n 'Anakinra': 'Not available',\n 'Anastrozole': 'Not available',\n 'Andexanet Alfa (Coagulation Factor Xa [Recombinant], Inactivated)': {'Anti-FXa activity assay': 'falsely elevated'},\n 'Angiotensin II': 'Not available',\n 'Anidulafungin': 'Not available',\n 'Anifrolumab': 'Not available',\n 'Ansuvimab': 'Not available',\n 'Anthralin': 'Not available',\n 'Anthrax Immune Globulin (Human)': {'Glucose monitoring devices and test strips utilizing the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase based methods': 'falsely elevated blood glucose levels',\n  'Urinalysis after anthrax immune globulin administration': 'transiently elevated glucose',\n  'Passively transferred antibodies': 'false-positive serologic testing results, false-positive direct and indirect Coombs’ test'},\n 'Anthrax Vaccine Adsorbed': 'Not available',\n 'Anti-inhibitor Coagulant Complex (Human)': {'blood group isohemagglutinins': 'may interfere with serological tests for red cell antibodies (eg, Coombs test)'},\n 'Anticoagulant Citrate Dextrose': 'Not available',\n 'Anticoagulant Sodium Citrate': 'Not available',\n 'Antihemophilic Factor (Human)': 'Not available',\n 'Antihemophilic Factor (Recombinant [Fc Fusion Protein])': 'Not available',\n 'Antihemophilic Factor (Recombinant [Fc-VWF-XTEN Fusion Protein])': 'Not available',\n 'Antihemophilic Factor (Recombinant [Pegylated])': 'Not available',\n 'Antihemophilic Factor (Recombinant [Porcine Sequence])': 'Not available',\n 'Antihemophilic Factor (Recombinant)': 'Not available',\n 'Antihemophilic Factorvon Willebrand Factor Complex (Human)': 'Not available',\n 'Antithrombin': 'Not available',\n 'Antithymocyte Globulin (Equine)': 'Not available',\n 'Antithymocyte Globulin (Rabbit)': {'rabbit antibody-based immunoassays': 'Potential interference',\n  'cross-match or panel-reactive antibody cytotoxicity assays': 'Potential interference',\n  'routine clinical laboratory tests which do not use immunoglobulins': 'Has not been shown to interfere'},\n 'Antivenin (Latrodectus mactans)': 'Not available',\n 'Antivenin (Micrurus fulvius)': 'Not available',\n 'Apalutamide': 'Not available',\n 'Apixaban': {'anti-Factor Xa assays': 'falsely elevated results and leading to inappropriate heparin dose reduction',\n  'aPTT': 'little or minor effect'},\n 'Apomorphine': 'Not available',\n 'Apraclonidine': 'Not available',\n 'Apremilast': 'Not available',\n 'Aprepitant': 'Not available',\n 'Arformoterol': 'Not available',\n 'Argatroban': {'PT/INR levels': 'elevated',\n  'chromogenic factor X assay': 'monitored',\n  'Factor Xa levels': '<45%'},\n 'Arginine': 'Not available',\n 'ARIPiprazole Lauroxil': 'Not available',\n 'ARIPiprazole': 'Not available',\n 'Armodafinil': 'Not available',\n 'Arsenic Trioxide': 'Not available',\n 'Artemether and Lumefantrine': 'Not available',\n 'Artesunate': 'Not available',\n 'Articaine and Epinephrine': 'Not available',\n 'Artichoke': 'Not available',\n 'Artificial Tears': 'Not available',\n 'Asciminib': 'Not available',\n 'Ascorbic Acid': {'stool occult blood': 'false-negative',\n  'glucose testing': 'falsely elevated',\n  'nitrite and bilirubin levels': 'interfered',\n  'leucocyte count': 'interfered'},\n 'Asenapine': 'Not available',\n 'Asfotase Alfa': {'ALP-conjugated test systems': 'interfered'},\n 'Asparaginase (Erwinia [Recombinant])': 'Not available',\n 'Asparaginase (Erwinia)': 'Not available',\n 'Aspirin and Dipyridamole': 'See individual agents',\n 'Aspirin and Omeprazole': 'Not available',\n 'Aspirin, Citric Acid, and Sodium Bicarbonate': 'Not available',\n 'Aspirin': {'Glucose oxidase urinary glucose tests (Clinistix)': 'False-negative',\n  'cupric sulfate method (Clinitest)': 'false-positives',\n  'Gerhardt test': 'interferes',\n  'VMA determination': 'interferes',\n  '5-HIAA': 'interferes',\n  'xylose tolerance test': 'interferes',\n  'T3': 'interferes',\n  'T4': 'interferes',\n  'aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Atazanavir and Cobicistat': 'See individual agents',\n 'Atazanavir': 'Not available',\n 'Atenolol and Chlorthalidone': 'Not available',\n 'Atenolol': {'glucose': 'Increased',\n  'HDL': 'decreased',\n  'aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Atezolizumab-Bevacizumab (Hepatocellular)': 'Not available',\n 'Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Atezolizumab-Carboplatin-Etoposide (Small Cell Lung Cancer)': 'Not available',\n 'Atezolizumab-Carboplatin-Paclitaxel (Protein Bound) (NSCLC)': 'Not available',\n 'Atezolizumab-Cobimetinib-Vemurafenib (Melanoma)': 'Not available',\n 'Atezolizumab': 'Not available',\n 'Atogepant': 'Not available',\n 'Atoltivimab, Maftivimab, and Odesivimab': 'Not available',\n 'Atomoxetine': 'Not available',\n 'Atorvastatin': 'Not available',\n 'Atovaquone and Proguanil': 'Not available',\n 'Atovaquone': 'Not available',\n 'Atracurium': 'Not available',\n 'Atropine (Ophthalmic)': 'Not available',\n 'Atropine (refer to route-specific monograph)': 'Not available',\n 'Atropine (Systemic)': 'Not available',\n 'Atropine and Pralidoxime': 'Not available',\n 'Auranofin': 'Not available',\n 'Avacopan': 'Not available',\n 'Avalglucosidase Alfa': 'Not available',\n 'Avanafil': 'Not available',\n 'Avapritinib': 'Not available',\n 'Avatrombopag': 'Not available',\n 'Avelumab-Axitinib (RCC)': 'Not available',\n 'Avelumab': 'Not available',\n 'Avocado': 'Not available',\n 'Axicabtagene Ciloleucel': 'Not available',\n 'Axitinib': 'Not available',\n 'AzaCITIDine': 'Not available',\n 'AzaTHIOprine': {'TPMT phenotyping': 'may not be accurate'},\n 'Azelaic Acid': 'Not available',\n 'Azelastine (Nasal)': 'Not available',\n 'Azelastine (Ophthalmic)': 'Not available',\n 'Azelastine (refer to route-specific monograph)': 'Not available',\n 'Azelastine and Fluticasone': 'Not available',\n 'Azilsartan and Chlorthalidone': 'Not available',\n 'Azilsartan': {'aldosterone/renin ratio (ARR)': 'May lead to false-negative'},\n 'Azithromycin (Ophthalmic)': 'Not available',\n 'Azithromycin (refer to route-specific monograph)': 'Not available',\n 'Azithromycin (Systemic)': 'Not available',\n 'Aztreonam (Oral Inhalation)': 'Not available',\n 'Aztreonam (refer to route-specific monograph)': 'Not available',\n 'Aztreonam (Systemic)': {\"urine glucose tests containing cupric sulfate (Benedict's solution, Clinitest)\": 'May interfere',\n  \"Coombs' test\": 'positive'},\n 'Bacitracin (Ophthalmic)': 'Not available',\n 'Bacitracin (refer to route-specific monograph)': 'Not available',\n 'Bacitracin (Systemic)': 'Not available',\n 'Bacitracin (Topical)': 'Not available',\n 'Bacitracin and Polymyxin B (Ophthalmic)': 'Not available',\n 'Bacitracin and Polymyxin B (refer to route-specific monograph)': 'Not available',\n 'Bacitracin and Polymyxin B (Topical)': 'Not available',\n 'Bacitracin, Neomycin, and Polymyxin B (Ophthalmic)': 'Not available',\n 'Bacitracin, Neomycin, and Polymyxin B (refer to route-specific monograph)': 'Not available',\n 'Bacitracin, Neomycin, and Polymyxin B (Topical)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Ophthalmic)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (refer to route-specific monograph)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Topical)': 'Not available',\n 'Bacitracin, Neomycin, Polymyxin B, and Pramoxine': 'Not available',\n 'Baclofen': 'Not available',\n 'Balanced Salt Solution': 'Not available',\n 'Baloxavir Marboxil': 'Not available',\n 'Balsalazide': {'Urinary normetanephrine levels': \"falsely elevated when measured by liquid chromatography with electrochemical detection because of similarity in chromatograms of normetanephrine and mesalamine's main metabolite\"},\n 'Balsam Peru and Castor Oil': 'Not available',\n 'Bamlanivimab and Etesevimab': 'Not available',\n 'Bamlanivimab': 'Not available',\n 'Baricitinib': 'Not available',\n 'Barium': 'Not available',\n 'Basiliximab': 'Not available',\n 'BCG (Intravesical)': {'tuberculin reactivity': 'positive'},\n 'BCG (refer to route-specific monograph)': 'Not available',\n 'BCG Vaccine (Immunization)': {'tuberculin skin test': 'positive/reactive',\n  'active tuberculosis': 'rule out',\n  'PPD reaction': '<5 mm induration',\n  'interferon-gamma release assay (IGRA)': 'acceptable'},\n 'BEACOPP Escalated (Hodgkin)': 'Not available',\n 'BEACOPP Escalated Plus Standard (Hodgkin)': 'Not available',\n 'BEACOPP Standard (Hodgkin)': 'Not available',\n 'BEACOPP-14 (Hodgkin)': 'Not available',\n 'Bebtelovimab': 'Not available',\n 'Becaplermin': 'Not available',\n 'Beclomethasone (Nasal)': 'Not available',\n 'Beclomethasone (Oral Inhalation)': 'Not available',\n 'Beclomethasone (refer to route-specific monograph)': 'Not available',\n 'Beclomethasone (Topical)': 'Not available',\n 'Bedaquiline': 'Not available',\n 'Belantamab Mafodotin': 'Not available',\n 'Belatacept': 'Not available',\n 'Belimumab': 'Not available',\n 'Belinostat': 'Not available',\n 'Belladonna and Opium': 'Not available',\n 'Belumosudil': 'Not available',\n 'Belzutifan': 'Not available',\n 'Bempedoic Acid and Ezetimibe': 'Not available',\n 'Bempedoic Acid': 'Not available',\n 'Benazepril and Hydrochlorothiazide': 'See individual agents',\n 'Benazepril': {'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Bendamustine-Bortezomib-Rituximab (NHL-Follicular)': 'Not available',\n 'Bendamustine-Lenalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bendamustine-Obinutuzumab (NHL-Follicular)': 'Not available',\n 'Bendamustine-Rituximab (CLL)': 'Not available',\n 'Bendamustine-Rituximab (NHL-Follicular)': 'Not available',\n 'Bendamustine-Rituximab (NHL-Mantle Cell)': 'Not available',\n 'Bendamustine-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Bendamustine': 'Not available',\n 'Benralizumab': 'Not available',\n 'Benserazide and Levodopa': {'Catecholamines testing': 'affected by Levodopa',\n  'Creatinine testing': 'affected by Levodopa',\n  'Uric acid testing': 'affected by Levodopa',\n  'Glucose testing': 'affected by Levodopa',\n  'Urine test for ketone bodies': 'false positive due to Levodopa'},\n 'Bentoquatam': 'Not available',\n 'Benzalkonium Chloride and Benzocaine': 'Not available',\n 'Benzhydrocodone and Acetaminophen': 'Not available',\n 'Benznidazole': 'Not available',\n 'Benzocaine and Docusate': 'Not available',\n 'Benzocaine, Butamben, and Tetracaine': 'Not available',\n 'Benzocaine': 'Not available',\n 'Benzoin': 'Not available',\n 'Benzonatate': 'Not available',\n 'Benzoyl Peroxide and Hydrocortisone': 'Not available',\n 'Benzoyl Peroxide': 'Not available',\n 'Benzphetamine': 'Not available',\n 'Benztropine': 'Not available',\n 'Benzydamine': 'Not available',\n 'Benzyl Alcohol': 'Not available',\n 'Benzylpenicilloyl Polylysine': 'Not available',\n 'BEP (Ovarian)': 'Not available',\n 'BEP (Testicular)': 'Not available',\n 'Bepotastine': 'Not available',\n 'Beractant': 'Not available',\n 'Berotralstat': 'Not available',\n 'Besifloxacin': 'Not available',\n 'Beta-Carotene': 'Not available',\n 'Betahistine': 'Not available',\n 'Betaine': 'Not available',\n 'Betamethasone (refer to route-specific monograph)': 'Not available',\n 'Betamethasone (Systemic)': {'skin test antigens': 'wheal and flare reactions suppressed'},\n 'Betamethasone (Topical)': {'wheal and flare reactions to skin test antigens': 'may suppress'},\n 'Betamethasone and Clotrimazole': 'See individual agents',\n 'Betamethasone and Gentamicin': 'Not available',\n 'Betamethasone and Salicylic Acid': 'Not available',\n 'Betaxolol (Ophthalmic)': 'Not available',\n 'Betaxolol (refer to route-specific monograph)': 'Not available',\n 'Betaxolol (Systemic)': {'Glaucoma screening tests': 'interference by oral betaxolol',\n  'Aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Bethanechol': 'Not available',\n 'Betibeglogene Autotemcel': {'polymerase chain reaction assays': 'positive for HIV due to integrated BB305 LVV proviral DNA, resulting in a false-positive test for HIV',\n  'PCR-based assay': 'should not be used for screening HIV infection'},\n 'Bevacizumab + FOLFIRI (Colorectal)': 'Not available',\n 'Bevacizumab + XELOX (Colorectal)': 'Not available',\n 'Bevacizumab FOLFOX (Colorectal)': 'Not available',\n 'Bevacizumab-Carboplatin-Doxorubicin (Liposomal) (Ovarian)': 'Not available',\n 'Bevacizumab-Carboplatin-Gemcitabine (Ovarian)': 'Not available',\n 'Bevacizumab-Carboplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Bevacizumab-Carboplatin-Paclitaxel (Ovarian)': 'Not available',\n 'Bevacizumab-Carboplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Bevacizumab-Cisplatin-Paclitaxel (Cervical)': 'Not available',\n 'Bevacizumab-Cisplatin-Pemetrexed (Mesothelioma)': 'Not available',\n 'Bevacizumab-Cisplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Bevacizumab-Doxorubicin (Liposomal) (Ovarian)': 'Not available',\n 'Bevacizumab-Fluorouracil-Leucovorin (Colorectal)': 'Not available',\n 'Bevacizumab-Irinotecan (Glioblastoma)': 'Not available',\n 'Bevacizumab-Lomustine (Glioblastoma)': 'Not available',\n 'Bevacizumab-Lonsurf (Colorectal)': 'Not available',\n 'Bevacizumab-Paclitaxel (Breast)': 'Not available',\n 'Bevacizumab-Paclitaxel (Ovarian)': 'Not available',\n 'Bevacizumab-Paclitaxel-Topotecan (Cervical)': 'Not available',\n 'Bevacizumab-Topotecan Daily (Ovarian)': 'Not available',\n 'Bevacizumab-Topotecan Weekly (Ovarian)': 'Not available',\n 'Bevacizumab': 'Not available',\n 'Bexagliflozin': 'Not available',\n 'Bexarotene (refer to route-specific monograph)': 'Not available',\n 'Bexarotene (Systemic)': {'CA125 assay': 'interference'},\n 'Bexarotene (Topical)': 'Not available',\n 'Bezafibrate': 'Not available',\n 'Bezlotoxumab': 'Not available',\n 'Bicalutamide': 'Not available',\n 'Bictegravir, Emtricitabine, and Tenofovir Alafenamide': 'Not available',\n 'Bilastine': 'Not available',\n 'Bimatoprost': 'Not available',\n 'Bimekizumab': 'Not available',\n 'Binimetinib': 'Not available',\n 'Biotin': {'troponin': 'false-negative',\n  'thyroid function tests': 'false-positive'},\n 'Bisacodyl': 'Not available',\n 'Bismuth Subcitrate, Metronidazole, and Tetracycline': 'See individual agents',\n 'Bismuth Subgallate': 'Not available',\n 'Bismuth Subsalicylate': 'Not available',\n 'Bisoprolol and Hydrochlorothiazide': 'See individual agents',\n 'Bisoprolol': {'aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Bivalirudin': {'PT/INR levels': 'elevated'},\n 'Bleomycin': 'Not available',\n 'Blinatumomab': 'Not available',\n 'Boric Acid (Vaginal)': 'Not available',\n 'Bortezomib-Dexamethasone (Amyloidosis)': 'Not available',\n 'Bortezomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bortezomib-Dexamethasone-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Bortezomib-Doxorubicin (Liposomal) (Multiple Myeloma)': 'Not available',\n 'Bortezomib-Doxorubicin-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bortezomib-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Bortezomib-Thalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Bortezomib': 'Not available',\n 'Bosentan': 'Not available',\n 'Bosutinib': 'Not available',\n 'Botulism Antitoxin, Heptavalent': {'blood glucose': 'falsely elevated'},\n 'Botulism Immune Globulin (Intravenous-Human)': 'Not available',\n 'Bovine Lipid Extract Surfactant': 'Not available',\n 'Bremelanotide': 'Not available',\n 'Brentuximab Vedotin': 'Not available',\n 'Bretylium': 'Not available',\n 'Brexanolone': 'Not available',\n 'Brexpiprazole': 'Not available',\n 'Brexucabtagene Autoleucel': 'Not available',\n 'Brigatinib': 'Not available',\n 'Brilliant Blue G': 'Not available',\n 'Brimonidine (Ophthalmic)': 'Not available',\n 'Brimonidine (refer to route-specific monograph)': 'Not available',\n 'Brimonidine (Topical)': 'Not available',\n 'Brimonidine and Timolol': 'Not available',\n 'Brincidofovir': 'Not available',\n 'Brinzolamide and Brimonidine': 'Not available',\n 'Brinzolamide and Timolol': 'Not available',\n 'Brinzolamide': 'Not available',\n 'Brivaracetam': 'Not available',\n 'Brodalumab': 'Not available',\n 'Brolucizumab': 'Not available',\n 'Bromazepam': 'Not available',\n 'Bromfenac': 'Not available',\n 'Bromocriptine': 'Not available',\n 'Brompheniramine and Phenylephrine': 'See individual agents',\n 'Brompheniramine and Pseudoephedrine': 'See individual agents',\n 'Brompheniramine, Dextromethorphan, and Phenylephrine': 'Not available',\n 'Brompheniramine, Pseudoephedrine, and Dextromethorphan': 'See individual agents',\n 'Budesonide (Nasal)': 'Not available',\n 'Budesonide (Oral Inhalation)': 'Not available',\n 'Budesonide (refer to route-specific monograph)': 'Not available',\n 'Budesonide (Systemic)': 'Not available',\n 'Budesonide (Topical)': 'Not available',\n 'Budesonide and Formoterol': 'Not available',\n 'Budesonide, Glycopyrrolate, and Formoterol': 'Not available',\n 'Bumetanide': {'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'BUPivacaine (Liposomal)': 'Not available',\n 'Bupivacaine and Epinephrine': 'Not available',\n 'Bupivacaine and Meloxicam': 'Not available',\n 'BUPivacaine': 'Not available',\n 'Buprenorphine and Naloxone': 'Not available',\n 'Buprenorphine': 'Not available',\n 'BuPROPion': {'urine detection of amphetamine/methamphetamine': 'false-positive'},\n 'Burosumab': 'Not available',\n 'Buserelin': {'pituitary gonadotropic and gonadal function tests': 'interference during treatment, may last up to a few weeks after discontinuation'},\n 'BusPIRone': {'Urinary assay for metanephrine/catecholamine': 'false positive'},\n 'Busulfan': 'Not available',\n 'Butabarbital': 'Not available',\n 'Butalbital and Acetaminophen': {'Urinary 5-hydroxyindoleacetic acid': 'false positive'},\n 'Butalbital, Acetaminophen, and Caffeine': {'Urinary 5-hydroxyindoleacetic acid': 'false positive'},\n 'Butalbital, Acetaminophen, Caffeine, and Codeine': 'See individual agents',\n 'Butalbital, Aspirin, and Caffeine': 'Not available',\n 'Butalbital, Aspirin, Caffeine, and Codeine': 'See individual agents',\n \"Butcher's Broom\": 'Not available',\n 'Butenafine': 'Not available',\n 'Butoconazole': 'Not available',\n 'Butorphanol': 'Not available',\n 'C-MOPPABV Hybrid (Hodgkin)': 'Not available',\n 'C1 Inhibitor (Human)': 'Not available',\n 'C1 Inhibitor (Recombinant)': 'Not available',\n 'Cabazitaxel-Prednisone (Prostate)': 'Not available',\n 'Cabazitaxel': 'Not available',\n 'Cabergoline': 'Not available',\n 'Cabotegravir and Rilpivirine': 'Not available',\n 'Cabotegravir': 'Not available',\n 'Cabozantinib-Nivolumab (RCC)': 'Not available',\n 'Cabozantinib': 'Not available',\n 'Caffeine': 'Not available',\n 'Calamine': 'Not available',\n 'Calaspargase Pegol': 'Not available',\n 'Calcifediol': 'Not available',\n 'Calcipotriene and Betamethasone': 'See individual agents',\n 'Calcipotriene': 'Not available',\n 'Calcitonin': 'Not available',\n 'Calcitriol (refer to route-specific monograph)': 'Not available',\n 'Calcitriol (Systemic)': 'Not available',\n 'Calcitriol (Topical)': 'Not available',\n 'Calcium Acetate': 'Not available',\n 'Calcium and Vitamin D': 'Not available',\n 'Calcium Carbonate and Magnesium Carbonate': 'Not available',\n 'Calcium Carbonate and Magnesium Hydroxide': 'Not available',\n 'Calcium Carbonate and Simethicone': 'Not available',\n 'Calcium Carbonate': 'Not available',\n 'Calcium Chloride': 'Not available',\n 'Calcium Citrate': 'Not available',\n 'Calcium Dobesilate and Lidocaine': 'Not available',\n 'Calcium Glubionate': {'Magnesium': 'Decreased'},\n 'Calcium Gluconate': {'Serum magnesium concentration': 'falsely decreased',\n  'Urine magnesium concentration': 'falsely decreased'},\n 'Calcium Hydroxylapatite': {'CT scans': 'Visible calcium hydroxylapatite particles',\n  'Standard radiography': 'Possible visible calcium hydroxylapatite particles'},\n 'Calcium Lactate': 'Not available',\n 'Calcium Polystyrene Sulfonate': 'Not available',\n 'Calfactant': 'Not available',\n 'CALGB 8811 Regimen (ALL)': 'Not available',\n 'CALGB 9111 Regimen (ALL)': 'Not available',\n 'Camphor and Menthol': 'Not available',\n 'Camphor and Phenol': 'Not available',\n 'Camphor': 'Not available',\n 'Canagliflozin and Metformin': 'Not available',\n 'Canagliflozin': {'1,5-anhydroglucitol (1,5-AG) assay': 'interfered with by positive test for glucosuria',\n  'glycemic control monitoring': 'alternative methods should be used'},\n 'Canakinumab': 'Not available',\n 'Candesartan and Hydrochlorothiazide': 'See individual agents',\n 'Candesartan': {'aldosterone/renin ratio (ARR)': 'may be false-negative'},\n 'Candida albicans (Monilia)': 'Not available',\n 'Cangrelor': 'Not available',\n 'Cannabidiol': {'cannabis screening': 'may be false-positive'},\n 'Cannabis': {'drugs of abuse screening tests': 'include cannabinoids',\n  'medical use of cannabis': 'may result in a positive drug screen'},\n 'Cantharidin, Podophyllin Resin, and Salicylic Acid': 'Not available',\n 'Cantharidin': 'Not available',\n 'Capecitabine + Lapatinib (Breast)': 'Not available',\n 'Capecitabine-Docetaxel (Breast)': 'Not available',\n 'Capecitabine-Docetaxel (Gastric Cancer)': 'Not available',\n 'Capecitabine-Gemcitabine (Pancreatic)': 'Not available',\n 'Capecitabine-Ixabepilone (Breast)': 'Not available',\n 'Capecitabine-Oxaliplatin (Gastric)': 'Not available',\n 'Capecitabine-Oxaliplatin (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Capecitabine-Trastuzumab (Breast)': 'Not available',\n 'Capecitabine': 'Not available',\n 'Caplacizumab': 'Not available',\n 'Capmatinib': 'Not available',\n 'CAPOX (Biliary Cancer)': 'Not available',\n 'CAPOX (Pancreatic)': 'Not available',\n 'Capreomycin': 'Not available',\n 'Caprylidene': 'Not available',\n 'Capsaicin': 'Not available',\n 'Captopril and Hydrochlorothiazide': 'See individual agents',\n 'Captopril': {'Aldosterone/Renin Ratio Test': 'False Negative'},\n 'Carbachol': 'Not available',\n 'CarBAMazepine': {'Serum TCA Screen': 'False Positive',\n  'Pregnancy Test': 'Interference'},\n 'Carbamide Peroxide': 'Not available',\n 'Carbetocin': 'Not available',\n 'Carbidopa and Levodopa': {'Urinary glucose': 'false-positive',\n  'Glucosuria': 'false-negative',\n  'Urine ketones': 'false-positive',\n  'Pheochromocytoma diagnosis based on plasma and urine levels of catecholamines': 'false'},\n 'Carbidopa': {'Clinitest®': 'false-positive reaction for urinary glucose',\n  'Clinistix®': 'false-negative reaction',\n  'Acetest®': 'false-positive urine ketones',\n  'Ketostix®': 'false-positive urine ketones',\n  'Labstix®': 'false-positive urine ketones'},\n 'Carbinoxamine': 'Not available',\n 'Carbon 14 Urea': 'Not available',\n 'Carboplatin-Cetuximab (Head and Neck Cancer)': 'Not available',\n 'Carboplatin-Docetaxel (Ovarian)': 'Not available',\n 'Carboplatin-Docetaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Carboplatin-Docetaxel (Unknown Primary, Squamous Cell)': 'Not available',\n 'Carboplatin-Docetaxel-Trastuzumab (Breast)': 'Not available',\n 'Carboplatin-Doxorubicin (Liposomal) (Ovarian)': 'Not available',\n 'Carboplatin-Etoposide (Ovarian Germ Cell Tumor)': 'Not available',\n 'Carboplatin-Etoposide (Small Cell Lung Cancer)': 'Not available',\n 'Carboplatin-Etoposide-Paclitaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Carboplatin-Fluorouracil (Head and Neck)': 'Not available',\n 'Carboplatin-Gemcitabine (Bladder)': 'Not available',\n 'Carboplatin-Gemcitabine (NSCLC)': 'Not available',\n 'Carboplatin-Gemcitabine (Ovarian)': 'Not available',\n 'Carboplatin-Irinotecan (Small Cell Lung Cancer)': 'Not available',\n 'Carboplatin-Paclitaxel (Cervical Cancer)': 'Not available',\n 'Carboplatin-Paclitaxel (Endometrial)': 'Not available',\n 'Carboplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel (Ovarian)': 'Not available',\n 'Carboplatin-Paclitaxel (Protein Bound) (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel (Protein Bound)-Pembrolizumab (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel (ThymomaThymic)': 'Not available',\n 'Carboplatin-Paclitaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Carboplatin-Paclitaxel-Pembrolizumab (NSCLC)': 'Not available',\n 'Carboplatin-Paclitaxel-Trastuzumab (Breast)': 'Not available',\n 'Carboplatin-Pemetrexed (Mesothelioma)': 'Not available',\n 'Carboplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Carboplatin-Pemetrexed-Pembrolizumab (NSCLC)': 'Not available',\n 'CARBOplatin': 'Not available',\n 'Carboprost Tromethamine': 'Not available',\n 'Carboxymethylcellulose': 'Not available',\n 'Cardioplegic Solution': 'Not available',\n 'Carfilzomib, Cyclophosphamide, Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Carfilzomib, Lenalidomide, Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Carfilzomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Carfilzomib-Dexamethasone-Daratumumab (Multiple Myeloma)': 'Not available',\n 'Carfilzomib': 'Not available',\n 'Carglumic Acid': 'Not available',\n 'Cariprazine': 'Not available',\n 'Carisoprodol and Aspirin': 'Not available',\n 'Carisoprodol, Aspirin, and Codeine': 'Not available',\n 'Carisoprodol': 'Not available',\n 'Carmustine': 'Not available',\n 'Carteolol (Ophthalmic)': 'Not available',\n 'Carvedilol': {'Aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Casimersen': {'pyrogallol red reagent': 'interfere with detection of urine protein (false positive)',\n  'laboratory test': 'use a laboratory test that does not contain pyrogallol red reagent',\n  'casimersen': 'use urine free of casimersen (eg, urine obtained prior to infusion or ≥48 hours after infusion)'},\n 'Casirivimab and Imdevimab': 'Not available',\n 'Caspofungin': 'Not available',\n 'Castor Oil': 'Not available',\n 'CAV (Small Cell Lung Cancer)': 'Not available',\n 'Cefaclor': {\"Direct Coombs' test\": 'Positive',\n  \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'False-positive'},\n 'Cefadroxil': {'Direct Coombs': 'Positive',\n  'Urinary Glucose': 'False-positive',\n  'Serum Creatinine': 'False-positive',\n  'Urine Creatinine': 'False-positive'},\n 'CeFAZolin': {\"Direct Coombs' Test\": 'positive',\n  \"Indirect Coombs' Test\": 'positive',\n  \"Urinary Glucose Test (based on Benedict's copper reduction reaction)\": 'false-positive',\n  'Serum or Urine Creatinine Test (with Jaffé reaction)': 'false-positive',\n  'Aminoglycoside Serum Concentration Test': 'may be underestimated'},\n 'Cefdinir': {'urinary ketones': 'false-positive',\n  'urine glucose': 'false-positive',\n  'direct Coombs’ test': 'positive'},\n 'Cefepime': {\"direct Coombs'\": 'positive',\n  'urinary glucose test': 'false-positive',\n  'serum or urine creatinine': 'false-positive',\n  'urinary proteins and steroids': 'false-positive'},\n 'Cefiderocol': {'Urine Protein': 'False-positive',\n  'Ketones': 'False-positive',\n  'Occult Blood': 'False-positive'},\n 'Cefixime': {\"direct Coombs'\": 'Positive',\n  \"urinary glucose test with cupric sulfate (Benedict's solution)\": 'False-positive',\n  'urinary glucose test with Clinitest®': 'False-positive',\n  \"urinary glucose test with Fehling's solution)\": 'False-positive',\n  'serum or urine creatinine with alkaline picrate-based Jaffé reaction': 'False-positive',\n  'urine ketones using tests with nitroprusside': 'False-positive'},\n 'Cefotaxime': {\"direct Coombs'\": 'Positive',\n  \"urinary glucose test with cupric sulfate (Benedict's solution)\": 'False-positive',\n  'urinary glucose test with Clinitest®': 'False-positive',\n  \"urinary glucose test with Fehling's solution)\": 'False-positive',\n  'serum or urine creatinine with Jaffé reaction': 'False-positive'},\n 'CefoTEtan': {\"Positive direct Coombs'\": 'positive',\n  \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'false-positive',\n  'serum or urine creatinine with Jaffé reaction': 'false-positive'},\n 'CefOXitin': {\"Positive direct Coombs'\": 'positive',\n  \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\": 'false-positive',\n  'serum or urine creatinine with Jaffé reaction': 'false-positive'},\n 'Cefpodoxime': {\"Positive direct Coombs'\": 'positive',\n  \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\": 'false-positive',\n  'serum or urine creatinine with Jaffé reaction': 'false-positive'},\n 'Cefprozil': {'Direct Coombs': 'positive',\n  \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\": 'false positive',\n  'Enzyme-based tests for glycosuria (eg, Clinistix)': 'negative',\n  'Ferricyanide test for blood glucose': 'false negative'},\n 'Ceftaroline Fosamil': 'Not available',\n 'Ceftazidime and Avibactam': {'Ceftazidime': 'positive direct Coombs',\n  'Urinary glucose test with certain methods': 'false positive',\n  'Glucose tests based on enzymatic glucose oxidase reactions': 'true'},\n 'CefTAZidime': {\"Direct Coombs'\": 'positive',\n  \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\": 'false positive',\n  'Serum or urine creatinine with Jaffé reaction': 'false positive'},\n 'Ceftibuten': {\"Direct Coombs' test\": 'Positive',\n  'Urinary glucose test using cupric sulfate': 'False-positive',\n  'Serum or urine creatinine with Jaffé reaction': 'False-positive'},\n 'Ceftobiprole': {'Direct antiglobulin (Coombs) test': 'Positive',\n  'Urinary glucose test using cupric sulfate': 'False-positive',\n  'Serum or urine creatinine with Jaffé reaction assay': 'Falsely elevated'},\n 'Ceftolozane and Tazobactam': 'Not available',\n 'CefTRIAXone': {\"Direct Coombs' test\": 'Positive',\n  'Urinary glucose test using nonenzymatic methods': 'False-positive',\n  'Galactosemia tests': 'False-positive'},\n 'Cefuroxime': {\"Direct Coombs' test\": 'positive',\n  'Urinary glucose test using cupric sulfate': 'false-positive',\n  'Ferricyanide test': 'false-negative'},\n 'Celecoxib and Tramadol': 'Not available',\n 'Celecoxib': 'Not available',\n 'Cellulose (Oxidized Regenerated)': 'Not available',\n 'Cellulose and Citric Acid': 'Not available',\n 'Cemiplimab': 'Not available',\n 'Cenegermin': 'Not available',\n 'Cenobamate': 'Not available',\n 'Centruroides Immune F(ab)2 (Equine)': 'Not available',\n 'Cephalexin': {\"Direct Coombs' test\": 'positive',\n  'Urinary glucose test using cupric sulfate': 'false-positive',\n  'Serum or urine creatinine with Jaffé reaction': 'false-positive',\n  'Urinary proteins and steroids': 'false-positive'},\n 'CEPP (NHL-DLBCL)': 'Not available',\n 'Ceritinib': 'Not available',\n 'Cerliponase Alfa': 'Not available',\n 'Certolizumab Pegol': {'Latent tuberculosis tests': 'falsely negative',\n  'aPTT assays with PTT-Lupus Anticoagulant (LA) and Standard Target Activated Partial Thromboplastin time (STA-PTT) tests from Diagnostica Stago': 'falsely elevated',\n  'aPTT assays with HemosiL APTT-SP liquid and HemosiL lyophilized silica tests from Instrumentation Laboratories': 'falsely elevated'},\n 'Cetirizine (Ophthalmic)': 'Not available',\n 'Cetirizine (refer to route-specific monograph)': 'Not available',\n 'Cetirizine (Systemic)': {'serum TCA screen': 'false-positive',\n  'wheal and flare reactions to skin test antigens': 'suppressed'},\n 'Cetirizine and Pseudoephedrine': 'See individual agents',\n 'Cetrorelix': 'Not available',\n 'Cetuximab (Biweekly)-Irinotecan (Colorectal)': 'Not available',\n 'Cetuximab + FOLFIRI (Colorectal)': 'Not available',\n 'Cetuximab-Carboplatin-Fluorouracil (Head and Neck Cancer)': 'Not available',\n 'Cetuximab-Cisplatin-Fluorouracil (Head and Neck Cancer)': 'Not available',\n 'Cetuximab-Encorafenib (Colorectal)': 'Not available',\n 'Cetuximab-Irinotecan (Colorectal)': 'Not available',\n 'Cetuximab': 'Not available',\n 'Cetylpyridinium': 'Not available',\n 'Cevimeline': 'Not available',\n 'Charcoal, Activated': 'Not available',\n 'Chenodiol': 'Not available',\n 'Chlophedianol and Dexbrompheniramine': 'Not available',\n 'Chlophedianol, Dexbrompheniramine, and Pseudoephedrine': 'Not available',\n 'Chloral Hydrate': {'copper sulfate tests for glycosuria': 'interference',\n  'fluorometric urine catecholamine tests': 'interference',\n  'urinary 17-hydroxycorticosteroid tests': 'interference'},\n 'Chlorambucil-Obinutuzumab (CLL)': 'Not available',\n 'Chlorambucil-Ofatumumab (CLL)': 'Not available',\n 'Chlorambucil-Prednisone (CLL)': 'Not available',\n 'Chlorambucil': 'Not available',\n 'Chloramphenicol (Systemic)': 'Not available',\n 'ChlordiazePOXIDE': 'Not available',\n 'Chlorhexidine Gluconate (Oral)': 'Not available',\n 'Chlorhexidine Gluconate (refer to route-specific monograph)': 'Not available',\n 'Chlorhexidine Gluconate (Topical)': {'midstream urine collection': 'chlorhexidine disinfectant can cause false-positive urine protein (when using dipstick method based upon a pH indicator color change)'},\n 'Chlorophyll': 'Not available',\n 'Chloroprocaine (Ophthalmic)': 'Not available',\n 'Chloroprocaine (refer to route-specific monograph)': 'Not available',\n 'Chloroprocaine (Systemic)': 'Not available',\n 'Chloroquine': 'Not available',\n 'Chlorothiazide': {'parathyroid function': 'may interfere',\n  'aldosterone/renin ratio (ARR)': 'may lead to false-negative'},\n 'Chlorpheniramine and Acetaminophen': 'See individual agents',\n 'Chlorpheniramine and Phenylephrine': 'See individual agents',\n 'Chlorpheniramine and Pseudoephedrine': 'See individual agents',\n 'Chlorpheniramine, Phenylephrine, and Dextromethorphan': 'See individual agents',\n 'Chlorpheniramine, Pseudoephedrine, and Codeine': 'See individual agents',\n 'Chlorpheniramine': {'skin test antigens': 'may suppress wheal and flare reactions'},\n 'ChlorproMAZINE': {'phenylketonuria': 'false-positives',\n  'amylase': 'false-positives',\n  'uroporphyrins': 'false-positives',\n  'urobilinogen': 'false-positives',\n  'pregnancy test': 'may cause false-positive',\n  'amphetamine/methamphetamine and methadone test': 'may interfere with urine detection (false-positives)'},\n 'Chlorthalidone': {'serum protein bound iodine': 'decreased',\n  'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Chlorzoxazone': 'Not available',\n 'Cholecalciferol': 'Not available',\n 'Cholera Vaccine': 'Not available',\n 'Cholestyramine Resin': {'Prothrombin time': 'Increased'},\n 'Cholic Acid': 'Not available',\n 'Choline C 11': 'Not available',\n 'Choline Magnesium Trisalicylate': {'glucose oxidase urinary glucose tests': 'false-negative results',\n  'cupric sulfate method': 'false-positives',\n  'Gerhardt test (urinary ketone analysis)': 'interference',\n  'VMA determination': 'interference',\n  '5-HIAA': 'interference',\n  'xylose tolerance test': 'interference',\n  'T3': 'interference',\n  'T4': 'interference',\n  'PBI': 'increased'},\n 'CHOP (NHL-AIDS-Related)': 'Not available',\n 'Chorionic Gonadotropin (Human)': {'radioimmunoassay of gonadotropins': 'cross-reacts, especially LH'},\n 'Chorionic Gonadotropin (Recombinant)': {'pregnancy tests': 'interference with interpretation',\n  'radioimmunoassay of luteinizing hormone and other gonadotropins': 'cross-reactivity'},\n 'Chromic Chloride': 'Not available',\n 'Ciclesonide (Nasal)': 'Not available',\n 'Ciclesonide (Oral Inhalation)': 'Not available',\n 'Ciclesonide (refer to route-specific monograph)': 'Not available',\n 'Ciclopirox': 'Not available',\n 'Cidofovir': 'Not available',\n 'Cilazapril and Hydrochlorothiazide': 'See individual agents',\n 'Cilazapril': {'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Cilostazol': 'Not available',\n 'Ciltacabtagene Autoleucel': 'Not available',\n 'Cimetidine': 'Not available',\n 'Cinacalcet': 'Not available',\n 'Ciprofloxacin (Ophthalmic)': 'Not available',\n 'Ciprofloxacin (Otic)': 'Not available',\n 'Ciprofloxacin (refer to route-specific monograph)': 'Not available',\n 'Ciprofloxacin (Systemic)': {'Urine screening result for opioids using commercially-available immunoassay kits': 'false-positive',\n  'levofloxacin and ofloxacin': 'most consistent demonstration of producing false-positive result',\n  'other quinolones': 'shown cross-reactivity in certain assay kits'},\n 'Ciprofloxacin and Dexamethasone': 'Not available',\n 'Ciprofloxacin and Fluocinolone': 'Not available',\n 'Ciprofloxacin and Hydrocortisone': 'See individual agents',\n 'Cisapride': 'Not available',\n 'Cisatracurium': 'Not available',\n 'Cisplatin-Capecitabine (Esophageal Cancer)': 'Not available',\n 'Cisplatin-Capecitabine (Gastric Cancer)': 'Not available',\n 'Cisplatin-Cetuximab (Head and Neck Cancer)': 'Not available',\n 'Cisplatin-Docetaxel (NSCLC)': 'Not available',\n 'Cisplatin-Docetaxel (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Cisplatin-Docetaxel (Unknown Primary, Squamous Cell)': 'Not available',\n 'Cisplatin-Docetaxel-Fluorouracil (Unknown Primary, Squamous Cell)': 'Not available',\n 'Cisplatin-Docetaxel-Gemcitabine (Bladder)': 'Not available',\n 'Cisplatin-Doxorubicin (Endometrial)': 'Not available',\n 'Cisplatin-Doxorubicin-Paclitaxel (Endometrial)': 'Not available',\n 'Cisplatin-Etoposide (NSCLC)': 'Not available',\n 'Cisplatin-Etoposide (Small Cell Lung Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil (Bladder Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil (Esophageal Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil (Head and Neck Cancer)': 'Not available',\n 'Cisplatin-Fluorouracil-Paclitaxel (Unknown Primary, Squamous Cell)': 'Not available',\n 'Cisplatin-Gemcitabine (Bladder)': 'Not available',\n 'Cisplatin-Gemcitabine (Cervical)': 'Not available',\n 'Cisplatin-Gemcitabine (Mesothelioma)': 'Not available',\n 'Cisplatin-Gemcitabine (NSCLC)': 'Not available',\n 'Cisplatin-Gemcitabine (Pancreatic)': 'Not available',\n 'Cisplatin-Gemcitabine (Unknown Primary, Adenocarcinoma)': 'Not available',\n 'Cisplatin-Gemcitabine-Necitumumab (NSCLC)': 'Not available',\n 'Cisplatin-Irinotecan (Gastric)': 'Not available',\n 'Cisplatin-Irinotecan (NSCLC)': 'Not available',\n 'Cisplatin-Irinotecan (Small Cell Lung Cancer)': 'Not available',\n 'Cisplatin-Paclitaxel (Cervical Cancer)': 'Not available',\n 'Cisplatin-Paclitaxel (Head and Neck Cancer)': 'Not available',\n 'Cisplatin-Paclitaxel (NSCLC)': 'Not available',\n 'Cisplatin-Paclitaxel Intraperitoneal (Ovarian)': 'Not available',\n 'Cisplatin-Pemetrexed (Mesothelioma)': 'Not available',\n 'Cisplatin-Pemetrexed (NSCLC)': 'Not available',\n 'Cisplatin-Pemetrexed-Pembrolizumab (NSCLC)': 'Not available',\n 'Cisplatin-Raltitrexed (Mesothelioma)': 'Not available',\n 'Cisplatin-Topotecan (Cervical Cancer)': 'Not available',\n 'Cisplatin-Vinblastine (NSCLC)': 'Not available',\n 'Cisplatin-Vinorelbine (Adjuvant NSCLC)': 'Not available',\n 'Cisplatin-Vinorelbine (Cervical Cancer)': 'Not available',\n 'Cisplatin-Vinorelbine (Metastatic NSCLC)': 'Not available',\n 'CISplatin': 'Not available',\n 'Citalopram': 'Not available',\n 'Citric Acid, Magnesium Carbonate, and Glucono-Delta-Lactone': 'Not available',\n 'Citric Acid, Sodium Citrate, and Potassium Citrate': 'Not available',\n 'Cladribine-Rituximab (NHL-Mantle Cell)': 'Not available',\n 'Cladribine-Rituximab (Waldenstrom Macroglobulinemia)': 'Not available',\n 'Cladribine': 'Not available',\n 'CLAG (AML Induction)': 'Not available',\n 'CLAG-M (AML Induction)': 'Not available',\n 'Clarithromycin': 'Not available',\n 'Clascoterone': 'Not available',\n 'Clemastine': 'Not available',\n 'Clevidipine': {'aldosterone/renin ratio (ARR)': 'false-negative'},\n 'Clidinium and Chlordiazepoxide': 'Not available',\n 'Clindamycin (refer to route-specific monograph)': 'Not available',\n 'Clindamycin (Systemic)': 'Not available',\n 'Clindamycin (Topical)': 'Not available',\n 'Clindamycin and Benzoyl Peroxide': 'Not available',\n 'Clindamycin and Tretinoin': 'Not available',\n 'Clioquinol and Flumethasone': {'Thyroid function tests': 'decreased 131I uptake',\n  'ferric chloride test for phenylketonuria': 'false-positive'},\n 'Clioquinol and Hydrocortisone': {'Thyroid function tests': '',\n  'ferric chloride test for phenylketonuria': 'false-positive'},\n 'CloBAZam': 'Not available',\n 'Clobetasol': 'Not available',\n 'Clobetasone': 'Not available',\n 'Clocortolone': 'Not available',\n 'Clodronate': {'technetium-99m-diphosphonate in bone scans': 'interference with diagnostic imaging agents',\n  'radiopharmaceutical bone imaging': 'no interference.'},\n 'Clofarabine-Cyclophosphamide-Etoposide (ALL)': 'Not available',\n 'Clofarabine-Cytarabine (AML)': 'Not available',\n 'Clofarabine': 'Not available',\n 'Clofazimine': 'Not available',\n 'Clofedanol': 'Not available',\n 'ClomiPHENE': 'Not available',\n 'ClomiPRAMINE': {'urine detection of methadone': 'interference (false-positive)'},\n 'ClonazePAM': 'Not available',\n 'CloNIDine': {\"Coombs' test\": 'positive',\n  'aldosterone/renin ratio': 'false-positive'},\n 'Clopidogrel': 'Not available',\n 'Clorazepate': {'hematocrit': 'decreased',\n  'liver function tests': 'abnormal',\n  'renal function tests': 'abnormal'},\n 'Clotrimazole (Oral)': 'Not available',\n 'Clotrimazole (refer to route-specific monograph)': 'Not available',\n 'Clotrimazole (Topical)': 'Not available',\n 'Cloxacillin': {'urinary glucose tests': 'interference',\n  'aminoglycosides': 'inactivated in vitro',\n  'urine proteins': 'false-positive',\n  'serum proteins': 'false-positive',\n  'uric acid': 'false-positive',\n  'urinary steroids': 'false-positive'},\n 'CloZAPine': 'Not available',\n 'CMF Oral (Breast)': 'Not available',\n 'CMV (Bladder)': 'Not available',\n 'Coal Tar and Salicylic Acid': 'Not available',\n 'Coal Tar': 'Not available',\n 'Cobicistat': {'serum creatinine': '>0.4 mg/dL'},\n 'Cobimetinib-Vemurafenib (Melanoma)': 'Not available',\n 'Cobimetinib': 'Not available',\n 'Cocaine (Topical)': 'Not available',\n 'Coccidioides immitis Skin Test': 'Not available',\n 'Codeine and Chlorpheniramine': 'See individual agents',\n 'Codeine, Phenylephrine, and Triprolidine': 'Not available',\n 'Codeine': {'levofloxacin': 'false-positive',\n  'ofloxacin': 'false-positive',\n  'other quinolones': 'cross-reactivity'},\n 'CODOX-M (NHL-Burkitt)': 'Not available',\n 'CODOX-MIVAC (NHL-Burkitt)': 'Not available',\n 'Colchicine and Probenecid': 'Not available',\n 'Colchicine': {'urine tests for erythrocytes': 'false-positive',\n  'urine tests for hemoglobin': 'false-positive'},\n 'Colesevelam': {'Prothrombin time': 'Increased'},\n 'Colestipol': 'Not available',\n 'Colistimethate': 'Not available',\n 'Collagen (AbsorbableDental)': 'Not available',\n 'Collagen Hemostat': 'Not available',\n 'Collagenase (refer to route-specific monograph)': 'Not available',\n 'Collagenase (Systemic)': 'Not available',\n 'Collagenase (Topical)': 'Not available',\n 'Conivaptan': 'Not available',\n 'Continuous Renal Replacement Therapy Solutions': 'Not available',\n 'Copanlisib': 'Not available',\n 'Copper Cu 64 Dotatate': 'Not available',\n 'Copper IUD': 'Not available',\n 'Copper': 'Not available',\n 'Corticorelin': 'Not available',\n 'Corticotropin': {'Skin test antigen wheal and flare reactions': 'May be suppressed'},\n 'Cortisone': {'Skin test antigen wheal and flare reactions': 'May be suppressed'},\n 'Cosyntropin': {'spironolactone': 'concurrent or recent use',\n  'hydrocortisone': 'concurrent or recent use',\n  'cortisone': 'concurrent or recent use',\n  'etomidate': 'concurrent or recent use',\n  'estrogens': 'concurrent or recent use'},\n 'COVID-19 Vaccine (Adenovirus Vector)': {'Rapid Plasma Reagin (RPR)': 'possible false-positive for ≥5 months after COVID-19 vaccination',\n  'SARS-CoV-2 viral testing (antigen or nucleic acid amplification tests)': 'not affected by COVID-19 vaccines',\n  'test that detects nucleocapsid protein antibody': 'used to assess for prior infection in COVID-19–vaccinated individuals',\n  'SARS-CoV-2 spike protein antibody test': 'may indicate either prior infection or vaccination'},\n 'COVID-19 Vaccine (mRNA)': {'Rapid Plasma Reagin (RPR)': 'possible false-positive results',\n  'Treponemal testing': 'does not appear to be affected',\n  'SARS-CoV-2 viral testing (antigen or nucleic acid amplification tests)': 'not affected by COVID-19 vaccine',\n  'nucleocapsid protein antibody test': 'used to assess prior infection in COVID-19 vaccinated individuals',\n  'SARS-CoV-2 spike protein antibody test': 'positive results may indicate either prior infection or vaccination'},\n 'COVID-19 Vaccine (Subunit)': 'Not available',\n 'COVID-19 Vaccine (Virus-like Particles)': 'Not available',\n 'Crisaborole': 'Not available',\n 'Crizanlizumab': {'Automated platelet counts': 'unevaluable or falsely decreased',\n  'Dehydrogenase pyrroloquinolinequinone or glucose-dye-oxidoreductase testing methods on the day of infusion': 'falsely elevated'},\n 'Crizotinib': 'Not available',\n 'Crofelemer': 'Not available',\n 'Cromolyn (Nasal)': 'Not available',\n 'Cromolyn (Ophthalmic)': 'Not available',\n 'Cromolyn (Oral Inhalation)': 'Not available',\n 'Cromolyn (refer to route-specific monograph)': 'Not available',\n 'Cromolyn (Systemic)': 'Not available',\n \"Crotalidae Immune F(ab')2 (Equine)\": 'Not available',\n 'Crotalidae Polyvalent Immune FAB (Ovine)': 'Not available',\n 'Crotamiton': 'Not available',\n 'Cyanocobalamin': {'Folic acid and vitamin B12 diagnostic blood assays': 'invalidated'},\n 'Cyclobenzaprine': {'Serum TCA screen': 'false-positive'},\n 'Cyclopentolate and Phenylephrine': 'Not available',\n 'Cyclopentolate': 'Not available',\n 'Cyclophosphamide-Bortezomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Cyclophosphamide-Epirubicin (Breast)': 'Not available',\n 'Cyclophosphamide-Topotecan (Ewing Sarcoma)': 'Not available',\n 'Cyclophosphamide-Topotecan (Rhabdomyosarcoma)': 'Not available',\n 'CycloPHOSphamide': 'Not available',\n 'CycloSERINE': 'Not available',\n 'CycloSPORINE (Ophthalmic)': 'Not available',\n 'CycloSPORINE (refer to route-specific monograph)': 'Not available',\n 'CycloSPORINE (Systemic)': {'Specific whole blood assay for cyclosporine': 'falsely elevated'},\n 'Cyproheptadine': {'Diagnostic antigen skin test results': 'suppressed',\n  'serum TCA screen': 'false positive'},\n 'Cyproterone and Ethinyl Estradiol': {'coagulation factors': 'altered',\n  'lipids': 'altered',\n  'glucose tolerance': 'altered',\n  'thyroxine-binding globulin': 'altered',\n  'sex hormone-binding globulin': 'altered',\n  'cortisol-binding globulin': 'altered'},\n 'Cyproterone': 'Not available',\n 'Cysteamine (Ophthalmic)': 'Not available',\n 'Cysteamine (refer to route-specific monograph)': 'Not available',\n 'Cysteamine (Systemic)': 'Not available',\n 'Cysteine': {'estimations of nitrogen containing substances': 'may interfere',\n  'venous blood for blood chemistries': 'do not withdraw through the peripheral infusion site'},\n 'Cytarabine (Conventional)': 'Not available',\n 'Cytarabine (High Dose)-Daunorubicin (AML Induction)': 'Not available',\n 'Cytarabine (High Dose)-Daunorubicin-Etoposide (AML Induction)': 'Not available',\n 'Cytarabine (High-Dose Single-Agent AML Induction Regimen)': 'Not available',\n 'Cytarabine (Liposomal)': 'Not available',\n 'Cytarabine (Single-Agent AML Consolidation Regimen)': 'Not available',\n 'Cytarabine (SUBQ Single-Agent AML Induction Regimen)': 'Not available',\n 'Cytomegalovirus Immune Globulin (Intravenous-Human)': 'Not available',\n 'Dabigatran Etexilate': 'Not available',\n 'Dabrafenib-Trametinib (Melanoma)': 'Not available',\n 'Dabrafenib-Trametinib (NSCLC)': 'Not available',\n 'Dabrafenib': 'Not available',\n 'Dacarbazine': 'Not available',\n 'Daclatasvir': 'Not available',\n 'Dacomitinib': 'Not available',\n 'DACTINomycin': 'Not available',\n 'Dalbavancin': 'Not available',\n 'Dalfampridine': 'Not available',\n 'Dalteparin': 'Not available',\n 'Danaparoid': {'PT/INR': 'not reliable within 5 hours following danaparoid administration'},\n 'Danazol': {'Estradiol (Kishino 2010)': '',\n  'testosterone': 'may interfere with laboratory tests',\n  'androstenedione': 'may interfere with laboratory tests',\n  'dehydroepiandrosterone': 'may interfere with laboratory tests'},\n 'Dantrolene': 'Not available',\n 'Dapagliflozin and Metformin': {'Glucosuria test': 'positive',\n  '1,5-anhydroglucitol (1,5-AG) assay': 'inaccurate'},\n 'Dapagliflozin and Saxagliptin': {'Glucosuria test': 'positive',\n  '1,5-anhydroglucitol (1,5-AG) assay': 'inaccurate'},\n 'Dapagliflozin': {'Glucosuria test': 'positive',\n  '1,5-anhydroglucitol (1,5-AG) assay': 'inaccurate'},\n 'Daprodustat': 'Not available',\n 'Dapsone (refer to route-specific monograph)': 'Not available',\n 'Dapsone (Systemic)': {'HbA1c': 'may artificially lower by reducing erythrocyte survival time through hemolysis'},\n 'Dapsone (Topical)': 'Not available',\n 'DAPTOmycin': {'PT/INR': 'elevated'},\n 'Daratumumab and Hyaluronidase': {'Indirect antiglobulin test (indirect Coombs test)': 'positive',\n  'Serum protein electrophoresis and immunofixation assays': 'interference'},\n 'Daratumumab-Bortezomib-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Bortezomib-Melphalan-Prednisone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Bortezomib-Thalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Lenalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab-Pomalidomide-Dexamethasone (Multiple Myeloma)': 'Not available',\n 'Daratumumab': {'CD38 on RBCs compatibility testing': 'interfered with by daratumumab binding',\n  'antibody screening': 'interfered with by daratumumab binding',\n  'cross matching': 'interfered with by daratumumab binding',\n  'serum protein electrophoresis (SPE) assay': 'may have false positive results for patients with IgG kappa myeloma protein',\n  'immunofixation (IFE) assay': 'may have false positive results for patients with IgG kappa myeloma protein',\n  'daratumumab-specific IFE assay': 'used to distinguish daratumumab from any residual endogenous M protein in patients with persistent very good partial response'},\n 'Darbepoetin Alfa': {'HbA1c': 'may be artificially lowered by erythropoiesis-stimulating agents through increased circulation of immature erythrocytes with less exposure to glucose'},\n 'Daridorexant': 'Not available',\n 'Darifenacin': 'Not available',\n 'Darolutamide': 'Not available',\n 'Darunavir and Cobicistat': 'Not available',\n 'Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide': 'Not available',\n 'Darunavir': 'Not available',\n 'Dasatinib': 'Not available',\n 'Dasiglucagon': 'Not available',\n 'DAUNOrubicin (Conventional)': 'Not available',\n 'DAUNOrubicin (Liposomal)': 'Not available',\n 'Daunorubicin and Cytarabine (Liposomal)': 'Not available',\n 'DaxibotulinumtoxinA': 'Not available',\n 'Decitabine and Cedazuridine': 'Not available',\n 'Decitabine': 'Not available',\n 'Deferasirox': 'Not available',\n 'Deferiprone': 'Not available',\n 'Deferoxamine': {'TIBC': 'may be falsely elevated with high serum iron concentrations or deferoxamine therapy'},\n 'Defibrotide': 'Not available',\n 'Deflazacort': 'Not available',\n 'Degarelix': {'pituitary-gonadal function': 'suppressed',\n  'diagnostic tests of pituitary gonadotropic': 'affected',\n  'diagnostic tests of gonadal functions': 'affected'},\n 'Delafloxacin': 'Not available',\n 'Delavirdine': 'Not available',\n 'Demeclocycline': 'Not available',\n 'Dengue Tetravalent Vaccine (Live)': 'Not available',\n 'Denosumab': 'Not available',\n 'Deoxycholic Acid': 'Not available',\n 'Dequalinium': 'Not available',\n 'Desflurane': 'Not available',\n 'Desipramine': {'amphetamines/methamphetamines': 'false-positive'},\n 'Desirudin': 'Not available',\n 'Desloratadine and Pseudoephedrine': 'See individual agents',\n 'Desloratadine': {'wheal reactions to skin test antigens': 'suppressed',\n  'flare reactions to skin test antigens': 'suppressed'},\n 'Desmopressin': 'Not available',\n 'Desonide': 'Not available',\n 'Desoximetasone': 'Not available',\n 'Desvenlafaxine': {'Urine detection of phencyclidine and amphetamine': 'false-positive'},\n 'Deucravacitinib': 'Not available',\n 'Deutetrabenazine': 'Not available',\n 'DexAMETHasone (Ophthalmic)': 'Not available',\n 'DexAMETHasone (refer to route-specific monograph)': 'Not available',\n 'DexAMETHasone (Systemic)': {'Skin test antigens': 'suppressed wheal and flare reactions'},\n 'Dexbrompheniramine and Phenylephrine': 'Not available',\n 'Dexchlorpheniramine and Pseudoephedrine': 'Not available',\n 'Dexchlorpheniramine, Dextromethorphan, and Phenylephrine': 'Not available',\n 'Dexchlorpheniramine': 'Not available',\n 'Dexlansoprazole': {'Serum chromogranin A (CgA) levels': 'false-positive due to decreased gastric acidity and temporarily stopping dexlansoprazole'},\n 'DexmedeTOMIDine': 'Not available',\n 'Dexmethylphenidate': 'Not available',\n 'Dexrazoxane': 'Not available',\n 'Dextran': {'Serum glucose testing methods that use high concentrations of acid': 'Falsely elevated',\n  'Bilirubin assays that use alcohol': 'Interference',\n  'Total protein assays using biuret reagents': 'Interference',\n  'Dextran 70': 'Erythrocyte aggregation and interference with blood typing and cross matching of blood'},\n 'Dextranomer and Hyaluronate Derivatives': 'Not available',\n 'Dextroamphetamine and Amphetamine': {'Plasma corticosteroid levels': 'Significantly elevated',\n  'Urinary steroid testing': 'Interference'},\n 'Dextroamphetamine': {'Plasma corticosteroid levels': 'Elevated',\n  'Urinary steroid determinations': 'Interference'},\n 'Dextromethorphan and Bupropion': {'urine detection of amphetamine/methamphetamine': 'false-positive'},\n 'Dextromethorphan and Chlorpheniramine': 'See individual agents',\n 'Dextromethorphan and Menthol': 'Not available',\n 'Dextromethorphan and Phenylephrine': 'See individual agents',\n 'Dextromethorphan and Pyrilamine': {'phencyclidine': 'False-positive',\n  'opioids': 'False-positive',\n  'heroin': 'False-positive'},\n 'Dextromethorphan and Quinidine': 'See individual agents',\n 'Dextromethorphan': {'phencyclidine': 'False-positive',\n  'opioids': 'False-positive',\n  'heroin': 'False-positive'},\n 'Dextrose 25% and Sodium Chloride 10%': 'Not available',\n \"Dextrose and Ringer's Injection (Lactated)\": 'Not available',\n 'Dextrose and Sodium Chloride': 'Not available',\n 'Dextrose': 'Not available',\n 'DHAP (Hodgkin)': 'Not available',\n 'DHAP (NHL-DLBCL)': 'Not available',\n 'Diamorphine': 'Not available',\n 'Diatrizoate Meglumine and Diatrizoate Sodium': {'Protein bound iodine uptake studies': 'inaccurate for up to 1 year after enteral administration of iodinated contrast agents',\n  'Radioactive iodine update studies': 'inaccurate for up to 1 year after enteral administration of iodinated contrast agents',\n  'Trypsin values (determined spectrophotometrically)': 'false low due to oral contrast agents'},\n 'Diatrizoate Meglumine': {'Urine specimen assay': 'may be interfered with by contrast agent instillation into bladder'},\n 'DiazePAM': {'Urinary glucose determinations when using Clinistix® or Diastix®': 'false-negative'},\n 'Diazoxide': {'Serum renin concentrations': 'increased',\n  'IgG concentrations': 'increased',\n  'Serum cortisol concentrations': 'decreased',\n  'Insulin response to glucagon': 'false-negative'},\n 'Dibekacin [INT]': 'Not available',\n 'Dibucaine': 'Not available',\n 'Dichlorphenamide': 'Not available',\n 'Diclofenac (Ophthalmic)': 'Not available',\n 'Diclofenac (refer to route-specific monograph)': 'Not available',\n 'Diclofenac (Systemic)': {'aldosterone/renin ratio (ARR)': 'false-positive'},\n 'Diclofenac (Topical)': 'Not available',\n 'Diclofenac and Misoprostol': 'Not available',\n 'Dicloxacillin': {'Urine proteins': 'false-positive',\n  'Serum proteins': 'false-positive',\n  'Uric acid': 'false-positive',\n  'Urinary steroids': 'false-positive',\n  'Urinary glucose tests using cupric sulfate': 'interference',\n  'Aminoglycosides': 'inactivated'},\n 'Dicyclomine': 'Not available',\n ...}"
     },
     "execution_count": 74,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drug_test"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T09:15:49.308587200Z",
     "start_time": "2023-08-29T09:15:49.263189200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "outputs": [],
   "source": [
    "generic_names, lab_names, result_collect = [],[],[]\n",
    "\n",
    "for drug in drug_test.keys():\n",
    "    if type(drug_test[drug]) == dict:\n",
    "        for test in drug_test[drug].keys():\n",
    "            res = drug_test[drug][test]\n",
    "\n",
    "            try:\n",
    "                if res.strip() == 'FALSE':\n",
    "                    res = 'False results'\n",
    "                res = res.capitalize(); res = res.strip()\n",
    "                generic_names.append(drug); lab_names.append(test); result_collect.append(res)\n",
    "            except:\n",
    "                res = ''\n",
    "\n",
    "    else:\n",
    "        generic_names.append(drug); lab_names.append('No test available'); result_collect.append('No result available')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T09:45:15.064617Z",
     "start_time": "2023-08-29T09:45:15.044149200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "outputs": [
    {
     "data": {
      "text/plain": "['5 + 2 (Cytarabine-Daunorubicin) (AML Induction)',\n '5 + 2 (Cytarabine-Daunorubicin) (AML Postremission)',\n '5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)',\n '5 + 2 (Cytarabine-Mitoxantrone) (AML Consolidation)',\n '5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) (AML Consolidation)',\n '7 + 3 (Cytarabine-Daunorubicin) (AML Induction)',\n '7 + 3 (Cytarabine-Idarubicin) (AML Induction)',\n '7 + 3 (Cytarabine-Mitoxantrone) (AML Induction)',\n '7 + 3 + 7 (Cytarabine-Daunorubicin-Etoposide) (AML Induction)',\n 'A-AVD (Hodgkin)',\n 'Abacavir and Lamivudine',\n 'Abacavir, Dolutegravir, and Lamivudine',\n 'Abacavir, Lamivudine, and Zidovudine',\n 'Abacavir',\n 'Abaloparatide',\n 'Abatacept',\n 'Abatacept',\n 'Abciximab',\n 'Abemaciclib-Fulvestrant (Breast)',\n 'Abemaciclib',\n 'Abiraterone Acetate',\n 'Abiraterone-Methylprednisolone (Prostate)',\n 'Abiraterone-Prednisone (Prostate)',\n 'AbobotulinumtoxinA',\n 'Abrocitinib',\n 'ABV Hybrid (Hodgkin)',\n 'ABVD (Hodgkin)',\n 'ABVD Early Stage (Hodgkin)',\n 'AC (Breast)',\n 'AC (Dose-Dense) followed by Paclitaxel (Dose-Dense) (Breast)',\n 'AC (Dose-Dense) followed by Paclitaxel (Dose-Dense)-Trastuzumab (Breast)',\n 'AC (Dose-Dense) followed by Paclitaxel Weekly (Breast)',\n 'AC followed by Docetaxel Every 3 Weeks (Breast)',\n 'AC followed by Paclitaxel Weekly (Breast)',\n 'AC followed by Paclitaxel-Trastuzumab (Breast)',\n 'Acalabrutinib-Obinutuzumab (CLL)',\n 'Acalabrutinib',\n 'Acamprosate',\n 'Acarbose',\n 'Acebutolol',\n 'Acenocoumarol',\n 'Acetaminophen and Caffeine',\n 'Acetaminophen and Codeine',\n 'Acetaminophen and Diphenhydramine',\n 'Acetaminophen and Methocarbamol',\n 'Acetaminophen and Pamabrom',\n 'Acetaminophen and Phenylephrine',\n 'Acetaminophen and Phenyltoloxamine',\n 'Acetaminophen and Pseudoephedrine',\n 'Acetaminophen and Tramadol',\n 'Acetaminophen, Aspirin, and Caffeine',\n 'Acetaminophen, Caffeine, and Codeine',\n 'Acetaminophen, Caffeine, and Dihydrocodeine',\n 'Acetaminophen, Caffeine, and Pyrilamine',\n 'Acetaminophen, Codeine, and Doxylamine',\n 'Acetaminophen, Dextromethorphan, and Doxylamine',\n 'Acetaminophen, Dextromethorphan, and Phenylephrine',\n 'Acetaminophen, Diphenhydramine, and Phenylephrine',\n 'Acetaminophen, Guaifenesin, and Phenylephrine',\n 'Acetaminophen, Isometheptene, and Dichloralphenazone',\n 'Acetaminophen, Isometheptene, and Dichloralphenazone',\n 'Acetaminophen, Isometheptene, and Dichloralphenazone',\n 'Acetaminophen',\n 'AcetaZOLAMIDE',\n 'AcetaZOLAMIDE',\n 'AcetaZOLAMIDE',\n 'AcetaZOLAMIDE',\n 'AcetaZOLAMIDE',\n 'AcetaZOLAMIDE',\n 'AcetaZOLAMIDE',\n 'Acetic Acid (Otic)',\n 'Acetic Acid (refer to route-specific monograph)',\n 'Acetic Acid (Topical)',\n 'Acetic Acid and Hydrocortisone',\n 'Acetohydroxamic Acid',\n 'Acetone',\n 'Acetylcholine',\n 'Acetylcysteine',\n 'Acitretin',\n 'Aclidinium and Formoterol',\n 'Aclidinium',\n 'Acrivastine and Pseudoephedrine',\n 'Acyclovir (Ophthalmic)',\n 'Acyclovir (refer to route-specific monograph)',\n 'Acyclovir (Systemic)',\n 'Acyclovir (Topical)',\n 'Acyclovir and Hydrocortisone',\n 'AD (Soft Tissue Sarcoma)',\n 'Adagrasib',\n 'Adalimumab',\n 'Adapalene and Benzoyl Peroxide',\n 'Adapalene',\n 'Adefovir',\n 'Adenosine',\n 'Adenovirus (Types 4, 7) Vaccine',\n 'Ado-Trastuzumab Emtansine',\n 'Aducanumab',\n 'Afamelanotide',\n 'Afatinib',\n 'Aflibercept (Ophthalmic)',\n 'Aflibercept (refer to route-specific monograph)',\n 'Agalsidase Alfa',\n 'Agalsidase Beta',\n 'AIM (Soft Tissue Sarcoma)',\n 'Air Polymer-Type A',\n 'Albendazole',\n 'Albiglutide',\n 'Albumin',\n 'Albuterol and Budesonide',\n 'Albuterol and Budesonide',\n 'Albuterol',\n 'Albuterol',\n 'Alcaftadine',\n 'Alclometasone',\n 'Alcohol (Ethyl)',\n 'Alcohol (Isopropyl)',\n 'Aldesleukin',\n 'Alectinib',\n 'Alemtuzumab',\n 'Alendronate and Cholecalciferol',\n 'Alendronate and Cholecalciferol',\n 'Alendronate',\n 'Alendronate',\n 'Alfacalcidol',\n 'ALfentanil',\n 'Alfuzosin',\n 'Alglucosidase Alfa',\n 'Alirocumab',\n 'Aliskiren and Hydrochlorothiazide',\n 'Aliskiren',\n 'Alitretinoin (refer to route-specific monograph)',\n 'Alitretinoin (Systemic)',\n 'Alitretinoin (Topical)',\n 'Allopurinol',\n 'Almotriptan',\n 'Alogliptin and Metformin',\n 'Alogliptin and Pioglitazone',\n 'Alogliptin',\n 'Alosetron',\n 'Alpelisib-Fulvestrant (Breast)',\n 'Alpelisib',\n 'Alpha-Galactosidase',\n 'Alpha1-Proteinase Inhibitor',\n 'ALPRAZolam',\n 'Alprostadil',\n 'Alteplase',\n 'Altretamine',\n 'Alum Irrigation',\n 'Aluminum Acetate',\n 'Aluminum Chloride Hexahydrate',\n 'Aluminum Chloride',\n 'Aluminum Hydroxide and Magnesium Carbonate',\n 'Aluminum Hydroxide and Magnesium Hydroxide',\n 'Aluminum Hydroxide and Magnesium Trisilicate',\n 'Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone',\n 'Aluminum Hydroxide',\n 'Alvimopan',\n 'Amantadine',\n 'Ambrisentan',\n 'Amcinonide',\n 'Amifampridine',\n 'Amifostine',\n 'Amikacin (refer to route-specific monograph)',\n 'Amikacin (Systemic)',\n 'Amikacin Liposome (Oral Inhalation)',\n 'Amiloride and Hydrochlorothiazide',\n 'Amiloride and Hydrochlorothiazide',\n 'AMILoride',\n 'Amino Acid Injection',\n 'Aminocaproic Acid',\n 'Aminolevulinic Acid (refer to route-specific monograph)',\n 'Aminolevulinic Acid (Systemic)',\n 'Aminolevulinic Acid (Topical)',\n 'Aminophylline',\n 'Aminophylline',\n 'Aminophylline',\n 'Aminophylline',\n 'Aminophylline',\n 'Aminophylline',\n 'Aminophylline',\n 'Aminophylline',\n 'Aminosalicylic Acid',\n 'Amiodarone',\n 'Amiodarone',\n 'Amiodarone',\n 'Amisulpride (Injection)',\n 'Amitriptyline and Chlordiazepoxide',\n 'Amitriptyline and Perphenazine',\n 'Amitriptyline',\n 'Amivantamab',\n 'Amlodipine and Atorvastatin',\n 'Amlodipine and Benazepril',\n 'Amlodipine and Celecoxib',\n 'Amlodipine and Olmesartan',\n 'Amlodipine and Valsartan',\n 'Amlodipine, Valsartan, and Hydrochlorothiazide',\n 'AmLODIPine',\n 'Ammonia Spirit (Aromatic)',\n 'Amobarbital',\n 'Amorolfine [INT]',\n 'Amoxapine',\n 'Amoxicillin and Clavulanate',\n 'Amoxicillin and Clavulanate',\n 'Amoxicillin and Clavulanate',\n 'Amoxicillin and Clavulanate',\n 'Amoxicillin and Clavulanate',\n 'Amoxicillin',\n 'Amoxicillin',\n 'Amphetamine',\n 'Amphetamine',\n 'Amphotericin B (Lipid Complex)',\n 'Amphotericin B (Liposomal)',\n 'Amphotericin B Deoxycholate',\n 'Ampicillin and Sulbactam',\n 'Ampicillin and Sulbactam',\n 'Ampicillin',\n 'Ampicillin',\n 'Amsacrine',\n 'Amyl Nitrite',\n 'Anacaulase',\n 'Anagrelide',\n 'Anakinra',\n 'Anastrozole',\n 'Andexanet Alfa (Coagulation Factor Xa [Recombinant], Inactivated)',\n 'Angiotensin II',\n 'Anidulafungin',\n 'Anifrolumab',\n 'Ansuvimab',\n 'Anthralin',\n 'Anthrax Immune Globulin (Human)',\n 'Anthrax Immune Globulin (Human)',\n 'Anthrax Immune Globulin (Human)',\n 'Anthrax Vaccine Adsorbed',\n 'Anti-inhibitor Coagulant Complex (Human)',\n 'Anticoagulant Citrate Dextrose',\n 'Anticoagulant Sodium Citrate',\n 'Antihemophilic Factor (Human)',\n 'Antihemophilic Factor (Recombinant [Fc Fusion Protein])',\n 'Antihemophilic Factor (Recombinant [Fc-VWF-XTEN Fusion Protein])',\n 'Antihemophilic Factor (Recombinant [Pegylated])',\n 'Antihemophilic Factor (Recombinant [Porcine Sequence])',\n 'Antihemophilic Factor (Recombinant)',\n 'Antihemophilic Factorvon Willebrand Factor Complex (Human)',\n 'Antithrombin',\n 'Antithymocyte Globulin (Equine)',\n 'Antithymocyte Globulin (Rabbit)',\n 'Antithymocyte Globulin (Rabbit)',\n 'Antithymocyte Globulin (Rabbit)',\n 'Antivenin (Latrodectus mactans)',\n 'Antivenin (Micrurus fulvius)',\n 'Apalutamide',\n 'Apixaban',\n 'Apixaban',\n 'Apomorphine',\n 'Apraclonidine',\n 'Apremilast',\n 'Aprepitant',\n 'Arformoterol',\n 'Argatroban',\n 'Argatroban',\n 'Argatroban',\n 'Arginine',\n 'ARIPiprazole Lauroxil',\n 'ARIPiprazole',\n 'Armodafinil',\n 'Arsenic Trioxide',\n 'Artemether and Lumefantrine',\n 'Artesunate',\n 'Articaine and Epinephrine',\n 'Artichoke',\n 'Artificial Tears',\n 'Asciminib',\n 'Ascorbic Acid',\n 'Ascorbic Acid',\n 'Ascorbic Acid',\n 'Ascorbic Acid',\n 'Asenapine',\n 'Asfotase Alfa',\n 'Asparaginase (Erwinia [Recombinant])',\n 'Asparaginase (Erwinia)',\n 'Aspirin and Dipyridamole',\n 'Aspirin and Omeprazole',\n 'Aspirin, Citric Acid, and Sodium Bicarbonate',\n 'Aspirin',\n 'Aspirin',\n 'Aspirin',\n 'Aspirin',\n 'Aspirin',\n 'Aspirin',\n 'Aspirin',\n 'Aspirin',\n 'Aspirin',\n 'Atazanavir and Cobicistat',\n 'Atazanavir',\n 'Atenolol and Chlorthalidone',\n 'Atenolol',\n 'Atenolol',\n 'Atenolol',\n 'Atezolizumab-Bevacizumab (Hepatocellular)',\n 'Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel (NSCLC)',\n 'Atezolizumab-Carboplatin-Etoposide (Small Cell Lung Cancer)',\n 'Atezolizumab-Carboplatin-Paclitaxel (Protein Bound) (NSCLC)',\n 'Atezolizumab-Cobimetinib-Vemurafenib (Melanoma)',\n 'Atezolizumab',\n 'Atogepant',\n 'Atoltivimab, Maftivimab, and Odesivimab',\n 'Atomoxetine',\n 'Atorvastatin',\n 'Atovaquone and Proguanil',\n 'Atovaquone',\n 'Atracurium',\n 'Atropine (Ophthalmic)',\n 'Atropine (refer to route-specific monograph)',\n 'Atropine (Systemic)',\n 'Atropine and Pralidoxime',\n 'Auranofin',\n 'Avacopan',\n 'Avalglucosidase Alfa',\n 'Avanafil',\n 'Avapritinib',\n 'Avatrombopag',\n 'Avelumab-Axitinib (RCC)',\n 'Avelumab',\n 'Avocado',\n 'Axicabtagene Ciloleucel',\n 'Axitinib',\n 'AzaCITIDine',\n 'AzaTHIOprine',\n 'Azelaic Acid',\n 'Azelastine (Nasal)',\n 'Azelastine (Ophthalmic)',\n 'Azelastine (refer to route-specific monograph)',\n 'Azelastine and Fluticasone',\n 'Azilsartan and Chlorthalidone',\n 'Azilsartan',\n 'Azithromycin (Ophthalmic)',\n 'Azithromycin (refer to route-specific monograph)',\n 'Azithromycin (Systemic)',\n 'Aztreonam (Oral Inhalation)',\n 'Aztreonam (refer to route-specific monograph)',\n 'Aztreonam (Systemic)',\n 'Aztreonam (Systemic)',\n 'Bacitracin (Ophthalmic)',\n 'Bacitracin (refer to route-specific monograph)',\n 'Bacitracin (Systemic)',\n 'Bacitracin (Topical)',\n 'Bacitracin and Polymyxin B (Ophthalmic)',\n 'Bacitracin and Polymyxin B (refer to route-specific monograph)',\n 'Bacitracin and Polymyxin B (Topical)',\n 'Bacitracin, Neomycin, and Polymyxin B (Ophthalmic)',\n 'Bacitracin, Neomycin, and Polymyxin B (refer to route-specific monograph)',\n 'Bacitracin, Neomycin, and Polymyxin B (Topical)',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Ophthalmic)',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (refer to route-specific monograph)',\n 'Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Topical)',\n 'Bacitracin, Neomycin, Polymyxin B, and Pramoxine',\n 'Baclofen',\n 'Balanced Salt Solution',\n 'Baloxavir Marboxil',\n 'Balsalazide',\n 'Balsam Peru and Castor Oil',\n 'Bamlanivimab and Etesevimab',\n 'Bamlanivimab',\n 'Baricitinib',\n 'Barium',\n 'Basiliximab',\n 'BCG (Intravesical)',\n 'BCG (refer to route-specific monograph)',\n 'BCG Vaccine (Immunization)',\n 'BCG Vaccine (Immunization)',\n 'BCG Vaccine (Immunization)',\n 'BCG Vaccine (Immunization)',\n 'BEACOPP Escalated (Hodgkin)',\n 'BEACOPP Escalated Plus Standard (Hodgkin)',\n 'BEACOPP Standard (Hodgkin)',\n 'BEACOPP-14 (Hodgkin)',\n 'Bebtelovimab',\n 'Becaplermin',\n 'Beclomethasone (Nasal)',\n 'Beclomethasone (Oral Inhalation)',\n 'Beclomethasone (refer to route-specific monograph)',\n 'Beclomethasone (Topical)',\n 'Bedaquiline',\n 'Belantamab Mafodotin',\n 'Belatacept',\n 'Belimumab',\n 'Belinostat',\n 'Belladonna and Opium',\n 'Belumosudil',\n 'Belzutifan',\n 'Bempedoic Acid and Ezetimibe',\n 'Bempedoic Acid',\n 'Benazepril and Hydrochlorothiazide',\n 'Benazepril',\n 'Bendamustine-Bortezomib-Rituximab (NHL-Follicular)',\n 'Bendamustine-Lenalidomide-Dexamethasone (Multiple Myeloma)',\n 'Bendamustine-Obinutuzumab (NHL-Follicular)',\n 'Bendamustine-Rituximab (CLL)',\n 'Bendamustine-Rituximab (NHL-Follicular)',\n 'Bendamustine-Rituximab (NHL-Mantle Cell)',\n 'Bendamustine-Rituximab (Waldenstrom Macroglobulinemia)',\n 'Bendamustine',\n 'Benralizumab',\n 'Benserazide and Levodopa',\n 'Benserazide and Levodopa',\n 'Benserazide and Levodopa',\n 'Benserazide and Levodopa',\n 'Benserazide and Levodopa',\n 'Bentoquatam',\n 'Benzalkonium Chloride and Benzocaine',\n 'Benzhydrocodone and Acetaminophen',\n 'Benznidazole',\n 'Benzocaine and Docusate',\n 'Benzocaine, Butamben, and Tetracaine',\n 'Benzocaine',\n 'Benzoin',\n 'Benzonatate',\n 'Benzoyl Peroxide and Hydrocortisone',\n 'Benzoyl Peroxide',\n 'Benzphetamine',\n 'Benztropine',\n 'Benzydamine',\n 'Benzyl Alcohol',\n 'Benzylpenicilloyl Polylysine',\n 'BEP (Ovarian)',\n 'BEP (Testicular)',\n 'Bepotastine',\n 'Beractant',\n 'Berotralstat',\n 'Besifloxacin',\n 'Beta-Carotene',\n 'Betahistine',\n 'Betaine',\n 'Betamethasone (refer to route-specific monograph)',\n 'Betamethasone (Systemic)',\n 'Betamethasone (Topical)',\n 'Betamethasone and Clotrimazole',\n 'Betamethasone and Gentamicin',\n 'Betamethasone and Salicylic Acid',\n 'Betaxolol (Ophthalmic)',\n 'Betaxolol (refer to route-specific monograph)',\n 'Betaxolol (Systemic)',\n 'Betaxolol (Systemic)',\n 'Bethanechol',\n 'Betibeglogene Autotemcel',\n 'Betibeglogene Autotemcel',\n 'Bevacizumab + FOLFIRI (Colorectal)',\n 'Bevacizumab + XELOX (Colorectal)',\n 'Bevacizumab FOLFOX (Colorectal)',\n 'Bevacizumab-Carboplatin-Doxorubicin (Liposomal) (Ovarian)',\n 'Bevacizumab-Carboplatin-Gemcitabine (Ovarian)',\n 'Bevacizumab-Carboplatin-Paclitaxel (NSCLC)',\n 'Bevacizumab-Carboplatin-Paclitaxel (Ovarian)',\n 'Bevacizumab-Carboplatin-Pemetrexed (NSCLC)',\n 'Bevacizumab-Cisplatin-Paclitaxel (Cervical)',\n 'Bevacizumab-Cisplatin-Pemetrexed (Mesothelioma)',\n 'Bevacizumab-Cisplatin-Pemetrexed (NSCLC)',\n 'Bevacizumab-Doxorubicin (Liposomal) (Ovarian)',\n 'Bevacizumab-Fluorouracil-Leucovorin (Colorectal)',\n 'Bevacizumab-Irinotecan (Glioblastoma)',\n 'Bevacizumab-Lomustine (Glioblastoma)',\n 'Bevacizumab-Lonsurf (Colorectal)',\n 'Bevacizumab-Paclitaxel (Breast)',\n 'Bevacizumab-Paclitaxel (Ovarian)',\n 'Bevacizumab-Paclitaxel-Topotecan (Cervical)',\n 'Bevacizumab-Topotecan Daily (Ovarian)',\n 'Bevacizumab-Topotecan Weekly (Ovarian)',\n 'Bevacizumab',\n 'Bexagliflozin',\n 'Bexarotene (refer to route-specific monograph)',\n 'Bexarotene (Systemic)',\n 'Bexarotene (Topical)',\n 'Bezafibrate',\n 'Bezlotoxumab',\n 'Bicalutamide',\n 'Bictegravir, Emtricitabine, and Tenofovir Alafenamide',\n 'Bilastine',\n 'Bimatoprost',\n 'Bimekizumab',\n 'Binimetinib',\n 'Biotin',\n 'Biotin',\n 'Bisacodyl',\n 'Bismuth Subcitrate, Metronidazole, and Tetracycline',\n 'Bismuth Subgallate',\n 'Bismuth Subsalicylate',\n 'Bisoprolol and Hydrochlorothiazide',\n 'Bisoprolol',\n 'Bivalirudin',\n 'Bleomycin',\n 'Blinatumomab',\n 'Boric Acid (Vaginal)',\n 'Bortezomib-Dexamethasone (Amyloidosis)',\n 'Bortezomib-Dexamethasone (Multiple Myeloma)',\n 'Bortezomib-Dexamethasone-Rituximab (Waldenstrom Macroglobulinemia)',\n 'Bortezomib-Doxorubicin (Liposomal) (Multiple Myeloma)',\n 'Bortezomib-Doxorubicin-Dexamethasone (Multiple Myeloma)',\n 'Bortezomib-Rituximab (Waldenstrom Macroglobulinemia)',\n 'Bortezomib-Thalidomide-Dexamethasone (Multiple Myeloma)',\n 'Bortezomib',\n 'Bosentan',\n 'Bosutinib',\n 'Botulism Antitoxin, Heptavalent',\n 'Botulism Immune Globulin (Intravenous-Human)',\n 'Bovine Lipid Extract Surfactant',\n 'Bremelanotide',\n 'Brentuximab Vedotin',\n 'Bretylium',\n 'Brexanolone',\n 'Brexpiprazole',\n 'Brexucabtagene Autoleucel',\n 'Brigatinib',\n 'Brilliant Blue G',\n 'Brimonidine (Ophthalmic)',\n 'Brimonidine (refer to route-specific monograph)',\n 'Brimonidine (Topical)',\n 'Brimonidine and Timolol',\n 'Brincidofovir',\n 'Brinzolamide and Brimonidine',\n 'Brinzolamide and Timolol',\n 'Brinzolamide',\n 'Brivaracetam',\n 'Brodalumab',\n 'Brolucizumab',\n 'Bromazepam',\n 'Bromfenac',\n 'Bromocriptine',\n 'Brompheniramine and Phenylephrine',\n 'Brompheniramine and Pseudoephedrine',\n 'Brompheniramine, Dextromethorphan, and Phenylephrine',\n 'Brompheniramine, Pseudoephedrine, and Dextromethorphan',\n 'Budesonide (Nasal)',\n 'Budesonide (Oral Inhalation)',\n 'Budesonide (refer to route-specific monograph)',\n 'Budesonide (Systemic)',\n 'Budesonide (Topical)',\n 'Budesonide and Formoterol',\n 'Budesonide, Glycopyrrolate, and Formoterol',\n 'Bumetanide',\n 'BUPivacaine (Liposomal)',\n 'Bupivacaine and Epinephrine',\n 'Bupivacaine and Meloxicam',\n 'BUPivacaine',\n 'Buprenorphine and Naloxone',\n 'Buprenorphine',\n 'BuPROPion',\n 'Burosumab',\n 'Buserelin',\n 'BusPIRone',\n 'Busulfan',\n 'Butabarbital',\n 'Butalbital and Acetaminophen',\n 'Butalbital, Acetaminophen, and Caffeine',\n 'Butalbital, Acetaminophen, Caffeine, and Codeine',\n 'Butalbital, Aspirin, and Caffeine',\n 'Butalbital, Aspirin, Caffeine, and Codeine',\n \"Butcher's Broom\",\n 'Butenafine',\n 'Butoconazole',\n 'Butorphanol',\n 'C-MOPPABV Hybrid (Hodgkin)',\n 'C1 Inhibitor (Human)',\n 'C1 Inhibitor (Recombinant)',\n 'Cabazitaxel-Prednisone (Prostate)',\n 'Cabazitaxel',\n 'Cabergoline',\n 'Cabotegravir and Rilpivirine',\n 'Cabotegravir',\n 'Cabozantinib-Nivolumab (RCC)',\n 'Cabozantinib',\n 'Caffeine',\n 'Calamine',\n 'Calaspargase Pegol',\n 'Calcifediol',\n 'Calcipotriene and Betamethasone',\n 'Calcipotriene',\n 'Calcitonin',\n 'Calcitriol (refer to route-specific monograph)',\n 'Calcitriol (Systemic)',\n 'Calcitriol (Topical)',\n 'Calcium Acetate',\n 'Calcium and Vitamin D',\n 'Calcium Carbonate and Magnesium Carbonate',\n 'Calcium Carbonate and Magnesium Hydroxide',\n 'Calcium Carbonate and Simethicone',\n 'Calcium Carbonate',\n 'Calcium Chloride',\n 'Calcium Citrate',\n 'Calcium Dobesilate and Lidocaine',\n 'Calcium Glubionate',\n 'Calcium Gluconate',\n 'Calcium Gluconate',\n 'Calcium Hydroxylapatite',\n 'Calcium Hydroxylapatite',\n 'Calcium Lactate',\n 'Calcium Polystyrene Sulfonate',\n 'Calfactant',\n 'CALGB 8811 Regimen (ALL)',\n 'CALGB 9111 Regimen (ALL)',\n 'Camphor and Menthol',\n 'Camphor and Phenol',\n 'Camphor',\n 'Canagliflozin and Metformin',\n 'Canagliflozin',\n 'Canagliflozin',\n 'Canakinumab',\n 'Candesartan and Hydrochlorothiazide',\n 'Candesartan',\n 'Candida albicans (Monilia)',\n 'Cangrelor',\n 'Cannabidiol',\n 'Cannabis',\n 'Cannabis',\n 'Cantharidin, Podophyllin Resin, and Salicylic Acid',\n 'Cantharidin',\n 'Capecitabine + Lapatinib (Breast)',\n 'Capecitabine-Docetaxel (Breast)',\n 'Capecitabine-Docetaxel (Gastric Cancer)',\n 'Capecitabine-Gemcitabine (Pancreatic)',\n 'Capecitabine-Ixabepilone (Breast)',\n 'Capecitabine-Oxaliplatin (Gastric)',\n 'Capecitabine-Oxaliplatin (Unknown Primary, Adenocarcinoma)',\n 'Capecitabine-Trastuzumab (Breast)',\n 'Capecitabine',\n 'Caplacizumab',\n 'Capmatinib',\n 'CAPOX (Biliary Cancer)',\n 'CAPOX (Pancreatic)',\n 'Capreomycin',\n 'Caprylidene',\n 'Capsaicin',\n 'Captopril and Hydrochlorothiazide',\n 'Captopril',\n 'Carbachol',\n 'CarBAMazepine',\n 'CarBAMazepine',\n 'Carbamide Peroxide',\n 'Carbetocin',\n 'Carbidopa and Levodopa',\n 'Carbidopa and Levodopa',\n 'Carbidopa and Levodopa',\n 'Carbidopa and Levodopa',\n 'Carbidopa',\n 'Carbidopa',\n 'Carbidopa',\n 'Carbidopa',\n 'Carbidopa',\n 'Carbinoxamine',\n 'Carbon 14 Urea',\n 'Carboplatin-Cetuximab (Head and Neck Cancer)',\n 'Carboplatin-Docetaxel (Ovarian)',\n 'Carboplatin-Docetaxel (Unknown Primary, Adenocarcinoma)',\n 'Carboplatin-Docetaxel (Unknown Primary, Squamous Cell)',\n 'Carboplatin-Docetaxel-Trastuzumab (Breast)',\n 'Carboplatin-Doxorubicin (Liposomal) (Ovarian)',\n 'Carboplatin-Etoposide (Ovarian Germ Cell Tumor)',\n 'Carboplatin-Etoposide (Small Cell Lung Cancer)',\n 'Carboplatin-Etoposide-Paclitaxel (Unknown Primary, Adenocarcinoma)',\n 'Carboplatin-Fluorouracil (Head and Neck)',\n 'Carboplatin-Gemcitabine (Bladder)',\n 'Carboplatin-Gemcitabine (NSCLC)',\n 'Carboplatin-Gemcitabine (Ovarian)',\n 'Carboplatin-Irinotecan (Small Cell Lung Cancer)',\n 'Carboplatin-Paclitaxel (Cervical Cancer)',\n 'Carboplatin-Paclitaxel (Endometrial)',\n 'Carboplatin-Paclitaxel (NSCLC)',\n 'Carboplatin-Paclitaxel (Ovarian)',\n 'Carboplatin-Paclitaxel (Protein Bound) (NSCLC)',\n 'Carboplatin-Paclitaxel (Protein Bound)-Pembrolizumab (NSCLC)',\n 'Carboplatin-Paclitaxel (ThymomaThymic)',\n 'Carboplatin-Paclitaxel (Unknown Primary, Adenocarcinoma)',\n 'Carboplatin-Paclitaxel-Pembrolizumab (NSCLC)',\n 'Carboplatin-Paclitaxel-Trastuzumab (Breast)',\n 'Carboplatin-Pemetrexed (Mesothelioma)',\n 'Carboplatin-Pemetrexed (NSCLC)',\n 'Carboplatin-Pemetrexed-Pembrolizumab (NSCLC)',\n 'CARBOplatin',\n 'Carboprost Tromethamine',\n 'Carboxymethylcellulose',\n 'Cardioplegic Solution',\n 'Carfilzomib, Cyclophosphamide, Dexamethasone (Multiple Myeloma)',\n 'Carfilzomib, Lenalidomide, Dexamethasone (Multiple Myeloma)',\n 'Carfilzomib-Dexamethasone (Multiple Myeloma)',\n 'Carfilzomib-Dexamethasone-Daratumumab (Multiple Myeloma)',\n 'Carfilzomib',\n 'Carglumic Acid',\n 'Cariprazine',\n 'Carisoprodol and Aspirin',\n 'Carisoprodol, Aspirin, and Codeine',\n 'Carisoprodol',\n 'Carmustine',\n 'Carteolol (Ophthalmic)',\n 'Carvedilol',\n 'Casimersen',\n 'Casimersen',\n 'Casimersen',\n 'Casirivimab and Imdevimab',\n 'Caspofungin',\n 'Castor Oil',\n 'CAV (Small Cell Lung Cancer)',\n 'Cefaclor',\n 'Cefaclor',\n 'Cefadroxil',\n 'Cefadroxil',\n 'Cefadroxil',\n 'Cefadroxil',\n 'CeFAZolin',\n 'CeFAZolin',\n 'CeFAZolin',\n 'CeFAZolin',\n 'CeFAZolin',\n 'Cefdinir',\n 'Cefdinir',\n 'Cefdinir',\n 'Cefepime',\n 'Cefepime',\n 'Cefepime',\n 'Cefepime',\n 'Cefiderocol',\n 'Cefiderocol',\n 'Cefiderocol',\n 'Cefixime',\n 'Cefixime',\n 'Cefixime',\n 'Cefixime',\n 'Cefixime',\n 'Cefixime',\n 'Cefotaxime',\n 'Cefotaxime',\n 'Cefotaxime',\n 'Cefotaxime',\n 'Cefotaxime',\n 'CefoTEtan',\n 'CefoTEtan',\n 'CefoTEtan',\n 'CefOXitin',\n 'CefOXitin',\n 'CefOXitin',\n 'Cefpodoxime',\n 'Cefpodoxime',\n 'Cefpodoxime',\n 'Cefprozil',\n 'Cefprozil',\n 'Cefprozil',\n 'Cefprozil',\n 'Ceftaroline Fosamil',\n 'Ceftazidime and Avibactam',\n 'Ceftazidime and Avibactam',\n 'Ceftazidime and Avibactam',\n 'CefTAZidime',\n 'CefTAZidime',\n 'CefTAZidime',\n 'Ceftibuten',\n 'Ceftibuten',\n 'Ceftibuten',\n 'Ceftobiprole',\n 'Ceftobiprole',\n 'Ceftobiprole',\n 'Ceftolozane and Tazobactam',\n 'CefTRIAXone',\n 'CefTRIAXone',\n 'CefTRIAXone',\n 'Cefuroxime',\n 'Cefuroxime',\n 'Cefuroxime',\n 'Celecoxib and Tramadol',\n 'Celecoxib',\n 'Cellulose (Oxidized Regenerated)',\n 'Cellulose and Citric Acid',\n 'Cemiplimab',\n 'Cenegermin',\n 'Cenobamate',\n 'Centruroides Immune F(ab)2 (Equine)',\n 'Cephalexin',\n 'Cephalexin',\n 'Cephalexin',\n 'Cephalexin',\n 'CEPP (NHL-DLBCL)',\n 'Ceritinib',\n 'Cerliponase Alfa',\n 'Certolizumab Pegol',\n 'Certolizumab Pegol',\n 'Certolizumab Pegol',\n 'Cetirizine (Ophthalmic)',\n 'Cetirizine (refer to route-specific monograph)',\n 'Cetirizine (Systemic)',\n 'Cetirizine (Systemic)',\n 'Cetirizine and Pseudoephedrine',\n 'Cetrorelix',\n 'Cetuximab (Biweekly)-Irinotecan (Colorectal)',\n 'Cetuximab + FOLFIRI (Colorectal)',\n 'Cetuximab-Carboplatin-Fluorouracil (Head and Neck Cancer)',\n 'Cetuximab-Cisplatin-Fluorouracil (Head and Neck Cancer)',\n 'Cetuximab-Encorafenib (Colorectal)',\n 'Cetuximab-Irinotecan (Colorectal)',\n 'Cetuximab',\n 'Cetylpyridinium',\n 'Cevimeline',\n 'Charcoal, Activated',\n 'Chenodiol',\n 'Chlophedianol and Dexbrompheniramine',\n 'Chlophedianol, Dexbrompheniramine, and Pseudoephedrine',\n 'Chloral Hydrate',\n 'Chloral Hydrate',\n 'Chloral Hydrate',\n 'Chlorambucil-Obinutuzumab (CLL)',\n 'Chlorambucil-Ofatumumab (CLL)',\n 'Chlorambucil-Prednisone (CLL)',\n 'Chlorambucil',\n 'Chloramphenicol (Systemic)',\n 'ChlordiazePOXIDE',\n 'Chlorhexidine Gluconate (Oral)',\n 'Chlorhexidine Gluconate (refer to route-specific monograph)',\n 'Chlorhexidine Gluconate (Topical)',\n 'Chlorophyll',\n 'Chloroprocaine (Ophthalmic)',\n 'Chloroprocaine (refer to route-specific monograph)',\n 'Chloroprocaine (Systemic)',\n 'Chloroquine',\n 'Chlorothiazide',\n 'Chlorothiazide',\n 'Chlorpheniramine and Acetaminophen',\n 'Chlorpheniramine and Phenylephrine',\n 'Chlorpheniramine and Pseudoephedrine',\n 'Chlorpheniramine, Phenylephrine, and Dextromethorphan',\n 'Chlorpheniramine, Pseudoephedrine, and Codeine',\n 'Chlorpheniramine',\n 'ChlorproMAZINE',\n 'ChlorproMAZINE',\n 'ChlorproMAZINE',\n 'ChlorproMAZINE',\n 'ChlorproMAZINE',\n 'ChlorproMAZINE',\n 'Chlorthalidone',\n 'Chlorthalidone',\n 'Chlorzoxazone',\n 'Cholecalciferol',\n 'Cholera Vaccine',\n 'Cholestyramine Resin',\n 'Cholic Acid',\n 'Choline C 11',\n 'Choline Magnesium Trisalicylate',\n 'Choline Magnesium Trisalicylate',\n 'Choline Magnesium Trisalicylate',\n 'Choline Magnesium Trisalicylate',\n 'Choline Magnesium Trisalicylate',\n 'Choline Magnesium Trisalicylate',\n 'Choline Magnesium Trisalicylate',\n 'Choline Magnesium Trisalicylate',\n 'Choline Magnesium Trisalicylate',\n 'CHOP (NHL-AIDS-Related)',\n 'Chorionic Gonadotropin (Human)',\n 'Chorionic Gonadotropin (Recombinant)',\n 'Chorionic Gonadotropin (Recombinant)',\n 'Chromic Chloride',\n 'Ciclesonide (Nasal)',\n 'Ciclesonide (Oral Inhalation)',\n 'Ciclesonide (refer to route-specific monograph)',\n 'Ciclopirox',\n 'Cidofovir',\n 'Cilazapril and Hydrochlorothiazide',\n 'Cilazapril',\n 'Cilostazol',\n 'Ciltacabtagene Autoleucel',\n 'Cimetidine',\n 'Cinacalcet',\n 'Ciprofloxacin (Ophthalmic)',\n 'Ciprofloxacin (Otic)',\n 'Ciprofloxacin (refer to route-specific monograph)',\n 'Ciprofloxacin (Systemic)',\n 'Ciprofloxacin (Systemic)',\n 'Ciprofloxacin (Systemic)',\n 'Ciprofloxacin and Dexamethasone',\n 'Ciprofloxacin and Fluocinolone',\n 'Ciprofloxacin and Hydrocortisone',\n 'Cisapride',\n 'Cisatracurium',\n 'Cisplatin-Capecitabine (Esophageal Cancer)',\n 'Cisplatin-Capecitabine (Gastric Cancer)',\n 'Cisplatin-Cetuximab (Head and Neck Cancer)',\n 'Cisplatin-Docetaxel (NSCLC)',\n 'Cisplatin-Docetaxel (Unknown Primary, Adenocarcinoma)',\n 'Cisplatin-Docetaxel (Unknown Primary, Squamous Cell)',\n 'Cisplatin-Docetaxel-Fluorouracil (Unknown Primary, Squamous Cell)',\n 'Cisplatin-Docetaxel-Gemcitabine (Bladder)',\n 'Cisplatin-Doxorubicin (Endometrial)',\n 'Cisplatin-Doxorubicin-Paclitaxel (Endometrial)',\n 'Cisplatin-Etoposide (NSCLC)',\n 'Cisplatin-Etoposide (Small Cell Lung Cancer)',\n 'Cisplatin-Fluorouracil (Bladder Cancer)',\n 'Cisplatin-Fluorouracil (Esophageal Cancer)',\n 'Cisplatin-Fluorouracil (Head and Neck Cancer)',\n 'Cisplatin-Fluorouracil-Paclitaxel (Unknown Primary, Squamous Cell)',\n 'Cisplatin-Gemcitabine (Bladder)',\n 'Cisplatin-Gemcitabine (Cervical)',\n 'Cisplatin-Gemcitabine (Mesothelioma)',\n 'Cisplatin-Gemcitabine (NSCLC)',\n 'Cisplatin-Gemcitabine (Pancreatic)',\n 'Cisplatin-Gemcitabine (Unknown Primary, Adenocarcinoma)',\n 'Cisplatin-Gemcitabine-Necitumumab (NSCLC)',\n 'Cisplatin-Irinotecan (Gastric)',\n 'Cisplatin-Irinotecan (NSCLC)',\n 'Cisplatin-Irinotecan (Small Cell Lung Cancer)',\n 'Cisplatin-Paclitaxel (Cervical Cancer)',\n 'Cisplatin-Paclitaxel (Head and Neck Cancer)',\n 'Cisplatin-Paclitaxel (NSCLC)',\n 'Cisplatin-Paclitaxel Intraperitoneal (Ovarian)',\n 'Cisplatin-Pemetrexed (Mesothelioma)',\n 'Cisplatin-Pemetrexed (NSCLC)',\n 'Cisplatin-Pemetrexed-Pembrolizumab (NSCLC)',\n 'Cisplatin-Raltitrexed (Mesothelioma)',\n 'Cisplatin-Topotecan (Cervical Cancer)',\n 'Cisplatin-Vinblastine (NSCLC)',\n 'Cisplatin-Vinorelbine (Adjuvant NSCLC)',\n 'Cisplatin-Vinorelbine (Cervical Cancer)',\n 'Cisplatin-Vinorelbine (Metastatic NSCLC)',\n 'CISplatin',\n 'Citalopram',\n 'Citric Acid, Magnesium Carbonate, and Glucono-Delta-Lactone',\n 'Citric Acid, Sodium Citrate, and Potassium Citrate',\n 'Cladribine-Rituximab (NHL-Mantle Cell)',\n 'Cladribine-Rituximab (Waldenstrom Macroglobulinemia)',\n 'Cladribine',\n 'CLAG (AML Induction)',\n 'CLAG-M (AML Induction)',\n 'Clarithromycin',\n 'Clascoterone',\n 'Clemastine',\n 'Clevidipine',\n 'Clidinium and Chlordiazepoxide',\n 'Clindamycin (refer to route-specific monograph)',\n 'Clindamycin (Systemic)',\n 'Clindamycin (Topical)',\n 'Clindamycin and Benzoyl Peroxide',\n 'Clindamycin and Tretinoin',\n 'Clioquinol and Flumethasone',\n 'Clioquinol and Flumethasone',\n 'Clioquinol and Hydrocortisone',\n 'Clioquinol and Hydrocortisone',\n 'CloBAZam',\n 'Clobetasol',\n 'Clobetasone',\n 'Clocortolone',\n 'Clodronate',\n 'Clodronate',\n 'Clofarabine-Cyclophosphamide-Etoposide (ALL)',\n 'Clofarabine-Cytarabine (AML)',\n 'Clofarabine',\n 'Clofazimine',\n 'Clofedanol',\n 'ClomiPHENE',\n 'ClomiPRAMINE',\n 'ClonazePAM',\n 'CloNIDine',\n 'CloNIDine',\n 'Clopidogrel',\n 'Clorazepate',\n 'Clorazepate',\n 'Clorazepate',\n 'Clotrimazole (Oral)',\n 'Clotrimazole (refer to route-specific monograph)',\n 'Clotrimazole (Topical)',\n 'Cloxacillin',\n 'Cloxacillin',\n 'Cloxacillin',\n 'Cloxacillin',\n 'Cloxacillin',\n 'Cloxacillin',\n 'CloZAPine',\n 'CMF Oral (Breast)',\n 'CMV (Bladder)',\n 'Coal Tar and Salicylic Acid',\n 'Coal Tar',\n 'Cobicistat',\n 'Cobimetinib-Vemurafenib (Melanoma)',\n 'Cobimetinib',\n 'Cocaine (Topical)',\n 'Coccidioides immitis Skin Test',\n 'Codeine and Chlorpheniramine',\n 'Codeine, Phenylephrine, and Triprolidine',\n 'Codeine',\n 'Codeine',\n 'Codeine',\n 'CODOX-M (NHL-Burkitt)',\n 'CODOX-MIVAC (NHL-Burkitt)',\n 'Colchicine and Probenecid',\n 'Colchicine',\n 'Colchicine',\n 'Colesevelam',\n 'Colestipol',\n 'Colistimethate',\n 'Collagen (AbsorbableDental)',\n 'Collagen Hemostat',\n 'Collagenase (refer to route-specific monograph)',\n 'Collagenase (Systemic)',\n 'Collagenase (Topical)',\n 'Conivaptan',\n 'Continuous Renal Replacement Therapy Solutions',\n 'Copanlisib',\n 'Copper Cu 64 Dotatate',\n ...]"
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "generic_names"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T09:45:15.673783600Z",
     "start_time": "2023-08-29T09:45:15.635392600Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "outputs": [
    {
     "data": {
      "text/plain": "['No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Dehydrogenase pyrroloquinolinequinone testing method',\n 'Glucose-dye-oxidoreductase testing method',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Aldosterone / renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Urinary 5-hydroxyindoleacetic acid',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'urine glucose',\n 'urine catecholamine',\n 'urinary 5-hydroxyindoleacetic acid',\n 'urinary 5-hydroxyindoleacetic acid',\n 'urinary protein with Albustix',\n 'urinary protein with Labstix',\n 'urinary protein with Albutest',\n 'urinary protein with Bumintest',\n 'HPLC theophylline assay',\n 'serum uric acid levels',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'amphetamines',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Renin',\n 'Aldosterone',\n 'Renin',\n 'Aldosterone',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'diagnostic serum tests that utilize antibodies',\n 'bisphosphonates',\n 'diagnostic imaging agents such as technetium-99m-diphosphonate in bone scans',\n 'bisphosphonates',\n 'diagnostic imaging agents such as technetium-99m-diphosphonate in bone scans',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'coagulation and fibrinolytic activity tests',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'urine detection of amphetamines/methamphetamines',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Aminoglycoside serum concentration',\n 'No test available',\n 'Parathyroid function tests',\n 'Serum iodine (protein bound) test',\n 'Aldosterone/Renin Ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Plasma glucose',\n 'Uric acid',\n 'Free fatty acids',\n 'Total cholesterol',\n 'HDL',\n 'HDL/LDL ratio',\n 'Urinary free cortisol excretion',\n 'Triiodothyronine',\n 'No test available',\n 'T4 levels',\n 'Thyroid stimulating hormone levels',\n 'T3 levels',\n 'No test available',\n 'No test available',\n 'Pregnancy test',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n \"glucose tests using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\",\n 'total conjugated estriol',\n 'estriol-glucuronide',\n 'conjugated estrone',\n 'estradiol',\n \"glucose tests (Benedict's solution, Clinitest, Fehling's Solution)\",\n 'aminoglycoside serum concentration',\n 'Plasma corticosteroid levels',\n 'Urinary steroid determinations',\n 'No test available',\n 'serum phosphate',\n 'No test available',\n \"urinary glucose tests using cupric sulfate (Benedict's solution, Fehling’s solution, or Clinitest®)\",\n 'aminoglycoside serum concentration',\n \"Urinary glucose tests using cupric sulfate (Benedict's solution, Clinitest)\",\n 'Aminoglycoside serum concentration',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Anti-FXa activity assay',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Glucose monitoring devices and test strips utilizing the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase based methods',\n 'Urinalysis after anthrax immune globulin administration',\n 'Passively transferred antibodies',\n 'No test available',\n 'blood group isohemagglutinins',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'rabbit antibody-based immunoassays',\n 'cross-match or panel-reactive antibody cytotoxicity assays',\n 'routine clinical laboratory tests which do not use immunoglobulins',\n 'No test available',\n 'No test available',\n 'No test available',\n 'anti-Factor Xa assays',\n 'aPTT',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'PT/INR levels',\n 'chromogenic factor X assay',\n 'Factor Xa levels',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'stool occult blood',\n 'glucose testing',\n 'nitrite and bilirubin levels',\n 'leucocyte count',\n 'No test available',\n 'ALP-conjugated test systems',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Glucose oxidase urinary glucose tests (Clinistix)',\n 'cupric sulfate method (Clinitest)',\n 'Gerhardt test',\n 'VMA determination',\n '5-HIAA',\n 'xylose tolerance test',\n 'T3',\n 'T4',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'glucose',\n 'HDL',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'TPMT phenotyping',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n \"urine glucose tests containing cupric sulfate (Benedict's solution, Clinitest)\",\n \"Coombs' test\",\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Urinary normetanephrine levels',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'tuberculin reactivity',\n 'No test available',\n 'tuberculin skin test',\n 'active tuberculosis',\n 'PPD reaction',\n 'interferon-gamma release assay (IGRA)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Catecholamines testing',\n 'Creatinine testing',\n 'Uric acid testing',\n 'Glucose testing',\n 'Urine test for ketone bodies',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'skin test antigens',\n 'wheal and flare reactions to skin test antigens',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Glaucoma screening tests',\n 'Aldosterone/renin ratio (ARR)',\n 'No test available',\n 'polymerase chain reaction assays',\n 'PCR-based assay',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'CA125 assay',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'troponin',\n 'thyroid function tests',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'aldosterone/renin ratio (ARR)',\n 'PT/INR levels',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'blood glucose',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'urine detection of amphetamine/methamphetamine',\n 'No test available',\n 'pituitary gonadotropic and gonadal function tests',\n 'Urinary assay for metanephrine/catecholamine',\n 'No test available',\n 'No test available',\n 'Urinary 5-hydroxyindoleacetic acid',\n 'Urinary 5-hydroxyindoleacetic acid',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Magnesium',\n 'Serum magnesium concentration',\n 'Urine magnesium concentration',\n 'CT scans',\n 'Standard radiography',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n '1,5-anhydroglucitol (1,5-AG) assay',\n 'glycemic control monitoring',\n 'No test available',\n 'No test available',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'cannabis screening',\n 'drugs of abuse screening tests',\n 'medical use of cannabis',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Aldosterone/Renin Ratio Test',\n 'No test available',\n 'Serum TCA Screen',\n 'Pregnancy Test',\n 'No test available',\n 'No test available',\n 'Urinary glucose',\n 'Glucosuria',\n 'Urine ketones',\n 'Pheochromocytoma diagnosis based on plasma and urine levels of catecholamines',\n 'Clinitest®',\n 'Clinistix®',\n 'Acetest®',\n 'Ketostix®',\n 'Labstix®',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Aldosterone/renin ratio (ARR)',\n 'pyrogallol red reagent',\n 'laboratory test',\n 'casimersen',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n \"Direct Coombs' test\",\n \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\",\n 'Direct Coombs',\n 'Urinary Glucose',\n 'Serum Creatinine',\n 'Urine Creatinine',\n \"Direct Coombs' Test\",\n \"Indirect Coombs' Test\",\n \"Urinary Glucose Test (based on Benedict's copper reduction reaction)\",\n 'Serum or Urine Creatinine Test (with Jaffé reaction)',\n 'Aminoglycoside Serum Concentration Test',\n 'urinary ketones',\n 'urine glucose',\n 'direct Coombs’ test',\n \"direct Coombs'\",\n 'urinary glucose test',\n 'serum or urine creatinine',\n 'urinary proteins and steroids',\n 'Urine Protein',\n 'Ketones',\n 'Occult Blood',\n \"direct Coombs'\",\n \"urinary glucose test with cupric sulfate (Benedict's solution)\",\n 'urinary glucose test with Clinitest®',\n \"urinary glucose test with Fehling's solution)\",\n 'serum or urine creatinine with alkaline picrate-based Jaffé reaction',\n 'urine ketones using tests with nitroprusside',\n \"direct Coombs'\",\n \"urinary glucose test with cupric sulfate (Benedict's solution)\",\n 'urinary glucose test with Clinitest®',\n \"urinary glucose test with Fehling's solution)\",\n 'serum or urine creatinine with Jaffé reaction',\n \"Positive direct Coombs'\",\n \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\",\n 'serum or urine creatinine with Jaffé reaction',\n \"Positive direct Coombs'\",\n \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\",\n 'serum or urine creatinine with Jaffé reaction',\n \"Positive direct Coombs'\",\n \"urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\",\n 'serum or urine creatinine with Jaffé reaction',\n 'Direct Coombs',\n \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest, Fehling's solution)\",\n 'Enzyme-based tests for glycosuria (eg, Clinistix)',\n 'Ferricyanide test for blood glucose',\n 'No test available',\n 'Ceftazidime',\n 'Urinary glucose test with certain methods',\n 'Glucose tests based on enzymatic glucose oxidase reactions',\n \"Direct Coombs'\",\n \"Urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution)\",\n 'Serum or urine creatinine with Jaffé reaction',\n \"Direct Coombs' test\",\n 'Urinary glucose test using cupric sulfate',\n 'Serum or urine creatinine with Jaffé reaction',\n 'Direct antiglobulin (Coombs) test',\n 'Urinary glucose test using cupric sulfate',\n 'Serum or urine creatinine with Jaffé reaction assay',\n 'No test available',\n \"Direct Coombs' test\",\n 'Urinary glucose test using nonenzymatic methods',\n 'Galactosemia tests',\n \"Direct Coombs' test\",\n 'Urinary glucose test using cupric sulfate',\n 'Ferricyanide test',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n \"Direct Coombs' test\",\n 'Urinary glucose test using cupric sulfate',\n 'Serum or urine creatinine with Jaffé reaction',\n 'Urinary proteins and steroids',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Latent tuberculosis tests',\n 'aPTT assays with PTT-Lupus Anticoagulant (LA) and Standard Target Activated Partial Thromboplastin time (STA-PTT) tests from Diagnostica Stago',\n 'aPTT assays with HemosiL APTT-SP liquid and HemosiL lyophilized silica tests from Instrumentation Laboratories',\n 'No test available',\n 'No test available',\n 'serum TCA screen',\n 'wheal and flare reactions to skin test antigens',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'copper sulfate tests for glycosuria',\n 'fluorometric urine catecholamine tests',\n 'urinary 17-hydroxycorticosteroid tests',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'midstream urine collection',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'parathyroid function',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'skin test antigens',\n 'phenylketonuria',\n 'amylase',\n 'uroporphyrins',\n 'urobilinogen',\n 'pregnancy test',\n 'amphetamine/methamphetamine and methadone test',\n 'serum protein bound iodine',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Prothrombin time',\n 'No test available',\n 'No test available',\n 'glucose oxidase urinary glucose tests',\n 'cupric sulfate method',\n 'Gerhardt test (urinary ketone analysis)',\n 'VMA determination',\n '5-HIAA',\n 'xylose tolerance test',\n 'T3',\n 'T4',\n 'PBI',\n 'No test available',\n 'radioimmunoassay of gonadotropins',\n 'pregnancy tests',\n 'radioimmunoassay of luteinizing hormone and other gonadotropins',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Urine screening result for opioids using commercially-available immunoassay kits',\n 'levofloxacin and ofloxacin',\n 'other quinolones',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'aldosterone/renin ratio (ARR)',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'Thyroid function tests',\n 'ferric chloride test for phenylketonuria',\n 'Thyroid function tests',\n 'ferric chloride test for phenylketonuria',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'technetium-99m-diphosphonate in bone scans',\n 'radiopharmaceutical bone imaging',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'urine detection of methadone',\n 'No test available',\n \"Coombs' test\",\n 'aldosterone/renin ratio',\n 'No test available',\n 'hematocrit',\n 'liver function tests',\n 'renal function tests',\n 'No test available',\n 'No test available',\n 'No test available',\n 'urinary glucose tests',\n 'aminoglycosides',\n 'urine proteins',\n 'serum proteins',\n 'uric acid',\n 'urinary steroids',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'serum creatinine',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'levofloxacin',\n 'ofloxacin',\n 'other quinolones',\n 'No test available',\n 'No test available',\n 'No test available',\n 'urine tests for erythrocytes',\n 'urine tests for hemoglobin',\n 'Prothrombin time',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n 'No test available',\n ...]"
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "lab_names"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T09:43:47.797957500Z",
     "start_time": "2023-08-29T09:43:47.757068100Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name          Test Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)  No test available   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...  No test available   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)  No test available   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...  No test available   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...  No test available   \n...                                                 ...                ...   \n3904                                          Zopiclone  No test available   \n3905                    Zoster Vaccine (LiveAttenuated)  No test available   \n3906                       Zoster Vaccine (Recombinant)  No test available   \n3907                                        Zucapsaicin  No test available   \n3908                                     Zuclopenthixol  No test available   \n\n              Interaction  \n0     No result available  \n1     No result available  \n2     No result available  \n3     No result available  \n4     No result available  \n...                   ...  \n3904  No result available  \n3905  No result available  \n3906  No result available  \n3907  No result available  \n3908  No result available  \n\n[3909 rows x 3 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Interaction</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3904</th>\n      <td>Zopiclone</td>\n      <td>No test available</td>\n      <td>No result available</td>\n    </tr>\n    <tr>\n      <th>3905</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n    </tr>\n    <tr>\n      <th>3906</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n    </tr>\n    <tr>\n      <th>3907</th>\n      <td>Zucapsaicin</td>\n      <td>No test available</td>\n      <td>No result available</td>\n    </tr>\n    <tr>\n      <th>3908</th>\n      <td>Zuclopenthixol</td>\n      <td>No test available</td>\n      <td>No result available</td>\n    </tr>\n  </tbody>\n</table>\n<p>3909 rows × 3 columns</p>\n</div>"
     },
     "execution_count": 92,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_lab = pd.DataFrame()\n",
    "\n",
    "df_lab['Generic Name'] = generic_names; df_lab['Test Name'] = lab_names; df_lab['Interaction'] = result_collect\n",
    "df_lab"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T09:45:21.665781800Z",
     "start_time": "2023-08-29T09:45:21.634502600Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "outputs": [],
   "source": [
    "df_lab.to_csv('Notebooks/installations/Data/Results - Final Sprint Assignment/Drug-Test Interactions.csv',index=False,encoding='utf-8-sig')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T09:45:21.941902100Z",
     "start_time": "2023-08-29T09:45:21.908249200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "outputs": [],
   "source": [
    "drug_test = ''"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T10:01:18.520326100Z",
     "start_time": "2023-08-29T10:01:18.504706Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "outputs": [],
   "source": [
    "### Drug-Test Management\n",
    "import json\n",
    "\n",
    "path_json = 'Notebooks/installations/Data/Results - Final Sprint Assignment/drug-test-management.json'\n",
    "f = open(path_json)\n",
    "\n",
    "drug_test = json.load(f)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T10:01:53.960545500Z",
     "start_time": "2023-08-29T10:01:53.916480100Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "outputs": [],
   "source": [
    "generic_names, lab_names, result_collect = [],[],[]\n",
    "\n",
    "for drug in drug_test.keys():\n",
    "    if type(drug_test[drug]) == dict:\n",
    "        for test in drug_test[drug].keys():\n",
    "            res = drug_test[drug][test]\n",
    "\n",
    "            try:\n",
    "                if res.strip() == 'FALSE':\n",
    "                    res = 'False results'\n",
    "                res = res.capitalize(); res = res.strip()\n",
    "                generic_names.append(drug); lab_names.append(test); result_collect.append(res)\n",
    "            except:\n",
    "                res = ''\n",
    "\n",
    "    else:\n",
    "        generic_names.append(drug); lab_names.append('No test available'); result_collect.append('No management required')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T10:06:11.671815400Z",
     "start_time": "2023-08-29T10:06:11.640540800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "outputs": [
    {
     "data": {
      "text/plain": "['No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'Recommended',\n 'Recommended',\n 'Recommended',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'Recommended',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'Recommended',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n 'No management required',\n ...]"
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result_collect"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T10:06:13.038309500Z",
     "start_time": "2023-08-29T10:06:12.982504600Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name          Test Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)  No test available   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...  No test available   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)  No test available   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...  No test available   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...  No test available   \n...                                                 ...                ...   \n3157                                          Zopiclone  No test available   \n3158                    Zoster Vaccine (LiveAttenuated)  No test available   \n3159                       Zoster Vaccine (Recombinant)  No test available   \n3160                                        Zucapsaicin  No test available   \n3161                                     Zuclopenthixol  No test available   \n\n                  Management  \n0     No management required  \n1     No management required  \n2     No management required  \n3     No management required  \n4     No management required  \n...                      ...  \n3157  No management required  \n3158  No management required  \n3159  No management required  \n3160  No management required  \n3161  No management required  \n\n[3162 rows x 3 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Management</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>No test available</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>No test available</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>No test available</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3157</th>\n      <td>Zopiclone</td>\n      <td>No test available</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>3158</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>3159</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>3160</th>\n      <td>Zucapsaicin</td>\n      <td>No test available</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>3161</th>\n      <td>Zuclopenthixol</td>\n      <td>No test available</td>\n      <td>No management required</td>\n    </tr>\n  </tbody>\n</table>\n<p>3162 rows × 3 columns</p>\n</div>"
     },
     "execution_count": 105,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_lab = pd.DataFrame()\n",
    "\n",
    "df_lab['Generic Name'] = generic_names; df_lab['Test Name'] = lab_names; df_lab['Management'] = result_collect\n",
    "df_lab"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T10:06:14.364799600Z",
     "start_time": "2023-08-29T10:06:14.333486Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "outputs": [],
   "source": [
    "df_lab.to_csv('Notebooks/installations/Data/Results - Final Sprint Assignment/Drug-Test Management.csv',index=False,encoding='utf-8-sig')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T10:06:16.316467200Z",
     "start_time": "2023-08-29T10:06:16.316467200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "\n",
    "df_inter = pd.read_excel('Notebooks/installations/Data/Results - Final Sprint Assignment/Drug-Test Interactions.xlsx')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T14:42:44.672429Z",
     "start_time": "2023-08-29T14:42:44.390338500Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "outputs": [],
   "source": [
    "df_man = pd.read_excel('Notebooks/installations/Data/Results - Final Sprint Assignment/Drug-Test Management.xlsx')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T14:48:16.187539100Z",
     "start_time": "2023-08-29T14:48:15.917656800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "outputs": [],
   "source": [
    "df_ref  = pd.read_excel('Notebooks/installations/Data/Results - Final Sprint Assignment/Drug-Test Interactions - Reference.xlsx')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T14:42:45.270165900Z",
     "start_time": "2023-08-29T14:42:45.073690400Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "outputs": [],
   "source": [
    "df_ref\n",
    "df_refer = pd.DataFrame()\n",
    "df_refer[['Generic Name','Test Interactions Reference']] = df_ref[['Drug Name','Test Interactions Reference']]"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T14:42:45.292435200Z",
     "start_time": "2023-08-29T14:42:45.270165900Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name          Test Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)  No test available   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...  No test available   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)  No test available   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...  No test available   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...  No test available   \n...                                                 ...                ...   \n3903                                          Zopiclone  No test available   \n3904                    Zoster Vaccine (LiveAttenuated)  No test available   \n3905                       Zoster Vaccine (Recombinant)  No test available   \n3906                                        Zucapsaicin  No test available   \n3907                                     Zuclopenthixol  No test available   \n\n              Interaction Test Interactions Reference  \n0     No result available                         NaN  \n1     No result available                         NaN  \n2     No result available                         NaN  \n3     No result available                         NaN  \n4     No result available                         NaN  \n...                   ...                         ...  \n3903  No result available                         NaN  \n3904  No result available                         NaN  \n3905  No result available                         NaN  \n3906  No result available                         NaN  \n3907  No result available                         NaN  \n\n[3908 rows x 4 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Interaction</th>\n      <th>Test Interactions Reference</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3903</th>\n      <td>Zopiclone</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3904</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3905</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3906</th>\n      <td>Zucapsaicin</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3907</th>\n      <td>Zuclopenthixol</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>3908 rows × 4 columns</p>\n</div>"
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#df_out = pd.concat([df_inter,df_refer])\n",
    "df_out1 = pd.merge(\n",
    "    df_inter,\n",
    "    df_refer,\n",
    "    how=\"inner\")\n",
    "df_out1"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T08:26:27.066134300Z",
     "start_time": "2023-08-30T08:26:27.019556300Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "outputs": [],
   "source": [
    "#df_out.to_csv('Notebooks/installations/Data/Results - Final Sprint Assignment/v_merged/Drug-Test Interactions.csv',index=False)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T14:47:00.489415100Z",
     "start_time": "2023-08-29T14:47:00.432881700Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name          Test Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)  No test available   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...  No test available   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)  No test available   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...  No test available   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...  No test available   \n...                                                 ...                ...   \n3157                                          Zopiclone  No test available   \n3158                    Zoster Vaccine (LiveAttenuated)  No test available   \n3159                       Zoster Vaccine (Recombinant)  No test available   \n3160                                        Zucapsaicin  No test available   \n3161                                     Zuclopenthixol  No test available   \n\n                  Management Test Interactions Reference  \n0     No management required                         NaN  \n1     No management required                         NaN  \n2     No management required                         NaN  \n3     No management required                         NaN  \n4     No management required                         NaN  \n...                      ...                         ...  \n3157  No management required                         NaN  \n3158  No management required                         NaN  \n3159  No management required                         NaN  \n3160  No management required                         NaN  \n3161  No management required                         NaN  \n\n[3162 rows x 4 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Management</th>\n      <th>Test Interactions Reference</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3157</th>\n      <td>Zopiclone</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3158</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3159</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3160</th>\n      <td>Zucapsaicin</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3161</th>\n      <td>Zuclopenthixol</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>3162 rows × 4 columns</p>\n</div>"
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#df_out = pd.concat([df_inter,df_refer])\n",
    "df_out2 = pd.merge(\n",
    "    df_man,\n",
    "    df_refer,\n",
    "    how=\"inner\")\n",
    "df_out2"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T08:26:46.425533Z",
     "start_time": "2023-08-30T08:26:46.394245400Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "outputs": [],
   "source": [
    "#df_out.to_csv('Notebooks/installations/Data/Results - Final Sprint Assignment/v_merged/Drug-Test Management.csv',index=False)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T14:49:09.299581800Z",
     "start_time": "2023-08-29T14:49:09.252719500Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name          Test Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)  No test available   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...  No test available   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)  No test available   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...  No test available   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...  No test available   \n...                                                 ...                ...   \n3903                                          Zopiclone  No test available   \n3904                    Zoster Vaccine (LiveAttenuated)  No test available   \n3905                       Zoster Vaccine (Recombinant)  No test available   \n3906                                        Zucapsaicin  No test available   \n3907                                     Zuclopenthixol  No test available   \n\n              Interaction Test Interactions Reference  \n0     No result available                         NaN  \n1     No result available                         NaN  \n2     No result available                         NaN  \n3     No result available                         NaN  \n4     No result available                         NaN  \n...                   ...                         ...  \n3903  No result available                         NaN  \n3904  No result available                         NaN  \n3905  No result available                         NaN  \n3906  No result available                         NaN  \n3907  No result available                         NaN  \n\n[3908 rows x 4 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Interaction</th>\n      <th>Test Interactions Reference</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3903</th>\n      <td>Zopiclone</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3904</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3905</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3906</th>\n      <td>Zucapsaicin</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3907</th>\n      <td>Zuclopenthixol</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>3908 rows × 4 columns</p>\n</div>"
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_out1"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T08:26:55.644431500Z",
     "start_time": "2023-08-30T08:26:55.612787700Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name Test Name Interaction  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)                         \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...                         \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)                         \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...                         \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...                         \n...                                                 ...       ...         ...   \n3903                                          Zopiclone                         \n3904                    Zoster Vaccine (LiveAttenuated)                         \n3905                       Zoster Vaccine (Recombinant)                         \n3906                                        Zucapsaicin                         \n3907                                     Zuclopenthixol                         \n\n     Test Interactions Reference  \n0                            NaN  \n1                            NaN  \n2                            NaN  \n3                            NaN  \n4                            NaN  \n...                          ...  \n3903                         NaN  \n3904                         NaN  \n3905                         NaN  \n3906                         NaN  \n3907                         NaN  \n\n[3908 rows x 4 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Interaction</th>\n      <th>Test Interactions Reference</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3903</th>\n      <td>Zopiclone</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3904</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3905</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3906</th>\n      <td>Zucapsaicin</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3907</th>\n      <td>Zuclopenthixol</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>3908 rows × 4 columns</p>\n</div>"
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_out11 = pd.DataFrame()\n",
    "df_out11[['Generic Name','Test Name','Interaction','Test Interactions Reference']] = \\\n",
    "    df_out1[['Generic Name','Test Name','Interaction','Test Interactions Reference']]\n",
    "for i in range(3908):\n",
    "    if df_out11['Test Name'].iloc[i] == 'No test available':\n",
    "        df_out11['Test Name'].iloc[i] = ''\n",
    "    if  df_out11['Interaction'].iloc[i] == 'No result available':\n",
    "        df_out11['Interaction'].iloc[i] = ''\n",
    "df_out11"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T08:28:17.409697200Z",
     "start_time": "2023-08-30T08:28:15.925577600Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name          Test Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)  No test available   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...  No test available   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)  No test available   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...  No test available   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...  No test available   \n...                                                 ...                ...   \n3157                                          Zopiclone  No test available   \n3158                    Zoster Vaccine (LiveAttenuated)  No test available   \n3159                       Zoster Vaccine (Recombinant)  No test available   \n3160                                        Zucapsaicin  No test available   \n3161                                     Zuclopenthixol  No test available   \n\n                  Management Test Interactions Reference  \n0     No management required                         NaN  \n1     No management required                         NaN  \n2     No management required                         NaN  \n3     No management required                         NaN  \n4     No management required                         NaN  \n...                      ...                         ...  \n3157  No management required                         NaN  \n3158  No management required                         NaN  \n3159  No management required                         NaN  \n3160  No management required                         NaN  \n3161  No management required                         NaN  \n\n[3162 rows x 4 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Management</th>\n      <th>Test Interactions Reference</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3157</th>\n      <td>Zopiclone</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3158</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3159</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3160</th>\n      <td>Zucapsaicin</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3161</th>\n      <td>Zuclopenthixol</td>\n      <td>No test available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>3162 rows × 4 columns</p>\n</div>"
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_out2"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T08:28:44.003907300Z",
     "start_time": "2023-08-30T08:28:43.972768800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name Test Name Management  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)                        \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...                        \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)                        \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...                        \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...                        \n...                                                 ...       ...        ...   \n3157                                          Zopiclone                        \n3158                    Zoster Vaccine (LiveAttenuated)                        \n3159                       Zoster Vaccine (Recombinant)                        \n3160                                        Zucapsaicin                        \n3161                                     Zuclopenthixol                        \n\n     Test Interactions Reference  \n0                            NaN  \n1                            NaN  \n2                            NaN  \n3                            NaN  \n4                            NaN  \n...                          ...  \n3157                         NaN  \n3158                         NaN  \n3159                         NaN  \n3160                         NaN  \n3161                         NaN  \n\n[3162 rows x 4 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Management</th>\n      <th>Test Interactions Reference</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3157</th>\n      <td>Zopiclone</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3158</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3159</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3160</th>\n      <td>Zucapsaicin</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3161</th>\n      <td>Zuclopenthixol</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>3162 rows × 4 columns</p>\n</div>"
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_out21 = pd.DataFrame()\n",
    "df_out21[['Generic Name','Test Name','Management','Test Interactions Reference']] = \\\n",
    "    df_out2[['Generic Name','Test Name','Management','Test Interactions Reference']]\n",
    "for i in range(3162):\n",
    "    if df_out21['Test Name'].iloc[i] == 'No test available':\n",
    "        df_out21['Test Name'].iloc[i] = ''\n",
    "    if  df_out21['Management'].iloc[i] == 'No management required':\n",
    "        df_out21['Management'].iloc[i] = ''\n",
    "df_out21"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T08:30:54.723101800Z",
     "start_time": "2023-08-30T08:30:53.410340900Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name Test Name Interaction  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)                         \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...                         \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)                         \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...                         \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...                         \n...                                                 ...       ...         ...   \n3157                                          Zopiclone                   NaN   \n3158                    Zoster Vaccine (LiveAttenuated)                   NaN   \n3159                       Zoster Vaccine (Recombinant)                   NaN   \n3160                                        Zucapsaicin                   NaN   \n3161                                     Zuclopenthixol                   NaN   \n\n     Test Interactions Reference Management  \n0                            NaN        NaN  \n1                            NaN        NaN  \n2                            NaN        NaN  \n3                            NaN        NaN  \n4                            NaN        NaN  \n...                          ...        ...  \n3157                         NaN             \n3158                         NaN             \n3159                         NaN             \n3160                         NaN             \n3161                         NaN             \n\n[7070 rows x 5 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Interaction</th>\n      <th>Test Interactions Reference</th>\n      <th>Management</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td></td>\n      <td></td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3157</th>\n      <td>Zopiclone</td>\n      <td></td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3158</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td></td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3159</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td></td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3160</th>\n      <td>Zucapsaicin</td>\n      <td></td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3161</th>\n      <td>Zuclopenthixol</td>\n      <td></td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>\n<p>7070 rows × 5 columns</p>\n</div>"
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_out = pd.concat([df_out11,df_out21])\n",
    "df_out"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T08:30:58.671396600Z",
     "start_time": "2023-08-30T08:30:58.628621900Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name Test Name Interaction  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)                         \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...                         \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)                         \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...                         \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...                         \n...                                                 ...       ...         ...   \n3906                                        Zucapsaicin                         \n3161                                     Zuclopenthixol                         \n2554                              mFOLFOX6 (Colorectal)                         \n2573                                mini-BEAM (Hodgkin)                         \n3853                von Willebrand Factor (Recombinant)                         \n\n     Test Interactions Reference Management  \n0                                            \n1                                            \n2                                            \n3                                            \n4                                            \n...                          ...        ...  \n3906                                         \n3161                                         \n2554                                         \n2573                                         \n3853                                         \n\n[4439 rows x 5 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Interaction</th>\n      <th>Test Interactions Reference</th>\n      <th>Management</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3906</th>\n      <td>Zucapsaicin</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3161</th>\n      <td>Zuclopenthixol</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>2554</th>\n      <td>mFOLFOX6 (Colorectal)</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>2573</th>\n      <td>mini-BEAM (Hodgkin)</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n    <tr>\n      <th>3853</th>\n      <td>von Willebrand Factor (Recombinant)</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>\n<p>4439 rows × 5 columns</p>\n</div>"
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "for i in range(7070):\n",
    "    if type(df_out['Test Name'].iloc[i]) != str:\n",
    "        df_out['Test Name'].iloc[i] = ''\n",
    "    if type(df_out['Management'].iloc[i]) != str:\n",
    "        df_out['Management'].iloc[i] = ''\n",
    "    if type(df_out['Test Interactions Reference'].iloc[i]) != str:\n",
    "        df_out['Test Interactions Reference'].iloc[i] = ''\n",
    "    if type(df_out['Interaction'].iloc[i]) != str:\n",
    "        df_out['Interaction'].iloc[i] = ''\n",
    "\n",
    "df_out = df_out.sort_values(by=['Generic Name'])\n",
    "df_out = df_out.drop_duplicates()\n",
    "df_out"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T08:34:15.597840900Z",
     "start_time": "2023-08-30T08:34:14.597811800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name          Test Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)  No test available   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...  No test available   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)  No test available   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...  No test available   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...  No test available   \n...                                                 ...                ...   \n3157                                          Zopiclone  No test available   \n3158                    Zoster Vaccine (LiveAttenuated)  No test available   \n3159                       Zoster Vaccine (Recombinant)  No test available   \n3160                                        Zucapsaicin  No test available   \n3161                                     Zuclopenthixol  No test available   \n\n              Interaction Test Interactions Reference              Management  \n0     No result available                         NaN  No management required  \n1     No result available                         NaN  No management required  \n2     No result available                         NaN  No management required  \n3     No result available                         NaN  No management required  \n4     No result available                         NaN  No management required  \n...                   ...                         ...                     ...  \n3157  No result available                         NaN  No management required  \n3158  No result available                         NaN  No management required  \n3159  No result available                         NaN  No management required  \n3160  No result available                         NaN  No management required  \n3161  No result available                         NaN  No management required  \n\n[7070 rows x 5 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Interaction</th>\n      <th>Test Interactions Reference</th>\n      <th>Management</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>3157</th>\n      <td>Zopiclone</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>3158</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>3159</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>3160</th>\n      <td>Zucapsaicin</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n      <td>No management required</td>\n    </tr>\n    <tr>\n      <th>3161</th>\n      <td>Zuclopenthixol</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>NaN</td>\n      <td>No management required</td>\n    </tr>\n  </tbody>\n</table>\n<p>7070 rows × 5 columns</p>\n</div>"
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "for i in range(len(df_out)):\n",
    "    if type(df_out['Interaction'].iloc[i]) != str:\n",
    "        df_out['Interaction'].iloc[i] = 'No result available'\n",
    "\n",
    "    if type(df_out['Management'].iloc[i]) != str:\n",
    "        df_out['Management'].iloc[i] = 'No management required'\n",
    "df_out"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T14:58:20.951517Z",
     "start_time": "2023-08-29T14:58:18.740107Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "outputs": [],
   "source": [
    "df_out.to_csv('Notebooks/installations/Data/Results - Final Sprint Assignment/v_merged/Drug-Test Interaction-Management.csv',index=False)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-29T14:58:30.406178800Z",
     "start_time": "2023-08-29T14:58:30.352360400Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "\n",
    "df_inter_merged = pd.read_excel('Notebooks/installations/Data/Results - Final Sprint Assignment/v_merged/Drug-Test Interaction-Management.xlsx')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T09:26:33.210445200Z",
     "start_time": "2023-08-30T09:26:32.491776600Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name          Test Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)  No test available   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...  No test available   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)  No test available   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...  No test available   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...  No test available   \n...                                                 ...                ...   \n4420                                          Zopiclone  No test available   \n4421                    Zoster Vaccine (LiveAttenuated)  No test available   \n4422                       Zoster Vaccine (Recombinant)  No test available   \n4423                                        Zucapsaicin  No test available   \n4424                                     Zuclopenthixol  No test available   \n\n              Interaction              Management Test Interactions Reference  \n0     No result available  No management required                         NaN  \n1     No result available  No management required                         NaN  \n2     No result available  No management required                         NaN  \n3     No result available  No management required                         NaN  \n4     No result available  No management required                         NaN  \n...                   ...                     ...                         ...  \n4420  No result available  No management required                         NaN  \n4421  No result available  No management required                         NaN  \n4422  No result available  No management required                         NaN  \n4423  No result available  No management required                         NaN  \n4424  No result available  No management required                         NaN  \n\n[4425 rows x 5 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Interaction</th>\n      <th>Management</th>\n      <th>Test Interactions Reference</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>4420</th>\n      <td>Zopiclone</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4421</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4422</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4423</th>\n      <td>Zucapsaicin</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4424</th>\n      <td>Zuclopenthixol</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>4425 rows × 5 columns</p>\n</div>"
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_inter_merged"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T09:26:33.226076300Z",
     "start_time": "2023-08-30T09:26:33.210445200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "outputs": [
    {
     "data": {
      "text/plain": "{'Refer to individual agents.\\n\\n',\n 'Refer to individual agents.\\n\\n\\n\\n',\n 'Refer to individual monographs.\\n\\n',\n 'Refer to the individual Acetaminophen and Hydrocodone monographs.\\n\\n',\n 'See individual agents.\\n\\n',\n 'See individual agents.\\n\\n\\n\\n',\n 'See individual monographs.\\n\\n'}"
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "comms =[]\n",
    "for i in range(4425):\n",
    "    if type(df_inter_merged['Test Interactions Reference'].iloc[i]) == str:\n",
    "        sent = df_inter_merged['Test Interactions Reference'].iloc[i]\n",
    "        if 'See individual' in sent or 'Refer to individual' in sent or 'Refer to the individual' in sent:\n",
    "            comms.append(df_inter_merged['Test Interactions Reference'].iloc[i])\n",
    "        else:\n",
    "            if df_inter_merged['Test Name'].iloc[i] == 'No test available':\n",
    "                df_inter_merged['Test Name'].iloc[i] = ''\n",
    "                df_inter_merged['Generic Name'].iloc[i] = ''\n",
    "                df_inter_merged['Test Interactions Reference'].iloc[i] = ''\n",
    "comms = set(comms)\n",
    "comms"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T09:26:45.398254400Z",
     "start_time": "2023-08-30T09:26:45.038455900Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "outputs": [
    {
     "data": {
      "text/plain": "                                           Generic Name          Test Name  \\\n0       5 + 2 (Cytarabine-Daunorubicin) (AML Induction)  No test available   \n1     5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...  No test available   \n2     5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)  No test available   \n3     5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...  No test available   \n4     5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...  No test available   \n...                                                 ...                ...   \n4420                                          Zopiclone  No test available   \n4421                    Zoster Vaccine (LiveAttenuated)  No test available   \n4422                       Zoster Vaccine (Recombinant)  No test available   \n4423                                        Zucapsaicin  No test available   \n4424                                     Zuclopenthixol  No test available   \n\n              Interaction              Management Test Interactions Reference  \n0     No result available  No management required                         NaN  \n1     No result available  No management required                         NaN  \n2     No result available  No management required                         NaN  \n3     No result available  No management required                         NaN  \n4     No result available  No management required                         NaN  \n...                   ...                     ...                         ...  \n4420  No result available  No management required                         NaN  \n4421  No result available  No management required                         NaN  \n4422  No result available  No management required                         NaN  \n4423  No result available  No management required                         NaN  \n4424  No result available  No management required                         NaN  \n\n[3915 rows x 5 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Generic Name</th>\n      <th>Test Name</th>\n      <th>Interaction</th>\n      <th>Management</th>\n      <th>Test Interactions Reference</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Induction)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>5 + 2 (Cytarabine-Daunorubicin) (AML Postremis...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>5 + 2 (Cytarabine-Idarubicin) (AML Consolidation)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>5 + 2 (Cytarabine-Mitoxantrone) (AML Consolida...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5 + 2 + 5 (Cytarabine-Daunorubicin-Etoposide) ...</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>4420</th>\n      <td>Zopiclone</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4421</th>\n      <td>Zoster Vaccine (LiveAttenuated)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4422</th>\n      <td>Zoster Vaccine (Recombinant)</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4423</th>\n      <td>Zucapsaicin</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4424</th>\n      <td>Zuclopenthixol</td>\n      <td>No test available</td>\n      <td>No result available</td>\n      <td>No management required</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>3915 rows × 5 columns</p>\n</div>"
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_merged =df_inter_merged.drop_duplicates()\n",
    "df_merged"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T09:26:53.767645Z",
     "start_time": "2023-08-30T09:26:53.726220600Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "outputs": [],
   "source": [
    "df_merged.to_csv('Notebooks/installations/Data/Results - Final Sprint Assignment/v_merged/Drug-Test Interaction-Management.csv',\n",
    "                 index=False, encoding='utf-8-sig')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-08-30T09:29:42.460656800Z",
     "start_time": "2023-08-30T09:29:42.413972500Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "outputs": [],
   "source": [],
   "metadata": {
    "collapsed": false
   }
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
